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Summary	  
The	   global	   burden	   of	   tuberculosis	   (TB)	   in	   children	   is	   high	  with	   a	   high	  morbidity	   and	  
mortality,	  especially	  amongst	  young	  and	  HIV-­‐infected	  children.	  The	  emerging	  epidemic	  
of	  multidrug-­‐resistant	  (MDR)-­‐TB	  is	  a	  threat	  to	  children,	  while	  information	  on	  the	  use	  of	  
second-­‐line	  drugs	  in	  children	  is	  very	  limited.	  
By	   reviewing	   the	   literature	   on	   the	   first-­‐line	   anti-­‐tuberculosis	   agents	   it	   is	   shown	   that	  
isoniazid	   (INH)	   and	   rifampicin	   (RMP)	   exhibit	   a	   dose-­‐dependent	   activity	   against	  
Mycobacterium	   tuberculosis.	   For	   effective	   anti-­‐tuberculosis	   therapy,	   2-­‐hour	   serum	  
concentrations	   of	   INH	   3-­‐5µg/ml,	   RMP	   8-­‐24µg/ml	   and	   pyrazinamide	   (PZA)	   >35µg/ml	  
have	  been	  proposed.	  Although	  not	  optimal,	  the	  major	  tools	  at	  hand	  to	  determine	  desired	  
serum	  concentrations	  of	  an	  anti-­‐tuberculosis	  drug	   in	   children	  are	  comparative	  clinical	  
data	  from	  adults	  and	  their	  pharmacokinetic	  “optimal”	  target	  values.	  In	  order	  to	  achieve	  
serum	   concentrations	   in	   children	   comparable	   to	   those	   in	   adults	   and	   which	   are	  
correlated	  with	  efficacy,	   the	  existing	  evidence	  advocates	  the	  use	  of	  higher	  mg/kg	  body	  
weight	  doses	  of	  INH	  and	  RMP	  in	  younger	  children	  compared	  to	  adults.	  For	  PZA,	  similar	  
mg/kg	  body	  weight	  doses	  lead	  to	  PZA	  maximum	  concentrations	  (Cmax)	  similar	  to	  those	  
in	   adults.	   In	   2009,	   the	   World	   Health	   Organization	   (WHO)	   increased	   their	   dosing	  
recommendations	  and	  now	  advises	  giving	  INH	  at	  10	  mg/kg	  (range:	  7-­‐15	  mg/kg),	  RMP	  
15	   mg/kg	   (10-­‐20	   mg/kg)	   and	   PZA	   35	   mg/kg	   (30-­‐40	   mg/kg).	   Studies	   of	   the	  
pharmacokinetics	  of	  the	  first-­‐line	  agents	  in	  representative	  cohorts	  of	  children	  especially	  
in	   younger	   ages	   and	  with	   different	   genetic	   backgrounds	   are	   limited;	   these	   needed	   to	  
better	  define	  the	  doses	  appropriate	  for	  children.	  
I	  performed	  a	  pharmacokinetic	   study	  on	   the	   first-­‐line	  agents	   INH,	  RMP	  and	  PZA	   in	  20	  
children	  <2	  years	  of	  age	  (mean	  age	  1.09	  years),	  following	  the	  previous	  and	  revised	  WHO	  
dosing	   recommendations.	   Mean	   (95%	   confidence	   interval)	   Cmaxs	   [µg/ml],	   following	  
previous/revised	   doses,	   were:	   INH	   3.2	   (2.4-­‐4.0)/8.1	   (6.7-­‐9.5)µg/ml,	   PZA	   30.0	   (26.2-­‐
33.7)/47.1	   (42.6-­‐51.6)µg/ml,	   and	   RMP	   6.4	   (4.4-­‐8.3)/11.7	   (8.7-­‐14.7)µg/ml.	   The	   mean	  
(95%	   confidence	   interval)	   area	   under	   the	   time-­‐concentration	   curves	   (AUC)	   [µg⋅h/ml]	  
were:	   INH	   8.1	   (5.8-­‐10.4)/20.4	   (15.8-­‐25.0)µg∙h/ml,	   PZA	   118.0	   (101.3-­‐134.7)/175.2	  
(155.5-­‐195.0)µg∙h/ml,	   and	   RMP	   17.8	   (12.8-­‐22.8)/36.9	   (27.6-­‐46.3)µg∙h/ml.	   This	   study	  




provides	   the	   first	   evidence	   for	   the	   implementation	   of	   the	   revised	  WHO	   guidelines	   for	  
first-­‐line	  anti-­‐tuberculosis	  therapy	  in	  children	  younger	  than	  two	  years	  of	  age.	  
Because	   drug-­‐resistant	   TB	   is	   increasing	   globally,	   pharmacokinetic	   studies	   to	   guide	  
dosing	   and	   safe	   use	   of	   the	   second-­‐line	   agents	   in	   children	   have	   become	   a	   matter	   of	  
urgency.	   In	   this	   thesis,	   priority	   is	   given	   to	   the	   thioamides	   (ethionamide	   [ETH]	   and	  
prothionamide	   [PTH])	   and	   the	   3	   most	   frequently	   used	   fluoroquinolones,	   ofloxacin	  
(OFX),	  levofloxacin	  (LFX)	  and	  moxifloxacin	  (MFX).	  
By	  reviewing	  the	  literature,	  I	  have	  demonstrated	  that	  ETH	  has	  shown	  to	  be	  effective	  in	  in	  
vitro	   studies	   against	  M.	   tuberculosis	   and	   in	   combination	   with	   other	   drugs	   had	   good	  
outcome	  in	  MDR-­‐TB	  and	  tuberculous	  meningitis	  patients,	   including	  children.	  ETH/PTH	  
exhibit	  dose-­‐dependent	  activity	  and	  are	  bactericidal	  at	  higher	  doses,	  although	  dosing	  is	  
limited	  mainly	  by	  gastro-­‐intestinal	  adverse	  effects.	  During	  long-­‐term	  ETH/PTH	  therapy	  
hypothyroidism	  might	  also	  occur.	  An	  oral	  daily	  dose	  of	  ETH	  or	  PTH	  of	  15-­‐20mg/kg	  with	  
a	   maximum	   daily	   dose	   of	   1,000mg	   is	   recommended	   in	   children.	   No	   child-­‐friendly	  
formulations	  of	  the	  thioamides	  exist.	  Studies	  on	  dosing	  and	  toxicity	  of	  ETH	  and	  PTH	  in	  
childhood	  TB	  are	  needed.	  
With	   the	   first	   study	   ever	   conducted	   on	   the	   pharmacokinetics	   of	   ETH	   in	   31	   children	  
(mean	  age	  4.25	  years),	  supportive	  evidence	   for	   the	  current	  dosing	  recommendation	  of	  
ETH	  15-­‐20mg/kg	  in	  children	  with	  TB	  is	  provided.	  Mean	  Cmax	  was	  4.14μg/ml	  (range	  1.48	  
–	  6.99μg/ml)	  and	  was	  reached	  within	  two	  hours	  (mean	  tmax	  1.29h,	  range	  0.87	  –	  2.97h).	  
Young	   children	   and	   HIV-­‐infected	   children	   were	   at	   risk	   for	   lower	   ETH	   serum	  
concentrations,	   but	   the	   mean	   drug	   exposure	   was	   still	   within	   range	   of	   the	   adult	   Cmax	  
reference	  target	  (2.5µg/ml).	  	  
In	   a	   retrospective	   study	   on	   137	   children	   (median	   age	   2.9	   years)	   receiving	   anti-­‐
tuberculosis	   therapy	   including	  ETH,	  abnormal	   thyroid	   function	   tests	  were	   recorded	   in	  
79	  (58%)	  children.	  The	  risk	  for	  biochemical	  hypothyroidism	  was	  higher	  for	  children	  on	  
regimens	   including	   para-­‐aminosalicylic	   acid	   (PAS)	   and	   in	   HIV-­‐infected	   children.	   This	  
high	  frequency	  of	  thyroid	  function	  abnormalities	  in	  children	  treated	  with	  ETH	  indicates	  
the	   need	   for	   careful	   thyroid	   function	   test	   monitoring	   in	   children	   on	   long-­‐term	   ETH	  
treatment,	  especially	  in	  case	  of	  HIV	  co-­‐infection	  and	  concomitant	  use	  of	  PAS.	  




The	  literature	  review	  on	  the	  use	  of	  fluoroquinolones	  in	  childhood	  TB	  revealed	  that	  the	  
strong	   bactericidal	   and	   sterilizing	   activity,	   favourable	   pharmacokinetics,	   and	   toxicity	  
profile	  have	  made	  the	  fluoroquinolones	  the	  most	  important	  component	  of	  existing	  MDR-­‐
TB	   treatment	   regimens,	   not	   only	   in	   adults,	   but	   also	   in	   children.	   Proposed	  
pharmacodynamic	   targets	   for	   fluoroquinolones	  against	  Mycobacterium	  tuberculosis	  are	  
AUC0-­‐24/MIC	   >100	   or	   Cmax/MIC	   8-­‐10.	   In	   vitro	   and	   murine	   studies	   demonstrated	   the	  
potential	  of	  MFX	  to	  shorten	  drug-­‐susceptible	  TB	  treatment,	  but	  in	  multiple	  randomized	  
controlled	  trials	  in	  adults,	  shortened	  fluoroquinolone-­‐containing	  regimens	  have	  found	  to	  
be	  inferior	  compared	  to	  standard	  therapy.	  Resistance	  occurs	  frequently	  via	  mutations	  in	  
the	   gyrA	   gene,	   and	   emerges	   rapidly	   depending	   on	   the	   fluoroquinolone	   concentration.	  
Fluoroquinolone	   resistance	   occurs	   in	   4-­‐30%	   in	   MDR-­‐TB	   strains	   depending	   on	   the	  
region/country	  and	  setting.	  	  
Emerging	  data	  from	  paediatric	  studies	  underlines	  the	  importance	  of	  fluoroquinolones	  in	  
the	   treatment	   of	   MDR-­‐TB	   in	   children.	   There	   is	   a	   paucity	   of	   pharmacokinetic	   data	  
especially	   in	   children	   <5	   years	   of	   age	   and	  HIV-­‐infected	   children.	   Fluoroquinolone	   use	  
has	   historically	   been	   restricted	   in	   children	   due	   to	   concerns	   about	   drug-­‐induced	  
arthropathy.	  The	  available	  data	  however	  does	  not	  demonstrate	  any	  serious	  arthropathy	  
or	  other	  severe	  toxicity	  in	  children.	  	  
In	   order	   to	   fill	   the	   gap	   in	   knowledge	   on	   fluoroquinolone	   dosing	   in	   children	   with	   TB,	  
prospective,	   intensive-­‐sampling	   pharmacokinetic	   studies	   on	   OFX,	   LFX,	   and	   MFX	  
including	  assessment	  of	  cardiac	  effects	  were	  conducted.	  
In	   the	   study	   on	   the	   pharmacokinetics	   of	   OFX	   and	   LFX,	   23	   children	   (median	   age	   3.14	  
years)	  were	  enrolled;	  4	  were	  HIV-­‐infected	  (all	  >	  6	  years	  of	  age)	  and	  6	  were	  underweight-­‐
for-­‐age	  (z-­‐score	  <-­‐2).	  The	  median	  Cmax	  [µg/ml],	  median	  AUC(0-­‐8)	  [µg⋅h/ml]	  and	  mean	  tmax	  
[h]	  for	  OFX	  were:	  9.67	  (IQR	  7.09-­‐10.90),	  43.34	  (IQR	  36.73-­‐54.46)	  and	  1.61	  (SD	  0.72);	  for	  
LFX:	   6.71	   (IQR	   4.69-­‐8.06),	   29.89	   (IQR	   23.81-­‐36.39)	   and	   1.44	   (SD	   0.51),	   respectively.	  
Children	   in	   this	   study	  eliminated	  OFX	  and	  LFX	  more	   rapidly	   than	  adults,	   and	   failed	   to	  
achieve	   the	   proposed	   adult	   pharmacodynamic	   target	   of	   an	   AUC0-­‐24/MIC	   >100.	  
Nevertheless,	   the	   estimated	   pharmacodynamic	   indices	   favoured	   LFX	   over	   OFX.	   The	  
mean	   corrected	  QT	   (QTc)	  was	   361,4ms	   (SD	   37,4)	   for	  OFX	   and	   369,1ms	   (SD	   21.9)	   for	  
LFX,	  respectively	  and	  no	  QTc	  prolongation	  occurred.	  




In	  the	  study	  on	  MFX,	  23	  children	  (median	  age	  11.1	  years)	  were	  included;	  6/23	  (26.1%)	  
were	  HIV-­‐infected.	  The	  median	  (IQR)	  Cmax	  [µg/ml],	  AUC(0-­‐8)	  [µg⋅h/ml],	  tmax	  [h]	  and	  half-­‐
life	   for	  MFX	  were:	   3.08	   (2.85-­‐3.82),	   17.24	   (14.47-­‐21.99),	   2.0	   (1.0-­‐8.0);	   and	   4.14	   (IQR	  
3.45-­‐6.11),	  respectively.	  AUC0-­‐8	  was	  reduced	  by	  6.85μg∙h/ml	  (95%	  CI	  11.15-­‐2.56)	  in	  HIV-­‐
infected	   children.	   tmax	   was	   shorter	   with	   crushed	   versus	   whole	   tablets	   (p=0.047).	   	   In	  
conclusion,	   children	   7-­‐15	   years	   of	   age	   have	   low	   serum	   concentration	   compared	  with	  
adults	  receiving	  400mg	  MFX	  daily.	  MFX	  was	  well	  tolerated	  in	  children	  treated	  for	  MDR-­‐
TB.	  The	  mean	  corrected	  QT-­‐interval	  was	  403ms	  (SD	  30ms)	  and	  as	  for	  OFX	  and	  LFX,	  no	  
prolongation	  >450ms	  occurred.	  
In	   conclusion,	   my	   research	   identified	   and	   addressed	   critical	   gaps	   in	   the	   current	  
knowledge	   in	   the	   management	   of	   children	   with	   both	   drug-­‐susceptible	   and	   drug-­‐
resistant	  TB.	   I	   provided	   essential	   evidence	  on	  both	   the	  dosing	   and	   safety	  of	   first-­‐	   and	  
second-­‐line	   anti-­‐tuberculosis	   agents,	   informing	   international	   treatment	   guidelines	   for	  
childhood	  TB.	  Nevertheless,	  more	  studies	  in	  a	  larger	  number	  of	  children	  with	  different	  
genetic	   backgrounds,	   HIV	   co-­‐infection	   nutritional	   status	   and	   with	   higher	   drug	   doses,	  
novel	   treatment	   regimens	   and	   child-­‐friendly	   formulations	   are	   needed	   to	   further	  
optimize	  anti-­‐tuberculosis	  treatment	  in	  children.	  
	   	  






Die	   globale	   lading	   van	   tuberkulose	   (TB)	   in	   kinders	   is	   hoog,	   met	   ‘n	   hoë	   TB-­‐verwante	  
morbiditeit	   en	   mortaliteit,	   veral	   onder	   jong	   en	   MIV-­‐geïnfekteerde	   kinders.	   Die	  
toenemende	   epidemie	   van	  multimiddel-­‐weerstandige	   (MMW)-­‐TB	  hou	   ‘n	   bedreiging	   in	  
vir	   kinders,	   terwyl	   inligting	   oor	   die	   gebruik	   van	   tweede-­‐linie	  middels	   in	   kinders	   tans	  
baie	  beperk	  is.	  
Deur	  middel	  van	  ‘n	  oorsig	  van	  die	  literatuur	  oor	  eerste-­‐linie	  antituberkulose	  middels	  is	  
aangetoon	   dat	   isoniasied	   (INH)	   en	   rifampisien	   (RMP)	   ‘n	   dosisverwante	   aksie	   teen	  
Mycobacterium	   tuberculosis	   uitoefen.	   Vir	   effektiewe	   TB	   behandeling	   is	   2-­‐uur	  
serumkonsentrasies	   van	   INH	   3-­‐5μg/ml,	   RMP	   8-­‐24μg/ml	   en	   pirasienamied	   (PZA)	   van	  
>35μg/ml	  voorgestel.	  Alhoewel	  nie	  optimaal	  nie,	   is	  die	  voor-­‐die-­‐hand-­‐liggende	  manier	  
om	   die	   verlangde	   serumkonsentrasies	   van	   ‘n	   antituberkulose	   middel	   in	   kinders	   te	  
bepaal	   die	   vergelykbare	   kliniese	   data	   in	   volwassenes	   en	   hulle	   farmakokinetiese	  
“optimale”	   teikenwaardes.	   	  Om	  serumkonsentrasies	   in	  kinders	  gelykstaande	  aan	  dié	   in	  
volwassenes	  en	  met	  ooreenstemmende	  effektiwiteit	  te	  bereik,	  toon	  die	  beskikbare	  data	  
dat	  hoër	  mg/kg	   liggaamsmassa	  dosisse	  vir	   INH	  en	  RMP	   in	   jong	  kinders	   in	  vergelyking	  
met	  volwasse	  dosisse	  gegee	  behoort	  te	  word.	  Met	  PZA	  sal	  soortgelyke	  mg/kg	  dosisse	  per	  
liggaamsmassa	   in	   kinders	   lei	   tot	   soortgelyke	   maksimum	   konsentrasies	   (Cmax)	   in	  
volwassenes.	   In	   2009	   het	   die	   Wêreld	   Gesondheidsorganisasie	   (WGO)	   hulle	   dosis-­‐
aanbevelings	   verhoog,	   en	   tans	   beveel	   die	   WGO	   INH	   teen	   10mg/k	   (reikwydte	   7-­‐15	  
mg/kg),	   RMP	   15mg/kg	   (10-­‐20	   mg/kg)	   en	   PZA	   teen	   35mg/kg	   (30-­‐40	   mg/kg)	   aan	   in	  
kinders.	  Studies	  oor	  die	  farmakokinetika	  van	  die	  eerste-­‐linie	  antituberkulose	  middels	  in	  
verteenwoordigende	  groepe	  van	  kinders,	  veral	   in	  die	   jonger	  ouderdomsgroepe	  en	  met	  
verskillende	  genetiese	  agtergronde	  is	  beperk;	  sulke	  studies	  word	  dringend	  benodig	  om	  
toepaslike	  dosisse	  vir	  kinders	  met	  TB	  beter	  te	  definieer.	  
Ek	  het	   ‘n	   farmakokinetiese	   studie	  van	  die	  eerste-­‐linie	  middels	   INH,	  RMP	  en	  PZA	   in	  20	  
kinders	   <2	   jaar	   oud	   (gemiddelde	   ouderdom	   1.09	   jaar)	   volgens	   die	   vorige	   en	   huidige	  
WGO	  doseringsriglyne	  uitgevoer.	  Die	  gemiddelde	  (95%	  vertroue	  interval)	  Cmax	  [μg/ml]	  
volgens	  vorige/huidige	  doseringsriglyne	  was:	  INH	  3.2	  (2.4-­‐4.0)/8.1	  (6.7-­‐9.5)µg/ml,	  PZA	  
30.0	   (26.2-­‐33.7)/47.1	   (42.6-­‐51.6)µg/ml,	   and	   RMP	   6.4	   (4.4-­‐8.3)/11.7	   (8.7-­‐14.7)µg/ml.	  
Die	   gemiddelde	   (95%	   vertroue	   interval)	   oppervlakte	   onder	   die	   tyd-­‐konsentrasie	  
kromme	   (AUC)	   [µg⋅h/ml]	  was:	   INH	  8.1	   (5.8-­‐10.4)/20.4	   (15.8-­‐25.0)µg∙h/ml,	   PZA	  118.0	  




(101.3-­‐134.7)/175.2	   (155.5-­‐195.0)µg∙h/ml,	   and	   RMP	   17.8	   (12.8-­‐22.8)/36.9	   (27.6-­‐
46.3)µg∙h/ml.	   Hierdie	   studie	   voorsien	   die	   eerste	   bewyse	   vir	   die	   toepassing	   van	   die	  
hersiene	  WGO-­‐riglyne	  vir	  eerste-­‐linie	  antituberkulose	  behandeling	  in	  kinders	  jonger	  as	  
twee	  jaar	  oud.	  
Omdat	   middelweerstandige	   TB	   wêreldwyd	   aan	   die	   toeneem	   is,	   het	   studies	   oor	   die	  
farmakokinetika	   en	   veiligheid	   van	   die	   gebruik	   van	   tweede-­‐linie	   middels	   in	   kinders	  
‘dringend	   nodig	   geword.	   In	   hierdie	   verhandeling	   word	   voorkeur	   gegee	   aan	   die	  
tioamiede	   (etionamied	   [ETH]	   en	   protionamied	   [PTH])	   en	   die	   drie	   mees	   algemeen	  
gebruikte	   fluorokwinolone,	   ofloksasien	   [OFX],	   levofloksasien	   [LFX]	   en	  moksifloksasien	  
[MFX].	  
Deur	   ‘n	  oorsig	   van	  die	   literatuur	  het	   ek	   aangetoon	  dat	  ETH	   in	   in	   vitro	   studies	   teen	  M.	  
tuberculosis	  effektief	   is	  en	   in	  kombinasie	  met	  ander	  middels	  goeie	  uitkomste	   in	  MMW-­‐
TB	   en	   tuberkuleuse	  meningitis,	   insluitend	   kinders,	   het.	   ETH/PTH	   toon	   dosisverwante	  
aktiwiteit	   en	   is	  bakteriedodend	   teen	  hoër	  dosisse,	   alhoewel	  dosering	  hoofsaaklik	  deur	  
gastrointestinale	   newe-­‐effekte	   beperk	   word.	   Tydens	   langtermyn	   behandeling	   met	  
ETH/PTH	  kan	  hipotireose	  ook	  voorkom.	  ‘n	  Daaglikse	  mondelingse	  dosis	  van	  ETH	  of	  PTH	  
van	   15-­‐20mg/kg	   met	   ‘n	   maksimum	   daaglikse	   dosis	   van	   1,000	   mg	   word	   vir	   kinders	  
aanbeveel.	   Daar	   bestaan	   tans	   geen	   kindervriendelike	   formulerings	   vir	   die	   tioamiedes	  
nie.	  	  
Met	  die	   eerste	   studie	   ooit	  wat	  handel	   oor	  die	   farmakokinetika	   van	  ETH	   in	  31	  kinders	  
(gemiddelde	   ouderdom	   4.25	   jaar),	   verleen	   ek	   	   ondersteunende	   bewys	   vir	   die	   huidig	  
aanbevole	  dosis	  van	  ETH	  	  van15-­‐20mg/kg	  in	  kinders	  met	  TB..	  Die	  gemiddelde	  ETH	  Cmax	  
was	  4.14μg/ml	  (reikwydte	  1.48-­‐6.99μg/ml)	  en	  hierdie	  konsentrasie	  was	  binne	  twee	  ure	  
(gemiddelde	   tmax	   1.29h,	   reikwydte	   0.87-­‐2.97h)	   bereik.	   Jong	   en	   MIV-­‐geïnfekteerde	  
kinders	   het	   geneig	   om	   laer	   ETH	   konsentrasies	   te	   toon,	   maar	   die	   gemiddelde	  
middelblootstelling	   was	   steeds	   binne	   die	   reikwydte	   van	   die	   volwasse	   Cmax	   teiken	  
(2.5μg/ml).	  
In	   ‘n	   retrospektiewe	   studie	   van	   137	   kinders	   (gemiddelde	   ouderdom	   2.9	   jaar)	   wat	  
antituberkulose	   behandeling	   insluitende	   ETH	   ontvang	   het,	   is	   abnormale	  
tiroïedfunksietoetse	   in	   79	   (58%)	   kinders	   gedokumenteer.	   Die	   risiko	   vir	   biochemiese	  
hipotireose	   was	   hoër	   in	   kinders	   op	   behandeling	   wat	   para-­‐aminosalisielsuur	   (PAS)	  
ingesluit	   het,	   asook	   in	   MIV-­‐geïnfekteerde	   kinders.	   Hierdie	   hoë	   voorkoms	   van	  




tiroïedfunksie	   abnormaliteite	   in	   kinders	   wat	   ETH	   behandel	   ontvang	   het,	   dui	   op	   die	  
belang	  	  van	  die	  versigtige	  monitering	  van	  tiroïedfunksietoetse	  in	  kinders	  op	  langtermyn	  
ETH	  behandeling,	  veral	  in	  die	  geval	  van	  MIV	  ko-­‐infeksie	  en	  met	  meegaande	  gebruik	  van	  
PAS.	  
Die	   literatuuroorsig	  oor	  die	   gebruik	   van	   fluorokwinolone	   in	  kindertuberkulose	  het	  dit	  
duidelik	   gemaak	   dat	   die	   sterk	   bakteriedodende	   effek,	   gunstige	   farmakokinetika	   en	  
toksisteitsprofiel	   die	   fluorokwinolone	   die	   belangrikste	   deel	   van	   die	   huidige	  MMW-­‐TB	  
behandeling	   gemaak	   het,	   nie	   alleen	   in	   volwassenes	   nie,	   maar	   ook	   in	   kinders.	  
Voorgestelde	  farmakodinamiese	  teikens	  vir	  die	  fluorokwinolone	  teen	  M.	  	  tuberculosis	  is	  
AUC0-­‐24/MIC	  >100	  of	  Cmax/MIC	  8-­‐10.	  In	  vitro	  en	  muisstudies	  het	  die	  potensiaal	  van	  MFX	  
om	  die	  behandeling	  van	  middelsensitiewe	  TB	  te	  verkort,	  aangetoon,	  maar	  in	  veelvuldige	  
ewekansig-­‐gekontroleerde	   studies	   in	   volwassenes	   het	   verkorte	   fluorokwinoloon-­‐
bevattende	   regimens	   egter	   geblyk	   om	   minderwaardig	   te	   wees	   in	   vergelyking	   met	  
huidige	  standaardbehandeling.	  Weerstandigheid	  kom	  dikwels	  via	  mutasies	  in	  die	  gyrA-­‐
gene	   voor	   en	   kom	   vining	   na	   vore	   afhangend	   van	   die	   fluorokwinoloonkonsentrasie.	  
Fluorokwinoloon-­‐weerstandigheid	   kom	   voor	   in	   4-­‐30%	   van	   MMW-­‐TB	   stamme,	  
afhangend	  van	  die	  konteks	  en	  streek.	  	  
Data	  van	  kinders	  wat	  na	  vore	  kom	  versterk	  die	  belang	  van	  die	   fluorokwinolone	   in	  die	  
behandeling	  van	  kindertuberkulose.	  Daar	  is	  veral	  ‘n	  tekort	  aan	  farmakokinetiese	  data	  in	  
kinders	  <5	  jaar	  oud	  en	  in	  MIV-­‐geïnfekteerde	  kinders.	  Die	  gebruik	  van	  fluorokwinolone	  
in	  kinders	  is	  geskiedkundig	  beperk	  as	  gevolg	  van	  besorgdheid	  oor	  middel-­‐geïnduseerde	  
gewrigsaantasting.	   Die	   beskikbare	   inligting	   dui	   egter	   nie	   op	   enige	   erge	  
gewrigsaantasting	  of	  enige	  ander	  erge	  toksisiteit	  in	  kinders	  nie.	  
Ten	  einde	  die	  gaping	  in	  kennis	  oor	  die	  dosering	  van	  fluorokwinolone	  in	  kinders	  met	  TB	  
te	  vul,	  is	  ‘n	  prospektiewe,	  intensiewe-­‐monsterneming	  farmakokinetiese	  studies	  oor	  OFX,	  
LFX	  en	  MFX,	  insluitend	  evaluering	  van	  kardiotoksiese	  effekte,	  uitgevoer.	  
In	  die	  studie	  oor	  die	  farmakokinetika	  van	  OFX	  en	  LFX	  is	  23	  kinders	  (mediane	  ouderdom	  
3.14	  jaar)	  ingesluit;	  4	  was	  MIV-­‐geïnfekteer	  (almal	  >6	  jaar	  oud)	  en	  6	  was	  ondergewig-­‐vir-­‐
ouderdom	   (z-­‐telling	   <-­‐2).	   Die	   mediane	   Cmax	   [μg/ml],	   mediane	   AUC0-­‐8	   [µg⋅h/ml]	   en	  
gemiddelde	   tmax	   [h]	   vir	   OFX	   was:	   9.67	   (interkwartielreikwydte	   IKR	   4.69-­‐8.06),	   43.34	  
(IKR	  36.73-­‐54.46)	   en	  1.61	   (SD	  0.72);	   vir	   LFX:	   6.71	   (IKR	  4.69-­‐8.06),	   29.89	   (IKR	  23.81-­‐
36.39)	   en	   1.44	   (SD	   0.51),	   onderskeidelik.	   Kinders	   in	   hierdie	   studie	   het	   OFX	   en	   LFX	  




vinniger	   as	   volwassenes	  uigeskei	   en	  het	   nie	   daarin	   geslaag	   om	  voorgestelde	   volwasse	  
farmakodinamiese	   teikens	   van	   AUC0-­‐24/MIC	   >100	   te	   behaal	   nie.	   Nogtans	   was	   die	  
berekende	   farmakodinamiese	   indekse	   ten	   gunste	   van	   LFX	   bo	   OFX.	   Die	   gemiddelde	  
gekorrigeerde	  QT-­‐interval	  (QTc)	  was	  361.4ms	  (SD	  37.4)	  vir	  OFX	  en	  369.1ms	  (SD	  21.9)	  
vir	  LFX,	  onderskeidelik,	  en	  geen	  verlenging	  van	  QTc-­‐interval	  het	  voorgekom	  nie.	  
In	   die	   studie	   oor	  MFX	  was	   23	   kinders	   (mediane	   ouderdom	   11.1	   jaar)	   ingesluit;	   6/23	  
(26.1%)	  was	  MIV-­‐geïnfekteerd.	  Die	  mediane	   (IKR)	  Cmax	   [μg/ml],	  AUC0-­‐8	   [µg⋅h/ml],	   tmax	  
[h]	   en	   half-­‐lewe	   van	  MFX	  was:	   3.08	   (2.85-­‐3.82),	   17.24	   (14.47-­‐21.99),	   2.0	   (1.0-­‐8.0)	   en	  
4.14	   (3.45-­‐6.11),	   onderskeidelik.	   Die	   AUC0-­‐8	   was	   met	   6.85µg⋅h/ml	   (95%	  
vertrouensinterval	   11.15-­‐2.56)	   verminder	   in	   MIV-­‐geïnfekteerde	   kinders.	   Die	   tmax	   was	  
korter	  met	  fyngemaakte	  teenoor	  heel	  tablette	  (p=0.047).	  Ter	  samevatting,	  kinders	  7-­‐15	  
jaar	  oud	  het	   lae	   serumkonsentrasies	   in	   vergelyking	  met	  volwassenes	  wat	  400mg	  MFX	  
per	   dag	   ontvang,	   getoon.	   	   MFX	   was	   goed	   verdra	   in	   kinders	   met	   MMW-­‐TB.	   Die	  
gemiddelde	  QTc-­‐interval	  was	  403ms	  (SD	  30ms).	  Soos	  in	  die	  geval	  van	  OFX	  en	  LFX,	  het	  
geen	  verlenging	  >450ms	  voorgekom	  nie.	  
Ter	   samevatting	   spreek	   	   my	   navorsing	   kritiese	   gapings	   in	   die	   hudige	   kennis	   oor	   die	  
hantering	  van	  kinders	  met	  middelsensitiewe	  en	  middelweerstandige	  TB	  aan..	  Ek	  verskaf	  
belangrike	   bewyse	   oor	   beide	   die	   dosering	   en	   veiligheid	   van	   eerste-­‐	   en	   tweede-­‐linie	  
antituberkulose	  middels,	  	  wat	  internasionale	  behandelingsriglyne	  vir	  kindertuberkulose	  
toegelig	   het.	   Nogtans	   is	   verdere	   studies	   met	   groter	   getalle	   kinders	   uit	   verskillende	  
genetiese	   agtergronde,	   MIV	   ko-­‐infeksie,	   voedingstatus,	   en	   met	   hoër	   doserings	   van	  
antituberkulose	   middels,	   nuwe	   behandelingsregimens	   en	   kindervriendelike	  
formulerings	  nodig	  om	  die	  behandeling	  van	  tuberkulose	  in	  kinders	  verder	  te	  verbeter.	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Burden	  of	  childhood	  tuberculosis	  
Tuberculosis	  (TB)	  remains	  a	  major	  global	  health	  problem,	  particularly	  in	  the	  developing	  
countries	   of	   sub-­‐Saharan	   Africa	   and	   Asia.	   The	   World	   Health	   Organization	   (WHO)	  
estimated	  that	  in	  2013	  there	  were	  550,000	  new	  cases	  of	  TB	  in	  children	  <15	  years	  of	  age	  
and	  80,000	  deaths	  from	  TB	  in	  HIV-­‐negative	  children	  (1).	  Children	  account	  for	  up	  to	  15-­‐
20%	  of	  TB	  cases	  in	  high-­‐burden	  countries	  and	  this	  proportion	  may	  reach	  40%	  in	  some	  
communities	   (2).	   South	  Africa	   has	   one	   of	   the	   highest	   TB	   notification	   rates	  worldwide	  
with	   328,896	   cases	   registered	   in	   2013	   and	   an	   estimated	   notification	   rate	   of	   860	   per	  
100,000	  (1).	  WHO	  estimates	   for	  paediatric	  TB	   likely	  underestimate	   the	   true	  burden	  of	  
childhood	  TB	  due	   to	   diagnostic	   challenges	   and	  poor	   recording	   and	   reporting	   of	   TB	   in	  
children	   (3,	   4).	   Using	   a	   mathematical	   model	   based	   on	   the	   22	   WHO-­‐classified	   high-­‐
burden	   TB	   countries	   in	   2010,	   Dodd	   et	   al.	   estimated	   that	   approximately	   7.6	   million	  
children	   became	   infected	   with	  Mycobacterium	   tuberculosis	   and	   that	   650,000	   children	  
developed	   TB	   disease	   with	   an	   estimated	   case	   detection	   rate	   of	   only	   35%	   in	   these	  
countries	  (5).	   In	  the	  Western	  Cape	  Province,	  South	  Africa,	  childhood	  TB	  (0-­‐14	  years	  of	  
age)	   contributed	   to	   approximately	   14%	  of	   the	   total	   disease	   burden	   in	   2004,	   rising	   to	  
17.3%	  in	  2008,	  with	  an	  annual	  notification	  rate	  of	  407	  versus	  620	  childhood	  TB	  cases	  
per	  100,000	   respectively	   (6)	   (unpublished	  Data,	  Western	  Cape	  Department	  of	  Health)	  
with	   emerging	   drug-­‐resistant	   (DR)-­‐TB	   amongst	   children	   as	   an	   important	   additional	  
challenge.	  
The	   global	   threat	   of	   TB	   is	   further	   aggravated	   by	   the	   spread	   of	   DR-­‐TB.	   Multidrug-­‐
resistant	  (MDR)-­‐TB	  is	  defined	  as	  M.	  tuberculosis	  resistant	  to	  at	  least	  the	  first-­‐line	  drugs	  
isoniazid	   (INH)	   and	   rifampicin	   (RMP),	   while	   extensively	   drug-­‐resistant	   (XDR)-­‐TB	  
involves	   additional	   resistance	   to	   any	   fluoroquinolone	   and	   any	   of	   the	   second-­‐line	   anti-­‐
tuberculosis	  injectable	  drugs.	  WHO	  estimated	  that	  480,000	  patients	  developed	  MDR-­‐TB	  
in	   2013,	   with	   only	   about	   20%	   (97,000)	   of	   cases	   receiving	   appropriate	   treatment	   (1).	  
Failure	   to	   treat	   infectious	   (adult)	   MDR-­‐TB	   cases	   facilitates	   ongoing	   transmission	   and	  
exposes	  vulnerable	  young	  children	  to	  infection	  with	  MDR-­‐TB	  strains	  (7).	  In	  contrast	  to	  




adults,	  in	  whom	  drug	  resistance	  results	  from	  both	  acquisition	  and	  transmission,	  children	  
with	  MDR-­‐TB	  usually	  have	   transmitted	   (primary)	   resistance,	   as	   it	   is	  more	  difficult	   for	  
children	   to	   acquire	   drug	   resistance	   due	   to	   the	   paucibacillary	   nature	   of	   TB	   disease	   in	  
children.	   In	   addition,	   the	  practical	   challenges	  of	   obtaining	   respiratory	   specimens	   from	  
young	   children	   add	   to	   the	   typical	   low	   bacteriologic	   (culture/molecular	   tests)	   yield	  
achieved	   in	   children	   with	   pulmonary	   TB	   of	   20-­‐40%	   (8).	   Without	   bacteriological	  
confirmation,	   drug	   susceptibility	   testing	   (DST)	   cannot	   be	   performed	   and	   confirmed	  
MDR-­‐TB	   is	   therefore	   infrequent	   in	   children	   (9).	   Model-­‐based	   estimates	   suggest	   that	  
32,000	  children	  had	  MDR-­‐TB	   in	  2010	  (3).	  New	  molecular	  diagnostic	   tools,	   such	  as	   the	  
Xpert	   MTB/RIF	   may	   increase	   the	   number	   of	   MDR-­‐TB	   cases	   detected	   in	   adults	   and	  
children,	   increasing	   the	   number	   of	   children	   needing	   MDR-­‐TB	   treatment.	   In	   Southern	  
Africa,	   the	   spread	   of	   MDR-­‐TB	   and	   outbreaks	   of	   XDR-­‐TB	   have	   caused	   considerable	  
concern	   and	   drug	   resistance	   is	   now	   also	   a	   significant	   problem	   amongst	   children.	   In	   a	  
recent	   surveillance	  study	  of	   children	  0-­‐13	  years	  with	  culture-­‐confirmed	  TB	   from	  Cape	  
Town,	  MDR-­‐TB	  was	  found	  in	  7.1%	  of	  all	  patients;	  21.9%	  of	  the	  children	  were	  also	  HIV-­‐
infected	  (10).	  
Despite	  available	  treatment,	  TB	  is	  amongst	  the	  10	  major	  causes	  of	  childhood	  mortality	  in	  
developing	   countries	   as	   young	   children	   have	   an	   increased	   risk	   of	   severe,	   rapidly	  
progressive	  forms	  of	  TB,	  a	  tendency	  exacerbated	  by	  the	  epidemic	  spread	  of	  HIV	  infection	  
(6,	  11,	  12).	  
Without	  preventive	  therapy	  intervention,	  infants	  (<12	  months	  of	  age)	  have	  a	  risk	  of	  up	  
to	  50%	  of	  developing	  TB	  disease	  following	  primary	  infection	  with	  M.tuberculosis,	  with	  a	  
high	   proportion	   of	   disseminated	   forms	   of	   disease,	   such	   as	   miliary	   TB	   or	   tuberculous	  
meningitis	   (TBM)	   even	   in	   the	   absence	   of	   HIV	   infection	   (13).	   Adult-­‐type	   disease	   with	  
cavities	  and	  a	  high	  bacterial	   load	  is	  a	  phenomenon	  that	  appears	  around	  puberty	  (from	  
about	  8	  years	  of	  age),	  probably	  due	   to	   inappropriate	   containment	  of	  a	   recent	  primary	  
infection	  (14).	  
HIV	  infection	  and	  tuberculosis	  
HIV	  infection	  not	  only	  increases	  the	  risk	  of	  acquiring	  infection	  with	  M.	  tuberculosis	  after	  
exposure,	  but	  also	  the	  risk	  to	  progress	  rapidly	  from	  primary	  infection	  to	  TB	  disease	  and	  
to	   develop	   re-­‐activation	   of	   latent	   TB	   infection	   (15).	   Compared	   to	   HIV-­‐uninfected	  
children,	  HIV-­‐infected	  children	  have	  greater	  morbidity	  and	  mortality	  from	  TB,	  especially	  




in	  the	  absence	  of	  antiretroviral	  therapy	  (ART)	  (12,	  16-­‐18).	  Initiation	  of	  ART	  reduces	  the	  
number	  of	  TB	  cases	  in	  children	  substantially	  (12).	  
Reduced	  plasma	  concentrations	  of	  several	  anti-­‐tuberculosis	  drugs	  have	  been	  reported	  in	  
HIV-­‐infected	  adults	  and	  children	  and	  have	  been	  attributed	  to	  malabsorption	  caused	  by	  
drug-­‐drug	  interactions,	  diarrhea	  and/or	  concurrent	  gastro-­‐intestinal	  infections	  (19-­‐24).	  
Reduced	   drug	   exposure	   has	   been	   associated	   with	   worse	   treatment	   outcome	   and	   the	  
development	  of	  drug	  resistance	  in	  adult	  studies	  (23,	  24).	  
Plasma	   concentrations	   of	   several	   antiretroviral	   agents	   are	   reduced	   if	   co-­‐administered	  
with	  RMP.	  RMP	   is	   a	   potent	   inducer	   of	   CYP450	   system	  and	  P-­‐glycoprotein	   resulting	   in	  
decreased	   plasma	   concentration	   of	   protease	   inhibitors	   and	   non-­‐nucleoside	   reverse	  
transcriptase	   inhibitors.	   RMP	   also	   leads	   to	   an	   upregulation	   of	   UDP-­‐
glucuronosyltransferase,	  an	  enzyme	  metabolizing	  integrase	  inhibitors	  (25,	  26).	  In	  adult	  
HIV-­‐infected	   patients	   with	   TB,	   co-­‐trimoxazole	   prophylaxis	   was	   associated	   with	   an	  
increase	   in	   INH-­‐half-­‐life,	   possibly	   due	   to	   competitive	   interactions	   between	   INH	   and	  
sulphamethoxazole	  in	  the	  N-­‐acetyltransferase	  pathway	  (27).	  
	  
Preventive	  anti-­‐tuberculosis	  therapy	  
Following	   infection	  with	  DS-­‐TB,	   INH	  preventive	   therapy	   (IPT)	  given	   for	  6-­‐9	  months	   is	  
the	  most	  commonly	  recommended	  preventive	  regimen	  (28,	  29).	   It	  reduces	  the	  risk	  for	  
TB	  disease	  in	  exposed	  children	  by	  at	  least	  two-­‐thirds,	  probably	  by	  more	  than	  90%	  in	  the	  
presence	   of	   good	   adherence	   (30).	   Based	   on	   the	   high	   risk	   of	   TB	   disease	   progression	  
following	   infection	   with	  M.	   tuberculosis,	   the	  WHO	   and	   the	   South	   African	   National	   TB	  
programme	  (SANTP)	  recommend	  contact	  investigation	  and	  treatment	  of	  M.	  tuberculosis	  
exposure/infection	   in	   children	   less	   than	   5	   years	   of	   age	   and	   all	   HIV-­‐infected	   children	  
irrespective	   of	   age	   in	   contact	   with	   an	   infectious	   TB	   case	   (28,	   29).	   Alternatively,	   a	  
combination	  therapy	  of	  INH	  and	  RMP	  given	  for	  3	  months	  has	  shown	  comparable	  efficacy	  
in	   the	   prevention	   of	   disease	   after	   infection	   with	  M.	   tuberculosis	   (31).	   A	   once	   weekly	  
administration	  of	  rifapentine	  and	  INH	  as	  preventive	  treatment	  in	  children	  2	  to	  17	  years	  
of	   age	   has	   very	   recently	   been	   investigated	   and	   showed	  non-­‐inferiority	   compared	   to	   9	  
months	  of	  INH	  only	  (32).	  	  
	  




Therapy	  of	  drug-­‐susceptible	  and	  drug-­‐resistant	  tuberculosis	  
The	  first-­‐line	  anti-­‐tuberculosis	  drugs	  INH,	  RMP	  and	  pyrazinamide	  (PZA)	  with	  or	  without	  
ethambutol	  (EMB)	  form	  the	  backbone	  of	  anti-­‐tuberculosis	  treatment	  in	  all	  types	  of	  DS-­‐
TB	   and	   are	   routinely	   prescribed	   in	   children	   with	   TB	   disease	   (28,	   33).	   The	   overall	  
treatment	  success	  rate	  (cure	  or	  treatment	  completion)	  in	  children	  with	  TB	  is	  reported	  to	  
be	  between	  72-­‐93%,	  while	  young	  age,	  extrapulmonary	  TB	  and	  HIV	  infection	  are	  related	  
with	  poor	  treatment	  outcome	  (34-­‐36).	  	  
While	   there	   is	  extensive	  knowledge	  on	  the	  mode	  of	  action,	  efficacy	  and	  safety	  of	   these	  
first-­‐line	   agents,	   information	   on	   their	   pharmacokinetics	   in	   paediatric	   TB,	   especially	   in	  
young	   and	   HIV-­‐infected	   children,	   is	   lacking.	   Therefore	   TB	   treatment	   guidelines	   for	  
children	  are	  largely	  inferred	  from	  adult	  data	  (37,	  38).	  	  
I	   hypothesized	   that	   there	   is	   insufficient	   data	   to	   guide	   the	   appropriate	   use	   of	   first-­‐line	  
anti-­‐tuberculosis	   agents	   in	  HIV-­‐infected	  and	  –uninfected	   children	  with	  TB.	   In	  order	   to	  
address	   this	   question,	   I	   performed	   a	   literature	   review	   on	   their	   use	   in	   childhood	   TB	  
focusing	  on	  pharmacokinetcs	  and	  safety	  (chapter	  2).	  	  
	  
Pharmacokinetic	  considerations	  of	  anti-­‐tuberculosis	  therapy	  in	  children	  
For	   optimal	   dose	   finding,	   characteristics	   particular	   to	   children	   have	   to	   be	   considered	  
which	   may	   have	   an	   influence	   on	   pharmacokinetics.	   During	   growth,	   children	   undergo	  
profound	  developmental	  changes	  in	  absorption,	  distribution,	  metabolism	  and	  excretion	  
of	  a	  drug	  (39-­‐41).	  These	  changes	  are	  greatest	  within	  the	  first	  year	  of	  life	  (39,	  42).	  Only	  
by	  the	  age	  of	  8	  years,	  organ	  function	  and	  body	  composition	  approximate	  that	  of	  young	  
adults	  (40).	  Dosing	  according	  to	  body	  surface	  area	  has	  been	  suggested,	  but	  never	  been	  
studied	   in	   a	   larger	   paediatric	   population	   (43,	   44).	   Allometric	   scaling	   has	   also	   been	  
proposed	  to	  predict	  clearance	  in	  children,	  but	  has	  shown	  substantial	  potential	  for	  error	  
in	  children	  less	  than	  5	  years	  of	  age	  (45).	  	  
Because	   of	   the	   complexity	   of	   current	   drug	   regimens	   against	   TB,	   it	   is	   challenging	   to	  
evaluate	   efficacy	   against	   the	   serum	   concentration	   of	   a	   single	   drug.	   In	   children,	  
evaluation	   is	   even	   more	   complicated,	   because	   of	   the	   lack	   of	   reliable	   parameters	   to	  
measure	  microbiological	  and	  clinical	  outcome.	  In	  adults,	  reduction	  of	  the	  bacterial	  load	  




in	  sputum	  and/or	  culture	  negativity	  is	  used	  as	  surrogate	  markers	  for	  treatment	  success.	  
However,	  these	  parameters	  are	  not	  feasible	  in	  children,	  due	  to	  the	  paucibacillary	  nature	  
of	  most	  TB	  disease	  in	  children.	  Thus,	  the	  major	  tools	  at	  hand	  to	  determine	  desired	  blood	  
concentrations	   of	   an	   anti-­‐tuberculosis	   drug	   in	   children	   are	   comparative	   clinical	   data	  
from	   adults	   and	   their	   pharmacokinetic	   “optimal”	   target	   values.	   The	   validity	   of	   the	  
currently	  proposed	   targets	   is	   a	   subject	  of	   ongoing	  debate,	   especially	   for	  RMP	   (46,	  47)	  
and	   doses	   of	   the	   latter	   might	   be	   increased	   in	   the	   foreseeable	   future.	   Additionally,	  
different	   TB	   disease	   types	   (e.g.	   TB	  meningitis)	   may,	   however	   need	   different	   (higher)	  
doses	   to	   achieve	   adequate	   drug	   concentrations	   at	   the	   site	   of	   infection	   (48,	   49).	  
Notwithstanding	   these	   limitations,	   there	   is	   now	   good	   evidence	   that	   using	   the	   same	  
mg/kg	  body	  weight	  doses	  of	   some	   first-­‐line	  agents	   leads	   to	   children	  being	  exposed	   to	  
considerably	   lower	  concentrations	  of	  anti-­‐tuberculosis	  agents	  compared	  to	  adults,	  and	  
that	  doses	  of	  anti-­‐tuberculosis	  drugs	  in	  children	  need	  to	  be	  increased	  to	  yield	  the	  same	  
exposure	  and	  drug	  concentrations	  as	  in	  adults	  (44,	  50-­‐55).	  Based	  on	  a	  recent	  systematic	  
literature	   review	   and	   expert	   consultation,	   the	   WHO	   has	   issued	   revised	   dose	  
recommendations	  in	  September	  2009	  for	  the	  dosing	  of	  children	  with	  first-­‐line	  TB	  drugs	  
(56).	  These	  recommended	  doses	  are	  considerably	  higher	  than	  previously	  recommended	  
for	   TB	   treatment	   in	   children,	   and	   are	   as	   follows,	   according	   to	   body	   weight:	   INH	   10	  
versus	  5	  mg/kg/day,	  RMP	  15	  versus	  10	  mg/kg/day,	  PZA	  35	  versus	  25	  mg/kg/day	  and	  
EMB	   20	   versus	   15	  mg/kg/day.	   There	   is	   no	   data	   whether	   these	   recommendations	   on	  
higher	  doses	  are	  also	  appropriate	  in	  children	  less	  than	  2	  years	  of	  age,	  as	  the	  maturation	  
of	   enzyme	   systems	   is	   still	   ongoing	   in	   the	   first	   two	   years	   of	   life	   (especially	   infants	   i.e.	  
younger	  than	  12	  months	  of	  age).	  Serum	  concentrations	  in	  this	  age	  group	  may	  therefore	  
be	  different	  (higher	  or	  lower)	  than	  in	  older	  children	  or	  adults	  receiving	  the	  same	  mg/kg	  
body	  weight	  dose.	   In	  order	  to	  create	  evidence	  for	  optimal	  dosing	  of	   first-­‐line	  agents	   in	  
this	  age	  group,	   I	  performed	  a	  prospective	  pharmacokinetic	  study	   in	  HIV-­‐infected	  and	  -­‐
uninfected	  children	   less	  than	  2	  years	  of	  age	  receiving	  INH,	  RMP	  and	  PZA	  at	  previously	  
and	  currently	  recommended	  doses	  as	  per	  WHO	  TB	  treatment	  guidelines	  (chapter	  3).	  
	  
Therapy	  of	  drug-­‐resistant	  tuberculosis	  in	  children	  
In	   contrast	   to	   the	   relatively	   good	   body	   of	   evidence	   for	   the	   management	   of	   DS-­‐TB	   in	  
children,	   there	  are	  still	  major	  gaps	   in	  our	  knowledge	  on	  management	  of	  children	  with	  
DR-­‐TB.	   Currently,	   due	   to	   an	   absence	   of	   data,	   there	   is	   no	   consensus	   about	   the	  




management	  of	  children	  exposed	  to	  infectious	  MDR-­‐TB	  cases	  and	  recommendations	  for	  
preventive	  therapy	  in	  international	  guidelines	  vary	  widely.	  After	  ruling	  out	  TB	  disease,	  
the	   WHO	   suggests	   to	   only	   follow	   up	   contacts	   of	   infectious	   MDR-­‐TB	   cases	   without	  
recommending	   a	   specific	   drug	   regimen,	  while	   South	  African	   guidelines	   recommend	   to	  
give	  high-­‐dose	  of	   INH	   (15mg/kg)	   to	   children	  <5	   years	   of	   age	   (29,	   57).	   In	   a	   consensus	  
statement,	   the	   American	   Thoracic	   Society,	   the	   Infectious	   Diseases	   Society	   of	   America,	  
and	  the	  US	  Centers	  of	  Disease	  Control	  and	  Prevention	  advocate	  that	  preventive	  therapy	  
including	   two	   drugs	   to	  which	   the	   source	   case’s	   isolate	   is	   susceptible	   should	   be	   given	  
(58).	  A	  combination	  of	  either	  PZA	  plus	  EMB,	  or	  PZA	  plus	  a	  fluoroquinolone	  according	  to	  
the	   DST	   result,	   are	   recommended	   (58).	   Ofloxacin	   (OFX)	   and	   sparfloxacin	   are	   the	  
fluoroquinolones	  recommended	  in	  these	  guidelines	  for	  adults,	  but	  not	  for	  children.	  In	  a	  
more	   recent	   report	   on	   management	   of	   children	   exposed	   to	   MDR-­‐TB,	   the	   use	   of	   the	  
fluoroquinolones	  OFX	  or	  levofloxacin	  (LFX)	  are	  suggested	  (59).	  Fluoroquinolone-­‐based	  
treatment	   regimens	   (OFX	   or	   LFX)	   have	   provided	   evidence	   suggesting	   that	  
fluoroquinolones	  may	   prevent	   progression	   from	  TB	   infection	   to	   disease	   in	   adults	   and	  
children	   (60,	   61).	   Further	   second-­‐line	   drugs	   suggested	   for	   preventive	   therapy	   are	  
ethionamide	   (ETH)	  or	  prothionamide	   (PTH)	   (59).	   Future	  drugs	   that	  might	  be	   suitable	  
for	  preventive	   treatment	  against	  MDR-­‐TB	  are	  bedaquiline	  (TMC	  207),	  delamanid	  (OPC	  
67683)	   or	   pretomanid	   (PA-­‐824)	   (62).	   These	   drugs	   are	   in	   phase	   3	   trials	   in	   adults	   and	  
some	  have	  already	  been	  provisionally	  licensed	  for	  the	  treatment	  of	  MDR-­‐TB	  in	  adults.	  	  
The	  management	   and	   outcome	   of	   children	  with	  MDR-­‐TB	   have	   only	   been	   reported	   as	  
case	  series	  and	  a	  single	  meta-­‐analysis	  (63-­‐66).	  Children	  should	  be	  treated	  according	  to	  
their	   DST	   results	   or,	   if	   not	   available,	   to	   the	   DST	   results	   of	   the	   source	   case.	   Three	   or	  
preferably	  four	  drugs	  to	  which	  the	  isolates	  are	  susceptible	  or	  naïve	  should	  be	  included	  
in	  an	  MDR-­‐TB	   treatment	   regimen.	   In	   individualized	   treatment,	   a	   treatment	   regimen	   is	  
built	  from	  different	  drug	  groups	  according	  to	  WHO	  classification	  (see	  table	  1),	  including	  
first-­‐line	  anti-­‐tuberculosis	  drug(s)	   to	  which	   the	  organism	   is	  still	   susceptible,	  a	  second-­‐
line	   injectable	   agent,	   a	   fluoroquinolone,	   and	   one	   or	  more	   oral	   second-­‐line	   drugs,	   to	   a	  
total	  of	  four	  active	  drugs	  (67,	  68).	  If	  these	  drugs	  are	  not	  sufficient	  to	  build	  an	  effective	  
regimen	  of	  four	  active	  drugs,	  then	  drugs	  from	  group	  5	  (agents	  of	  uncertain	  value)	  should	  
be	  added	  (67).	  Two	  cohort	  studies	  of	  children	  with	  confirmed	  or	  probable	  MDR-­‐TB	  gave	  
an	  overview	  on	  the	  treatment	  regimens	  used	  in	  Western	  Cape	  province	  (63,	  69).	  In	  the	  
majority	   of	   cases,	   high-­‐dose	   INH	   (15-­‐20mg/kg)	   was	   used	   to	   overcome	   resistance	   in	  




isolates	   with	   an	   inhA	   promoter	   region	   mutation	   and	   an	   expected	   low-­‐level	   INH	  
resistance.	   Amikacin	   for	   up	   to	   6	   months	   was	   most	   frequently	   used	   as	   the	   injectable	  
agent,	   substituted	   by	   capreomycin	   if	   resistance	   to	   amikacin	   was	   detected.	   In	   these	  
studies,	  OFX	  was	  used	  from	  the	  fluoroquinolone	  group.	  Further	  drugs	  used	  in	  this	  cohort	  
were:	   ETH,	   para-­‐aminosalicylic	   acid	   (PAS),	   terizidone,	   amoxicillin/clavulanic	   acid,	  
clarithromycin	  and	  linezolid.	  Favourable	  treatment	  outcome	  was	  seen	  in	  82%	  in	  the	  first	  
study	  including	  only	  children	  with	  culture-­‐confirmed	  MDR-­‐TB	  (n=111)	  (63)	  and	  in	  92%	  
of	  children	  with	  confirmed	  or	  probable	  MDR	  TB	  (n=149)	  (69).	  Nevertheless,	  death	  still	  
occurred	   in	   a	   small	   proportion	   of	   children	   and	   was	   associated	   with	   HIV	   infection,	  
malnutrition	  and	  extrapulmonary	  involvement	  (63,	  69).	  
Following	   recent	   studies	   showing	   efficacy	   of	   newer	   fluoroquinolones	   in	   adults	   for	   the	  
treatment	  of	  MDR-­‐TB,	  the	  treatment	  policy	  of	  MDR-­‐TB	  has	  been	  changed	  in	  South	  Africa,	  
also	  for	  children,	  from	  OFX,	  to	  LFX	  or	  moxifloxacin	  (MFX)	  (70,	  71),	  depending	  on	  the	  age	  
of	  the	  child.	  
Data	  on	  the	  use	  of	  second-­‐line	  anti-­‐tuberculosis	  agents	  in	  children	  are	  urgently	  needed.	  
Priority	  might	   be	   given	   to	   ETH	   and	   the	   fluoroquinolones;	   ETH,	   because	   it	   is	   not	   only	  
frequently	  used	  in	  treatment	  of	  MDR-­‐TB,	  but	  also	  for	  the	  treatment	  of	  DS-­‐TB	  meningitis	  
or	   miliary	   TB	   due	   to	   its	   good	   penetration	   into	   the	   cerebrospinal	   fluid	   (CSF)	   and	   its	  
potential	   bactericidal	   activity	   (72);	   and	   fluoroquinolones	   because	   they	   form	   the	  
backbone	  of	  MDR-­‐TB	  preventive	  therapy	  and	  treatment	  of	  MDR-­‐TB	  not	  only	  in	  current	  
regimens,	  but	  will	  most	   likely	  also	  be	  used	   in	   future	   regimens	  with	  novel	   compounds,	  
both	  for	  DS-­‐TB	  and	  DR-­‐TB.	  
I	   performed	   a	   scoping	   literature	   review	   on	   the	   thioamide	   (ETH	   and	   PTH)	   and	   the	  
fluoroquinolones	   (OFX,	   LFX,	   MFX)	   to	   identify	   the	   existing	   evidence	   on	   their	   use	   in	  
childhood	  TB	  (chapter	  4).	  To	  better	  define	  the	  optimal	  dosage	  of	  the	  second-­‐line	  drugs,	  
pharmacokinetic	  and	  safety	  studies	  of	  these	  agents	  in	  children	  are	  a	  matter	  of	  urgency.	  
To	  address	   this	   gap	   in	   current	  knowledge,	   I	  performed	   the	   first	   ever	  pharmacokinetic	  
studies	  of	  ETH,	  OFX,	  LFX	  and	  MFX	  in	  children	  with	  TB	  (chapter	  5).	  
Dosing	   does	   not	   only	   depend	   on	   efficacy,	   but	   also	   on	   safety,	   and	   for	   second-­‐line	   anti-­‐
tuberculosis	   agents,	   the	  margin	  of	   efficacy	  and	   toxicity	   is	  much	  narrower	   than	   for	   the	  
first-­‐line	   anti-­‐tuberculosis	   drugs.	   I	   therefore	   assessed	   specific	   adverse	   effects	   of	   these	  
agents	   (chapter	   6).	   Beside	   mainly	   gastro-­‐intestinal	   intolerance,	   ETH	   may	   cause	  




hypothyroidism	   during	   long-­‐term	   therapy;	   this	   has	   never	   been	   studied	   in	   children.	  
Changes	   in	   thyroid	   function	   tests	  were	   therefore	  assessed	   in	  a	  cohort	  of	  children	  with	  
MDR-­‐TB	  receiving	  ETH	  as	  part	  of	  their	  MDR-­‐TB	  regimen	  (Chapter	  6.1.).	  	  
Fluoroquinolone	  use	  has	  been	  traditionally	  restricted	  in	  children	  due	  to	  safety	  concerns,	  
especially	   drug-­‐induced	   arthropathy.	   Their	   use	   has	   also	   been	   associated	   with	  
prolongation	  of	  the	  QT	  interval	  in	  adults,	  not	  previously	  investigated	  in	  children.	  Further	  
evaluation	  of	  QT	  prolongation	  in	  children	  is	  warranted,	  given	  that	  in	  future	  MFX	  may	  be	  
combined	   with	   novel	   TB	   drugs	   also	   known	   to	   cause	   QT	   prolongation,	   such	   as	  
bedaquiline,	  delamanid	  and	  pretomanid.	  	  
I	  therefore	  assessed	  adverse	  effects	  of	  OFX,	  LFX,	  and	  MFX	  including	  electrocardiogram-­‐
related	   cardiotoxicity	   in	   children	   on	   MDR	   anti-­‐tuberculosis	   therapy,	   as	   part	   of	   the	  
pharmacokinetic	  studies	  completed.	  
Taken	  together,	  paediatric	  TB	  has	  become	  a	  public	  health	  problem	  of	  special	  significance	  
not	   only	   because	   it	   is	   a	   marker	   of	   recent	   transmission	   of	   TB	   (also	   DR-­‐TB),	   but	   also	  
because	  it	  is	  a	  major	  cause	  of	  disease	  and	  death	  in	  children	  from	  areas	  endemic	  for	  TB.	  
Children	  with	  TB	  or	  exposed	  to	  M.	  tuberculosis	  urgently	  require	  optimized	  treatment	  to	  
prevent	  disease	  after	  infection,	  to	  prevent	  paediatric	  morbidity	  and	  mortality,	  as	  well	  as	  
to	  reduce	  the	  future	  burden	  of	  TB.	  	  Knowledge	  of	  the	  optimal	  use	  of	  the	  existing	  drugs	  is	  
also	   required	   to	   guide	   the	   evaluation	   of	   novel	   and	   treatment	   shortening	   regimens	   for	  
DS-­‐	  and	  DR-­‐TB	  in	  children.	  	  
The	  overall	  objective	  of	   the	  proposed	  research	  thesis	  was	   to	  generate	  robust	  evidence	  
which	  would	   contribute	   to	   the	   optimal	   dosing	   of	   relevant	   first-­‐	   and	   second-­‐line	   anti-­‐
tuberculosis	  drugs	  in	  children.	  	  
Table	  1.	  	  WHO	  classification	  of	  anti-­‐tuberculosis	  drugs	  
Group	   Group	  Name	   Drugs	  
1	   First-­‐line	  oral	  agents	   isoniazid,	  rifampicin,	  ethambutol,	  pyrazinamide	  (rifabutin,	  rifapentine)	  
2	   Injectable	  agents	   kanamycin,	  amikacin,	  capreomycin,	  streptomycin	  
3	   Fluoroquinolones	   moxifloxacin,	  levofloxacin,	  ofloxacin	  
4	   Oral	  bacteriostatic	  second-­‐line	  agents	  
ethionamide,	  prothionamide,	  cycloserine,	  terizidone,	  
para-­‐aminosalicylic	  acid	  
5	   Agents	  with	  unclear	  efficacy	  or	  concerns	  regarding	  usage	  
clofazimine,	  linezolid,	  amoxicillin-­‐clavulanic	  acid,	  
thiacetazone,	  imipenem/cilastatin,	  high	  dose	  isoniazid,	  
clarithromycin	  




Chapter	  2	  	  
The	  use	  of	  isoniazid,	  rifampicin	  and	  pyrazinamide	  in	  children	  with	  





In	   order	   to	   review	   the	   current	   evidence	   base	   on	   the	   use	   of	   first-­‐line	   anti-­‐tuberculosis	  
agents	  in	  children,	  a	  structured	  descriptive	  review	  of	  the	  available	  published	  literature	  
was	  performed.	  For	  the	  initial	  search,	  Pubmed	  was	  used.	  Additionally,	  the	  reference	  lists	  
of	  identified	  articles	  were	  reviewed	  for	  further	  relevant	  reports.	  An	  extensive	  review	  of	  
the	  first-­‐line	  anti-­‐tuberculosis	  agents	  is	  beyond	  the	  scope	  of	  this	  thesis,	  and	  therefore	  I	  
focused	   on	   pharmacokinetics	   and	   safety	   in	   children	   with	   TB.	   The	   first-­‐line	   drugs	  
isoniazid	  (INH),	  rifampicin	  (RMP)	  and	  pyrazinamide	  (PZA)	  were	  included	  in	  this	  review.	  
Where	   data	   on	   childhood	   TB	   were	   limited,	   literature	   on	   adults	   with	   TB	   and	   on	   the	  
agents’	  use	  in	  conditions	  other	  than	  TB	  has	  also	  been	  consulted.	  
	  
2.2.	  Isoniazid	  	  
	  
INH	  plays	  an	  important	  role	  in	  the	  treatment	  of	  TB	  disease	  as	  well	  as	  of	  Mycobacterium	  
tuberculosis	  infection.	  It	  is	  valued	  for	  its	  good	  early	  bactericidal	  activity	  (EBA)	  as	  well	  as	  
for	   its	   ability	   to	   prevent	   the	   development	   of	   resistance	   in	   companion	   drugs	   in	   the	  
intensive	  phase	  of	  anti-­‐tuberculosis	  treatment	  (73).	  	  
	  
Mode	  of	  action	  of	  isoniazid	  
INH	  has	  a	  bactericidal	   effect	  on	   rapidly	  dividing	  mycobacteria	  but	  has	  a	  bacteriostatic	  
effect	   if	   the	   bacteria	   are	   slow	   growing.	   INH	   is	   a	   pro-­‐drug	   that	   is	   converted	   by	   a	  
mycobacterial	   catalase-­‐peroxidase	   to	   an	   active	   metabolite.	   Following	   activation,	   INH	  
inhibits	  the	  biosynthesis	  of	  mycolic	  acids	  in	  the	  mycobacterial	  cell	  wall	  (74).	  





The	  activating	  catalase-­‐peroxidase	  is	  encoded	  by	  the	  katG	  gene.	  Mutations	   in	  this	  gene	  
region	   are	   a	   common	   cause	   for	   INH	   resistance	   (75-­‐77).	   Activated	   INH	   binds	   to	   the	  
product	   of	   the	   inhA	   gene	  which	   is	   involved	   in	   the	  mycolic	   acid	   biosynthetic	   pathway	  
correlating	  with	  cell	  death	  (76).	  In	  a	  systematic	  review,	  mutations	  in	  the	  katG	  gene	  were	  
underlying	  in	  64%	  of	  all	  observed	  phenotypic	  INH	  resistance	  worldwide	  and	  mutations	  
in	   the	   inhA	  promoter	  region	   in	  about	  20%	  (77).	  Regional	  variation	   in	   the	   frequency	  of	  
individual	  mutations	  exists.	  In	  the	  Western	  Cape	  Province,	  South	  Africa,	  inhA	  mutations	  
are	   found	   in	  about	  60%	  of	   INH-­‐resistant	  M.	  tuberculosis	   isolates	  (10,	  78).	  Mutations	   in	  
the	  katG	  gene	  usually	  confer	  high-­‐level	  INH	  resistance	  and	  those	  in	  the	  inhA	  gene,	  low-­‐
level	  INH	  resistance	  that	  can	  be	  overcome	  by	  giving	  INH	  at	  higher	  doses	  (15-­‐20mg/kg)	  
(79).	  The	  latter	  mutation	  also	  confers	  ethionamide	  (ETH)	  resistance,	   limiting	  its	  use	  in	  
the	  presence	  of	  inhA	  mutations.	  
	  
Clinical	  efficacy	  of	  isoniazid	  
Since	  its	  discovery	  in	  1952	  (80),	  INH	  has	  been	  the	  cornerstone	  of	  TB	  chemotherapy.	  In	  
adults,	   the	  standard	  daily	   recommended	  dose	   is	  5	  mg/kg	  with	  a	  maximum	  of	  300	  mg.	  
International	  treatment	  recommendations	  for	  children	  vary	  widely.	  While	  the	  WHO	  and	  
Centers	   for	   Disease	   Control	   and	   Prevention	   (CDC)	   recommend	   a	   dose	   of	   10-­‐15mg/kg	  
(81,	  82),	  the	  British	  Thoracic	  Society	  recommends	  the	  same	  dose	  of	  5	  mg/kg	  for	  adults	  
and	  children	  (although	  these	  guidelines	  are	  currently	  being	  updated)	  (83).	  	  
In	  very	  early	  studies,	  INH	  as	  a	  single	  drug	  showed	  a	  high	  potential	   in	  acute	  TB	  disease	  
with	   a	   reduction	   in	   number	   of	   deaths	   due	   to	   TB	   and	   increase	   in	   sputum	   culture	  
conversion	  (84).	  Since	  its	  potential	  to	  prevent	  progression	  from	  M.	  tuberculosis	  infection	  
to	  disease	  has	  been	  evaluated,	  INH	  as	  a	  single	  drug	  has	  been	  widely	  used	  for	  preventive	  
therapy	  (85).	  	  
The	   therapeutic	   efficacy	   of	   INH	   is	   determined	   by	   the	   exposure	   to	   the	   drug	   (86).	   INH	  
causes	   rapid	   decrease	   in	   the	   number	   of	   bacilli	   in	   sputum	   in	   the	   first	   two	   days	   of	  
treatment	   and	   thereafter	   shows	   a	   comparable	   bactericidal	   activity	   to	   other	   anti-­‐
tuberculosis	   drugs	   (73).	   The	   EBA	   increases	   proportionally	   to	   the	   INH	   dose	   until	   a	  
maximum	  effect	  is	  reached	  (EBA	  0.54	  log10	  cfu/ml	  sputum/d)	  at	  an	  INH	  dose	  of	  600mg	  




(73).	  A	  further	  INH	  EBA	  study	  showed	  that	  a	  maximum	  decline	  in	  colony	  forming	  units	  
is	  obtained	  at	  a	  INH	  serum	  concentration	  of	  2-­‐3µg/ml	  and	  that	  a	  further	  increase	  of	  the	  
concentrations	   does	   not	   increase	   INH	   EBA	   (87).	   An	   early	   report	   by	   the	   East	  
African/British	  Medical	  Research	  Councils	   showed	   that	   increasing	   the	   INH	  dose,	  when	  
used	   in	   combination	   with	   thiacetazone,	   from	   200	   mg	   daily	   to	   300	   mg	   improved	   the	  
clinical	   response,	   but	   that	   a	   further	   increase	   to	   a	   single	   daily	   dose	   of	   450	  mg	   left	   the	  
response	  unchanged	  (88).	  Whether	  these	  findings	  are	  still	  valid	  today	  in	  the	  context	  of	  
high	  prevalence	  of	  HIV	  infection	  and	  an	  increased	  average	  body	  weight	  compared	  to	  the	  
weight	  of	  the	  study	  participants	  in	  these	  early	  studies,	  leading	  to	  a	  lower	  mg/kg	  dose,	  is	  
subject	  of	  ongoing	  debate	  (47).	  
Inactivation	  of	  INH	  occurs	  mainly	  by	  acetylation	  in	  the	  liver	  and	  the	  small	  intestine	  and	  
N-­‐acetyltransferase	   type	  2	   (NAT2)	  has	  been	   identified	  as	   the	  responsible	  enzyme.	  The	  
activity	  of	   the	  NAT2	   is	   genetically	  determined	  and	  a	   trimodality	   in	   elimination	  of	   INH	  
has	  been	  demonstrated	  (51,	  89,	  90).	  Therefore	  individuals	  may	  be	  slow,	  intermediate	  or	  
fast	   acetylators.	   Distribution	   of	   each	   phenotype	   differs	   between	   different	   populations.	  
For	  example,	  Japanese	  and	  the	  Inuit	  population	  are	  predominately	  fast	  acetylators	  (91),	  
while	   in	   the	   Scandinavian	   population	   slow	   acetylators	   are	   more	   common	   than	   fast	  
acetylators	  (92).	  
In	  an	  early	  study,	  patients	  who	  were	  fast	  acetylators	  of	  INH	  responded	  less	  favourably	  to	  
INH-­‐containing	  treatment	  regimens	  (93).	  In	  patients	  receiving	  once	  weekly	  treatment	  of	  
INH	  and	  rifapentine,	  failure	  and	  relapse	  were	  also	  associated	  with	  fast	  acetylator	  status	  
(94).	  This	  has	  been	  attributed	  to	  a	  reduced	  area	  under	  the	  curve	  (AUC)	  and	  associated	  
diminished	  post-­‐antibiotic	  effect	  of	  INH	  (73,	  94).	  This	  is	  consistent	  with	  in	  vitro	  findings,	  
identifying	   the	   AUC/minimum	   inhibitory	   concentration	   (MIC)	   as	   the	  
pharmacokinetic/pharmacodynamics	   index	   associated	   with	   microbial	   killing	   and	  
development	  of	  resistance	  (95).	  In	  adult	  TB,	  low	  drug	  AUCs0-­‐24	  were	  predictors	  of	  poor	  
long-­‐term	   outcome	   (as	   microbiological	   failure,	   death	   or	   relapse)	   (23).	   The	   proposed	  
AUC	   for	   INH	   was	   52mg·h/L	   (23).	   In	   a	   pharmacokinetic	   study	   on	   Indian	   children,	  
decreased	  maximum	  serum	  concentration	  (Cmax)	  of	  INH	  and	  RMP	  were	  associated	  with	  
unfavourable	   treatment	   outcome	   (death,	   default)	   (96),	   while	   in	   a	   further	   study	   from	  
India	   treatment	   outcome	  was	  not	   influenced	  by	  Cmax	   of	   INH,	  RMP,	   PZA	  or	   ethambutol	  
(EMB)	  (97).	  In	  children	  with	  TB,	  it	  was	  shown,	  that	  the	  2-­‐hour	  serum	  concentration	  as	  
well	   as	   the	   Cmax	   of	   INH	   were	   poor	   predictors	   of	   INH	   AUC0-­‐24	   (98),	   probably	   due	   to	  




differences	   in	   elimination	  depending	  on	   the	  acetylator	   status.	  Because	  of	   the	   lack	  of	   a	  
gold	   standard	   for	   measuring	   treatment	   success	   in	   children	   with	   TB,	  
pharmacokinetic/pharmacodynamic	   studies	   investigating	   AUC/MIC	   in	   children	   may	  
have	   the	   potential	   for	   surrogate	   markers	   to	   predict	   clinical	   outcome.	   However,	   this	  
implies	   that	   the	   AUC	   concentrations	   needed	   for	   an	   optimal	   effect	   are	   identical	   in	  
children	   and	   adults.	   Given	   the	   differences	   in	   bacterial	   burden	   and	   immune	   response	  
(especially	  in	  young	  children)	  between	  adults	  and	  children,	  some	  uncertainty	  regarding	  
this	  assumption	  exists	  (37).	  
	  
Pharmacokinetics	  of	  isoniazid	  
In	   adults,	   absorption	   of	   INH	   from	   the	   intestinal	   tract	   is	   almost	   complete	   when	  
administered	  on	  an	  empty	  stomach	  but	  reduced	  when	  given	  with	  food	  (99).	  For	  children	  
no	   difference	   of	   resulting	   INH	   serum	   concentrations	   after	   oral	   or	   intramuscular	  
administration	  of	  INH	  was	  found	  (100).	  A	  Cmax	  of	  3-­‐5μg/ml	  is	  reached	  1	  to	  2	  hours	  after	  
an	  oral	  standard	  dose	  of	  300mg	  in	  adults	  and	  are	  associated	  with	  efficacy	  (86,	  99,	  101,	  
102).	  More	   recent	   studies	   have	  proposed	   the	  AUC0-­‐24	   as	   the	  primary	  pharmacokinetic	  
index,	  with	  a	  target	  for	  INH	  of	  52mg·h/L	  (23).	  
Several	  studies	  have	  demonstrated	  that	  INH	  serum	  concentrations	  are	  lower	  in	  children	  
than	   in	   adults	   following	   the	   same	  mg/kg	   dose	   (44,	   51,	   103,	   104).	   INH	   is	   distributed	  
throughout	   the	   body	   water	   and	   diffuses	   rapidly	   into	   all	   the	   tissue	   and	   body	   fluids	  
including	  cerebrospinal	  fluid	  (CSF)	  without	  being	  appreciably	  bound	  to	  plasma	  protein.	  
Thus,	  serum	  concentrations	  in	  infants	  and	  young	  children	  are	  expected	  to	  be	  lower	  than	  
in	   older	   children	   and	   adults	   following	   the	   same	  mg/kg	   body	  weight	   doses	   because	   of	  
age-­‐dependent	  changes	  in	  body	  composition	  with	  higher	  relative	  volumes	  of	  body	  water	  
early	   in	   life	   (105).	  Also,	   an	   age-­‐dependent	   elimination	  of	   INH	  has	  been	  demonstrated,	  
with	  younger	  children	  eliminating	  INH	  faster	  than	  older	  children	  and	  children	  as	  a	  group	  
faster	   than	   adults	   (51,	   96,	   104,	   106).	   This	   has	   been	   ascribed	   to	   the	   relatively	   greater	  
mass	  of	   the	   liver	   in	  proportion	   to	   total	  body	  weight	   in	  young	  children.	  However,	   very	  
long	   half-­‐lives	   of	   up	   to	   20	   hours	   have	   been	   reported	   in	   neonates	   probably	   due	   to	  
immature	  enzyme	  function	  (101,	  107,	  108),	  indicating	  that	  caution	  should	  be	  used	  when	  
dosing	  this	  paediatric	  group.	  




INH	   is	   eliminated	   by	   NAT2-­‐acetylation	   predominantly	   in	   the	   liver,	   and	   then	   mainly	  
excreted	  by	  the	  urine	  (86,	  101).	  
There	   is	  evidence	   that	  maturation	  of	  enzymes	  responsible	   for	  acetylation	  occurs	   (106,	  
109).	   In	   a	   study	   on	   44	   children	   with	   sequential	   testing	   of	   INH	   serum	   concentration,	  
12/30	  children	  phenotypically	  classified	  as	  slow	  acetylators	  initially,	  were	  classified	  as	  
fast	   acetylators	   over	   time	   (109).	   It	   was	   proposed,	   that	   NAT2	   maturation	   reaches	   a	  
plateau	  at	  4	  years	  of	  age	  (109).	  In	  order	  to	  separate	  the	  effects	  of	  body	  size	  change	  and	  
enzyme	  maturation	   on	   the	   clearance	   of	   INH,	   a	   pharmacokinetic	  model	  was	   applied	   to	  
data	   from	  151	  perinatally	  HIV-­‐exposed	   infants	   receiving	   INH	   in	   the	   first	  24	  months	  of	  
life	  (110).	  It	  was	  shown	  that	  after	  the	  age	  of	  3	  months,	  the	  apparent	  clearance	  increases	  
in	   the	   fast	   and	   intermediate	   acetylator	   groups	  with	   no	   significant	   change	   in	   the	   slow	  
acetylator	  group	  (110).	  Due	  to	  the	  strong	  influence	  on	  pharmacokinetic	  parameters,	  the	  
acetylator	  status	  of	  the	  children	  should	  be	  known	  for	  comparison	  of	  study	  results.	  
To	   date,	   there	   has	   been	   no	   association	   found	   between	   sex	   or	   HIV	   infection	   and	   INH	  
pharmacokinetic	  parameters	  in	  paedatric	  studies	  (51,	  104).	  Reports	  on	  the	  influence	  of	  
malnutrition	   on	   INH	   pharmacokinetic	   have	   shown	   no	   or	   moderate	   influence	   on	   INH	  
serum	  concentrations	   (96,	   111,	   112).	  The	   extent	   of	  malnutrition	  differed	  between	   the	  
studies,	  possibly	  accounting	  for	  some	  of	  the	  differences	  in	  the	  study	  results.	  
	  
Although	  INH	  is	  the	  anti-­‐tuberculosis	  drug	  most	  extensively	  studied,	  in	  previous	  studies,	  
the	  age	  of	  children	  was	  often	  not	  documented,	  there	  was	  inadequate	  inclusion	  of	  young	  
children	   (especially	   below	   the	   age	   of	   2	   years),	   NAT2	   status	  was	   not	   known,	   or	   doses	  
differed	  from	  the	  current	  WHO	  recommendation	  (100,	  103,	  113-­‐116).	  	  
Prior	   to	   the	   study	   described	   in	   chapter	   3,	   there	   were	   only	   two	   reports	   of	   INH	  
pharmacokinetic	  in	  children	  younger	  than	  3	  years	  of	  age	  (except	  neonates),	  one	  dating	  
from	  1978,	  the	  other	  from	  2001,	  where	  INH	  was	  given	  at	  a	  similar	  dose	  (15mg/kg	  and	  
10mg/kg	  respectively)	  as	  currently	  recommended	  by	  the	  WHO	  (7-­‐15mg/kg)	  (116,	  117).	  
In	  these	  studies	  targeted	  Cmax	  of	  INH	  3-­‐5µg/ml	  were	  achieved	  while	  information	  on	  the	  
AUC	  was	  not	  provided	  (116,	  117).	  
In	   the	   study	   completed	   in	   children	  younger	   than	  2	   years	  of	   age	   (chapter	  3),	  we	   could	  
confirm	   that	  an	   INH	  dose	  of	  at	   least	  10mg/kg	   is	  needed	   in	  children	  younger	   than	   two	  




years	   of	   age	   to	   achieve	   adequate	   serum	   concentrations	   independently	   of	   acetylator	  
status	  or	  co-­‐infection	  with	  HIV	  (118).	  	  	  
Several	   studies	   provide	   further	   evidence	   for	   the	   implementation	   of	   the	   revised	  WHO	  
dosing	   recommendations	   of	   INH	   10mg/kg	   in	   infants	   and	   children	   (97,	   119,	   120).	  
Although	  in	  children	  older	  than	  eight	  years	  of	  age	  organ	  function	  and	  body	  composition	  
approximate	   that	   of	   young	   adults	   (40),	   low	   INH	   serum	   concentrations	   compared	   to	  
adults	  were	   also	   found	   in	   children	   up	   to	   13-­‐16	   years	   of	   age	   (51,	   97,	   120).	   Even	  with	  
increased	  doses	  of	   INH,	   subtherapeutic	   serum	  concentrations	  have	  been	   reported,	  not	  
only	  illustrating	  the	  large	  inter-­‐patient	  pharmacokinetic	  variability	  but	  also	  the	  possible	  
influence	  of	  demographic,	  genetic	  and	  clinical	   factors	  (98).	  Nevertheless,	  care	  needs	  to	  
be	  taken	  in	  low-­‐birth	  weight	  and	  premature	  babies.	  In	  a	  recent	  study	  in	  this	  population,	  
an	   INH	  dose	   of	   10mg/kg	   led	   to	   targeted	   serum	   concentrations	   but	   prolonged	  half-­‐life	  
and	  reduced	  elimination	  of	  INH	  were	  noted	  (108).	  
In	   order	   to	   administer	   recommended	   anti-­‐tuberculosis	   drug	   doses	   adequately	   to	  
paediatric	  patients,	  child-­‐friendly	  drug	  formulations	  are	  required.	  A	  common	  practice	  is	  
to	  crush	  or	  split	  tablets	  where	  child-­‐friendly	  formulations	  are	  not	  available.	  None	  of	  the	  
studies	   above	  have	   assessed	   the	   influences	   of	   different	   drug	   formulations	   (e.g.	   tablets	  
versus	   syrup),	   or	   the	   crushing	   of	   INH	   tablets,	   which	   is	   common	   clinical	   practice,	  
especially	   in	   young	   children,	   given	   the	   lack	   of	   child-­‐friendly	   scored	   fixed	   dose	  
combinations	  consistent	  with	  WHO	  dosing	  recommendations.	  	  
	  
Adverse	  effects	  of	  isoniazid	  
In	   adults,	   the	   incidence	   of	   adverse	   effects	   of	   INH	   treatment	   is	   estimated	   to	   be	   5.4%	  
(121).	  The	  most	  frequent	  adverse	  effects	  are	  rash,	   fever,	  hepatotoxicity	  and	  peripheral	  
neuritis.	  	  
Hepatotoxicity	   is	   the	   most	   serious	   adverse	   effect	   related	   to	   INH.	   Subclinical,	  
asymptomatic	   elevated	   liver	   enzymes	  were	   found	   in	   5-­‐10%	  of	   children	   receiving	   INH	  
preventive	   therapy,	   with	   a	   higher	   incidence	   in	   adolescents	   (122-­‐127).	   Large	   studies	  
including	  more	   than	  2,000	  children	   receiving	  10-­‐20mg/kg	   INH	   for	  preventive	   therapy	  
did	   not	   report	   a	   single	   case	   of	   discontinuation	   due	   to	   hepatotoxicity	   (126,	   127).	  
Contrarily,	  a	  very	  recent	  report	   found	  elevated	  transaminases	  to	  be	  common	  (41%)	  in	  




children	  on	  preventive	  therapy	  for	  TB,	  with	  a	  higher	  incidence	  in	  children	  younger	  than	  
9	  years	  of	  age	  (128).	  INH	  had	  to	  be	  discontinued	  in	  4/277	  children	  due	  to	  hepatotoxicity	  
(128).	   Severe	   hepatotoxicity	   possibly	   leading	   to	   liver	   failure	   has	   occasionally	   been	  
reported	  previously	  in	  children	  receiving	  INH	  at	  a	  dose	  of	  10mg/kg	  or	  less	  (129-­‐132).	  In	  
adults,	   slow	   acetylator	   status	   has	   shown	   to	   be	   associated	  with	   a	   higher	   risk	   of	   drug-­‐
induced	   hepatotoxicity	   in	   different	   populations	   (133-­‐136).	   While	   others	   could	   not	  
identify	   acetylator	   status	   as	   a	   risk	   factor	   for	   drug	   induced	   hepatotoxicity	   (137,	   138).	  
Different	   study	   populations	   with	   different	   treatment	   regimens,	   co-­‐morbidities	   and	  
additional	  risk	  factors	  are	  possible	  explanations	  for	  the	  different	  findings	  on	  the	  impact	  
of	  the	  acetylator	  status.	  In	  children,	  the	  influence	  of	  NAT2-­‐status	  on	  INH	  toxicity	  has	  not	  
been	   systematically	   assessed	   (122).	   In	   a	   cohort	  of	   children	  with	  TB,	   the	   risk	  of	   raised	  
liver	  enzymes	   tended	  to	  be	   increased	   in	   those	  receiving	  higher	  doses	  of	   INH,	  although	  
this	  may	  have	  been	  confounded	  by	  disease	  related	  factors	  (104).	  A	  literature	  review	  on	  
anti-­‐tuberculosis	  drug-­‐induced	  hepatotoxicity	  in	  children	  indicated	  that	  increased	  INH-­‐
doses	  as	  well	  as	  being	  slow-­‐acetylator,	   infection	  versus	  disease	  and	  disease	  severity	  as	  
well	  as	  combination	  therapy	  with	  RMP	  increases	  the	  risk	  for	  hepatotoxicity	  (122).	  
Peripheral	  neuritis	  and	  central	  nervous	  system	  (CNS)	  adverse	  effects	  of	  INH	  are	  caused	  
by	   pyridoxine	   depletion,	   interfering	   with	   the	   synthesis	   of	   synaptic	   neurotransmitter	  
(139).	   Resulting	   dose-­‐related	   neurotoxicity	   can	   present	   as	   peripheral	   neuropathy,	  
seizures,	  psychosis,	  ataxia	  or	  optic	  neuritis.	  It	  is	  reversed	  (or	  prevented)	  by	  pyridoxine	  
administration	  (140).	  Even	  at	  doses	  of	  up	   to	  20mg/kg,	  children	  receiving	   INH	  are	   less	  
susceptible	  to	  developing	  INH-­‐related	  neurotoxicity	  than	  adults	  (141).	  In	  a	  study	  on	  38	  
children	   receiving	   INH	   as	   part	   anti-­‐tuberculosis	   therapy,	   5	   children	   (13%)	   showed	  
pyridoxine	  deficiency	  on	   assay,	  with	  higher	   incidence	   in	   children	   receiving	  more	   than	  
INH	  10mg/kg,	  but	  no	  child	  had	  clinical	  symptoms	  of	  pyridoxine	  deficiency	  (142).	  Similar	  
results	  were	   reported	   from	   a	   study	   from	   Zaire	   (143)	   and	   from	   Cape	   Town	   (144).	   No	  
signs	   of	   neurologic	   disorder	  were	   found	   in	   85	   children	   on	   INH	   therapy,	   regardless	   of	  
whether	   they	  received	  additional	  pyridoxine	  supplementation	  or	  not	  (143).	  Therefore,	  
pyridoxine	   supplementation	   is	   not	   routinely	   used	   in	   children,	   but	   supplementation	   is	  
recommended	   in	   HIV-­‐infected	   and/or	  malnourished	   children	   treated	   for	   TB,	   or	   those	  
receiving	  high-­‐dose	  INH	  (15-­‐20mg/kg)	  as	  part	  of	  MDR-­‐TB	  treatment	  (81,	  144)	  not	  being	  
based	  on	  level	  1	  evidence.	  	  




Slow	  acetylators	  are	  also	  more	  likely	  to	  develop	  polyneuropathy	  during	  INH	  therapy	  and	  
pyridoxine	   supplementation	   should	   be	   considered	   in	   these	   patients	   (145).	   In	   a	  
systematic	   review	  on	   the	   role	   of	   pyridoxine	   administration	  on	  polyneuropathy	  during	  
anti-­‐tuberculosis	  therapy	  the	  authors	  concluded	  that	  it	  appears	  prudent	  to	  support	  the	  
co-­‐administration	   of	   pyridoxine	  with	   INH	   in	   the	   light	   of	   its	   potential	   benefit	   and	   low	  
costs	  (146).	  
	  
Conclusions	  of	  isoniazid	  literature	  review	  
INH	   has	   dose-­‐dependent	   activity	   against	   M.	   tuberculosis.	   To	   achieve	   serum	  
concentrations	   in	   children	   comparable	   to	   those	   in	   adults	   correlated	  with	   efficacy,	   the	  
existing	   evidence	   advocates	   for	   the	   use	   of	   higher	   doses	   of	   INH	   in	   younger	   children	  
compared	  to	  adults,	  although	  the	  optimal	  pharmacokinetic/pharmacodynamic	  target(s)	  
in	   children	   still	   need	   to	   be	   established.	   The	   effect	   of	   different	   formulations	   or	  
crushing/splitting	  of	  tablets	  on	  pharmacokinetic	  measures	  in	  children	  is	  not	  known.	  In	  
children,	  severe	  hepatotoxicity	  or	  peripheral	  neuropathy	  is	  rare.	  The	  influence	  of	  NAT2-­‐
acetylator	   status	   on	   efficacy	   and	   toxicity	   of	   INH	   in	   children	   in	   different	   populations	  




RMP	  is	  active	  against	  a	  wide	  range	  of	  Gram-­‐positive	  and	  many	  Gram-­‐negative	  bacteria,	  
but	  it	  has	  principally	  been	  developed	  for	  use	  in	  the	  treatment	  of	  TB.	  RMP	  has	  a	  moderate	  
EBA	  against	  M.	  tuberculosis	  but	  in	  combination	  with	  INH,	  its	  sterilizing	  ability	  is	  unique	  
(147).	  With	  the	  introduction	  of	  RMP	  into	  anti-­‐tuberculosis	  treatment	  regimens	  together	  
with	   PZA,	   it	   has	   allowed	   for	   the	   shortening	   of	   the	   duration	   of	   treatment	   from	   the	  
conventional	  9	  to	  12	  months	  to	  the	  so-­‐called	  “short-­‐	  course	  treatment”	  of	  6	  months.	  
	  
Mode	  of	  action	  of	  rifampicin	  
RMP	   inhibits	  DNA-­‐dependent	  RNA	  synthesis	  by	   inhibiting	  RNA	  polymerase	  of	  bacteria	  
by	  binding	  its	  β-­‐unit,	  leading	  to	  suppression	  of	  initiation	  of	  chain	  formation	  (148).	  This	  




halts	   mRNA	   transcription,	   therefore	   preventing	   translation	   of	   proteins.	   Resistance	   to	  
RMP	   is	  almost	  exclusively	  associated	   to	  mutations	   in	   the	  rpoB	   gene	  encoding	   the	  RNA	  
polymerase	   β-­‐subunit	   (149,	   150).	   The	   mutations	   reduce	   binding	   of	   RMP	   to	   the	  
polymerase.	  Eucaryotic	  cells	  are	  unaffected	  by	  RMP	  as	  it	  does	  not	  bind	  to	  their	  nuclear	  
RNA	   polymerase.	   Efflux	   pump	   mediated	   drug	   resistance	   has	   been	   identified	   as	   an	  
alternative	  mechanism	  in	  RMP	  drug-­‐resistant	  isolates	  of	  M.	  tuberculosis	  (151).	  
In	   in-­‐vitro	   as	   well	   as	   in	   in-­‐vivo	   studies	   it	   has	   been	   demonstrated	   that	   RMP	   efficacy	  
depends	   on	   concentration	   of	   RMP	   rather	   than	   time	   (147,	   152,	   153).	   In	   an	   in-­‐vitro	  
pharmacokinetic/pharmacodynamic	   model	   RMP	   AUC/MIC	   has	   been	   identified	   as	   the	  
primary	  pharmacodynamic	  index	  for	  predicting	  efficacy	  of	  RMP,	  while	  the	  suppression	  
of	  resistance	  has	  been	  associated	  with	  the	  free	  Cmax/MIC	  ratio	  (152).	  
	  
Clinical	  efficacy	  of	  rifampicin	  
After	   its	   introduction,	   a	   series	   of	   randomized	   trials	   established	   that	   RMP-­‐containing	  
regimens	  achieved	  a	  high	  cure	  rate	  even	  when	  given	  intermittently	  (154).	  RMP	  is	  seen	  
as	   the	  main	   contributor	   to	   the	   shortening	   of	   anti-­‐tuberculosis	   treatment	   to	   6-­‐months	  
caused	  by	  drug	  susceptible	  organisms.	  The	  standard	  daily	  RMP	  dose	  in	  adults	  is	  600mg.	  
There	   is	   evidence	   against	   treatment	   regimens	   using	   RMP	   only	   during	   the	   intensive	  
phase	  (first	  2	  months	  of	  therapy),	  as	  these	  have	  been	  shown	  to	  be	  inferior	  to	  regimens	  
that	  use	  RMP	  throughout	  a	  6-­‐month	  course	  of	  therapy	  (155).	  	  
In	  clinical	  trials	  using	  different	  doses	  of	  RMP,	  it	  was	  shown	  that	  a	  drop	  in	  colony	  forming	  
units	  (CFU)	  of	  M.	  tuberculosis	   in	  the	  sputum	  of	  patients	  with	  pulmonary	  TB	  was	  higher	  
when	  higher	  doses	  of	  RMP	  were	  given	  (147,	  156).	  The	  EBA	  of	  a	  1,200mg	  RMP	  dose	  was	  
almost	  double	  that	  found	  after	  a	  dose	  of	  600mg	  in	  adults	  (147,	  157).	  Two	  studies	  show	  a	  
direct	   correlation	  between	  higher	  RMP	  plasma	  concentrations	  and	  an	   increased	   fall	   in	  
cfu	   (158,	   159).	   A	   literature	   review	   concluded	   that	   there	   is	   little	   evidence	   for	   the	  
currently	  recommended	  dose	  of	  RMP	  600mg	  daily	  (46).	  It	  has	  been	  proposed	  that	  higher	  
RMP	   doses	   of	   up	   to	   1,200-­‐1,800mg	   should	   be	   studied	   in	   the	   context	   of	   current	   four-­‐
drug-­‐regimens	   (46,	   47,	   160)	   in	   adults	   with	   TB.	   Clinical	   outcome,	   as	   manifested	   by	   a	  
lower	  rate	  of	  sputum	  conversion	  and	  a	  higher	  rate	  of	  treatment	  failure,	  was	  found	  to	  be	  
inferior	  in	  adult	  TB	  patients	  treated	  with	  doses	  of	  450mg	  RMP	  per	  day	  than	  in	  patients	  




treated	  with	  600mg	  per	  day	  (153).	  In	  adult	  TB	  patients	  it	  was	  shown	  that	  a	  RMP	  AUC0-­‐24	  
≤13mg·h/L	   as	   well	   as	   low	   AUCs	   of	   INH	   and	   PZA	   predict	   failure	   to	   convert	   sputum	  
culture	  at	  2	  months	  as	  well	  as	  long-­‐term	  poor	  treatment	  outcome	  (23).	  Preliminary	  data	  
from	  a	  recent	  phase	   IIb	  study	  shows	  that	  high-­‐dose	  RMP	  results	   in	   faster	  killing	  of	  TB	  
bacilli	  during	  treatment,	  compared	  to	  the	  current	  standard	  treatment	  (PanACEA	  MAMS-­‐
TB-­‐01,	   NCT01785186).	   Over	   12	   weeks	   of	   treatment,	   high-­‐dose	   (35mg/kg)	   RMP,	   in	  
combination	  with	  standard	  dose	  of	  INH,	  PZA,	  and	  EMB,	  led	  to	  a	  significant	  shortening	  of	  
time	  to	  culture	  conversion	  (hazard	  ratio	  of	  1.75,	  95%	  CI	  1.21-­‐2.55).	  
To	  our	  knowledge	  there	  are	  no	  published	  studies	  assessing	  the	  use	  and	  dose	  of	  RMP	  in	  
relation	   to	   treatment	   outcome	   in	   children	  with	   TB.	   In	   the	   case	   of	   latent	   TB	   infection,	  
RMP	   alone	   or	   in	   combination	   with	   INH	   has	   been	   shown	   to	   efficaciously	   prevent	  
progression	  to	  disease	  in	  children	  and	  adults	  (161-­‐163).	  
	  
Pharmacokinetics	  of	  rifampicin	  
In	  adults,	  following	  oral	  ingestion,	  RMP	  is	  well	  absorbed	  from	  the	  intestinal	  tract	  (164).	  
There	  is	  evidence	  that	  absorption	  might	  be	  significantly	  reduced	  in	  children	  (165).	  Cmax	  
is	  achieved	  within	  2	  hours	  when	  RMP	   is	  given	  on	  an	  empty	  stomach,	  but	  delayed	  and	  
incomplete	  when	  ingested	  with	  food	  (166).	  Following	  a	  single	  dose	  of	  different	  RMP	  oral	  
formulations	  as	  preventive	  therapy	  against	  Haemophilus	  influenzae,	  co-­‐adminstration	  of	  
apple	  juice	  resulted	  in	  a	  reduced	  AUC	  of	  RMP	  in	  a	  paediatric	  cohort	  (167).	  
Despite	  protein	  binding	  of	  80%	  RMP	  is	  distributed	  throughout	  the	  body	  (164).	  Effective	  
concentrations	  can	  be	  found	  in	  many	  organs	  and	  body	  fluids	  although	  penetration	  into	  
the	   CSF	   can	   be	   poor	   (168-­‐170).	   RMP	   is	   extensively	  metabolized	   in	   the	   liver	   to	   25-­‐O-­‐
desacetyl-­‐RMP,	   which	   is	   also	   active	   against	   M.	   tuberculosis.	   The	   main	   route	   of	  
elimination	   is	   biliary	   excretion,	   and	   to	   a	   much	   lesser	   extent,	   renal	   excretion.	   RMP	  
induces	  its	  own	  metabolism	  leading	  to	  a	  progressively	  shortened	  half-­‐life	  within	  the	  first	  
14	   days	   of	   treatment	   (164,	   171,	   172).	   Because	   RMP	   is	   a	   strong	   inducer	   of	   the	  
cytochrome	  P450	  (CYP450)	  system,	  concomitant	  treatment	  results	  in	  decreased	  half-­‐life	  
for	   a	   number	   of	   compounds,	   including	   HIV	   protease	   inhibitors	   and	   non-­‐nucleoside	  
reverse	   transcriptase	   inhibitors	   (26).	   RMP	   also	   activates	   the	   pregnane	   X	   receptor,	   an	  
important	   component	   of	   the	   body’s	   adaptive	   defense	   mechanism	   against	   toxic	  




substances	   including	  xenobiotics	   (173).	  Activation	  of	  pregnane	  X	  receptor	   leads	   to	   the	  
induction	  of	  CYP3A4,	  an	  important	  phase	  I	  oxidative	  enzyme	  that	  is	  responsible	  for	  the	  
metabolism	  of	  many	  drugs,	  as	  well	  as	  to	  up-­‐regulation	  of	  phase	  II	  conjugating	  enzymes	  
and	   p-­‐glycoprotein,	   an	   efflux	   transporter	   (173).	   It	   has	   been	   noted	   for	   adults	   and	  
children,	   that	   inter-­‐individual	   variability	   in	   RMP	  pharmacokinetics	   is	   high	   (174,	   175).	  
Possible	  reasons	  include	  raw	  material	  characteristics,	  changes	  in	  the	  crystalline	  habit	  of	  
the	  RMP,	  excipients,	  manufacturing	  and/or	  process	  variables	  (176,	  177),	  degradation	  in	  
the	   gastro-­‐intestinal	   tract,	   influence	   of	   co-­‐administration	   of	   food	   (166)	   and	   inherent	  
variability	  in	  absorption	  and	  metabolism.	  In	  children,	  tablets	  are	  often	  grinded	  or	  split	  to	  
be	  administered	  with	  unknown	  effect	  on	  bioavailability.	  Recently	  a	  polymorphism	  in	  the	  
SLCO1B1	   gene	   was	   identified.	   Low	   RMP	   exposure	   was	   associated	   with	   the	  
polymorphism	   of	   the	  SLC01B1	   c,463C>A	   gene	   (178).	   Furthermore,	   the	   ontogeny	   of	   p-­‐
glycoprotein	  may	  also	  play	  a	  role	  in	  the	  variable	  absorption	  in	  children	  (179).	  
In	  anti-­‐tuberculosis	  treatment	  in	  adults	  it	  has	  been	  suggested	  that	  RMP	  concentrations	  
of	   less	  than	  8μg/ml	  2-­‐hours	  post	  administration	  should	  be	  regarded	  as	  low	  and	  values	  
less	  than	  4μg/ml	  as	  very	  low	  (180,	  181).	  In	  children,	  lower	  serum	  concentrations	  than	  in	  
adults	  have	  been	  documented	   in	  several	   reports	   regardless	  of	   the	  presence	  of	  HIV	  co-­‐
infection	   (55,	   98,	   120,	   172,	   182-­‐187).	   In	   2009,	   the	   WHO	   revised	   the	   paediatric	   TB	  
treatment	  guidelines,	  recommending	  an	  increased	  oral	  daily	  dose	  of	  RMP	  15mg/kg	  with	  
a	  range	  of	  10-­‐20mg/kg	  daily	  (56).	  
Many	  of	  the	  pharmacokinetic	  studies	  of	  RMP	  in	  children	  were	  performed	  after	  a	  single	  
dose	  of	  RMP	  and	  not	  after	  anti-­‐tuberculosis	   therapy	  had	  been	  established,	  at	  so-­‐called	  
“steady-­‐state”.	   Due	   to	   self-­‐induction	   of	   RMP	   metabolism,	   these	   findings	   might	   show	  
higher	   serum	   concentrations	   than	   would	   actually	   be	   present	   during	   established	   anti-­‐
tuberculosis	   therapy.	   In	  1974,	  a	  study	  was	  undertaken	   in	  children	  from	  2	  months	  to	  5	  
years	  of	  age	  after	  a	  dose	  of	  15mg/kg;	  low	  maximum	  serum	  concentrations	  of	  5.2μg/ml	  
were	   found	   (188).	  We	   conducted	   the	   first	   study	   on	   pharmacokinetics	   of	   the	   first-­‐line	  
agents	  in	  children	  younger	  than	  2	  years	  of	  age	  (see	  chapter	  3)	  (118).	  These	  data	  provide	  
supportive	   evidence	   for	   the	   revised	   WHO	   guidelines	   recommending	   a	   dose	   of	   RMP	  
15mg/kg	   in	   children	   younger	   than	   two	   years	   of	   age;	   we	   also	   showed	   that	   previous	  
recommendations	   of	   RMP	  10mg/kg	   indeed	   lead	   to	   insufficient	   concentrations	   of	   RMP	  
(118).	   	  In	  a	  study	  from	  India	  on	  HIV-­‐infected	  children	  with	  TB,	  receiving	  thrice-­‐weekly	  
anti-­‐tuberculosis	   therapy,	   a	   RMP	   dose	   of	   10mg/kg	   also	   led	   to	   sub-­‐therapeutic	   RMP	  




serum	  concentrations	   in	  97%	  of	   children	   (185).	   In	   children	  <5years	  of	   age,	  RMP	  drug	  
exposure	   was	   even	   lower	   than	   in	   children	   older	   than	   5years	   (185).	   Based	   on	   a	  
pharmacokinetic	  model	   it	   could	   be	   confirmed	   that	   a	  RMP	  dose	   of	   at	   least	   15mg/kg	   is	  
required	   for	   adequate	   RMP	   serum	   concentrations	   (174).	   Ongoing	   studies	   provide	  
preliminary	   evidence	   that	   higher	  RMP	  doses	   (35mg/kg)	  might	   optimize	  TB	   treatment	  
and	  pending	  on	  the	  final	  results,	  higher	  doses	  need	  to	  be	  evaluated	  in	  children	  as	  well.	  
In	  a	  group	  of	  children	  with	  TB	  (median	  age	  of	  2.3	  years),	  even	  weight	  banded	  drug	  doses	  
according	  to	  new	  WHO	  recommendations	  led	  to	  insufficient	  serum	  concentrations	  (98).	  
It	   has	   been	  noted	   that	   inter-­‐patient	   variability	   in	  RMP	  pharmacokinetics	   is	   high	   (118,	  
174).	  There	   is	   very	   limited	   information	  on	   the	  pharmacokinetics	   of	  RMP	   in	  newborns	  
and	   infants	   (<12	   months).	   It	   is	   therefore	   important	   to	   further	   evaluate	   optimal	   RMP	  
dosing	  strategies	  in	  children,	  especially	  given	  future	  planned	  treatment	  shortening	  trials	  
in	  children	  with	  DS-­‐TB.	  	  
	  
Adverse	  effects	  of	  rifampicin	  
RMP	  is	  generally	  well	  tolerated.	  When	  given	  at	  a	  standard	  dose	  of	  10mg/kg,	  significant	  
adverse	   effects	   are	   seen	   in	   less	   than	  4%	  of	   adult	   patients.	  The	  most	   common	  adverse	  
effects	   are	   rash	   (0.8%),	   fever	   (0.5%)	   and	   nausea	   and	   vomiting	   (1.5%)	   (189).	  
Hepatotoxicity	  rarely	  occurs	  and	  has	  been	  observed	  mainly	  in	  patients	  with	  underlying	  
liver	  disease.	  Also	  the	  combination	  of	  RMP	  plus	  PZA	  used	  for	  preventive	  therapy	  in	  HIV-­‐
uninfected	  patients	  has	  been	  associated	  with	  severe	  and	  sometimes	  fatal	  hepatotoxicity	  
(190).	   In	   a	   study	   on	   RMP	   dose	   of	   600mg	   in	   adult	   TB	   patients,	   mild	   hepatotoxicity	  
occurred	   in	   about	  half	   of	   the	  patients,	   but	  no	  patient	  developed	   severe	  hepatotoxicity	  
(191).	   In	   an	   ongoing	   study	   investigating	   RMP	   at	   a	   dose	   of	   35mg/kg,	   the	   preliminary	  
analysis	   of	   safety	   events	   showed	   no	   increase	   in	   adverse	   events	   compared	   to	   control	  
arms	  (PanACEA	  MAMS-­‐TB-­‐01,	  NCT01785186).	  
There	  are	  indications	  that	  RMP	  toxicity	  is	  rarely	  dose-­‐related	  but	  idiosyncratic	  (160).	  In	  
intermittent	   therapy	   a	   “flu-­‐like”	   syndrome	  might	   occur	   (160,	   189).	   There	   is	   evidence	  
that	   adding	   RMP	   to	   an	   INH	   containing	   regimen	   increases	   the	   risk	   of	   INH-­‐induced	  
hepatotoxicity,	  especially	  in	  patients	  being	  slow	  acetylators	  (122,	  192).	  
Reports	   on	   adverse	   effects	   in	   children	   are	   rare	   and	   even	   higher	   doses	   seem	   to	   be	  




tolerated	  well	  (122,	  193-­‐195).	  In	  a	  study	  of	  children	  receiving	  RMP	  alone	  as	  preventive	  
therapy	  (n=25),	  no	  adverse	  events	  occurred	  (196).	  In	  a	  larger	  study	  on	  157	  adolescents,	  
mild	  adverse	  effects	  were	  reported	  in	  41	  children	  (26%),	  but	  only	  in	  one	  child	  did	  RMP	  
need	   to	   be	   discontinued,	   because	   of	   increasing	   liver	   enzymes	   (197).	   In	   a	   literature	  
review	  on	   anti-­‐tuberculosis	   drug-­‐induced	   hepatotoxicity,	   elevated	   liver	   enzymes	  were	  
abnormal	  in	  380/3855	  children	  evaluated	  (9.9%)	  and	  jaundice	  occurred	  in	  75	  children	  
(0.83%)	  (122).	  In	  this	  review,	  it	  has	  also	  been	  concluded	  that	  RMP	  increases	  the	  risk	  of	  
hepatotoxicity	   if	   added	   to	   INH,	   regardless	   of	   the	   RMP	   dose	   used	   and	   that	   the	   risk	   of	  
hepatotoxicity	  is	  increased	  in	  severe	  TB	  disease	  (122).	  	  
	  
Conclusions	  of	  rifampicin	  literature	  review	  
RMP	  has	  a	  dose-­‐dependent	  activity	  against	  M.	  tuberculosis	  with	  AUC0-­‐24	  being	  identified	  
a	   surrogate	  marker	   for	   efficacy,	   while	   RMP	   Cmax	   is	   associated	   with	   the	   prevention	   of	  
resistance.	  As	  for	  INH,	  several	  paediatric	  studies	  have	  shown	  that	  higher	  doses	  of	  RMP	  
may	  be	  needed	   to	   achieve	  RMP	   serum	  concentrations	   comparable	   to	   those	   associated	  
with	   efficacy	   in	   adults.	   For	   adults,	   even	   higher	   doses	   than	   currently	   used	   have	   been	  
proposed	   and	   are	   currently	   being	   evaluated	   to	   optimize	   RMP	   efficacy;	   corresponding	  
doses	  should	   therefore	   in	   future	  also	  be	  evaluated	   in	  children.	  Evidence	  regarding	   the	  
pharmacokinetics	  in	  young	  children,	  especially	  newborns	  and	  infants,	  is	  very	  limited.	  As	  
for	   INH,	   the	   effect	   of	   different	   RMP	   formulations	   or	   crushing/splitting	   of	   tablets	   and	  
opening	  of	  capsules	  on	  pharmacokinetic	  measures	  is	  not	  known.	  RMP	  is	  well	  tolerated	  in	  
children	   and	   RMP-­‐related	   toxicity	   does	   not	   seem	   to	   be	   dose-­‐related	   and	   occurs	   very	  
rarely	  in	  children.	  More	  research	  on	  optimal	  RMP	  dosing	  strategies	  is	  needed,	  especially	  





Pyrazinamide	   (PZA)	   has	   important	   sterilizing	   activity	   against	   semi-­‐dormant	   M.	  
tuberculosis	  and	  is	  essential	  in	  the	  intensive	  phase	  of	  anti-­‐tuberculosis	  treatment.	  PZA	  is	  
bactericidal	   against	   intracellular	  mycobacteria	   in	  acidic	  medium,	  and	   is	  highly	   specific	  




for	  M.	  tuberculosis	  (198).	  
	  
Mode	  of	  action	  of	  pyrazinamide	  
Although	   one	   of	   the	   most	   frequently	   used	   anti-­‐tuberculosis	   drugs,	   the	   mechanism	   of	  
action	   of	   PZA	   is	   not	   fully	   understood	   (199,	   200).	   The	   bactericidal	   activity	   of	   PZA	  
increases	  as	  the	  metabolism	  of	  the	  bacteria	  decreases,	  e.g.	  in	  the	  dormant	  growth	  phase	  
(200).	  
PZA	   is	   a	   pro-­‐drug	   that	   is	   converted	   to	   its	   active	   form,	   pyrazinoic	   acid,	   by	  
pyrazinamidase,	   in	   the	   bacterial	   cytoplasm	   (200).	   Pyrazinamidase	   is	   encoded	   by	   the	  
pncA	   gene.	   Mutations	   in	   the	   pncA	   gene	   often	   underly	   PZA	   resistance	   (201,	   202).	  
Pyrazinoic	  acid	  diffuses	  slowly	  extracellulary.	  In	  an	  acidic	  environment,	  pyrazinoic	  acid	  
diffuses	  again	  through	  the	  cell	  wall	  as	  the	  protonated	  molecule	  and	  accumulates	  inside	  
the	  mycobacterium.	   Protonated	   pyrazinoic	   acid	   is	   toxic	   to	   the	  mycobacterial	   cell	  wall	  
(203).	   Recent	   studies	   have	   shown	   that	   both	   PZA	   and	   pyrazinoic	   acid	   have	   several	  
different	   targets	   interfering	   with	   diverse	   biochemical	   pathways,	   especially	   in	   the	  
NAD(+)	  and	  energy	  metabolism	  (204).	  PZA	  displays	  a	  pH-­‐dependent	  minimal	  inhibitory	  
concentration	  (MIC)	  against	  M.	  tuberculosis.	  In	  an	  in-­‐vitro	  study,	  a	  sharp	  decline	  in	  viable	  
mycobacteria	   occurred	   at	   a	   PZA	   concentration	   of	   50	   μg/ml	   in	   broth	   in	   an	   acidic	  
environment	  (pH	  4.8-­‐5.0)	  (205).	  
	  
Clinical	  efficacy	  of	  pyrazinamide	  
The	   unique	   sterilizing	   activity	   of	   PZA	   at	   a	   dose	   of	   30-­‐40mg/kg	   was	   shown	   in	   early	  
studies	  on	  PZA	  and	  RMP	  containing	  regimens	   in	  adults	  with	  pulmonary	  TB	  (206-­‐209).	  
These	   studies	   also	   showed	   that	   continuing	   PZA	   beyond	   the	   first	   two	   months	   of	  
treatment	   had	   little	   advantage	   (210).	   Today	   PZA	   is	   an	   important	   component	   in	   the	  
intensive	  phase	  of	   short-­‐course	  multiple-­‐drug	   therapy	   for	  drug-­‐susceptible	  TB	   in	  both	  
adults	  and	  children.	  
Following	   a	   PZA	   dose	   of	   40mg/kg,	   little	   activity	   of	   PZA	   was	   evident	   in	   EBA	   studies.	  
However,	   during	   the	   10	   following	   days,	   the	   bactericidal	   activity	   of	   PZA	   at	   this	   dose	  
matched	   that	   of	   other	   drugs	   evaluated	   (147).	   For	   anti-­‐tuberculosis	   therapy	   there	   are	  




only	   few	   studies	   directly	   linking	   PZA	   pharmacokinetics	   to	   efficacy.	   Target	   PZA	   serum	  
concentrations	   of	   20-­‐60µg/ml	   1-­‐2	   hours	   post-­‐dosing	   have	   been	   suggested	   (180);	   a	  
serum	  concentration	  below	  20µg/ml	  has	  been	   identified	  as	   low	  and	  <10µg/ml	  as	  very	  
low	   (211).	   In	   a	   study	   on	   HIV-­‐infected	   and	   HIV-­‐uninfected	   TB	   patients,	   poor	   outcome	  
(treatment	  failure	  or	  death)	  was	  associated	  with	  a	  PZA	  maximum	  serum	  concentration	  
<35µg/ml	   (22).	   In	   a	   more	   recent	   study,	   low	   PZA	   AUC	   over	   24	   hours	   was	   the	   main	  
predictor	  for	  poor	  long-­‐term	  clinical	  outcome	  (23).	  	  
PZA	  has	  recently	  been	  investigated	  as	  a	  potent	  companion	  to	  new	  treatment	  shortening	  
drug	   regimens	   for	   drug-­‐susceptible	   and	   drug-­‐resistant	   TB	   (212-­‐214).	   Different	  
combinations	   of	  moxifloxacin,	   pretomanid,	   bedaquiline,	   clofazimine	   and	   pyrazinamide	  
showed	   comparable	   bactericidal	   activity	   to	   the	   standard	   first-­‐line	   therapy	   (INH,	   RMP,	  
PZA,	  EMB)	  (212-­‐214).	  
	  
Pharmacokinetics	  of	  pyrazinamide	  
In	   adults,	   PZA	   is	   readily	   absorbed	   from	   the	   gastrointestinal	   tract	   after	   oral	   intake,	   is	  
modestly	   protein	   bound	   (10-­‐20%)	   and,	   thus,	   distributed	   throughout	   the	   body.	  
Comparable	  concentrations	  are	  reached	   in	  serum,	  CSF	  and	  body	  tissue	  (215-­‐217).	  The	  
apparent	  PZA	  volume	  of	  distribution	  of	  0.57-­‐0.84	   l/kg	  suggests	  distribution	   in	  a	  space	  
comparable	   to	   total	   body	   water	   (42).	   In	   adults,	   maximum	   serum	   concentrations	   are	  
achieved	  within	  1	  hour	  after	  oral	  ingestion	  (218).	  In	  different	  studies	  it	  could	  be	  shown	  
that	  PZA	   serum	  concentrations	   increase	   linearly	  with	  dose	   in	   volunteers	   as	  well	   as	   in	  
adults	  and	  children	  with	  TB	  (215,	  219,	  220).	  There	  is	  little	  intra-­‐individual	  variation	  in	  
absorption	   or	   excretion	   in	   adults	   of	   the	   same	   study	   population	   (215).	   Following	   PZA	  
dosages	   of	   30mg/kg,	   Cmax	   range	   from	   40-­‐55µg/ml	   in	   adult	   TB	   patients	   and	   from	   30-­‐
45µg/ml	  in	  patients	  receiving	  a	  dosage	  of	  20-­‐<30mg/kg	  (220).	  
Food	  might	  reduce	  absorption,	  therefore	  administration	  of	  PZA	  on	  an	  empty	  stomach	  is	  
preferred	   (221,	   222).	   In	   adults	   t½	   is	   10	  hours	   therefore	  PZA	   is	   suitable	   for	   once	  daily	  
dosing.	  PZA	  is	  hydrolysed	  in	  the	  liver	  to	  pyrazinoic	  acid	  and	  subsequently	  hydroxylated	  
to	   5-­‐hydroxypyrazinoic	   acid,	   the	   main	   excretory	   product	   (215).	   It	   is	   then	   excreted	  
primarily	  by	  glomerular	   filtration.	  Only	  4%	  of	  PZA	   is	  excreted	  unchanged	   in	   the	  urine	  
(215).	   HIV	   infection	   does	   not	   appear	   to	   be	   associated	   with	   reduced	   PZA	   serum	  




concentrations	  (20,	  211).	  
There	   are	   several	   published	   reports	   on	   studies	   investigating	   the	   pharmacokinetics	   of	  
PZA	  in	  children	  (19,	  97,	  120,	  219,	  223-­‐226).	  In	  two	  studies	  prior	  to	  our	  study	  (chapter	  
3),	  PZA	  was	  used	  at	  a	  dose	  of	  35mg/kg,	  the	  dose	  that	  is	  currently	  recommended	  by	  the	  
WHO;	   in	   the	   first	   study	   from	   India,	   conducted	   in	   children	   between	   6-­‐12	   years	   of	   age	  
(n=10),	   a	  mean	   Cmax	   of	   PZA	   of	   41.2µg/ml	  was	   found,	  while	   in	   the	   second	   study	   from	  
Malawi,	   maximum	   PZA	   serum	   concentrations	   were	   36.6µg/ml	   (19).	   In	   the	   Malawian	  
study	   (n=27,	  median	  age	  5.7	  years)	  PZA	  was	  given	   thrice	  weekly	   (19).	   In	   four	   further	  
studies	  on	  the	  pharmacokinetics	  of	  PZA	  in	  children	  from	  India,	  using	  doses	  of	  15mg/kg,	  
25-­‐30mg/kg	   and	   30-­‐35mg/kg	   (mean	   31.9mg/kg),	   surprisingly	   high	   PZA	   serum	  
concentration	  of	  approximately	  39µg/ml,	  42µg/ml	  and	  43-­‐49µg/ml,	  respectively,	  were	  
reported	  (185,	  223,	  225,	  227).	  In	  the	  study	  by	  Roy	  et	  al.	  (227),	  PZA	  was	  given	  as	  a	  single	  
dose	   to	   two	   treatment	   groups	   at	   a	   mean	   dose	   of	   28.1mg/kg	   or	   31.9mg/kg	   before	  
starting	   standard	  anti-­‐tuberculosis	   therapy.	   	  An	   increase	   in	  PZA	  serum	  concentrations	  
following	  the	  start	  of	  treatment	  occurs,	  probably	  due	  to	  the	  amount	  of	  PZA	  still	  present	  
24	   hours	   after	   dosing	   (50).	   Therefore	   PZA	   serum	   concentrations	   of	   this	   study	   cohort	  
might	  have	  been	  even	  higher	  during	  continuous	  therapy.	  These	  difference	  compared	  to	  
other	  paediatric	  studies	  might	  possibly	  be	  due	  to	  underlying	  genetic	  factors	  or	  different	  
sampling	   schemes	   (223).	   Additionally,	   a	   relatively	   low	   volume	   of	   distribution	   of	   PZA	  
compared	  to	  previous	  paediatric	  studies	  has	  been	  reported	  in	  the	  study	  by	  Gupta	  et	  al.	  
(223).	  Because	  PZA	  is	  a	  moderately	  lipophylic	  small	  molecule	  (228),	  differences	  in	  body	  
fat	   might	   possibly	   influence	   the	   volume	   of	   distribution	   with	   lower	   fat	   mass	   being	  
associated	  with	  lower	  volume	  of	  distribution.	  
Following	  daily	  PZA	  doses	  ranging	  between	  20-­‐30mg/kg,	  a	  PZA	  Cmax	  of	  30-­‐40	  has	  been	  
reported	  in	  children	  with	  TB	  from	  Germany,	  South	  Africa,	  Venezuela	  and	  Malawi	  (120,	  
186,	  219,	  224),	  similar	  to	  the	  findings	  in	  adult	  TB	  patients	  (215).	  Whether	  there	  are	  true	  
regional	  differences	  in	  the	  metabolism	  of	  PZA	  possibly	  due	  to	  underlying	  genetic	  factors	  
or	   if	   these	  differences	   are	  only	  due	   to	  high	   inter-­‐individual	   variability	  has	  never	  been	  
investigated.	  
Absorption	   seems	   to	   be	   delayed	   in	   children,	  with	   a	   tmax	   of	   2-­‐3.5hours	   (19,	   224,	   226).	  
Although	   a	   tendency	   towards	   lower	   PZA	   serum	   concentrations	   has	   been	   reported,	  
clinical	   co-­‐variates	   including	   HIV	   infection	   or	   malnutrition	   are	   not	   significantly	  
associated	  with	  PZA	  Cmax	  (19,	  219).	  	  	  




Very	   few	   children	   younger	   than	   2	   years	   of	   age	  were	   included	   in	   the	   pharmacokinetic	  
studies	   completed	   to	   date.	   In	   our	   study	   on	   children	   <2	   years	   of	   age	   (chapter	   3)	   we	  
provide	   further	   evidence	   that	   a	   daily	   oral	   PZA	   dose	   of	   35mg/kg	   is	   needed	   in	   young	  
children	   to	   achieve	   the	   proposed	   adult	   drug	   target	   of	   >35μg/ml.	   HIV	   infection,	  
malnutrition,	  gender	  and	  type	  of	  disease	  (pulmonary	  versus	  extrapulmonary	  TB)	  did	  not	  
seem	  to	  influence	  the	  PZA	  pharmacokinetic	  measures	  substantially	  in	  children	  <2	  years	  
(118).	   In	   another	   study	   from	   South	   Africa	   in	   children	  with	   TB	   (mean	   age	   2.3	   years),	  
targeted	  PZA	  2h	  serum	  concentration	  of	  30µg/ml	  were	  only	  achieved	   in	  55%	  (17/31)	  
children	   following	   the	   revised	   WHO	   dose	   recommendations	   (98).	   Simulation	   in	   a	  
population	  based	  pharmacokinetic	  model	   gave	   further	   evidence	   that	   younger	   children	  
would	  achieve	  relatively	   low	  exposures	   to	  PZA	  compared	  to	  adult	  data	  (174).	  Because	  
PZA	  distributes	  in	  the	  whole	  body	  water	  compartment,	  lower	  PZA	  serum	  concentrations	  
in	  younger	  children	  would	  be	  expected	  (42).	  
All	  of	  the	  above	  studies	  used	  PZA	  tablets	  administered	  either	  as	  a	  whole	  or	  split/crushed	  
tablet	  depending	  on	  the	  ability	  of	  the	  child	  to	  swallow	  tablets.	  As	  for	  INH	  and	  RMP,	  there	  
is	   no	   information	   available	   on	   the	   influence	   of	   this	   formulation	  manipulation	   on	   PZA	  
bioavailability.	  A	  suspension	  formulation	  of	  PZA	  is	  available	  in	  some	  countries,	  but	  has	  
not	  been	  evaluated	  to	  our	  knowledge.	  
In	  an	  extensive	  literature	  review	  on	  the	  pharmacokinetics	  of	  PZA,	  Donald	  concluded	  that	  
similar	  mg/kg	  body	  weight	  dosages	  of	  PZA	  in	  children	  lead	  to	  PZA	  serum	  Cmax	  similar	  to	  
those	  in	  adults	  (220).	  Some	  evidence	  exist	  that	  children	  younger	  than	  5	  years	  of	  age	  may	  
be	  exposed	  to	  lower	  PZA	  serum	  concentrations,	  but	  the	  data	  are	  limited	  (120,	  185,	  219).	  
In	  our	  study	  on	  children	  <2	  years	  of	  age,	  similar	  PZA	  serum	  concentrations	  as	  reported	  
in	  adult	  TB	  patients	  following	  a	  similar	  mg/kg	  dose	  were	  found	  (118,	  215).	  
	  
Adverse	  effects	  of	  pyrazinamide	  
The	  most	  serious	  adverse	  effect	  in	  PZA	  therapy	  is	  dose	  dependent	  liver	  injury.	  In	  adults,	  
after	  an	  oral	  dose	  of	  40	  to	  50mg/kg,	  symptoms	  of	  hepatic	  disease	  appear	  in	  about	  15%	  
of	   patients	   (121).	   Rarely,	   hepatic	   failure	   and	   death	   attributed	   to	   PZA	   occurs	   (229).	  
Contrarily,	   a	   literature	   review	   concluded	   that	   PZA	   induced	   hepatotoxicity	   is	  
idiosyncratic	   rather	   than	  dose-­‐dependent,	   and	   that	  doses	  of	  30-­‐40mg/kg	   shown	   to	  be	  




efficacious	   in	  early	  clinical	   trials	  are	  safe	   to	  use	   in	  anti-­‐tuberculosis	   therapy	  (206-­‐209,	  
230).	   There	   are	   a	   limited	   number	   of	   reports	   on	   PZA	   adverse	   effects	   in	   children.	  
Transient	   elevation	   of	   liver	   enzymes	   in	   children	   treated	   with	   an	   anti-­‐tuberculosis	  
regimen	   including	  PZA	  was	  reported	  occasionally,	  but	  reports	  of	  severe	  hepatotoxicity	  
are	   rare	   (231-­‐235).	   In	   these	   reports	   on	   children	   a	   daily	   PZA	   dose	   of	   <30mg/kg	   was	  
typically	   used,	   while	   for	   intermittent	   therapy,	   doses	   of	   up	   to	   50-­‐70mg/kg	   were	  
prescribed	   (236).	  Studies	   in	  children	  comparing	   lower	  doses	   in	  daily	  anti-­‐tuberculosis	  
treatment	  regimen	  including	  PZA	  compared	  to	  higher	  doses	  of	  anti-­‐tuberculosis	  agents	  
given	  2-­‐3	  times	  weekly,	  did	  not	  find	  an	  increase	  in	  adverse	  effects	  with	  the	  use	  of	  higher	  
doses	   (237-­‐239).	   There	   is	   no	   evidence	   to	   assume	   an	   increase	   in	   hepatotoxicity	   in	  
children	  with	  the	  current	  WHO-­‐recommended	  dose	  of	  35mg/kg	  (230).	  
Hyperuricaemia	  is	  commonly	  found	  in	  PZA	  therapy	  as	  excretion	  of	  urate	  is	  inhibited	  by	  
PZA;	  this	  is	  sometimes	  associated	  with	  arthralgia	  in	  adults,	  but	  rarely	  in	  children	  (216,	  
240).	  Acute	  episodes	  of	  gout	  following	  treatment	  with	  PZA	  have	  been	  reported	  in	  adults	  
(241,	   242).	   Hyperuricemia	   found	   in	   children	   was	   mostly	   mild	   and	   asymptomatic.	  
Increased	  serum	  uric	  acid	  levels	  returned	  to	  normal	  after	  cessation	  of	  PZA	  therapy	  (231,	  
232).	   Other	   less	   severe	   adverse	   effects	   include	   gastrointestinal	   disturbances,	   pruritus	  
and	  skin	  rashes.	  	  
	  
Conclusions	  of	  pyrazinamide	  literature	  review	  	  
A	  PZA	  dose	  of	  30-­‐40mg/kg	  resulting	  in	  a	  Cmax	  of	  40-­‐55µg/ml	  has	  shown	  high	  sterilizing	  
activity	   in	   anti-­‐tuberculosis	   treatment	   of	  DS-­‐TB	   in	   adults.	   For	   children,	   similar	  mg/kg	  
body	   weight	   dosages	   of	   PZA	   lead	   to	   PZA	   Cmax	   similar	   to	   those	   in	   adults,	   although	  
evidence	  in	  children	  younger	  than	  5	  years	  of	  age	  remains	  limited.	  As	  for	  INH	  and	  RMP,	  
the	  effect	  of	  different	   formulations	  or	  crushing/splitting	  of	   tablets	  on	  pharmacokinetic	  
measures	   is	   not	   known.	   Regional	   differences	   in	   PZA	   pharmacokinetics	   might	   exist.	  
Mildly	   elevated	   liver	   transaminases	   and	   transient	   hyperuricemia	   during	   PZA	   therapy	  
occur,	  but	  severe	  adverse	  effects	  in	  children	  even	  at	  higher	  PZA	  doses	  are	  rare.	  Studies	  
of	   PZA	   pharmacokinetics	   in	   a	   larger	   number	   of	   children	   of	   different	   ages	   and	   genetic	  
background	   may	   be	   needed	   to	   better	   define	   the	   PZA	   doses	   appropriate	   for	   children	  
across	  different	  ages.	  





Pharmacokinetics	  of	  isoniazid,	  rifampicin	  and	  pyrazinamide	  in	  
children	  younger	  than	  two	  years	  of	  age	  with	  tuberculosis:	  evidence	  for	  
implementation	  of	  revised	  World	  Health	  Organization	  
recommendations	  
	  
The	   aim	   of	   this	   study	   was	   to	   evaluate	   the	   pharmacokinetic	   parameters	   of	   isoniazid	  
(INH),	   rifampicin	   (RMP)	   and	   pyrazinamide	   (PZA)	   at	   the	   previous	   and	   current	   WHO-­‐
recommended	  doses	  in	  the	  young	  (<2	  years)	  paediatric	  population.	  	  
The	  current	  recommended	  doses	  are	  considerably	  higher	  than	  previously	  recommended	  
for	  TB	  treatment	   in	  children,	  and	  are	  as	   follows:	   INH	  10	  versus	  5	  mg/kg/day,	  RMP	  15	  
versus	  10	  mg/kg/day,	  PZA	  35	  versus	  25	  mg/kg/day	  and	  EMB	  20	  versus	  15	  mg/kg/day	  
(28,	   81).	   In	   the	   absence	   of	   pharmacodynamic	   data	   in	   children,	   optimal	   TB	   therapy	   in	  
children	   should	   aim	   to	   produce	   the	   targeted	   serum	   concentrations	   2-­‐hour	   post-­‐dose	  
that	   have	   been	   determined	   in	   adult	   pharmacokinetic	   and	   pharmacodynamic	   studies.	  
These	   are	   as	   follows:	   INH	  3-­‐5µg/mL	   (72,	   180),	  RMP	  8-­‐24µg/ml	   and	  PZA	  20-­‐60µg/ml.	  
RMP	   serum	   levels	   (2	   hours	   post-­‐dose)	   below	   8µg/ml	   are	   considered	   low	   and	   below	  
4µg/ml	   very	   low	   (160,	   243).	   Poor	   treatment	   outcome	   of	   pulmonary	  TB	   in	   adults	  was	  
associated	  with	  PZA	  serum	  concentrations	  <35µg/ml	  (22).	  
I	   designed	   and	   implemented	   a	   prospective,	   hospital-­‐based,	   observational	   intensive	  
sampling	   pharmacokinetic	   study	   on	   children	   treated	   for	   TB	   at	   Brooklyn	   Hospital	   for	  
Chest	   Diseases	   (BHCD),	   utilizing	   a	   cross-­‐over	   design.	   Resulting	   serum	   concentrations	  
following	   the	  previous	   and	   revised	  doses	  were	   assessed	  on	   two	  days	  one	  week	  apart.	  
Blood	   samples	  were	   taken	   at	   baseline	   (pre-­‐dose)	   and	   at	   0.5,	   1.5,	   3	   and	   5	   hours	   after	  
dosing.	   The	   serum	   concentrations	   were	   determined	   by	   high	   performance	   liquid	  
chromatography	   (HPLC)	  and	  ultraviolet	   (UV)	  detection,	  RMP	  serum	  concentrations	  by	  
HPLCS/MS	   technology.	   Pharmacokinetic	   measures	   were	   calculated	   using	  
noncompartemental	  analysis	  (NCA)	  for	  each	  study	  drug.	  A	  secondary	  aim	  of	  this	  study	  
was	   to	   determine	   the	   influence	   of	   the	   polymorphism	   in	   INH	   acetylation	   on	   the	   INH	  
serum	  concentrations.	  	  




Of	  the	  twenty	  children	  included	  (mean	  age	  1.09	  years)	  11	  children	  had	  pulmonary	  and	  9	  
extrapulmonary	  TB,	  5	  children	  were	  HIV-­‐infected.	  Following	  the	  previous/revised	  WHO	  
recommended	   doses	   the	   mean	   (95%	   confidence	   interval)	   pharmacokinetic	   measures	  
were	  as	   follows:	  Cmax:	   INH	  3.2	   (2.4-­‐4.0)/8.1	   (6.7-­‐9.5)µg/ml,	  PZA	  30.0	   (26.2-­‐33.7)/47.1	  
(42.6-­‐51.6)µg/ml,	   and	   RMP	   6.4	   (4.4-­‐8.3)/11.7	   (8.7-­‐14.7)µg/ml	   and	   the	   AUC:	   INH	   8.1	  
(5.8-­‐10.4)/20.4	   (15.8-­‐25.0)	   µg∙h/ml,	   PZA	   118.0	   (101.3-­‐134.7)/175.2	   (155.5-­‐
195.0)µg∙h/ml,	   and	   RMP	   17.8	   (12.8-­‐22.8)/36.9	   (27.6-­‐46.3)µg∙h/ml.	   Therefore,	   in	  
children	  less	  than	  2	  years	  of	  age,	  the	  target	  concentrations	  of	  first-­‐line	  anti-­‐tuberculosis	  
agents	  were	  only	  achieved	  using	  the	  revised	  WHO	  dose	  recommendations.	  For	  INH,	  this	  
was	   irrespective	   of	   the	   acetylator	   status.	   HIV-­‐infected	   children	   had	   lower	   serum	  
concentrations	  of	   all	   of	   the	   first-­‐line	  drugs	   tested,	  but	  only	   for	  PZA	  did	   this	  difference	  
reach	  statistical	  significance.	  Inter-­‐patient	  variability	  of	  the	  pharmacokinetic	  parameters	  
was	   high,	   leading	   to	   sub-­‐therapeutic	   concentrations	   in	   some	   children	  while	   in	   others	  
concentrations	  exceeded	  the	  recommended	  therapeutic	  range	  (esp.	  INH	  Cmax).	  This	  has	  
possible	   implications	  on	  efficacy	  and	   toxicity,	   respectively.	  The	   study	   is	   limited	  by	   the	  
modest	  sample	  size	  and	  the	  inability	  to	  correlate	  the	  pharmacokinetic	  parameters	  with	  
treatment	  outcome.	  This	  study	  provided	  the	  first	  evidence	  for	  the	  implementation	  of	  the	  
revised	  WHO	  guidelines	  for	  first-­‐line	  anti-­‐tuberculosis	  therapy	  in	  children	  younger	  than	  
two	  years	  of	  age	  (118).	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The World Health Organization (WHO) recently issued revised first-line antituberculosis (anti-TB) drug
dosage recommendations for children. No pharmacokinetic studies for these revised dosages are available for
children <2 years. The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents
in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10
mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and
to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and
type of tuberculosis (TB), and the effect of NAT2 acetylator status. Serum INH, PZA, and RMP levels were
prospectively assessed in 20 children <2 years of age treated for TB following the previous and the revised
WHO dosage recommendations. Samples were taken prior to dosing and at 0.5, 1.5, 3, and 5 h following dosing.
The maximum drug concentration in serum (Cmax), the time to Cmax (tmax), and the area under the concen-
tration-time curve (AUC) were calculated. Eleven children had pulmonary and 9 had extrapulmonary TB. Five
were HIV infected. The mean Cmax (!g/ml) following the administration of previous/revised dosages were as
follows: INH, 3.19/8.11; RMP, 6.36/11.69; PZA, 29.94/47.11. The mean AUC (!g ! h/ml) were as follows: INH,
8.09/20.36; RMP, 17.78/36.95; PZA, 118.0/175.2. The mean Cmax and AUC differed significantly between doses.
There was no difference in the tmax values achieved. Children less than 2 years of age achieve target concen-
trations of first-line anti-TB agents using revised WHO dosage recommendations. Our data provided sup-
portive evidence for the implementation of the revised WHO guidelines for first-line anti-TB therapy in young
children.
Isoniazid (INH), rifampin (RMP), and pyrazinamide (PZA)
are routinely used to treat tuberculosis (TB) in children (23,
44). Recommendations for pediatric dosages are based on a
small number of pharmacokinetic studies, few of which in-
cluded children younger than 2 years of age. During early life,
children experience significant changes in the relative sizes of
their body compartments and their ability to absorb, metabo-
lize, and excrete drugs (5, 17). These changes are greatest
within the first 2 years of life (4). Most published studies on
first-line anti-TB drugs in children have not analyzed differ-
ences between older and younger children or the effect of HIV
coinfection. The pharmacokinetics of INH are further compli-
cated by genetic polymorphisms of N-acetyltransferase type 2
(NAT2) in the metabolic pathway of INH, which influences
INH concentrations (18, 26, 46).
In the absence of pharmacodynamic data for children and
therefore data that demonstrate an association between serum
drug concentration and clinical outcome, optimal anti-TB ther-
apy should aim to produce the targeted serum drug concen-
trations that have been determined in adult pharmacokinetic
and pharmacodynamic studies. For INH, the proposed optimal
maximum serum drug concentration (Cmax) for therapy is 3 to
5 !g/ml (15, 27). Target serum RMP concentrations in adults
after a standard oral dose of 600 mg are in the range of 8 to 24
!g/ml; serum RMP concentrations below 8 !g/ml are consid-
ered low, and those below 4 !g/ml are considered very low (28,
29). There is more uncertainty regarding the optimal thera-
peutic serum PZA concentration. In adults, serum PZA con-
centrations are targeted at 20 to 60 !g/ml (11, 28). However, in
a recent study of adults, poor treatment outcome of pulmonary
TB was associated with serum PZA concentrations of "35
!g/ml (8).
Optimal anti-TB therapy is important in all children but
particularly in young children ("2 years of age) and those HIV
infected, where there is a high risk of progression to severe
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forms of TB. Recent studies have demonstrated that children
require higher mg/kg body weight doses of anti-TB drugs to
achieve the same serum drug concentrations as in adults (6, 10,
34, 38, 39, 41, 45). Consequently, the World Health Organiza-
tion (WHO) has recently issued revised dosage recommenda-
tions (44) for the treatment of children with first-line drugs
based on a systematic review of the literature. The WHO now
advises giving INH at 10 mg/kg (range, 10 to 15 mg/kg), RMP
at 15 mg/kg (range, 10 to 20 mg/kg), and PZA at 35 mg/kg
(range, 30 to 40 mg/kg). This compares to the previous recom-
mendation of INH at 5 mg/kg (range, 4 to 6 mg/kg), RMP at 10
mg/kg (range, 8 to 12 mg/kg), and PZA at 25 mg/kg (range, 20
to 30 mg/kg). All doses are advised for once-daily administra-
tion.
The serum INH, RMP, and PZA concentrations achieved
following previous and revised WHO dosing guidelines for
young children have not been examined. The aim of the pres-
ent study was to investigate the pharmacokinetics of the first-
line anti-TB agents INH, RMP, and PZA at previous and
revised WHO-recommended doses for children younger than 2
years of age. We also investigated the effects of important
clinical covariates, including HIV coinfection, nutritional sta-
tus, age, gender, and type of TB, and the effect of NAT2
acetylator status.
MATERIALS AND METHODS
Study population and setting. This was a prospective, single-center hospital-
based, observational intensive sampling pharmacokinetic study. The study was
conducted at the Brooklyn Hospital for Chest Diseases (BHCD), Cape Town,
South Africa, from May to October 2010. Eligible children were "2 years of age
and on anti-TB treatment with a regimen that included INH and PZA, with or
without RMP (all licensed for use in South Africa). Children had to be medically
stable, and written informed consent was obtained from a parent or legal guard-
ian, including permission for HIV testing. The study was approved by the Health
TABLE 1. Demographic, diagnostic, and clinical features of 20
children with TB
Demographic, diagnostic, or clinical feature Value
Demographic features
Mean age, yr (SD) ............................................................ 1.09 (0.49)
No. (%) of females ........................................................... 9 (45)
No. (%) M. tuberculosis or AFBa
culture positive .............................................................. 9 (45)
No. (%) with household TB contact .............................. 16 (80)
No. (%) TSTb positive...................................................... 10/19 (53)
Mean no. of days on anti-TB treatment (SD) ..............106.0 (62.7)
No. (%) HIV infected ...................................................... 5 (25)
Mean no. of days on cARTc (SD) ..................................168.6 (97.7)
Clinical features
No. (%) with pulmonary TB ........................................... 11 (45)
No. (%) with extrapulmonary TB................................... 9 (45)
No. (%) with TB meningitis ............................................ 8 (40)
No. (%) with abdominal TB............................................ 1 (5)
No. (%) with hepatomegaly at inclusion ....................... 11 (55)
Nutritional status
No. (%) with mass "3rd percentile for age.................. 10 (50)
Mean Z score for wt (SD) ............................................... #1.74 (1.84)
Mean BMId (SD) .............................................................. 16.02 (2.62)
a AFB, acid-fast bacilli.
b TST, tuberculin skin test.
c cART, combination antiretroviral therapy.
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Research Ethics Committee of the Faculty of Health Sciences, Stellenbosch
University, Stellenbosch, South Africa.
Diagnosis of TB. The diagnosis of TB was based on a history of TB contact, a
positive tuberculin skin test (TST), a chest radiograph (CR) compatible with the
diagnosis of pulmonary TB, and/or clinical signs of extrapulmonary TB. When-
ever possible, the diagnosis was confirmed by culture of Mycobacterium tubercu-
losis from sputum or another clinical specimen. Children were treated according
to the mycobacterial drug susceptibility test pattern from the child or that
obtained from the most likely adult source case.
Drug administration. Fixed dosage combinations formulated for pediatric use
are routinely prescribed for anti-TB treatment, as recommended by the South
African National Tuberculosis Programme. Rimcure (INH at 30 mg, RMP at 60
mg and PZA at 150 mg) was manufactured by Sandoz SA Pty. Ltd., Spartan,
South Africa. The doses given were calculated according to body weight at both
WHO recommendations. For an adequate dose of INH, tablets (or fractions of
tablets, respectively) containing INH at 100 mg (Be-Tabs Isoniazid; Be-Tabs
Pharmaceuticals Pty. Ltd., Roodepoort, South Africa) were added. Fractions of
500-mg PZA (Pyrazide; Sanofi Aventis, Johannesburg, South Africa) and 100-mg
INH tablets were given to children not receiving RMP. All formulations used
were approved by the South African Medicines Control Council. Tablets were
routinely crushed and dissolved in 2 to 5 ml of water and orally administered. All
children were supplemented with pyridoxine and multivitamin syrup. Antiretro-
viral therapy (ART) consisted of two nucleoside reverse transcriptase inhibitors
(lamivudine and stavudine) and a protease inhibitor (lopinavir/ritonavir). This
was boosted with extra ritonavir if the child was prescribed RMP. Trimethoprim-
sulfamethoxazole was given to all HIV-infected children.
Pharmacokinetic sampling. The first pharmacokinetic assessment was per-
formed at 2 weeks or more following the initiation of anti-TB treatment. Two
days prior to the assessment, the child was prescribed PZA at the previous WHO
dosage of 25 mg/kg, due to the long half-life of the drug. On the morning of the
assessment, the child was fasted for 4 h prior to receiving medications. An
intravenous catheter was inserted, and a baseline blood sample was taken. The
child was given INH, PZA, and, if appropriate, RMP at the previous WHO
dosages. Further sampling took place at 0.5, 1.5, 3, and 5 h after dosing. Blood
samples were collected in EDTA-coated tubes and placed on ice immediately.
Plasma was separated by centrifugation within 15 min and then deep-frozen until
analysis. Children received breakfast only after the 1.5-h blood sample was taken.
If the child was HIV infected, combination ART (cART) was given with break-
fast, while for all children other treatment was given after the last blood sample
was taken. Following assessment, children were represcribed TB medications at
the revised WHO dosages. One week later, a second assessment of each child
took place, using identical methods but using the revised WHO dosages.
Laboratory sampling. The serum INH and PZA concentrations of plasma
extract was determined by high-performance liquid chromatography (HPLC)
and UV detection. INH had to be derivatized with cinnamaldehyde to be de-
tectable at 340 nm, while PZA could be measured directly at 269 nm. For both
compounds, a solvent gradient of 50 mM phosphate buffer (solvent A) and a 1:4
acetonitrile-isopropanol mixture (solvent B) was used. The RMP concentration
was determined by HPLC-tandem mass spectrometry technology with an m/z
ratio of 823.3/95.2, a gradient of water and acetonitrile, both containing 0.1%
formic acid, was used in this instance as previously described (36, 37). The lower
limit of detection was 0.5 !g/ml for both INH and PZA and 0.1 !g/ml for RMP;
the lower limit of quantification was determined at a concentration where the
inter- and intraday variations were less than 5.0% (n $ 10) for each compound.
For all three compounds, we found a linear calibration range of 8 spiked samples
(R2, %0.9950).
Following centrifugation, the remaining blood cells were pooled and used for
the extraction of DNA for NAT2 genotyping. After preparation of genomic DNA
by a salting-out procedure, the NAT2 gene was analyzed by PCR and restriction
fragment length polymorphism as previously described (22, 34). The NAT2 gene
was analyzed for single nucleotide polymorphisms defining the NAT2*5,
NAT2*6, NAT2*7, NAT2*12, NAT2*13, and NAT2*14 alleles. According to the
current NAT nomenclature, the wild-type allele is designated NAT2*4, which
together with the NAT2*12 and NAT2*13 alleles, defines the rapid-acetylator (F)
status. Decreased or impaired NAT2 enzyme activity is encoded by the mutant
alleles NAT2*5, NAT2*6, NAT2*7, and NAT2*14, which define the slow-acety-
lator (S) status. Accordingly, individuals were classified as homozygous fast (FF),
heterozygous intermediate (FS), or homozygous slow (SS) acetylators, depend-
ing upon the allele combinations observed.
Pharmacokinetic parameters. Study endpoints were the following standard
parameters for each patient: Cmax (the highest drug concentration measured),
tmax (the time after drug administration taken to reach Cmax), and the area under
FIG. 1. Serum INH, PZA, and RMP concentrations following old
and revised WHO dosage recommendations. Shown are means with
95% confidence intervals. Panels: a, INH; b, PZA; c, RMP.
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the concentration-time curve (AUC) from 0 to 5 h of INH, PZA, and RMP.
AUC was calculated according to the linear trapezoidal rule.
Statistical methods. Data were graphically checked for distribution and con-
sidered adequate to be analyzed using original (untransformed) values for all
subsequent analyses. Data were summarized as means and 95% confidence
intervals (95% CIs). Paired t tests were used to assess differences in pharmaco-
kinetic parameters between the two doses. Independent t tests were used to
assess the effect of HIV, type of TB, RMP coadministration, and gender on
pharmacokinetic parameters. The effect of the NAT2 genotype was evaluated
using one-way analysis of variance (ANOVA). The effects of age and nutritional
status (Z score for weight) was assessed by linear regression. The Z score for
weight was calculated according to WHO growth charts (43). All tests were two
sided, and the significance level was set at 5% without adjustment for multiple
testing. Data were analyzed using SAS for Windows, version 9.2 (SAS Institute,
Cary, NC).
RESULTS
Patient characteristics. Twenty children were studied (mean
age, 1.09 years; standard deviation [SD], 0.49 years); 9 (45%)
were female. Demographic, diagnostic, and clinical features
are displayed in Table 1. At enrolment, all HIV-infected chil-
dren (n $ 5) were established on cART. Eleven children re-
ceived a multidrug regimen including RMP, and nine children
received treatment excluding RMP due to the presence of
resistance. Eight children were treated for multidrug-resistant
TB (i.e., resistance to INH and RMP with or without other
drugs). INH at a dose of 20 mg/kg was continued in these
children to overcome possible low-dose INH resistance.
Differences between previous and revised WHO dosages.
Pharmacokinetic parameters for the two different dosages of
INH, PZA, and RMP are shown in Table 2. Giving INH at a
dose of 10 mg/kg resulted in a higher Cmax and a correspond-
ingly higher AUC than giving INH at 5 mg/kg. No difference in
tmax was seen between the two INH doses. The same was true
for the two doses of PZA and RMP: Cmax and AUC were
significantly higher following the revised dose, while there was
no difference regarding tmax (Fig. 1). A high intraindividual
variability was found: children with high serum drug concen-
trations at the lower INH, PZA, and RMP doses did not
necessarily have comparatively high serum drug concentrations
following the higher dose.
A low Cmax of INH ("3 !g/m) was seen in half of the
children (10 of 20) following an INH dose of 5 mg/kg, but in
none after an INH dose of 10 mg/kg. For PZA, 15 of 20
children had a low Cmax ("35 !g/ml) following a dose of 25
mg/kg (2 children "20 !g/ml), while only one child had a
concentration below this threshold following PZA at 35
mg/kg. Low ("8 !g/ml) RMP Cmaxs were found in 6 of 11
children following a 10-mg/kg dose of RMP compared with
three following a dose of 15 mg/kg. Very low ("4 !g/ml)
RMP Cmax s were found in 3 of the 11 children following 10
mg/kg, whereas none had such low concentrations following
dosing at 15 mg/kg.
Influence of RMP on pharmacokinetics. There were no dif-
ferences in INH pharmacokinetics (with either 5 or 10 mg/kg)
between children receiving RMP and those not receiving RMP
(Table 3). Children receiving RMP achieved a significantly
lower PZA Cmax and AUC following a PZA dose of 25 mg/kg
than children not receiving RMP (Table 4). Following the
higher PZA dose (35 mg/kg), the differences between children
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significantly different. The tmax of PZA was not influenced by
RMP at either the previous or the revised dosage.
Influence of patient characteristics on pharmacokinetics.
Nutritional status, assessed by weight for age, body mass index,
and weight-for-age Z score according to WHO growth charts,
did not influence the pharmacokinetics of any of the drugs,
irrespective of the dose (only data for Z scores are shown in
Tables 3 to 5).
There were no differences in the pharmacokinetics of INH
and RMP between HIV-infected and HIV-uninfected children
(Tables 3 and 5). Following a PZA dose of 35 mg/kg, HIV-
uninfected children achieved higher maximum serum PZA
concentrations than did HIV-infected children after a shorter
time (tmax, 1.08 versus 1.50 h) (Table 4). The AUC for HIV-
uninfected children was also greater than that for HIV-in-
fected children, but this difference was not significant. No
difference in Cmax, tmax, or AUC was found in HIV-infected
versus uninfected children following a PZA dose of 25 mg/kg.
Neither the type of TB (pulmonary versus extrapulmonary
disease) nor gender affected the pharmacokinetics of INH,
PZA, or RMP (Tables 3 to 5). Age had an impact on the
pharmacokinetic parameters of INH, but not on those of PZA
and RMP (Tables 3 to 5). At both INH dosages, younger age
was associated with a higher maximum serum INH concentra-
tion (INH at 5 mg/kg, P $ 0.04; INH at 10 mg/kg, P $ 0.22)
and a greater AUC (INH at 5 mg/kg, P $ 0.004; INH at 10
mg/kg, P $ 0.007). No difference was detected for tmax.
The influence of acetylator status. The NAT2 genotype was
distributed as follows: 8 children were FF acetylators (5 of 8
children "1 year old), 4 were FS acetylators (3 of 4 children
"1 year old), and 8 were SS acetylators (4 of 8 children "1
year old). The maximum serum INH concentration and the
AUC were greater for the SS acetylators than for the FF
acetylators following INH dosing at both 5 mg/kg and 10 mg/kg
(Table 6).
The impact of acetylator status is shown in Table 6. At both
doses, Cmax and AUC differ significantly between SS and FF
acetylators. There were no differences found regarding tmax
based on acetylator status.
At an INH dose of 5 mg/kg, 1 of 8 children with FF acety-
lator status, 1 of 4 with FS acetylator status, and 7 of 8 with SS
acetylator status achieved Cmaxs above the recommended min-
imal therapeutic concentration for INH (3 !g/ml), while with
INH at 10 mg/kg, all children achieved INH Cmaxs above the
therapeutic target concentration.
DISCUSSION
We show that following administration of INH, PZA, and
RMP at the revised WHO dosage recommendations, most
children under 2 years of age had serum drug concentrations
within the recommended therapeutic range. In contrast, at the
previous WHO dosages, serum INH, PZA, and RMP concen-
trations were significantly lower and often below the recom-
mended concentrations for anti-TB therapy. Serum INH con-
centrations in children are generally reported to be lower than
in adults following the same mg/kg dose (3, 21, 34, 41). Al-
though INH is the most extensively studied anti-TB drug, we
are aware of only two reports of INH pharmacokinetics that
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studies, INH was given at doses (15 mg/kg and 10 mg/kg,
respectively) similar to those currently recommended by the
WHO (10 to 15 mg/kg). The peak serum INH concentrations
were comparable to those in our study and above the thera-
peutic minimum concentration of INH. In a previous study by
our group, serum INH concentrations in children younger than
6 years of age receiving a dose of 4 to 6 mg/kg were significantly
lower than in children prescribed a dose of 8 to 10 mg/kg (2.39
!g/ml versus 5.71 !g/ml) (21). The proportion of children with
peak serum INH concentrations of "3 !g/ml following an INH
dose of 5 mg/kg was even higher than in the present study
(70% versus 50%).
In our study, coadministration with RMP had no influence
on INH pharmacokinetics, while some inconsistent influence
on PZA pharmacokinetics was found. Serum INH, PZA, and
RMP concentrations were not associated with nutritional sta-
tus, type of TB, or gender. The HIV status of the child did not
affect INH and RMP pharmacokinetics, while the findings for
PZA differed, dependent on the dosage given. Younger chil-
dren achieved higher serum INH concentrations than older
children, but for PZA and RMP, age did not influence the
pharmacokinetic profile (within this 2-year age range). Chil-
dren with a NAT2 fast-acetylator status had significantly lower
serum INH concentrations than children with slow-acetylator
status.
Rey et al. demonstrated a marked difference between slow
and fast INH acetylators, with slow acetylators achieving
higher serum INH levels. In further studies, a trimodal INH
elimination was demonstrated (18, 26). Several studies have
confirmed that fast- or intermediate-acetylator status is asso-
ciated with lower serum INH concentrations than slow-acety-
lator status (21, 34). The distribution of acetylator phenotypes
is population specific. This might explain the comparatively
higher serum INH concentrations among Indian children, with
mean serum INH concentrations of 4.75 !g/ml following an
INH dose of 5 mg/kg and 10.1 !g/ml following a dose of 10
mg/kg (31). Routine determination of the acetylator status for
clinical care is not feasible in resource-limited settings; how-
ever, with an INH dosage of 10 mg/kg, appropriate serum INH
concentrations can be ensured in most children, irrespective of
their acetylator status. Higher dosages might not be required in
pediatric populations with predominantly slow acetylators and
would unnecessarily expose patients to a higher risk of side
effects.
Age-dependent elimination of INH has been demonstrated,
with younger children eliminating INH more rapidly than
older children and adults (21, 34, 46). This has been attributed
mainly to a relatively larger liver size in proportion to total
body weight in young children (3, 34). In our study, however,
where all children were less than 2 years old, serum INH levels
were higher in the younger children despite more children "1
year of age with the fast- and intermediate-acetylator pheno-
types. In this very young age group, maturation of the NAT2
enzyme system might play an important role in INH metabo-
lism. There is some evidence that maturation of acetylation
occurs within the first 2 years of life and the cumulative per-
centage of fast acetylators increases with age, although the
final acetylator status is genetically determined (25, 46). The
effect of age in our study population might therefore be con-
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There are no published studies of the pharmacokinetics of
PZA specifically investigating children younger than 2 years of
age. In two studies of older children, PZA was used at 35
mg/kg, the same dosage currently recommended by the WHO;
in one study (n $ 10), the ages of the children studied ranged
from 6 to 12 years and in the second (n $ 27), the median age
was 5.7 years (12, 31, 44). The mean Cmax in these studies was
40 to 50 !g/ml, similar to that observed in our study. In a study
of serum PZA concentrations across different age groups, PZA
pharmacokinetics did not differ significantly with age (39). In
our study, no influence of age on PZA pharmacokinetics was
found. There is evidence that serum PZA concentrations in-
crease linearly with increasing dose (45). In our study, serum
PZA concentrations following a dose of 25 mg/kg were signif-
icantly lower than those following a 35-mg/kg dose. This is in
contrast to a small study of PZA pharmacokinetics in children
(%5 years of age) where serum PZA concentrations of 42.4
(SD, 3.3) !g/ml were reported following a dose of 25 mg/kg
(13).
Of note is that the lower recommended limit of serum PZA
concentrations (20 !g/ml) was achieved in 18 children follow-
ing the previous WHO dosage recommendations and in all 20
following the higher dosages. However, mean serum PZA con-
centrations above 35 !g/ml were only achieved following
higher doses.
Most of the published pharmacokinetic studies of RMP in
children were performed after a single dose of RMP and not
after anti-TB therapy with RMP had been established. Due to
self-induction of RMP metabolism, these findings might show
higher serum drug concentrations than actually present during
established anti-TB therapy. In a study with children 2 months
to 5 years of age, low maximum serum drug levels (5.2 !g/ml)
were found after a dose of 15 mg/kg (9). A more recent study
of children (mean age, 3.8 years) established on RMP therapy
assessed RMP parameters following a dose of 10 mg/kg (35).
Serum RMP concentrations and AUCs were comparable to
those in our younger study population. In both studies, the
mean peak serum drug concentrations were low ("8 !g/ml).
Again, our data confirm that the revised dosages recom-
mended by WHO are necessary to achieve satisfactory se-
rum RMP concentrations in young children. Although chil-
dren have been documented to achieve lower serum RMP
concentrations than adults in several studies, we could not
find any influence of age within our young study population
(1, 16, 35, 40).
Because RMP is a potent inducer of the cytochrome P450
system, concomitant treatment can result in a decreased half-
life of a number of compounds (20, 42). Serum INH concen-
trations in our study were not affected by RMP, as has been
previously described (24, 33). Our findings indicate that when
PZA is given at a dose of 25 mg/kg, the concomitant use of
RMP reduces the Cmax of PZA. However, following a PZA
dose of 35 mg/kg, RMP did not influence the PZA concentra-
tion. The clinical significance and mechanism of this finding
are not clear. In previous studies, concurrent RMP did not
influence the pharmacokinetics of PZA (2, 32). However,
Bouhlabal et al. reported significantly lower serum PZA con-
centrations in adults when the drug was given in combination
with INH and RMP rather than as monotherapy (7).
HIV-infected patients have been reported to achieve lower
serum anti-TB drug concentrations (8, 12, 14). This has been
attributed to malabsorption caused by drug-drug interactions,
gastrointestinal infections, or wasting, rather than the HIV
infection itself. The different anti-TB drugs seem to be affected
in various ways. Graham et al. demonstrated decreased serum
PZA levels in Malawian HIV-infected children, while serum
ethambutol concentrations were not lower in HIV-infected
children than in non-HIV-infected children (12). In our study,
HIV-infected children had lower serum concentrations of all of
the first-line drugs tested, but only for PZA did this difference
reach statistical significance. As only five children in our study
were HIV infected, we may, however, not have been suffi-
ciently powered to demonstrate such differences. The effect of
HIV coinfection on the pharmacokinetics of anti-TB drugs in
children requires further investigation.
Conclusions. Our data document low serum INH, PZA, and
RMP concentrations following the previous WHO dose rec-
ommendations for children younger than 2 years of age. In
contrast, administration of the revised WHO dose recommen-
dations of INH at 10 mg/kg, RMP at 15 mg/kg, and PZA at 35
mg/kg results in satisfactory serum drug concentrations. Our
data provide supportive evidence for the implementation of
the revised WHO guidelines for first-line anti-TB therapy in
young children.
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Reviews	  on	  the	  use	  of	  second-­line	  anti-­tuberculosis	  drugs	  in	  children	  




Abstract	  literature	  review	  thioamides	  (accepted	  for	  publication)	  
Ethionamide	  (ETH)	  and	  prothionamide	  (PTH),	  both	  thioamides,	  have	  proven	  efficacy	  in	  
clinical	   studies	   and	   form	   important	   components	   for	   multidrug-­‐resistant	   tuberculosis	  
treatment	  regimens	  and	  for	  treatment	  of	  tuberculous	  meningitis	  in	  adults	  and	  children.	  
ETH	  and	  PTH	  are	  pro-­‐drugs	  that,	  following	  enzymatic	  activation	  by	  mycobacterial	  EthA	  
inhibit	  InhA,	  a	  target	  shared	  with	  isoniazid	  (INH),	  and	  subsequently	  inhibit	  mycolic	  acid	  
synthesis	  of	  Mycobacterium	  tuberculosis.	  Co-­‐resistance	  to	  INH	  and	  ETH	  is	  conferred	  by	  
mutations	  in	  the	  mycobacterial	  inhA	  promoter	  region;	  mutations	  in	  the	  ethA	  gene	  often	  
underlie	  ETH	  and	  PTH	  monoresistance.	  An	  oral	  daily	  dose	  of	  ETH	  or	  PTH	  of	  15-­‐20mg/kg	  
with	  a	  maximum	  daily	  dose	  of	  1,000mg	   is	   recommended	   in	   children	   to	  achieve	  adult-­‐
equivalent	  serum	  concentrations	  shown	  to	  be	  efficacious	  in	  adults,	  although	  information	  
on	  optimal	  pharmacodynamic	  targets	  is	  still	   lacking.	  Gastrointestinal	  disturbances,	  and	  
hypothyroidism	   during	   long-­‐term	   therapy,	   are	   frequent	   adverse	   effects	   observed	   in	  
adults	  and	  children,	  but	  are	  rarely	  life-­‐threatening	  and	  seldom	  necessitate	  cessation	  of	  
ETH	  therapy.	  More	  thorough	  investigation	  of	  the	  therapeutic	  effects	  and	  toxicity	  of	  ETH	  
and	   PTH	   is	   needed	   in	   childhood	   TB	   while	   child-­‐friendly	   formulations	   are	   needed	   to	  
appropriately	  dose	  children.	  	  
	  





The	   thioamides,	   ethionamide	   (ETH)	   and	   its	   propyl-­‐analog	   prothionamide	   (PTH),	   are	  
among	   the	   most	   frequently	   used	   oral	   second-­‐line	   agents	   for	   the	   management	   of	  
paediatric	  tuberculosis	  (TB).	  Although	  ETH	  is	  more	  widely	  available,	  ETH	  and	  PTH	  are	  
considered	   interchangeable	   in	   TB	   chemotherapy	   regimens.	   ETH	   and	   PTH	   are	  
recommended	   for	   the	   treatment	   of	   multidrug-­‐resistant	   tuberculosis	   (MDR-­‐TB;	   i.e	  
resistance	   to	   both	   isoniazid	   [INH]	   and	   rifampicin	   [RMP]),	   but	   also	   to	   treat	   drug-­‐
susceptible	  tuberculous	  meningitis	  (TBM)	  and	  miliary	  TB	  in	  some	  settings,	  due	  to	  good	  
cerebrospinal	   fluid	  (CSF)	  penetration	  (170,	  244,	  245).	  Thioamides	  also	  exhibit	  activity	  
against	  Mycobacterium	  leprae	  (246).	  
There	   is	   limited	   data	   on	   the	   efficacy,	   pharmacokinetics	   and	   safety	   of	   thioamides	   in	  
children	   with	   TB,	   where	   treatment	   options	   especially	   for	   MDR-­‐TB,	   are	   limited.	   	   We	  
aimed	   to	   review	   the	   existing	   evidence	   for	   ETH	   and	   PTH	   use	   in	   the	   TB	   treatment	   in	  
children	   to	   inform	   treatment	   recommendations	   for	   ETH	   and	   PTH,	   and	   highlight	  
knowledge	  gaps	  for	  future	  research	  in	  children.	  
	  
Methods	  
A	  scoping	  review	  (247)	  was	  performed	  to	  assess	  the	  clinical	  evidence	  for	  thioamide	  use	  
in	  children	  with	  TB.	   	  We	  searched	  PubMed	  without	  date	  or	   language	  restrictions	  (only	  
English-­‐,	  French-­‐,	  Spanish-­‐	  and	  German-­‐language	  references	  were	  reviewed),	  using	  the	  
following	   search	   terms:	   tuberculosis,	   thioamides,	   ethionamide,	   prothionamide,	  
children/child,	   efficacy,	   therapy,	   treatment,	   resistance,	   pharmacokinetics,	  
pharmacodynamics,	   safety	   and	   toxicity.	   The	   initial	   broad	   search	   using	   the	   terms	  
“tuberculosis,	   children,	  ethionamide”	   retrieved	  100	  search	  results,	  using	   “tuberculosis,	  
children,	   prothionamide	   (protionamide)”	   8	   (9)	   results	   and	   “tuberculosis,	   children,	  
thioamide”	  only	  2	  results.	  Narrowing	  the	  search	  by	  adding	  the	  following	  search	  terms	  to	  
the	   initial	   broad	   ETH	   search	   resulted	   in	   the	   following	   subsets	   of	   articles:	   “efficacy”	  
yielded	   3	   results,	   “therapy	   or	   treatment”	   yielded	   84	   results,	   “resistance”	   yielded	   33	  
results,	  “pharmacokinetics”	  3	  results,	  “pharmacodynamics”	  63	  results,	  “safety”	  2	  results	  
and	   “toxicity”	   6	   results.	   Abstracts	   were	   reviewed	   and	   full	   text	   articles	   retrieved	   for	  
studies	   with	   relevant	   information.	   The	   reference	   lists	   of	   identified	   articles	   were	  
searched	   for	   additional	   relevant	   reports.	   Adult	   data	   were	   reviewed	   if	   paediatric	   data	  




were	   lacking	   for	   each	   separate	   section,	   and	   were	   also	   included	   for	   comparison	   for	  
pharmacokinetic	  reference	  points	  related	  to	  efficacy.	  
	  
Mode	  of	  action	  	  
ETH	  and	  PTH	  are	  structurally	  similar	  to	  INH,	  and	  like	  INH,	  cause	  actively	  growing	  bacilli	  
to	  lose	  acid-­‐fastness	  (248).	  Both	  INH	  and	  ETH	  (and	  PTH)	  are	  pro-­‐drugs	  that,	   following	  
activation,	   inhibit	   mycolic	   acid	   synthesis	   (249,	   250).	   ETH	   is	   activated	   by	   the	  
monooxygenase	  EthA,	  leading	  to	  the	  sulfoxide	  metabolite	  that	  has	  similar	  activity	  to	  the	  
parent	   drug	   (251-­‐253).	   	   It	   has	   been	  postulated	   that	   ETH	  and	   its	   sulfoxide	   are	   further	  
transformed	   by	   EthA	   to	   a	  metabolite	   that	   accumulates	   intracellularly	   and	   acts	   as	   the	  
final	   toxic	   compound	   (254).	   Activated	   ETH	   and	   PTH	   form	   adducts	   with	   nicotinamide	  
adenine	  dinucleotide	  (NAD),	  which	  are	  inhibitors	  of	  the	  InhA	  enzyme	  in	  Mycobacterium	  
tuberculosis	   (255-­‐257).	   Inhibition	   of	   InhA	   results	   in	   inhibition	   of	   mycolic	   acid	  
biosynthesis	  and	  cell	  lysis	  (258).	  	  
	  
Mechanism	  of	  resistance	  and	  clinical	  application	  
At	  an	  early	  stage	  of	  development	  it	  was	  noted	  that	  ETH	  was	  effective	  against	  strains	  of	  
M.	   tuberculosis	   that	  were	  highly	  resistant	   to	   INH,	  but	  was	   less	  effective	  against	  strains	  
that	  were	  “only	  slightly	  INH-­‐resistant”	  (248,	  259).	  More	  recent	  studies	  have	  shown	  that	  
INH	   resistance	   is	   usually	   caused	   by	   mutations	   in	   either	   the	   katG	   gene	   or	   the	   inhA	  
structural	   gene	   or	   the	   inhA	   promoter	   region	   (260).	   KatG	   encodes	   for	   catalase	  
peroxidase,	  the	  enzyme	  which	  converts	  the	  pro-­‐drug	  INH	  into	  its	  active	  form,	  and	  katG	  
mutations	  are	  usually	  associated	  with	  high-­‐level	  INH	  resistance.	   	  As	  katG	   is	  uninvolved	  
in	  ETH	  activation,	  the	  efficacy	  of	  ETH	  is	  not	  affected	  by	  katG	  mutations.	  ETH	  shares	  the	  
same	   final	   target	   with	   INH,	   and	   mutations	   in	   the	   inhA	   promoter	   region	   result	   in	   co-­‐
resistance	  to	  INH	  and	  ETH	  (256).	  However,	  INH	  resistance	  due	  to	  inhA	  promotor	  region	  
mutations	   usually	   manifests	   as	   low–level	   resistance,	   and	   can	   often	   be	   overcome	   by	  
giving	  INH	  at	  a	  higher	  dose	  (15-­‐20	  mg/kg),	  this	  being	  the	  rationale	  for	  the	  empirical	  use	  
of	  high-­‐dose	  INH	  combined	  with	  ETH	  in	  MDR-­‐TB	  treatment,	  also	  in	  children	  (78,	  79).	  	  
Resistance	   to	  ETH	   is	   further	   associated	  with	  mutations	   in	   the	  ethA	   gene	   encoding	   the	  
activation	  of	  the	  drug,	  thus	  preventing	  drug	  activation	  (257).	  




EthA	   transcription	   is	   repressed	   by	   ethR,	   thus	   over-­‐expression	   of	   ethR	   causes	   ETH	  
resistance	   (261,	   262).	   Less	   frequent	   mutations	   associated	   with	   ETH	   resistance	   are	  
mutations	   in	   mshA	   and	   ndh	   genes.	   MshA	   encodes	   a	   glycosyltransferase,	   an	   enzyme	  
involved	   in	   mycothiol	   biosynthesis.	   Mycothiol	   promotes	   ETH	   activation	   via	   EthA.	  
Therefore	   mycothiol	   biosynthesis	   might	   be	   essential	   for	   ETH	   susceptibility	   in	   M.	  
tuberculosis	   (263).	   Mutations	   in	   ndh	   gene	   result	   in	   increased	   intracellular	   NADH	  
concentration,	  competitively	  inhibiting	  the	  binding	  of	  INH-­‐NAD	  and	  ETH-­‐NAD,	  therefore	  
leading	  to	  co-­‐resistance	  of	  INH	  and	  ETH	  (264).	  
For	   phenotypic	   drug	   susceptibility	   testing	   (DST)	   critical	   concentrations	   against	   M.	  
tuberculosis	   using	  BACTEC	  MGIT	  960	   system	  of	   ETH	  5.0µg/ml	   and	  PTH	  2.5µg/ml	   and	  
using	  BACTEC	  460	  of	  ETH	  2.5µg/ml	  and	  PTH	  1.25µg/ml	  have	  been	  proposed	  (265).	  For	  
Middlebrook	   7H11	   agar,	   the	   critical	   concentration	   is	   10µg/ml	   (266).	   Using	   this	   ETH	  
concentration	   of	   10µg/ml,	   isolates	   with	   inhA	   mutations	   were	   not	   detected	   by	  
phenotypic	  testing	  in	  a	  surveillance	  study	  in	  children	  with	  MDR-­‐TB,	  indicating	  that	  this	  
critical	   concentration	   may	   be	   too	   high	   (10).	   Furthermore,	   ETH	   DST	   is	   notoriously	  
unreliable,	   partly	   because	   the	   change	   in	   minimal	   inhibitory	   concentrations	   (MICs)	  
associated	   with	   resistance	   is	   small,	   and	   partly	   because	   the	   drug	   is	   thermolabile.	  
Therefore,	  molecular	   testing	   of	   ETH	   resistance	  might	   be	   specifically	   helpful	   in	   future,	  
although	   not	   available	   in	   routine	   care	   settings	   (267,	   268).	   The	   correlation	   between	  
mutations	   conferring	  ETH	  resistance	  and	   the	  MIC	  warrants	   further	   studies.	   In	  a	   study	  
from	   the	  European	   region	  on	  137	  drug	   resistant	  M.	   tuberculosis	   isolates,	  mutations	   in	  
inhA-­	  or	  ethA-­‐gene	  (or	  both)	  could	  be	  identified	  in	  all	  57	  (42%)	  ETH-­‐resistant	  isolates,	  
but	  the	  level	  of	  resistance	  in	  phenotypic	  testing	  varied	  (269).	  
Regional	   differences	   in	   ETH	   resistance	   exist,	   but	   there	   is	   a	   global	   trend	   towards	  
increasing	  resistance	  to	  thioamides,	  with	  as	  many	  as	  50-­‐75%	  of	  MDR-­‐TB	  isolates	  having	  
ETH	   resistance	   in	   some	   populations	   (10,	   270-­‐274).	   Therefore	   the	   use	   of	   thioamides	  
might	   be	   precluded	   in	   some	   populations.	   In	   case	   of	   ETH	   resistance	   caused	   by	   inhA	  
mutations,	   the	  use	  of	  ETH	  boosters	  may	  be	  an	  option	   for	  ETH	   treatment	   in	   the	   future	  
(275,	  276).	  These	  boosters	  enhance	  expression	  of	  EthA	  by	  inhibiting	  binding	  of	  the	  EthA	  
regulator	  EthR,	  and	  have	  thereby	  shown	  to	  enhance	  the	  activity	  of	  ETH	  in	  M.	  tuberculosis	  
in	  in	  vitro	  and	  in	  murine	  studies,	  but	  have	  yet	  to	  be	  studied	  in	  humans	  (277).	  	  




Furthermore,	   optimal	   serum	   drug	   concentrations	   should	   be	   achieved	   in	   order	   to	  
minimize	  the	  risk	  of	  inadequate	  killing	  and	  the	  emergence	  of	  resistance.	  
	  
Efficacy	  against	  M.	  tuberculosis	  
Efficacy	  in	  in	  vitro	  studies	  
In	  vitro,	  more	   than	  99%	  of	   strains	  were	   inhibited	  at	  ETH	  concentrations	  between	  0.3-­‐
1.25µg/ml	  (MIC)	  in	  7H12	  broth,	  while	  at	  higher	  concentrations	  ETH	  showed	  bactericidal	  
activity.	   At	   ETH	   concentrations	   of	   2.5-­‐5.0µg/ml	   in	   7H12	   broth	   >99%	   of	   bacilli	   were	  
killed	   (minimal	   bactericidal	   concentration,	   MBC)	   (72).	   	   Further	   studies	   confirmed	  
bactericidal	   activity	   of	   ETH	   and	   PTH	   against	   M.	   tuberculosis,	   with	   PTH	   MICs	   often	  
reported	  as	  half	  that	  of	  ETH	  (265,	  278,	  279).	  
	  
Efficacy	  in	  animal	  studies	  
In	  an	  early	  report	  on	  studies	  in	  guinea	  pigs,	  increasing	  the	  daily	  ETH	  dose	  from	  10mg/kg	  
to	   20mg/kg,	   led	   to	   anti-­‐TB	   activity	   of	   ETH	   close	   to	   that	   of	   INH	   at	   5mg/kg	   (280).	   In	  
murine	  studies,	  ETH	  and	  PTH	  at	  dosages	  of	  25mg/kg	  were	  very	  effective	  in	  preventing	  
resistance	   to	   INH	   without	   further	   increasing	   INH	   bactericidal	   activity	   (281).	   In	   the	  
mouse	  model,	  ETH	  alone	  had	  activity	  against	  M.	  tuberculosis	  less	  than	  that	  of	  INH	  at	  an	  
equivalent	   dose	   (282).	   Following	   4	   weeks	   of	   therapy	   (5	   days/week)	   the	   log	   colony	  
forming	  units	  (CFUs)/lung	  for	  control,	  ETH	  25mg/kg,	  ETH	  50	  mg/kg,	  ETH	  75	  mg/kg	  and	  
INH	   25	   mg/kg	   were:	   8.01,	   6.67,	   6.79,	   6.58,	   and	   5.59	   respectively	   (282).	   In	   a	   further	  
murine	  model,	  ETH	  at	  a	  dose	  of	  125mg/kg	  showed	  activity	  against	  a	  clinical	  MDR-­‐strain	  
susceptible	   to	   ETH	   (MIC	   2.0µg/ml),	   while	   ETH	   at	   a	   dose	   of	   50mg/kg	   had	   no	   benefit	  
(283).	  	  
	  
Efficacy	  in	  adult	  studies	  
Shortly	   after	   the	   discovery	   of	   ETH	   activity	   in	  M.	   tuberculosis	   in	   vitro	   and	   in	   animal	  
studies,	  it	  was	  evaluated	  in	  a	  number	  of	  two-­‐	  and	  three-­‐drug	  regimens	  in	  adult	  patients	  
with	   TB.	   ETH	   showed	   favorable	   activity	   in	   the	   ‘reversal	   of	   infectiousness’	   and	   in	  




prevention	  of	   drug	   resistance	   in	   companion	  drugs	   in	   a	   study	  utilizing	   a	  dosage	  of	   1	   g	  
daily	  given	  in	  4	  doses	  of	  250	  mg	  or	  two	  doses	  of	  500	  mg	  in	  adults	  (284).	  If	  given	  as	  ETH	  
monotherapy,	   loss	   of	   susceptibility	   against	   ETH	   has	   been	   reported	   (284).	   In	   an	   early	  
study,	   investigating	   the	   efficacy	   of	   PTH	   in	   pulmonary	   TB,	   serial	   counts	   on	   CFU	   of	  M.	  
tuberculosis	   in	  sputum	  culture	  were	  performed.	  Patients	  were	  either	  treated	  with	  PTH	  
monotherapy	   at	   a	   dose	   of	   500mg	   or	   1,000mg,	   or	   with	   combination	   therapy	   of	   INH	  
(10mg/kg)	  and	  PTH	  (1.0g).	  Following	  14	  days	  of	  PTH	  monotherapy	  at	  both	  dosages,	  the	  
number	  of	  CFU	  in	  sputum	  were	  reduced	  to	  about	  a	  third,	  while	  in	  the	  INH/PTH	  group,	  a	  
reduction	  of	  CFU	  of	  >80%	  was	  found	  (285).	  
In	  a	  study	  of	  7	  adult	  patients	  with	  sputum	  acid-­‐fast	  bacilli	  (AFB)	  smear-­‐positive	  TB,	  ETH,	  
accompanied	  by	  streptomycin	   (SM)	  was	  given	   in	  a	  daily	  dose	  of	  1,000mg	  divided	   in	  4	  
doses.	   The	   full	   dose	   was	   achieved	   by	   increasing	   the	   dose	   over	   a	   week	   and	   was	   well	  
tolerated	  (286).	  At	  5	  months,	  all	  7	  patients	  were	  culture-­‐negative	  and	  ETH	  appeared	  to	  
prevent	  the	  development	  of	  SM	  resistance	  (286).	  Another	  study	  on	  ETH	  (1,000mg/d	  in	  4	  
doses)	   in	   combination	   with	   INH	   in	   previously	   untreated	   TB	   patients	   showed	   culture	  
conversion	  at	  6-­‐months	  of	  97%	  and	  at	  12-­‐months	  of	  100%	  in	  those	  patients	  completing	  
therapy	   (287).	   Because	   the	   rate	   of	   intolerance	   (mainly	   gastrointestinal)	   of	   ETH	   was	  
high,	  studies	  investigating	  an	  oral	  dose	  of	  750	  (divided	  in	  three	  doses)	  and	  500mg	  daily	  
(divided	   in	   two	  doses)	   followed	   (288,	  289).	  Efficacy	  of	   combination	   therapy	  with	   INH	  
and	  ETH	  even	  at	  a	  dose	  of	  ETH	  500mg	  was	  high	  (sputum	  culture	  conversion	  100%	  after	  
7	  months),	  without	  development	  of	  resistance.	  Following	  a	  dose	  of	  ETH	  1,000mg,	  750mg	  
and	  500mg,	  treatment	  with	  ETH	  had	  to	  be	  stopped	  due	  to	  adverse	  events	  in	  31%,	  18%	  
and	  8%,	  respectively	  (287,	  289).	  	  
In	   a	   direct	   randomized	   comparison	   in	   276	   patients,	   the	   response	   to	   6	   months	   of	  
treatment	  with	  ETH	  500mg	  twice	  daily	  and	  SM	  did	  not	  differ	  significantly	  from	  that	  of	  
INH	   and	   SM	   (also	   given	   for	   6	  months)	   (290).	   Bacteriological	   conversion	   at	   4	  months	  
occurred	  in	  80%	  of	  the	  INH/SM	  group	  and	  in	  74%	  of	  the	  ETH/SM	  group.	  With	  regard	  to	  
the	   emergence	   of	   resistance	   to	   SM,	   there	  was	   no	   difference	   between	   INH	   and	   ETH	   in	  
efficacy	  (290).	  Several	  other	   trials,	  mainly	   in	  adult	  patients	  polyresistant	   to	   INH,	  para-­
aminosalicylic	  acid	  (PAS)	  and	  SM,	  showed	  some	  activity	  of	  ETH	  in	  combination	  with	  one	  
or	  two	  other	  drugs	  (mostly	  cycloserine	  and	  pyrazinamide	  [PZA])	  (291-­‐293).	  	  




In	   a	   study	   on	   PTH	   given	   as	   either	   mono-­‐therapy	   at	   500mg	   or	   1,000g	   daily	   or	   in	  
combination	   with	   INH	   (PTH	   1,000mg	   +INH	   10mg/kg)	   for	   90	   days,	   sputum	   cultures	  
became	   negative	   in	   71%,	   70.5%	   and	   74%,	   respectively	   (285).	   Although	   culture	  
negativity	  after	  90	  days	  was	  similar	  following	  therapy	  with	  PTH	  1,000mg	  and	  500mg,	  it	  
occurred	  slower	  with	  PTH	  500mg,	  with	  a	  high	  bacterial	  load	  in	  those	  patients	  remaining	  
culture-­‐positive	  (285).	  
In	  a	  comparative	  study,	  PTH	  and	  ETH	  both	  at	  a	  dose	  of	  500mg	  daily	  (divided	  in	  2	  doses),	  
were	  equally	  effective	  in	  combination	  therapy	  with	  INH	  and	  SM.	  Sputum	  cultures	  after	  
six	  months	  treatment	  were	  negative	  in	  98%	  of	  patients	  treated	  with	  ETH	  and	  96%	  with	  
PTH,	  respectively	  (294).	  	  
Nonetheless,	   gastrointestinal	   intolerance	   is	   a	   significant	   problem	   and	   has	   prevented	  
ETH	  and	  PTH	  from	  playing	  a	  major	  role	  in	  first-­‐line	  regimens.	  	  With	  the	  growing	  burden	  
of	   MDR-­‐TB,	   interest	   in	   these	   agents	   has	   been	   rekindled.	   In	   a	   meta-­‐analysis	   of	   9,153	  
patients	  with	  MDR-­‐TB,	  treatment	  success	  was	  associated	  with	  the	  use	  of	  ETH/PTH	  in	  a	  
multi-­‐drug	  regimen	  (beside	  other	  factors)	  (295).	  	  
	  
Efficacy	  in	  paediatric	  studies	  
Information	   on	   the	   value	   of	   ETH	   and	   PTH	   in	   childhood	   TB	   is	   limited.	   In	   an	   early	  
anecdotal	   report	   on	   225	   children,	   it	   was	   stated	   that	   in	   30%	   the	   treatment	   outcome	  
results	  were	  better	  in	  children	  treated	  with	  ETH	  15-­‐25mg/kg	  in	  combination	  with	  INH	  
than	  in	  those	  treated	  with	  standard	  therapy	  at	  that	  time	  (INH	  plus	  PAS	  or	  SM);	  ETH	  was	  
tolerated	   well	   (296).	   In	   a	   study	   on	   34	   children	   with	   bacteriologically	   confirmed	   TB,	  
culture	   conversion	   was	   achieved	   within	   2	   months	   of	   treatment	   with	   ETH,	   mainly	  
accompanied	  by	  INH	  and	  radiographic	  improvement	  found	  in	  98%	  (297).	  In	  one	  study	  
ETH	  was	  given	   rectally	   at	  12-­‐35mg/kg	   (mean	  15mg/kg)	   together	  with	  oral	   INH	   in	  30	  
children;	   tolerability	   was	   good,	   and	   the	   combination	   of	   rectal	   ETH	   and	   oral	   INH	  was	  
found	  at	  least	  as	  good	  as	  INH	  plus	  SM	  (298).	  
Two	  studies	  on	  95	  and	  187	  children	  with	  TBM,	  respectively,	  report	  using	  ETH	  at	  a	  dose	  
of	  20mg/kg	  as	  part	  of	  an	  intensified	  short-­‐course	  regimen	  together	  with	  INH,	  RMP	  and	  
PZA	   for	   6	   months	   (299,	   300).	   The	   rationale	   for	   using	   ETH	   as	   a	   fourth	   drug	   in	   TBM	  




treatment	   is	   that	   after	   meningeal	   inflammation	   has	   subsided,	   RMP	   only	   poorly	  
penetrates	  into	  the	  CSF	  and	  ethambutol	  or	  SM	  almost	  not	  at	  all.	  It	  is	  therefore	  likely	  that	  
only	   INH,	  ETH	  and	  PZA	  reach	   their	  MIC	   in	   the	  CSF,	  which	  can	  be	  problematic	   in	  areas	  
with	   high	   rates	   of	   INH	   resistance	   (170).	   The	   majority	   of	   these	   children	   were	   safely	  
treated	  with	  this	  intensified	  short-­‐course	  treatment	  with	  a	  very	  low	  relapse	  rate	  and	  low	  
mortality	  (299,	  300).	  In	  the	  more	  recent	  study,	  the	  overall	  mortality	  was	  3.8%,	  and	  even	  
in	   children	  with	   severe	   disease	   (stage	   III)	  mortality	   of	   7.8%	   (5/64	   children)	  was	   low	  
(300).	  Good	  treatment	  outcome	  was	  seen	  in	  100%	  of	  children	  with	  stage	  I	  disease,	  97%	  
with	  stage	   II	  and	  47%	  with	  stage	   III	  disease,	  respectively.	  Therefore	  more	  than	  half	  of	  
the	  children	  with	  stage	  III	  disease	  had	  severe	  developmental	  and	  neurological	  sequelae.	  
Of	  note,	  using	  this	  treatment	  regimen	  for	  TBM,	  INH	  mono-­‐resistance	  was	  not	  associated	  
with	  poorer	  treatment	  outcome	  (300,	  301).	  	  
A	   systematic	   review	   of	   children	   treated	   for	   MDR-­‐TB	   reported	   a	   pooled	   treatment	  
success	  of	  81.67%;	  ETH	   formed	  part	  of	   the	   treatment	   regimen	   in	   all	   studies	   included,	  
(66),	   therefore	   the	   individual	   role	   of	  ETH	   could	  not	  be	   ascertained.	   In	   a	   retrospective	  
study	   on	   children	   with	   MDR-­‐TB,	   ETH,	   given	   for	   a	   median	   duration	   of	   13	   (10.5-­‐18)	  
months,	   was	   part	   of	   the	   treatment	   regimen	   in	   132	   of	   137	   children	   (98.5%)	   who	  
completed	  treatment	  (69).	  The	  overall	  treatment	  success	  was	  high	  (92%)	  (69).	  
In	  summary,	  ETH	  and	  PTH	  have	  significant	  activity	  against	  M.	  tuberculosis	  and	  prevent	  
drug	  resistance	  in	  companion	  drugs	  in	  adult	  studies.	  In	  vitro	  studies	  show	  a	  bactericidal	  
effect	   at	   higher	   doses,	   but	   due	   to	   intolerance	  doses	   of	   ETH/PTH	  of	   500mg	  or	   divided	  
doses	  have	  been	  used	  in	  adult	  studies.	  A	  dose	  of	  ETH	  500mg	  seems	  sufficient	  to	  prevent	  
development	   of	   drug	   resistance	   in	   the	   companion	   drugs	   (INH,	   SM).	   There	   is	   some	  
evidence	   that	   ETH/PTH	   at	   higher	   doses	   might	   add	   to	   the	   overall	   efficacy	   of	   anti-­‐TB	  
therapy,	   but	   robust	   evidence	   on	   exact	   dosing	   is	   lacking.	   In	   children,	   ETH	   at	   doses	  
between	  15-­‐20mg/kg	  is	  associated	  with	  good	  outcome	  as	  part	  of	  a	  multi-­‐drug	  regimen	  
against	  MDR-­‐TB,	  or	  disseminated	  forms	  of	  drug-­‐susceptible	  TB.	  	  
	  
Pharmacokinetics	  
Adult	  pharmacokinetic	  studies	  
In	  adults,	  absorption	  of	  ETH	  and	  PTH	  from	  the	   intestinal	   tract	   is	  almost	  complete	  and	  




food	  and	  antacids	  appear	  to	  have	  little	  effect	  on	  this	  process	  (302,	  303).	  Absorption	  can	  
however	   be	   erratic,	   possibly	   due	   to	   altered	   gastrointestinal	   motility	   induced	   by	   the	  
thioamides	  (160).	  
Protein	   binding	   is	   approximately	   30%	   (262,	   304).	   ETH	   is	   distributed	   throughout	   the	  
body	   with	   a	   reported	   volume	   of	   distribution	   of	   80	   liters.	   In	   adults,	   peak	   serum	  
concentrations	  (Cmax)	  of	  ETH	  occur	  at	  approximately	  2	  hours	  post-­‐dose	  and	  have	  been	  
reported	   to	   be	   between	   1.9	   to	   2.5µg/ml	   following	   an	   oral	   dose	   of	   500	  mg	   (303,	   305,	  
306).	   After	   a	   dose	   of	   250	  mg,	   Cmax	   ranges	   from	   0.9-­‐1.1	   µg/ml	   and	   is	   similar	   between	  
adult	   patients	   with	   and	   without	   acquired	   immunodeficiency	   syndrome	   (AIDS)	   (307).	  
ETH	  concentrations	  close	  to	  serum	  concentrations	  are	  reached	  in	  the	  lungs,	  tuberculous	  
lesions	  (308),	  and	  in	  the	  CSF	  (170,	  244,	  245).	  Considerably	  higher	  concentrations	  have	  
been	   found	   in	   pulmonary	   epithelial	   lining	   fluid	   than	   in	   serum	   or	   lung	   alveolar	   cells	  
(307).	  Significant	  variation	   in	  serum	  concentrations	  occurs,	  both	   in	   individual	  patients	  
and	   between	   patients	   (309,	   310).	   Bioavailability	   of	   ETH	   in	   TB	   patients	   has	   been	  
reported	  to	  be	  lower	  compared	  to	  healthy	  volunteers	  consistent	  with	  a	  higher	  clearance	  
and	  volume	  of	  distribution	  of	  ETH	  in	  TB	  patients.	  Table	  1	  summarizes	  the	  available	  data	  
on	  ETH	  pharmacokinetics	  in	  adults	  and	  children.	  
In	   patients	   receiving	   PTH	   at	   a	  mean	   dose	   of	   6mg/kg	   as	   part	   of	  MDR-­‐TB	   treatment,	   a	  
mean	  Cmax	  of	  2.2µg/ml	  occurred	  after	  approximately	  3.6	  hours	  (311).	  This	  differs	  from	  
an	  earlier	  report	  in	  healthy	  volunteers,	  where	  following	  a	  dose	  of	  PTH	  250mg	  a	  Cmax	  of	  
1.0-­‐1.5	  and	  a	  time	  to	  Cmax	  (Tmax)	  of	  about	  2	  hours	  have	  been	  reported	  (312).	  In	  the	  same	  
study,	  Cmax	  for	  ETH	  was	  about	  1.8	  times	  higher	  than	  for	  PTH,	  with	  the	  same	  ratios	  being	  
observed	   for	   the	  sulfoxide	  metabolites	   (312).	  The	  clinical	   implication	  of	   this	   finding	   is	  
unclear.	  	  	  
The	   first	   step	   of	   thioamide	   metabolism	   in	   the	   liver	   is	   transformation	   to	   sulphoxide	  
metabolites	  by	  flavin-­‐containing	  monooxygenase	  (FMO)	  in	  much	  the	  same	  manner	  as	  M.	  
tuberculosis	  bioactivation	  of	  this	  pro-­‐drug	  by	  EthA	  (313).	  Human	  FMOs	  appear	  to	  carry	  
out	  the	  first	  reaction	  to	  the	  sulfenic	  acid	  more	  readily	  than	  the	  bacterial	  enzyme,	  but	  are	  
slow	   to	   S-­‐oxygenate	   a	   second	   time	   (313).	   Following	   oral	   administration	   of	   ETH	  
intestinal	   (primarily	  FMO1)	  and	   liver	  FMO	  (FMO3)	  probably	  play	  an	   important	  role	   in	  
the	  pharmacokinetics	  of	  this	  pro-­‐drug	  and	  certainly	  in	  its	  demonstrated	  hepatotoxicity	  
(313).	  The	  sulphoxide	  metabolite	  is	  thought	  to	  be	  responsible	  for	  hepatotoxicity	  of	  ETH	  




(251).	  In	  human	  lungs,	  FMO2	  is	  expressed	  in	  high	  levels.	  A	  genetic	  polymorphism	  exists,	  
resulting	  in	  FMO2	  being	  inactive	  in	  individuals	  of	  Caucasian	  and	  Asian	  descent,	  while	  in	  
27%	  of	  individuals	  of	  African	  descent	  the	  active	  form	  of	  FMO2	  is	  expressed	  (313).	  The	  
influence	  of	  FMO2	  genetic	  polymorphism	  on	  activity	  and/or	  toxicity	  of	  ETH	  in	  the	  lung	  is	  
not	   yet	   known.	   These	   monooxygenases	   have	   many	   properties	   in	   common	   with	  
cytochrome	  P450	  system	  (CYP	  450)	  and	  often	  have	  overlapping	  substrate	  specificities	  
(313).	  RMP,	  commonly	  used	  with	  ETH,	  is	  a	  potent	  inducer	  of	  hepatic	  and	  intestinal	  P450	  
enzymes	   and	   information	   on	   the	   influence	   of	   RMP	   co-­‐administration	   on	   ETH	  
pharmacokinetics	  is	  limited.	  
Only	  a	  very	  small	  proportion	  of	  thioamides	  or	  their	  sulphoxide	  metabolites	  is	  recovered	  
in	  urine	  or	   faeces,	   and	   there	   is	   still	  much	  unknown	  about	  ETH/PTH	  elimination	   (101,	  
258,	  312,	  314).	  
In	  order	  to	  overcome	  gastrointestinal	  intolerance,	  the	  use	  of	  ETH	  suppositories	  has	  been	  
evaluated.	   The	   area	   under	   the	   time	   concentration	   curve	   (AUC)	   following	   rectal	   ETH	  
application	  was	   only	   57.3%	   of	   oral	   application	   and	   the	   Cmax	   33%,	   respectively	   (315),	  
making	  this	  a	  less	  attractive	  dosing	  option.	  	  
	  
Paediatric	  pharmacokinetic	  studies	  
There	  is	  limited	  information	  on	  the	  pharmacokinetics	  of	  ETH	  in	  children.	  Two	  children	  
were	  included	  in	  the	  study	  by	  Zhu	  et	  al.,	  and	  received	  a	  dose	  of	  ETH	  250mg	  orally:	  a	  12.3	  
year	   old	   (Cmax	   of	   0.48	   μg/ml,	   AUC	   of	   1.00	   μg-­‐h/ml)	   and	   a	   6.7	   year	   old	   (Cmax	   	   of	   1.11	  
μg/ml,	  AUC	  of	  9.88	  μg-­‐h/ml)	  (305).	  
In	   the	   first	   paediatric-­‐specific	   pharmacokinetic	   study	   of	   ETH	   in	   children,	   31	   children	  
overall	   were	   included,	   aged	   3	   months-­‐<2	   years,	   2-­‐<6	   years,	   and	   6-­‐12	   years	   of	   age	  
receiving	   the	  World	  Health	  Organization	   (WHO)	   recommended	  dosage	   of	   ETH	   (15-­‐20	  
mg/kg/day)	  (310).	  Of	  the	  31	  children	  (median	  age	  2.8	  years),	  12	  (39%)	  children	  were	  
HIV-­‐infected	  and	  16	  (52%)	  had	  pulmonary	  TB.	  Children	  younger	  than	  2	  years	  of	  age	  had	  
significantly	  lower	  ETH	  exposure	  (Cmax	  and	  AUC)	  compared	  to	  older	  children	  receiving	  
the	  same	  mg/kg	  dose.	  This	  may	  imply	  a	  need	  for	  a	  higher	  dosage	  in	  this	  age	  group.	  HIV	  
co-­‐infection	   was	   associated	   with	   reduced	   exposure	   (AUC),	   but	   not	   with	   delay	   in	  
absorption	   or	   elimination.	   RMP	   co-­‐administration,	   nutritional	   status	   or	   duration	   of	  




treatment	  did	  not	  affect	  the	  pharmacokinetics	  of	  ETH.	  Following	  a	  standard	  oral	  dose	  of	  
ETH	  15-­‐20mg/kg,	  the	  mean	  Cmax	  of	  ETH	  was	  above	  2.5µg/ml	  in	  all	  age	  groups,	  although	  
a	   low	   serum	   Cmax	   (<2.5	   µg/ml)	   was	   found	   in	   7	   children	   (5	   were	   <2	   years	   of	   age)	  
following	   4	   months	   of	   therapy;	   inter-­‐	   and	   intra-­‐individual	   variation	   was	   substantial	  
(310).	  Preliminary	  data	   from	  an	  ongoing	   study	   in	   the	   same	  study	   setting	   showed	   that	  
following	  an	  ETH	  dose	  of	  20mg/kg	   in	  34	  children,	  younger	  children	  had	  higher	  serum	  
concentrations	  compared	  to	  older	  children	  and	  overall	  ETH	  serum	  concentrations	  were	  
higher	  than	  found	  by	  Thee	  et	  al	  (316).	  This	  difference	  in	  findings	  from	  the	  same	  study	  
setting	  could	  be	  attributed	   to	  higher	  dosing	  and	  a	  different	  pharmacokinetic	   sampling	  
scheme	  used,	  different	  laboratory	  assays,	  as	  well	  as	  to	  a	  potential	  crushing	  of	  tablets	  in	  
the	   younger	   age	   group,	   which	   may	   alter	   bioavailability.	   In	   the	   follow-­‐up	   study,	   HIV-­‐
infected	  children	  were	  also	  exposed	  to	  lower	  serum	  concentrations	  than	  HIV-­‐uninfected	  
children	  (median	  AUC0-­‐8	  21.9	  vs	  28.1µgh/ml).	  	  
For	   treatment	   of	   TBM	   in	   children,	   an	   ETH	   doses	   of	   20mg/kg	   rather	   than	   15mg/kg	   is	  
needed	   to	   reach	   ETH	   concentration	   in	   the	   CSF	   >2.5µg/ml	   in	   the	  majority	   of	   children	  
(245).	  
In	   conclusion,	   an	   ETH	   dose	   of	   15-­‐20mg/kg	   in	   children	   seems	   appropriate	   to	   achieve	  
serum	   concentrations	   found	   in	   adults	   following	   a	   standard	   oral	   dose	   of	   500-­‐750mg,	  
although	  HIV-­‐infected	  children	  seem	  to	  be	  at	  risk	  for	  lower	  exposure.	  There	  are	  no	  child-­‐
friendly	   formulations	   of	   ETH,	   which	   is	   highly	   unpalatable,	   and	   the	   influence	   of	  
crushing/breaking	   tablets	   on	   its	   bioavailability	   has	   not	   been	   systematically	   assessed.	  
ETH	  suppositories	  use	  is	  associated	  with	  reduced	  bioavailability	  in	  adults,	  but	  paediatric	  
data	   are	   lacking.	   At	   present,	   we	   are	   not	   aware	   of	   any	   planned	   or	   completed	  
pharmacokinetic	  studies	  of	  PTH	  in	  children.	  
	  
Pharmacodynamics	  
There	   is	   limited	  data	   on	   the	  pharmacodynamics	   of	   thioamides.	   For	   anti-­‐TB	   therapy,	   a	  
targeted	   ETH	   Cmax	   for	   susceptible	   strains	   of	   M.	   tuberculosis	   have	   been	   proposed	   at	  
2.5µg/ml	   (317).	   In	   therapeutic	  drug	  monitoring,	   an	  ETH	  Cmax	  between	  1	  and	  5	  µg/ml,	  
following	  a	  dose	  of	  250-­‐500	  mg,	  are	  recommended	  targets	  (21,	  160).	  Broth-­‐determined	  
MICs	   of	   ETH	   for	   drug-­‐susceptible	   M.	   tuberculosis	   strains	   were	   0.60-­‐2.5µg/ml	   (317).	  
Therefore	  a	  Cmax	   target	  of	  2.5µg/ml	  has	  been	  proposed.	  M.	  tuberculosis	   strains	  with	  an	  




MIC	  <1.25µg/ml	  are	  classified	  as	  very	  susceptible	  and	  therefore	  an	  ETH	  Cmax	  of	  1.0µg/ml	  
might	  be	  efficacious	  against	  these	  strains.	  ETH	  has	  shown	  bactericidal	  activity	  at	  higher	  
concentration	  of	  2-­‐5µg/ml	  in	  vitro	  (72).	  	  
In	  a	  study	  establishing	  a	  population	  pharmacokinetic	  model	  for	  ETH	  pharmacodynamic	  
indices,	  such	  as	  the	  ratio	  of	  ETH	  Cmax/	  MIC	  or	  AUC/MIC,	  values	  were	  calculated	  using	  a	  
MIC	   against	   drug-­‐susceptible	   M.	   tuberculosis	   of	   1.0	   μg/ml	   (305).	   Only	   a	   dose	   of	  
750mg/day	  achieved	  concentrations	  above	  the	  MIC	  for	  3.6	  hours,	  while	  concentrations	  
following	  doses	  of	  ETH	  500mg	  once	  or	  twice	  daily	  or	  250mg	  twice	  or	  three	  times	  daily	  
did	  not	  reach	  the	  MIC	  value.	  Daily	  ETH	  doses	  of	  more	  than	  500mg	  are	  therefore	  required	  
to	   achieve	   an	   appropriate	   AUC/MIC	   in	   adults	   (305).	   	   Nevertheless,	   pharmacodynamic	  
targets	   of	   ETH	   in	   anti-­‐TB	   treatment	   have	   not	   been	   prospectively	   assessed	   and	   more	  




The	  main	  adverse	  effect	  of	  thioamides	  is	  gastrointestinal	  intolerance	  resulting	  in	  nausea,	  
vomiting,	   metallic	   taste,	   anorexia,	   abdominal	   discomfort,	   diarrhoea,	   weight	   loss,	   and	  
hepatotoxicity	  (see	  table	  2.).	  Gastrointestinal	  adverse	  effects	  of	  the	  thioamides	  are	  dose-­‐
related.	   In	   early	   studies	   on	   adults	   with	   TB,	   gastrointestinal	   disturbances	   occurred	   in	  
about	  half	  the	  patients	  taking	  ETH	  or	  PTH	  at	  an	  oral	  dose	  of	  500	  mg,	  while	  following	  a	  
dose	   of	   1,000	  mg,	   almost	   all	   patients	   reported	   gastrointestinal	   intolerance	   (290,	   318-­‐
320).	   Gastrointestinal	   intolerance	   is	   often	   transient	   or	   at	   least	   improves	   after	   two	   to	  
four	  weeks	  of	   therapy	  (284).	  To	   improve	  tolerability,	  divided	  daily	  doses	  can	  be	  given	  
and	  then	  gradually	  adjusted	  to	  a	  single	  daily	  dose	  (195,	  245).	  The	  use	  of	  suppositories	  
has	  been	  suggested	  (306,	  320)	  but	  pharmacokinetic,	  long-­‐term	  safety,	  and	  acceptability	  
data	  are	   lacking	   for	   this	  dosing	   strategy.	   Symptoms	  of	   intolerance	   (although	   less)	   still	  
occur	  with	  rectal	  administration	  in	  adults	  (321).	  	  In	  children	  tolerability	  following	  rectal	  
ETH	  administration	  has	  been	  demonstrated	   to	  be	  very	  good	   for	   short-­‐term	  use.	   In	  30	  
children	  rectal	  ETH	  at	  a	  mean	  dose	  of	  15mg/kg	  (12-­‐35mg/kg)	  was	  administered.	  Only	  3	  
children	   experienced	   mild	   gastrointestinal	   disturbances	   at	   the	   beginning	   of	   therapy,	  
which	   subsided	   during	   continuation	   of	   therapy	   (298).	   Following	   intravenous	  
administration,	   ETH	   as	   well	   as	   its	   sulphoxide	   are	   excreted	   in	   gastric	   juice,	   possibly	  




leading	  to	   the	  observed	  gastrointestinal	   intolerance	  of	  ETH	  occurring	  despite	  rectal	  or	  
intravenous	  administration	  (322).	  
The	  effect	  of	  supplementation	  with	  vitamin	  B	  complex	  on	  the	  tolerability	  of	  ETH/PTH	  is	  
controversial.	  While	   in	  some	  studies,	  vitamin	  B	  supplementation	  has	  been	  reported	   to	  
increase	   tolerability	   substantially	   and	   reduce	   nausea	   and	   vomiting	   in	   adults	   and	  
children	  (323),	  other	  have	  not	  found	  a	  positive	  effect	  (324).	  
Originally,	   PTH	   was	   developed	   as	   an	   alternative	   to	   ETH,	   with	   a	   focus	   on	   reducing	  
adverse	   effects.	   There	   is	   evidence	   that	   PTH	  might	   be	  better	   tolerated	   than	  ETH	   (324-­‐
326),	  although	  gastrointestinal	  disturbances	  and	  psychotoxic	  reactions	  still	  occur	  with	  
PTH	   (285).	   Following	   an	   oral	   daily	   dose	   of	   PTH	   or	   ETH	   750	   mg,	   anorexia,	   nausea,	  
vomiting	  was	  seen	  in	  17/53	  (32%)	  patients	  receiving	  PTH	  and	  in	  24/48	  (50%)	  receiving	  
ETH;	   in	   3	   (6%)	   versus	  9	   (19%)	   cases,	   these	   adverse	   effects	  were	   classified	   as	   severe.	  
These	   differences	   between	   ETH	   and	   PTH	   were	   not	   statistically	   significant	   (326).	  
However,	   in	   an	   African	   cohort	   directly	   comparing	   adverse	   effects	   of	   ETH,	   PTH	   and	  
placebo,	   there	   were	   more	   adverse	   effects	   with	   ETH	   than	   with	   PTH,	   although	   these	  
differences	  only	  attained	  statistical	  significance	  in	  male	  and	  not	  in	  female	  patients.	  It	  is	  
of	   interest	   that	   in	   this	   African	   cohort	   high	   doses	   of	   up	   to	   1.75g	   of	   ETH/PTH	   were	  
tolerated	  fairly	  well	  and	  most	  adverse	  effects	  were	  reported	  as	  being	  mild	  (324).	  	  
While	   asymptomatic	   elevation	   of	   liver	   transaminases	   occurs	   frequently	   during	  
treatment	  with	   ETH	   or	   PTH,	   severe	   hepatotoxicity	   is	   rare	   (195,	   246,	   327);	   significant	  
hepatotoxicity	  has	  been	  described	  in	  only	  about	  2%	  of	  patients	  treated	  with	  ETH	  or	  PTH	  
(195,	   328-­‐330).	   Nevertheless,	   occurrence	   of	   icterus	   was	   reported	   in	   4	   of	   29	   patients	  
receiving	  1,000mg/day	  PTH	  monotherapy,	  of	  which	  2	  patients	  had	  a	  history	  of	  alcohol-­‐
associated	  liver	  cirrhosis	  (285).	  	  In	  a	  study	  on	  treatment	  for	  leprosy,	  hepatotoxicity	  was	  
reported	   in	  4.5%	  of	   596	  patients.	   These	   findings	  differed	   from	  previous	   trials,	   in	   that	  
ETH	  and	  RMP	  had	  been	  used	   for	  anti-­‐leprosy	   treatment	  separately	  and	  hepatotoxicity	  
was	  not	  mentioned.	  Therefore,	  the	  combination	  of	  ETH	  and	  RMP	  has	  been	  suggested	  as	  
the	   toxic	   component	   (331).	   In	   a	   very	   early	   study	   on	   59	   children	   receiving	   ETH	   10-­‐
30mg/kg	   (in	   combination	  with	   either	   INH,	   PAS	  or	   SM),	   no	   rise	   in	   liver	   transaminases	  
above	  50U/l	  was	  found	  (323)	  and	  the	  level	  of	  liver	  enzyme	  elevation	  did	  	  not	  correlate	  
with	   increased	   ETH	   dose	   or	  with	   clinical	   features	   of	   nausea/vomiting	   (323).	   	   Similar	  
findings	   were	   observed	   in	   a	   study	   on	   107	   children	   treated	   with	   ETH	   20mg/kg.	   In	   7	  




children	  ETH	  had	   to	  be	  stopped	  due	   to	   intolerability,	  of	  which	  6	  were	  gastrointestinal	  
(297).	  Two	  studies	  on	  children	  with	  TBM	  treated	  with	  high	  doses	  of	  INH,	  RMP,	  PZA,	  and	  
ETH	  found	  mildly	  elevated	  liver	  enzymes	  in	  20%	  of	  cases	  (195,	  300).	  Grade	  3	  or	  4	  drug-­‐
induced	   hepatotoxicity	   occurred	   in	   5.6%	   of	   children,	   while	   no	   child	   was	   clinically	  
jaundiced	   (300).	   In	   all	   cases	   treatment	   was	   temporarily	   changed	   to	   liver-­‐friendly	  
regimens	  until	  normalization	  of	   liver	  enzymes,	  and	  the	  original	  regimen	  was	  restarted	  
without	  recurrence	  of	  hepatotoxicity	  (300).	  
During	  long-­‐term	  therapy	  hypothyroidism	  may	  occur	  (332,	  333)	  and	  has	  been	  recently	  
recognized	   as	   an	   often	   undiagnosed	   but	   frequent	   adverse	   effect	   during	   MDR-­‐TB	  
treatment	   in	   adults	   and	   children	   (334,	   335).	   ETH,	   which	   is	   structurally	   similar	   to	  
methimazole,	  seems	  to	  inhibit	  thyroid	  hormone	  synthesis	  by	  inhibition	  of	  organification	  
(336).	  From	   in	  vitro	  studies,	   it	  appears	  that	  ETH	  also	  inhibits	  the	  uptake	  of	   iodine	  into	  
thyroid	   cells	   (333).	   Hypothyroidism	   was	   reported	   in	   73/213	   (34.2%)	   of	   adults	   with	  
MDR-­‐TB	   in	   a	   retrospective	   cohort	   study	   from	   Botswana,	   in	   5/7	   (71.4%)	   in	   a	   British	  
cohort,	  and	  in	  11/52	  (21%)	  in	  an	  adult	  Indian	  cohort	  (335,	  337,	  338).	  
Combination	   therapy	   with	   para-­aminosalicylic	   acid	   (PAS),	   which	   also	   may	   inhibit	  
thyroid	  function	  (339),	   increases	  the	  risk	  of	  hypothyroidism	  (334,	  338,	  340,	  341).	   In	  a	  
study	  of	  adults	  with	  MDR-­‐TB	  where	  96.2%	  were	  treated	  with	  both	  ETH	  or	  PTH	  and	  PAS,	  
129	  (69%)	  had	  a	  TSH	  >10mIU/L	  (334).	   It	  was	  stated	  that	  hypothyroidism	  due	  to	  ETH	  
can	  be	  managed	  with	  thyroxine	  supplementation	  and	  was	  fully	  reversible	  after	  cessation	  
of	   ETH	   therapy	   in	   adults	   (338).	   In	   a	   retrospective	   study	   on	   137	   children	   with	   TB	  
treatment	   including	  ETH,	   abnormal	   thyroid	   function	   tests	  were	   reported	   in	   79	   (58%)	  
children;	  of	   those,	  at	   least	  41%	  were	   likely	  due	   to	  ETH	  treatment	   (340).	  HIV	   infection	  
and	   concomitant	   treatment	   with	   PAS	   were	   associated	   with	   a	   higher	   risk	   for	  
hypothyroidism	  (340).	  Of	  137	  children	  prospectively	  evaluated	  on	  MDR-­‐TB	  treatment,	  
135	   (98.6%)	   received	   ETH	   and	   27	   (19.7%)	   received	   PAS	   (69).	   Based	   on	   elevated	  
thyroid-­stimulating	   hormone	   (TSH)	   and	   low	   free	   thyroxine	   (fT4)	   levels,	   thyroxine	  
supplementation	   was	   provided	   in	   32	   (23.4%)	   children.	   It	   is	   unclear	   whether	   the	  
development	  of	  hypothyroidism	  on	  ETH	  and/or	  PAS	  is	  of	  clinical	  relevance	  in	  children.	  
However,	  given	  the	  potential	  impact	  of	  hypothyroidism	  on	  neurodevelopment	  in	  young	  
children,	  thyroid	  function	  tests	  should	  routinely	  be	  done	  in	  children	  on	  long-­‐term	  ETH	  
with	   or	   without	   concomitant	   PAS	   therapy,	   and	   thyroxine	   supplementation	   should	   be	  
given	  if	  hypothyroidism	  is	  evident.	  




A	  further	  adverse	  effect	  associated	  with	  the	  use	  of	  thioamides	  is	  central	  nervous	  system	  
toxicity.	  A	  high	   incidence	   (25-­‐30%)	  of	  neuropsychotoxic	   effects	  has	  been	  described	   in	  
adult	  patients	  receiving	  1,000mg	  ETH	  or	  PTH	  (318,	  319);	  however,	  these	  early	  studies	  
do	  not	  describe	  how	  toxicity	  was	  assessed	  nor	  were	  adverse	  effects	  further	  specified	  or	  
their	   severity	   graded.	   Nevertheless,	   there	   are	   several	   case	   reports	   of	   severe	   central	  
nervous	  system	  toxicity	  including	  psychosis,	  seizures,	  behavioral	  disorders	  or	  pellagra-­‐
like	  encephalopathy	  (342-­‐345).	  Nervous	  system	  toxicity	  may	  be	  responsive	  to	  niacin	  or	  
pyridoxine	  (345).	  These	  have	  not	  been	  reported	  in	  children.	  	  
Other	   rare	   adverse	   effects	   of	   thioamides	   reported	   include	   gynaecomastia	   (346,	   347),	  
pellagroid	  dermatitis	  (348)	  and	  hypoglycaemia	  (349).	  The	  management	  of	  patients	  with	  
diabetes	  mellitus	  may	  be	  more	  complicated	  in	  patients	  receiving	  ETH	  (350).	  
There	   are	   limited	   data	   on	   the	   use	   of	   ETH	   during	   breastfeeding	   and	   pregnancy	   (351,	  
352).	  In	  the	  mouse	  model,	  ETH	  has	  shown	  to	  reduce	  fertility	  and	  increase	  teratogenicity	  
and	   mortality	   of	   newborn	   mice	   (353).	   There	   are	   single	   case	   reports	   on	   its	   possible	  
teratogenic	  effect	  in	  humans,	  but	  this	  has	  never	  been	  studied	  systematically.	  In	  an	  early	  
German	  national	  survey,	  no	  teratogenic	  effects	  were	  seen	  in	  9	   infants	  born	  to	  mothers	  
receiving	  ETH	  during	  pregnancy	  (352).	  	  In	  a	  large	  study	  on	  1082	  delivering	  women	  with	  
pulmonary	   TB	   of	   whom	   22	   women	   received	   ETH	   before	   or	   during	   pregnancy,	  
developmental	   anomalies	   were	   described	   in	   7	   out	   of	   23	   (30.4%,)	   children	   born	   to	  
mothers	  receiving	  ETH	  compared	  to	  35	  out	  of	  1082	  (3.2%)	  children	  born	  to	  mothers	  on	  
anti-­‐TB	   therapy	   not	   including	   ETH.	   In	   2	   children	   with	   developmental	   anomalies	  
(congenital	  heart	  disease,	  spina	  bifida)	  ETH	  was	  only	  given	  to	  the	  mothers	  in	  the	  month	  
prior	  to	  labour	  and	  in	  two	  other	  children,	  the	  mothers	  had	  received	  ETH	  one	  year	  prior	  
to	  pregnancy	   (354).	   It	   is	   thus	  questionable	   if	   these	  abnormalities	   can	  be	  attributed	   to	  
ETH	  therapy,	  but	  the	  use	  of	  ETH	  is	  usually	  restricted	  during	  pregnancy.	  
	  
Research	  agenda	  
Although	   the	   efficacy	   of	   ETH/PTH	   against	  M.	   tuberculosis	   has	   been	   shown	   in	   in	   vitro	  
studies,	   as	   well	   as	   in	   studies	   in	   animals	   and	   humans,	   pharmacokinetic	   and	  
pharmacodynamic	  targets	  that	  correlate	  well	  with	  efficacy	  and	  prevention	  of	  resistance	  
development	  in	  companion	  drugs	  are	  not	  known	  for	  drug-­‐susceptible	  and	  drug-­‐resistant	  
TB	  in	  either	  adults	  or	  children.	  	  




Increased	   numbers	   of	   genetic	   mutations	   conferring	   ETH	   resistance	   in	  M.	   tuberculosis	  
have	  been	   identified	   and	  are	  detected	   in	  patients	  with	  modern	  molecular	   testing.	  The	  
correlation	  of	  molecular	  resistance	  testing	  with	  MIC	  needs	  further	  study.	  	  
In	  order	  to	  identify	  the	  optimal	  treatment	  for	  TBM,	  short	  intensified	  treatment	  regimens	  
including	   ETH	   should	   be	   compared	   to	   standard	  WHO	   treatment	   recommendations	   in	  
randomized	  controlled	  trials	  (355).	  A	  trial	  including	  high-­‐dose	  RMP	  and	  levofloxacin	  is	  
underway	  in	  India	  and	  Malawi	  (TBM-­‐Kids	  study,	  PI	  K.	  Dooley).	  
Because	  tolerability	  is	  a	  major	  issue	  in	  the	  use	  of	  ETH/PTH	  with	  the	  currently	  available	  
formulations,	   pharmacokinetic/pharmacodynamic	   and	   tolerability	   studies	   of	   new	   and	  
child-­‐friendly	   formulations	   (e.g.	   dispersible	   tablets	   or	   suppositories)	   are	   needed.	   For	  
child-­‐friendly	   formulations,	   issues	  of	  acceptability	  and	  palatability	  must	  be	  considered	  
in	  addition	  to	  bioavailability	  and	  toxicity.	  In	  India,	  125mg	  ETH	  tablet	  in	  addition	  to	  the	  
standard	  250mg	  tablets	  is	  available	  and	  a	  prototype	  of	  a	  scored	  dispersible	  ETH	  tablet	  is	  
in	   development	   (356).	   This	   is	   a	   positive	   step	   forward,	   however	   substantial	   additional	  
effort	   and	   resources	   will	   be	   needed	   to	   make	   this	   formulation	   widely	   available	   to	  
children	  in	  the	  field.	  
Genetic	   polymorphism	   in	   enzymes	   involved	   in	   ETH	  metabolism	   (e.g.	   FMO2)	   has	   been	  
identified	  but	   their	   impact	  on	  bioavailability	  and	   tolerability	  of	  ETH	   is	  not	  known	  and	  
should	  also	  be	  evaluated	  in	  future.	  	  
	  
Conclusions	  
ETH	   and	   PTH	   have	   substantial	   anti-­‐TB	   activity	   proven	   in	   clinical	   studies	   and	   form	  
important	   components	   of	   MDR-­‐TB	   treatment	   regimens	   and	   in	   the	   treatment	   of	  
disseminated	  forms	  of	  TB	  in	  adults	  and	  children.	  For	  children,	  an	  oral	  daily	  dose	  of	  ETH	  
or	  PTH	  of	  15-­‐20mg/kg	   is	  recommended	  to	  achieve	  serum	  concentrations	  shown	  to	  be	  
efficacious	   in	   adult	   studies,	   although	   information	   on	   the	   optimal	   pharmacodynamic	  
targets	  is	  still	  lacking	  and	  recommendations	  are	  based	  on	  a	  limited	  amount	  of	  paediatric	  
pharmacokinetic	   data.	   Gastrointestinal	   disturbances	   and	   hypothyroidism	   during	   long-­‐
term	   therapy	   are	   frequent	   adverse	   effects,	   but	   are	   rarely	   life-­‐threatening	   and	   seldom	  
necessitate	  cessation	  of	  ETH/PTH	  therapy.	  Child-­‐friendly	  formulations	  of	  ETH/PTH	  are	  
urgently	   needed;	   these	   need	   to	   be	   informed	   by	   rigorous	   pharmacokinetic	   and	   safety	  
studies.	  	  
	  




Table	  2.	  Ethionamide	  pharmacokinetic	  measures	  in	  adults	  and	  children	  	  




(years)	   Number	   ETH	  dosage	   Tmax	  (h)	   Cmax	  (µg/ml)	   t1/2	  (h)	   AUC	  
	  
Adults	  
	   	   	   	   	   	   	   	   	   	  
Eule	  1965	  
(306)	   Microbiolog.	   TB/healthy	   NA	   Adults	   28	   10mg/kg	   Not	  reported	   5.54	  
Not	  
reported	   Not	  reported	  
Jenner	  1984	  
(312)	   HPLC	   Healthy	   NA	   Adults	   9	   250mg	   2.0	   2.0	   2.1	   Not	  reported	  
Auclair	  et	  al.	  
2001(303)	   HPLC	   Healthy	   NA	  
36	  
(+/-­‐	  8)	  




































Zhu	  M,	  et	  al.	  

























	   	   Healthy	   NA	   	   12	   500mg	   1.50	   1.97	   1.04	   8.00	  




(0.75-­‐3.00)	   (0.99-­‐6.10)	   (0.39-­‐2.76)	   (5.90-­‐13.3)	  
Wyeth	  Inc.	  


























-­‐-­‐	   -­‐-­‐	   NA	   -­‐-­‐	   -­‐-­‐	  
250mg	  
Film-­‐coated	  tbl.	  
Not	  reported	   2,16	   1,92	   7,67	  
	  
Children	  
	   	   	   	   	   	   	   	   	   	  
Thee	  et	  al.	  

















































	   	   	   1	   6-­‐12	   5	   15-­‐20mg/kg	   1.97	   5.44	   Not	   15.04	  




(+RMP)	   (1.0-­‐2.1)	   (1.24)	   reported	   (5.50)	  
Hesseling	  






reported	   28.64	  (24.58-­‐33.41	  
















ETH:	  ethionamide,	  Cmax:	  maximum	  serum	  concentration,	  Tmax:	  time	  until	  Cmax,,	  t1/2:	  half-­‐life;	  AUC:	  area	  under	  the	  concentration	  time	  curve;	  	  
HPLC:	  high	  performance	  liquid	  chromatography,	  RMP:	  rifampicin,	  NA:	  not	  applicable,	  tbl:	  tablet	  




Table	  3	  Adverse	  effects	  associated	  with	  thioamide	  use	  in	  adults	  and	  children	   1 
Author	   Disease	   Number	   Drug	   Dose	   Concomitant	  drugs	   Adverse	  events	  
	   	   	   	   	   	   	  






group	  A	  14/20,	  
group	  B	  14/18,	  
group	  C	  10/15	  
ETH	  
group	  A:	  500mg	  single	  
dose	  or	  250mg	  bd;	  	  
group	  B	  750mg	  or	  
divided	  in	  2	  doses,	  	  
group	  C	  1,000mg	  single	  
dose	  or	  500mg	  bd	  
EMB,	  INH,	  PZA,	  CS	  
Group	  A	  56.6%,	  group	  B	  70%,	  group	  C	  100%,	  mainly	  GI-­‐
intolerance,	  	  
other:	  neuropsychotoxic	  reactions,	  skin-­‐reactions,	  alopecia,	  goitre,	  
hepatotoxicity;	  	  
toxicity	  increased	  in	  patients	  receiving	  PZA	  






group	  A	  20/25,	  
group	  B	  20/20,	  
group	  C	  15/20	  
PTH	  
group	  A:	  500mg	  single	  
dose	  or	  250mg	  bd;	  	  
group	  B	  750mg	  or	  
divided	  in	  2	  doses,	  	  
group	  C	  1,000mg	  single	  
dose	  or	  500mg	  bd	  
EMB,	  INH	  
70/114	  (61.4%)	  patients	  with	  adverse	  effects,	  	  	  
GI-­‐intolerance	  occurred	  in	  34.1%,	  42.1%	  and	  80%	  and	  
neuropsychotoxic	  reactions	  in	  4.8%,	  15.8%	  and	  25%	  of	  patients	  
receiving	  500mg,	  750mg	  or	  1,000mg	  PTH,	  respectively	  





82	   ETH	   1,000-­‐1,250mg	   KM,	  CA,	  PZA,	  EMB,	  CM	  
GI-­‐intolerance	  in	  almost	  all	  patients	  in	  the	  beginning,	  disappearing	  
after	  2-­‐3weeks	  of	  therapy	  classified	  as	  "important"	  in	  18/82	  
(26%)	  patients,	  1	  hepatotoxic	  reaction;	  in	  18/82	  patients	  rectal	  
administration	  of	  ETH	  
	   	   	   	   	   	   	  
(290)	   adults	  with	  TB	   112	   ETH	   500mg	  bd	   INH,	  SM	  
GI-­‐intolerance	  leading	  to	  treatment	  interruption	  in	  28/112	  (25%)	  
patients,	  hepatotoxicity	  in	  11/112	  (9.8%),	  1	  being	  jaundiced;	  
neuropsychotoxic	  reactions	  2/112	  (2%)	  




	   	   	   	   	   	   	  
(324)	   adults	  with	  TB	   	   ETH/PTH	   500-­‐1,750mg	   INH,	  SM	  
In	  87/297	  (29.3%)	  doses	  of	  ETH,	  45/164	  (27.4%)	  doses	  of	  PTH;	  
GI-­‐intolerance	  22%/23%,	  giddiness	  10%/13%,	  headache	  9%/4%	  
following	  ETH/PTH,	  respectively,	  	  toxicity	  increased	  with	  dose,	  no	  
effect	  of	  vit	  B	  supplementation	  
	   	   	   	   	   	   	  
(326)	   adults	  with	  TB	  
101	  	  
(53	  PTH,	  48	  ETH)	  
ETH/PTH	   375mg	  bd	   INH,	  SM	  
GI-­‐intolerance	  17/53	  (32%)	  and	  24/48	  (50%)	  for	  PTH	  and	  ETH,	  
respectively,	  severe	  in	  3	  (6%)	  and	  9	  (19%);	  hepatotoxicity	  in	  5/53	  
(9%)	  and	  5/48	  (5%)	  patients	  receiving	  PTH	  and	  ETH,	  respectively	  
	   	   	   	   	   	   	  
(284)	   adults	  with	  TB	   29	   PTH	   1,000mg	   	  
Jaundice	  in	  4/29	  (..%)patients,	  	  of	  which	  2	  patients	  had	  alcohol-­‐
associated	  liver	  cirrhosis	  
	   	   	   	   	   	   	  
(329)	   adult	  with	  TB	   1	   ETH	   500mg	  bd	   SM	   Jaundice	  
	   	   	   	   	   	   	  
(330)	   adults	  with	  TB	   44	   PTH	   500-­‐1,000mg	   not	  stated	   Elevated	  liver	  transaminases	  in	  10/44	  (22.7%)	  patients	  
	   	   	   	   	   	   	  
(333)	   NTM	  infection	   1	   ETH	   1,000mg	   RMP,	  EMB	   Hypothyroidism	  with	  goitre	  
	   	   	   	   	   	   	  
(332)	   MDR-­‐TB	   1	   ETH	   250mg	  bd	   not	  stated	   Severe	  hypothyroidism	  
	   	   	   	   	   	   	  
(338)	   MDR-­‐TB	   52	   ETH	   250mg	  bd	   not	  stated	  
11/53	  /21.1%)	  with	  hypothyroidism,	  3	  with	  goitre,	  reversible	  
after	  cessation	  of	  therapy,	  1	  patient	  not	  adherent	  to	  levothyroxine	  
therapy	  died	  of	  myxoedema	  coma	  
	   	   	   	   	   	   	  




(337)	   MDR-­‐TB	   7	   PTH	   not	  stated	   PAS+other	  	   5/7	  (71.4%)	  with	  hypothyroidism	  
	   	   	   	   	   	   	  
(335)	   MDR-­‐TB	   213	   ETH	   not	  stated	   not	  stated	   73/213	  (34.3%)	  with	  TSH	  level	  >10U/l	  
	   	   	   	   	   	   	  





PAS,	  PZA,	  CS,	  
fluoroquinolone,	  2nd-­‐
line	  injectable	  
129/186	  (69%)	  TSH	  >10U/l;	  100	  (54%)	  had	  TSH	  >20U/l	  
	   	   	   	   	   	   	  
(341)	   MDR-­‐TB	   1	   ETH	  	   500mg+250mg/d	   CS,	  OFX,	  PAS	   TSH	  28U/l,	  low	  thyroxine	  and	  low	  fT4-­‐serum	  level	  
	   	   	   	   	   	   	  
(343)	   TB	   1	   ETH	   750mg	   INH,	  SM	   severe	  psychologic	  changes	  after	  taking	  ETH	  for	  1	  year	  
	   	   	   	   	   	   	  
(344)	   TB	   1	   ETH	   500mg	   PAS,	  SM,	  INH	   psychotic	  reaction,	  patient	  died	  after	  jumping	  from	  the	  window	  
	   	   	   	   	   	   	  
(342)	   TB	   1	   ETH	   Not	  stated	   SM,	  INH,	  TAZ	   Psychotic	  reaction	  
	   	   	   	   	   	   	  
(345)	   TB	   3	   ETH	   750mg	   INH,	  CS,	  EMB,	  PAS	  
drug-­‐induced	  encephalopathy	  with	  signs	  of	  myelopathy	  in	  two	  
patients	  with	  symptoms	  similar	  to	  pellagra,	  rapid	  recovery	  with	  
nicotinamide	  and	  other	  B	  group	  vitamin	  supplementation	  
	   	   	   	   	   	   	  
(346)	   MDR-­‐TB	   1	   ETH	   750mg	   KM,	  OFX,	  EMB,	  PZA,	  PAS	   painful	  gynaecomastia,	  subsiding	  after	  cessation	  of	  ETH	  
	   	   	   	   	   	   	  
(347)	   MDR-­‐TB	   1	   ETH	   250mg	  bd	   Not	  stated	   gynaecomastia,	  subsiding	  after	  cessation	  of	  treatment	  




	   	   	   	   	   	   	  
(348)	   MDR-­‐TB/TBM	   2	   ETH	   250mg	  bd	   Not	  stated	  
pellagra-­‐like	  skin	  lesions	  healing	  completely	  after	  administration	  
of	  nicotinamide	  therapy	  
	   	   	   	   	   	   	  
(349)	   TB	   1	   ETH	   750mg	   INH,	  SM	   patient	  died	  of	  severe	  hypoglycemia	  
	   	   	   	   	   	   	  
CHILDREN	   	   	   	   	   	   	  
(358)	   TB	   30	   ETH	   15	  (12-­‐35)	  mg/kg	   INH+	  vitamin	  B	  
3/30	  children	  mild	  GI-­‐intolerance	  subsiding	  with	  continuation	  of	  
therapy,	  in	  5/30	  children	  transient	  leucopenia	  (3-­‐4,000/µl),	  ETH	  
administered	  rectally	  
	   	   	   	   	   	   	  
(195)	   TBM	   56	  	   ETH	   15mg/kg	   INH,	  RMP,	  PZA	  
Jaundice	  in	  1/56	  child,	  elevation	  of	  liver	  enzymes	  in	  75-­‐85%	  of	  
children	  
	   	   	   	   	   	   	  
(327)	   TB	   1	   ETH	   500mg	   INH,	  SM,	  PAS	   Patient	  died	  of	  acute	  hepatic	  failure	  
	   	   	   	   	   	   	  
(296)	   TB	   59	   ETH	   10-­‐30mg/kg	  
INH,	  SM	  or	  PAS	  
+	  vitamin	  B	  
No	  rise	  in	  liver	  transaminases	  >50	  IU/l	  
	   	   	   	   	   	   	  
(297)	   TB	   107	   ETH	   20mg/kg	   INH,	  SM	  or	  PAS	  
26/107	  (24%)	  experienced	  adverse	  events,	  in	  7	  children	  leading	  
to	  treatment	  interruption,	  mainly	  (6/7)	  because	  of	  GI-­‐intolerance	  
	   	   	   	   	   	   	  
(300)	   TBM	   184	   ETH	   20mg/kg	   INH,	  RMP,	  PZA	   8/143	  (5%)	  children	  with	  drug	  induced	  hepatotoxicity	  
	   	   	   	   	   	   	  




(340)	   TB/TBM	   137	   ETH	   20mg/kg	   INH,	  PAS,	  TZ,	  AMK,	  EMB	  
In	  79/137	  (58%)	  children	  abnormal	  thyroid	  function	  tests;	  
HIV	  infection	  and	  concomitant	  treatment	  with	  PAS	  associated	  with	  
higher	  risk	  for	  hypothyroidism;	  
thyroxine	  supplementation	  in	  32	  children	  
	   	   	   	   	   	   	  
TB	  tuberculosis;	  MDR	  multidrug	  resistant;	  TBM	  tuberculous	  meningitis;	  ETH	  ethionamide;	  PTH	  prothionamide;	  INH	  isoniazid;	  RMP	  rifampicin;	  SM	  streptomycin;	  PZA	  pyrazinamide;	  EMB	  ethambutol;	  PAS	  para-­‐ 1 
amino	  salicylic	  acid;	  TZ	  terizidone;	  AMK	  amikacin;	  CS	  cycloserine;	  CM	  capreomycin;	  KM	  kanamycin;	  TAZ	  thioacetazone;	  OFX	  ofloxacin	   2 
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s u m m a r y
The fluoroquinolones are key components of current multidrug-resistant tuberculosis (MDR-TB) treat-
ment regimens and are being evaluated in shortened treatment regimens as well as in the prevention of
drug-resistant TB. The objective of this review was to identify existing evidence for the use of the flu-
oroquinolones ofloxacin, levofloxacin and moxifloxacin in the treatment of TB in children.
Existing data from in vitro, animal and human studies consistently demonstrate the efficacy of the
fluoroquinolones against Mycobacterium tuberculosis, with superiority of levofloxacin and moxifloxacin
compared to ofloxacin. In vitro and murine studies demonstrated the potential of moxifloxacin to shorten
drug-susceptible TB treatment, but in multiple randomized controlled trials shortened fluoroquinolone-
containing regimens have not been non-inferior compared to standard therapy. Resistance occurs
frequently via mutations in the gyrA gene, and emerges rapidly depending on the fluoroquinolone
concentration, with newer more potent fluoroquinolones less likely to develop resistance. Emerging data
from paediatric studies underlines the importance of fluoroquinolones in the treatment of MDR-TB in
children. There is a paucity of pharmacokinetic data especially in children <5 years of age and HIV-
infected children; existing studies show substantially lower serum concentrations in children
compared to adults at currently recommended doses, probably due to faster elimination. This has im-
plications for optimizing paediatric treatment and for the development of resistance. Fluoroquinolone
use has been restricted in children due to concerns about drug-induced arthropathy. The available data
does not demonstrate any serious arthropathy or other severe toxicity in children. Although there is
limited paediatric safety data for the prolonged treatment of MDR-TB, extended administration of flu-
oroquinolones in adults with MDR-TB does not show serious adverse effects and there is no evidence
suggesting less tolerability of fluoroquinolones in children. Additional study of moxifloxacin and levo-
floxacin for TB treatment and prevention in children is an urgent priority.
© 2015 Elsevier Ltd. All rights reserved.
1. Introduction
The World Health Organization (WHO) estimated that in 2013
there were 550,000 new cases of TB in children <15 years of age
[267]. Multidrug-resistant TB (MDR-TB; i.e. resistance to both
rifampicin [RIF] and isoniazid [INH]) is an emerging epidemic.
Model-based estimates suggest 32,000 children had MDR-TB in
2010 [112,206]. Asmany as 900,000 childrenwere exposed toMDR-
TB in 2012. These figures likely underestimate the true burden of
childhood TB due to diagnostic challenges and poor recording and
reporting of TB in children [112,213]. New diagnostic tools, such as
the Xpert MTB/RIF may increase the number of MDR-TB cases
detected in adults and children, increasing the number of children
needing MDR-TB treatment.
Fluoroquinolones are key components of current MDR-TB
treatment regimens and are being evaluated as components of
future shortened regimens for the treatment of drug-susceptible TB
(DS-TB) [28,86,117,199]. They may also play an important role in the
prevention of drug-resistant TB. Despite their increasingly promi-
nent role in TB treatment, there is limited data on efficacy, phar-
macokinetics (PK) and safety of the fluoroquinolones in children
with TB. The objective of this review was to identify existing evi-
dence for the use of the fluoroquinolones ofloxacin (Ofx), levo-
floxacin (Lfx) and moxifloxacin (Mfx) in the treatment of TB in
children, to guide current treatment and highlight knowledge gaps
for future research.
* Corresponding author. Desmond Tutu TB Centre, Department of Paediatrics and
Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University,
South Africa.
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2. Methods
We performed a scoping review [251] to broadly assess the evi-
dence for fluoroquinolone use in children with TB. We searched
PubMedwithoutdateor languagerestrictions (althoughonlyEnglish-,
French-, Spanish- and German-language references were reviewed),
using the following search terms: tuberculosis, fluoroquinolone,
ofloxacin, levofloxacin, moxifloxacin, children/child, efficacy, therapy,
treatment, resistance, pharmacokinetics, pharmacodynamics, safety
andtoxicity.Abstractswere reviewedand full textarticles retrieved for
studies identified with relevant information. We reviewed the refer-
ence lists of identifiedarticles foradditional relevant reports andother
sources known to the authors. In vitro and animal datawere included
to provide information on efficacy of fluoroquinolones and resistance.
Adult datawere reviewed if paediatric datawere lacking, and also for
comparison purposes.
3. Efficacy of fluoroquinolones in TB
The fluoroquinolone target inMycobacterium tuberculosis is DNA
gyrase (topoisomerase II) [150]. Inhibition of DNA gyrase disrupts
bacterial DNA synthesis causing rapid cell death [107]. In adult TB
patients, efficacy of anti-TB treatment can be monitored by sputum
smear or culture conversion. In children, who frequently have
paucibacillary disease, monitoring of response to treatment is
challenging and is based on symptomatic improvement, weight
gain, or regression of radiographic finding [233] in the absence of
bacteriology. Given the lack of paediatric data on fluoroquinolone
efficacy, we looked closely at evidence from in vitro and animal data
as well as data from adult TB patients. As the principles of anti-TB
treatment do not differ between adults and children, children are
expected to respond as well or better, given similar drug exposures
as adults [64].
3.1. In vitro activity of fluoroquinolones against M. tuberculosis
The good in vitro efficacy of the fluoroquinolones Ofx, Lfx and
Mfx against M. tuberculosis has been extensively documented
(Table 1). Several studies also demonstrate in vitro synergy of the
fluoroquinolones given in combination with first-line and some
second-line anti-TB drugs [21,102,142,184,186,187].
Fluoroquinolones have shown in vitro activity against intracel-
lular and dormantM. tuberculosis, and therefore exhibit a sterilizing
potential [52,75,108,130,155,202,220,232,243,244,250], although
for Ofx data is conflicting [102]. The fluoroquinolones accumulate
in macrophages and granulocytes with intracellular drug concen-
trations exceeding extracellular concentrations at least four-to five-
fold (Mfx > Lfx > Ofx) [82,155,172,182,264]. Mfx had superior ac-
tivity compared to Ofx and Lfx in three different in vitro models of
RIF-tolerant persistent M. tuberculosis, predicting that Mfx may be
able to shorten anti-TB treatment [108]. In contrast, Lfx was more
active over 21 days than Mfx againstM. tuberculosis in the dormant
phase of an acid model [52,81].
Together, the in vitro data demonstrate that Ofx, Lfx and Mfx
have bactericidal activity against metabolizing bacilli, with a rela-
tive potency againstM. tuberculosis of Mfx > Lfx > Ofx; Lfx and Mfx
show the greatest sterilizing potential.
3.2. Activity of fluoroquinolones in murine studies
Inmurine studies, Ofx hasmoderate activity againstM. tuberculosis
compared to newer fluoroquinolones [114,115,131,140,245], while Lfx
and Mfx have dose-dependent bactericidal activity comparable or
even superior to that of INH [9,113,114,123,134,153,215,220,275]. High
dose Lfx andMfx showed similar activity after 2months of treatment,
but after 4 months, Lfx was inferior to Mfx in murine tuberculosis [3].
The potential of Mfx to shorten treatment suggested by in vitro
studies was confirmed in mice. Substitution of Mfx for INH reduced
the time needed to eradicateM. tuberculosis from the lungs of mice
by up to 2months [166], and relapse-free curewas established after
4 months of therapy with RIF, Mfx and pyrazinamide (PZA),
compared to 6 months with standard treatment [167]. These
studies have informed treatment-shortening trials in humans.
However, recently completed trials using gatifloxacin (Oflotub) or
Mfx (e.g. ReMox, RIFAQUIN) for treatment shortening could not
confirm the potential to shorten TB treatment in humans
[86,117,152].
Fluoroquinolones have also been studied in combination with
second-line anti-TB drugs.
In drug-susceptible murine TB, Mfx in combination with
different second-line drugs used for 9 months had bactericidal
activity comparable to 6 months of the standard regimen [257].
Against MDR-strains in mice, the efficacy of Lfx and Mfx in com-
bination with second-line agents were similar after 2 months of
therapy, while relapse rates after 7months of treatment were lower
in the Mfx group [72].
Few studies have investigated the efficacy of fluoroquinolones in
combination with newer anti-TB agents in the mouse model. A
regimen consisting of two weeks daily RIF, INH, PZA and Mfx fol-
lowed by a 5.5-months once weekly therapy with rifapentine, INH
andMfxwas only slightly inferior to the 6-month standard regimen
[139]. Mfx in combination with rifapentine also provided excellent
sterilizing activity and shortened the time needed to prevent re-
lapses [139,195,196]. Further evidence exists for the new anti-TB
agents bedaquiline and PA-824 in combination with Mfx and PZA
to shorten treatment with similar relapse rates compared to ther-
apy with first-line agents in murine studies [10,165]. Recently,
novel regimens to treat latent TB infection (LTBI) were identified in
a murine model [132]. The combination of PA-824 and Lfx has been
identified for the evaluation in future clinical trials of MDR pre-
vention [132].
Murine studies confirmed the superior activity of Lfx and Mfx
compared to Ofx againstM. tuberculosis as demonstrated by in vitro
studies. Evidence from themurinemodel further highlights the role
of Mfx in possible shortening of TB treatment in combination with
existing and novel anti-TB agents.
3.3. Activity in human TB
3.3.1. Early bactericidal activity (EBA)
The EBA of an anti-TB agent is defined as the fall in log10 colony
forming units (cfu) ofM. tuberculosis per ml sputum per day during
the first days of treatment [60,63,118,218]. Table 2 summarizes EBA
studies of Ofx, Lfx, and Mfx.
While the EBA of Ofx at 800 mg/day is lower than that of INH
[32,218], Lfx at a daily dose of 1000 mg and Mfx at a dose of
400 mg show an EBA comparable to that of INH [87,92,119,176].
The mean EBA of the novel three-drug regimen consisting of PA-
824/Mfx/PZA was comparable to that of a standard regimen
(INH/RIF/PZA/ethambutol) [59].
3.3.2. Drug-susceptible TB (DS-TB)
Early studies in TB patients utilized Ofx, as it was the most
widely available fluoroquinolone until recently. In one of the first
studies of fluoroquinolones in 13 TB patients, Ofx monotherapy
resulted in reduced sputum cfu counts, with sputum culture con-
version in five confirming the bactericidal activity of Ofx [247].
However Ofx resistance developed in all those not converting [246].
Two further studies provide additional evidence for the efficacy of
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Table 1
Minimum inhibitory concentrations (MIC) in mg/ml for ofloxacin, levofloxacin and moxifloxacin against Mycobacterium tuberculosis.








Clinical isolates Youmans broth;
1.0, 1.0 (MIC50,
MIC90)
Gorzynski EA et al. 1989
[91]




H37Rv, clinical isolates 0.5, 0.5 (MIC50,
MIC90)
Rastogi N, et al. 1991
[183]
H37Rv, clinical isolates 0.5, 1.0 (MIC50, MIC90) 0.5, 1.0 (MIC50,
MIC90)
Truffot-Pernot C, et al.
1991 [245]
H37Rv, Clinical isolates, DR
and DS
1.0, 2.0 (DS), 2.0, 2.0
(DR) (MIC50, MIC90)
Ji B, et al. 1991 [115] H37Rv, Clinical isolates, DS 1.0, 2.0 (MIC50, MIC90)
Tomioka H et al. 1993
[242]
0.78, 0.78 (MIC50, MIC90)





Ji B, et al. 1995 [114] Clinical isolates, DS 1.0, 1.0 (MIC50, MIC90)
Saito H, et al. 1995
[200]
0.78, 0.78 (MIC50, MIC90)
Rastogi N, et al. 1996
[184]
Clinical isolates DS and DR 0.75e1.0 (range
MIC99)
Guillemin I, et al. 1998
[97]
H37Rv 1.0 (MIC99)
Vacher S, et al. 1999
[250]
0.5, 1.0 (MIC50, MIC90)
Ruiz-Serrano MJ, et al.
2000 [197]
Clinical isolates, DS and DR 1.0, 2.0 (MIC50,
MIC90)
Rodriguez JC, et al. 2001
[192]
Clinical isolates, DS 1.0, 2.0 (MIC50, MIC90)
Hu Y, et al.2003 [16] H37Rv 0.71 (no growth)
Singh M, et al. 2009
[216]









Ji B, et al. 1995 [114] Clinical isolates, DS 0.5, 1.0 (MIC50, MIC90)
Saito H, et al. 1995
[200]
0.39, 0.39 (MIC50, MIC90)
Rastogi N, et al. 1996
[184]
Clinical isolates, DS and DR DS 0.5; DR 0.5e0.75
(MIC99)
Hoffner SE, et al. 1997
[105]
Clinical isolates, DS and DR 1e2 (range MIC99)





Clinical isolates 0.25, 0.5 (MIC50, MIC90)
Ruiz-Serrano MJ, et al.
2000 [197]
Clinical isolates, DS and DR 0.5, 1.0 (MIC50,
MIC90)
Tomioka H, et al. 2000
[244]
Clinical isolates, DS 0.39, 0.39 (MIC50, MIC90)
Clinical isolates, DR 3.13, 6.25 (MIC50, MIC90)
Rodriguez JC, et al. 2001
[192]
Clinical isolates, DS 0.5e1.0 (MIC50, MIC90)
Rodriguez JC, et al. 2002
[193]
Clinical isolates, DS and DR 0.25, 0.5 (MIC50, MIC90)
Hu Y, et al. 2003 [108] H37Rv 0.35 (no growth)
Lu T, DrlicaK. 2003
[142]
TN6515 0.65 (MIC90)
Aubry A, et al. 2004 [12] H37Rv 0.5 (MIC99)
Singh M, et al. 2009
[216]
H37Rv, Clinical isolates, DS
and DR
1.0 (MIC90)
Tan CK, et al. 2009
[235]
Clinical isolates, DS 0.5, 1.0 (MIC50,
MIC90)
Guerrini V, et al. 2013
[96]
H37vR 0.25 (no growth)
(continued on next page)
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Ofx in DS-TB, without being superior to a standard first-line therapy
[127,248]. Adding Lfx to first-line therapy had no impact on 2-
month culture conversion compared to standard therapy [68].
There is extensive evidence for the clinical efficacy of Mfx in
anti-TB treatment [22,28,33,35,49,65,174,180,198,199,252,260].
Three studies comparing Mfx to EMB added to INH, RIF, and PZA
demonstrated not only Mfx efficacy in the intensive phase of
treatment, but also the potential to shorten treatment [28,50,199].
In a further phase II trial comparing Mfx substituted for INH during
the intensive phase of standard TB therapy, the Mfx group had a
small, statistically non-significant increase in 2-month sputum
culture conversion [65].
These four studies provided sufficient evidence for phase III
trials of later generation fluoroquinolone-containing regimens for
treatment shortening in adults with DS-TB.
A randomized controlled trial (RCT) from India using either Mfx
or gatifloxacin in combination with INH plus RIF, and PZA in the
first two months in a 4-month intermittent regimen (thrice
weekly) in newly diagnosed smear-positive TB patients compared
with an intermittent 6-month regimen of INH and RIF with EMB
and PZA in the first twomonths was terminated prematurely due to
the high risk of TB recurrence in the fluoroquinolone arms [15,111].
If Mfx was given as part of a five-drug daily treatment (Mfx/INH/
RIF/PZA/EMB) in treatment-naïve patients with pulmonary TB,
higher sputum culture conversion was achieved at 2 months
compared to a thrice-weekly four-drug regimen (INH/RIF/PZA/
EMB) [255].
The RIFAQUIN trial evaluated the potential of rifapentine in
combination with Mfx to shorten anti-TB treatment to 4 months or
to reduce the frequency of dosing during a 4-month continuation
phase by giving rifapentine/Mfx once weekly. While the 4-month
regimen was inferior to standard therapy, the 6-month regimen
with once weekly rifapentine/Mfx continuation phase was not and
appeared more convenient than the current standard of care [117].
The REMox TB trial, comparing two 4-months Mfx-containing
treatment regimens to 6-month standard first-line treatment,
showed a more rapid initial decline in bacterial load, but again,
non-inferiority of 4 months therapy compared to standard 6-
month therapy could not be shown [86]
Taken together, a higher sputum culture conversion at two
months has been demonstrated in Mfx-containing regimens, but
current evidence does not support shortening treatment-duration
from 6 to 4-months in DS-TB.
3.3.3. MDR-TB
Several studies have demonstrated that the use of Ofx compared
to no fluoroquinolone is associated with higher treatment success
in adult MDR-TB patients and with lower rates of relapse or death
([37]; [106,271,273]). In two retrospective analyses on patients with
MDR-TB, Lfx had superior efficacy compared to Ofx [272] and high-
dose Lfx (1000 mg) appeared to further improve treatment success
[189,237].
Reports of Mfx efficacy in DR-TB are mainly from observational
studies. Two individual patient data (IPD) meta-analyses and
another systematic review reported improved treatment success
with the use of a later-generation fluoroquinolone compared to no
or earlier generation fluoroquinolone, and identified fluo-
roquinolone resistance as a risk factor for unfavourable outcome
[4,71,120]. However, another systematic review and meta-analysis
of outcomes of MDR-TB therapy found that the proportion of
Table 1 (continued )




Woodcock JM, et al.
1997 [265]
Clinical isolates, DS and DR 0.12e0.5 (range
MIC90)
Ji, et al. 1998 [113] H37Rv, clinical isolates, DS
and DR
0.5, 0.5 (MIC50, MIC90)
Gillespie SH, Billington
O. 1999 [85]
Clinical isolates 0.12, 0.5 (MIC50, MIC90)
Rodriguez JC, et al. 2001
[192]
Clinical isolates DS 0.5, 1.0 (MIC50, MIC90)
Rodriguez JC, et al. 2002
[193]
Clinical isolates, DS and DR 0.25, 0.5 (MIC50, MIC90)
Lu T, DrlicaK. 2003
[142]
TN6515 0.29 (MIC90)
Alvirez-Freites EJ, et al.
2002 [9]
Clinical isolates 0.062, 0.125 (MIC50,
MIC90)
Hu Y, et al.2003 [16] H37Rv 0.18 (no growth)
Aubry a, et al. 2004 [12] H37Rv 0.5 (MIC99)
Krüüner A, et al 2005
[129]
Clinical isolates DS 0.125 (no growth)
Kam KM, et al. 2006
[121]
Clinical isolates, DR/Ofx-S 0.5, 0.5 (MIC50,
MIC90)
Clinical isolates, DR/Ofx-R 1.0, 2.0 (MIC50,
MIC90)
Tan CK, et al. 2009
[235]
Clinical isolates, DS 0.25, 1.0 (MIC50,
MIC90)
Pucci MJ, et al. 2010
[181]
Erdmann strain 0.06 (no growth)
Clinical isolates DS 0.06 (no growth)




Drusano GL, et al. 2011
[67]
H37Ra 0.25 (MIC99)
DS ¼ drug susceptible, DR ¼ drug resistant, MDR ¼ multi-drug resistant.
MIC50/MIC90/MIC99: minimum drug concentration that inhibits 50%/90%/99% of bacterial isolates.
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patients treated with a fluoroquinolone was not predictive of
treatment success [168]. The authors stated that this might be due
to reporting insufficiency rather than the absence of a true
association.
No difference in early treatment outcomewas shown comparing
Lfx versus Mfx in MDR-TB treatment [116,126]. These findings are
consistent with data from the murine model; however, whether
Mfx is superior to Lfx measuring long-term outcome (and as found
in mouse studies), still needs evaluation [199].
For the treatment outcome of XDR-TB, the use of later-
generation fluoroquinolones significantly improves treatment
outcomes, even in the presence of drug-susceptibility testing (DST)
demonstrating resistance to a representative fluoroquinolone [110].
Several trials of MDR-TB prevention using Lfx are currently planned
in adults and children.
3.3.4. Paediatric TB
There are no prospective RCTs on efficacy of fluoroquinolones in
childrenwith TB, but there are limited data available on their use in
MDR-TB treatment. In a systematic review of children treated for
MDR-TB, fluoroquinolones were an important component of the
treatment regimen in all studies included, with a pooled treatment
success of 81.67% [70]. In a retrospective study including 149 chil-
dren with MDR-TB, Ofx was part of the regimen in 132 (96,4%) of
those treated, with a median duration of Ofx therapy of 13 (inter-
quartile range [IQR] 10.5e18) months and an overall treatment
success (cure or clinical cure [212]) in 137 children (92%) [211].
Similar findings were reported from a paediatric cohort (n ¼ 45)
from Georgia; most children were treated with a 6-drug regimen
including an injectable agent and Lfx; treatment success was 77%
[83]. Several other smaller case series were recently published. Six
children with MDR-TB received either Lfx (n ¼ 5) or Mfx (n ¼ 1) as
part of their regimen; four were cured, one had pulmonary
sequelae and one child was lost to follow-up [35]. Mfx and linezolid
were administered in 2 paediatric MDR-TB cases from Italy and cure
was achieved in both [174]. Another series from Italy showed
clinical and radiological cure in all 9 children treated with a
regimen including Mfx for MDR and DS-TB [78]. Two further case
reports show efficacy of fluoroquinolones in anti-TB therapy in
children where first-line agents could not be used [69,103].
Existing evidence from paediatric studies underlines the
importance of fluoroquinolones in the treatment of paediatric
MDR-TB, although data supporting the potential in treatment-
shortening is lacking.
4. Fluoroquinolone resistance
Mycobacterial resistance to the fluoroquinolones occurs
frequently via missense mutations in gyrA gene, in a highly
conserved region called the Quinolone Resistance Determining
Region (QRDR) [5,88,234]. The MTBDRsl test (Hain Lifescience,
Nehren, Germany), a line probe assay for rapid detection of resis-
tance to fluoroquinolones and other second-line TB drugs, detects
the most commonmutations in the gyrA gene, with a sensitivity for
fluoroquinolone resistance of 76%e91% [26,104,128]. Other muta-
tions, especially in the gyrB subunits, decrease cell wall perme-
ability, active drug efflux, or drug inactivation, and may account for
fluoroquinolone resistance not detected using current tools
[88,217]. Different mutations result in different levels of resistance
[36,121,125,269]; a single gyrA mutation increases the minimal
inhibitory concentration (MIC) 4- to 16-fold leading to clinically
significant Ofx resistance (MIC>2 mg/ml), while at least a double
gyrase mutation is required for high-level resistance [125]. There is
broad cross-resistance among the fluoroquinolones, although
differing degrees of resistance from one drug to another
[5,36,57,58,157].
Table 2
The early bactericidal activity (EBA) of fluoroquinolones.
Study Design Population Treatment Outcome
Chambers 1998 [32] Prospective, randomised,
2 study sites
31 adults with sputum
smear pos. TB
EBA0e2/EBA2e7
1) Amox./clavul. 1,000/250 mg; 1) amox./clavul. 0.34 (SD 0.03)/0.02 (SD 0.04)
2) Ofx 600 mg; 2) Ofx 0.32 (SD 0.05)/0.16 (0.02);
3) INH 300 mg 3) INH 0.21 (SD 0.04)/0.60 (SD 0.30);
Sirgel 2000 [218] Prospective, randomised,
4 study sites:
Total 233 patients with
sputum smear pos. DS-TB
EBA0e2/EBA3e5
1) INH 300 mg 1) INH 300 mg 0.37e1.01/0.00e0.08;
2) INH 18.5 mg 2) INH 18.5 mg "0.01e0.33/0.10e0.12
3) RIF 600 mg 3) RIF 600 mg 0.17e0.63/0.24e0.30
4) Ofx 800 mg 4) Ofx 800 mg 0.01e0.39/0.17e0.29
5) no drug 5) no drug "0.02e0.04/"0.06e0.09
Gosling 2003 [92] Prospective, randomised,
1 centre




1) INH 300 mg 1) INH 300 mg 0.77 (SD 0.37)
2) RIF 600 mg 2) RIF 600 mg 0.28 (SD 0.21)
3) Mfx 400 mg 3) Mfx 400 mg 0.53 (SD 0.31)
Pletz 2004 [176] Prospective, randomised,
1 centre
17 patients with sputum
smear-pos. TB
Mean EBA 0e5
1) Mfx 400 mg 1) Mfx 400 mg 0.21
2) INH 6e8 mg/kg 2) INH 6 mg/kg 0.27
Gillespie 2005 [87] Prospective, 1 centre 7 patients with sputum
smear pos. TB
Mfx 400 mg plus INH 300 mg Mean EBA0e2 0.60 (95% CI 0.23e0.97)
Johnson et al. 2006 [119] Prospective, randomised,
1 centre




1) Mfx 400 mg 0.21 1) INH 300 mg 0.67 (SD 0.17)/0.08 (SD 0.09),
2) Lfx 1000 mg 2) Lfx 1000 mg 0.45 (SD 0.35)/0.18 (SD 0.13)
3) gatifloxacin 400 mg 3) gatifloxacin 400 mg 0.35 (SD 0.27)/0.17 (SD 0.13)
4) Mfx 400 mg 4) Mfx 400 mg 0.33 (SD 0.39)/0.17 (SD 0.09)
INH ¼ isoniazid; RIF ¼ rifampicin, Oxf ¼ ofloxacin, Lfx ¼ levofloxacin, Mfx ¼ moxifloxacin, amox ¼ amoxicillin, clavul. ¼ clavulanic acid.
EBA ¼ early bactericidal activity defined as fall in log10 colony forming units (cfu)/ml sputum/day.
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In vitro, the development of M. tuberculosis resistance depends
on the fluoroquinolone concentration used. Low fluoroquinolone
concentration produces many low-level resistance mutants [279],
none containing alterations in the QRDR. As selection pressure in-
creases, a variety of gyrA variants become prevalent. High fluo-
roquinolone concentrations produce only a few mutation types,
and eventually a concentration is reached at which no mutant is
recovered. The minimum concentration allowing no mutant re-
covery when >1010 bacilli are applied to drug-containing agar was
defined as the mutant prevention concentration (MPC) [278], and
may be an important pharmacodynamic consideration. The MPC
for Mfx in vitro is 4e8 mg/ml, a target that is not achieved with Mfx
at current recommended doses, but possibly with new fluo-
roquinolones with more potent activity [89,239]. To date, combi-
nation therapy is the most effective strategy to prevent emergence
of resistance during TB treatment.
Fluoroquinolone resistance in clinical isolates of M. tuberculosis
is a growing problem, with 4e30% of MDR isolates having fluo-
roquinolone resistance depending on the region/country [266]. Of
great concern is the finding that resistance may emerge during
treatment of patients infected with initially fluoroquinolone-
susceptible M. tuberculosis strains [29,61,185,247]. The widespread
use of fluoroquinolones in various lower respiratory tract and other
infections is considered to be partially responsible for increasing
resistance among M. tuberculosis strains [88]. Previous treatment
with a fluoroquinolone is a risk factor for fluoroquinolone resis-
tance [259,274], and M. tuberculosis bacilli acquire fluoroquinolone
resistancewithin a fewweeks ([106,185,231,273]). Later-generation
fluoroquinolones like Mfx are more potent and appear to be less
likely to develop resistance [88]. Fluoroquinolone resistance might
further be due to activation of efflux pumps that seem to be
induced in RIF-resistantM. tuberculosis strains exposed to RIF [141].
Of particular clinical importance in MDR-TB, Mfx retains significant
activity in many Ofx-resistant isolates, withMfxminimal inhibitory
concentrations (MICs) 4e8-fold lower than those of Ofx
[36,121,149,177,219,255]. There are, however, mutations that only
confer resistance to Mfx, but not to Ofx or Lfx [145,258]. Never-
theless, improved treatment outcomes in patients with XDR-TB
have been observed if treated with a later-generation fluo-
roquinolone (Mfx, Lfx or gatifloxacin) [110,199,260].
An improved understanding of the fluoroquinolone resistance
mutations in M. tuberculosis could facilitate more rapid molecular
and clinical diagnosis and the initiation of appropriate treatment,
resulting in improved treatment outcomes and reduced
transmission.
5. Pharmacokinetics of fluoroquinolones
Given the challenges with assessing TB drug efficacy in children,
an understanding of the pharmacokinetics of TB drugs in children is
critical. As a general approach, the recommended dose of anti-TB
drugs in children should lead to a pharmacokinetic profile that
approximates the adult exposures associated with efficacy and
safety. As such, we have reviewed published studies of the phar-
macokinetics of Ofx, Lfx, and Mfx in adults with TB, and in children
with TB or other conditions.
5.1. General information
The fluoroquinolones are easily and rapidly absorbed after oral
administration [109,138,173]. The maximum serum concentration
(Cmax), as well as the area under the timeeconcentration curve
(AUC) of the fluoroquinolones increase linearly with dose [109,138].
Bioavailability of Ofx, Lfx and Mfx is > 85e99% following oral
administration [18,41,137,276]. Protein-binding might be
concentration-dependent for Ofx and Lfx [214], while for Mfx it is
consistent at about 48% over a range of plasma concentrations
[226]. Ofx and Lfx have a half-life of approximately 5 h in adults and
are eliminated mainly unchanged by the kidney (70e90%) [41,137].
Mfx has a relatively long half-life in adults of about
6e12 h [161,230]. About half of Mfx undergoes phase II biotrans-
formation in the liver [227], while 45% is excreted unchanged in
urine and faeces [161].
Fluoroquinolones are distributed widely with good tissue
penetration (including intrapulmonary tissue, bones and soft tis-
sue), with tissue concentrations exceeding serum concentrations
[43,51,76,191]. Fluoroquinolones penetrate well into the cerebro-
spinal fluid (CSF), with published CSF-concentrations of 60% of
serum concentrations for Ofx, >70% for Lfx and >80% for Mfx
[6,62,241].
Lfx accumulates only marginally following once-daily adminis-
tration and steady state is reached within 48 h [76]. For Mfx, steady
state is reached within 3 days after the first dose and the serum
concentrations at steady state are approximately 30% higher than
after the first dose [230]. Food delays absorption of fluo-
roquinolones, but has no effect on the AUC [228,229,256]. Ab-
sorption is decreased by co-administration of sucralfate, antacids,
vitamins and minerals containing divalent and trivalent cations
(e.g. zinc, iron) and these agents should not be taken within 2 h of
fluoroquinolone administration [137,138,170,178,229]. Calciummay
also reduce absorption, although the effect appears less than with
other cations, and administration of Lfx andMfxwith dairy has only
a minimal impact on drug concentrations [228]. These interactions
are of particular importance for children who often take crushed
adult tablets mixed in a multivitamin syrup, milk, or foods [17]. The
pharmacokinetics of fluoroquinolones are not appreciably affected
by gender or race [39,76]. HIV infection is associated with reduced
absorption of some anti-TB agents [94,99], although the influence
of HIV on the pharmacokinetics of fluoroquinolones has not been
systematically studied. Available data indicate that Lfx pharmaco-
kinetics in HIV-infected patients are comparable to that observed in
healthy subjects [90,175]. Information on drugedrug interactions
between fluoroquinolones and antiretroviral agents is still limited.
Co-administration of ciprofloxacin (Cfx) and didanosine might
reduce Cfx bioavailability due to the antacid-containing didanosine
formulation rather than a true drug interaction [53,124]. No influ-
ence on Lfx pharmacokinetics by concomitant zidovudine use has
been found [40]. In two studies in adults, oral solutions or crushing
of tablets did not result in altered drug exposure to Ofx compared to
published data [144,156]. Plasma drug concentrations of Mfx are
lowered by 30% with RIF co-administration due to induction of
hepatic enzymes involving phase II biotransformation [159,262].
The impact of this interaction on the outcome of TB treatment still
needs to be evaluated.
Table 3 summarizes pharmacokinetic data on Ofx, Lfx and Mfx
in adult patients with TB as well as the available paediatric data in
TB and other conditions.
5.2. Ofloxacin pharmacokinetics in children
In a randomized cross-over study Ofx 7.5 mg/kg bodyweight
was given either orally or intravenously to 17 childrenwith typhoid
fever (mean age 10.4 years, range 5e14 years) [20]. The time to
maximum concentration (Tmax), half-life (t1/2) and volume of dis-
tribution were similar to those obtained from adults, while the
systemic clearance was more rapid [20]. Following an oral dose of
Ofx 20 mg/kg in children <15 years of age Cmax approximated
published adult data following a standard oral dose of Ofx 800 mg,
while AUC was less than half the adult values [79,240]. This was
attributed to faster elimination in children. There was no difference
S. Thee et al. / Tuberculosis 95 (2015) 229e245236
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seen by HIV- or nutritional status or if Ofx was given for TB disease
or for preventive therapy [79,80]. Crushing tablets also did not
lower drug exposure compared to administration of whole Ofx
tablets [240].
5.3. Levofloxacin pharmacokinetics in children
There are two published pharmacokinetic studies of Lfx in
children with MDR-TB and one study in children with other bac-
terial infections [38,147,240]. Lfx pharmacokinetics was studied in
more than 80 children with bacterial infections after a single dose
of Lfx 7 mg/kg, given intravenously or orally. Elimination occurred
faster in children <5 years of age compared to older children. The
authors concluded that in order to approximate exposures in adults
after a 500 mg Lfx dose, children >5 years need a daily dose of
10 mg/kg, whereas children 6 months to <5 years should receive
10 mg/kg 12 hourly [38]. Applying pharmacometric techniques to
this data [38] in the context of treatment for post-exposure inha-
lational anthrax, Lfx doses of 8 mg/kg twice daily for children
<50 kg and 500 mg once daily for children >50 kg best approxi-
mated Lfx exposure in adults after a 500 mg dose [135].
Mase et al. studied the pharmacokinetics of Lfx in 33 children
(median age 8 years) with MDR-TB or MDR-TB exposure receiving a
median Lfx dose of 8 mg/kg [147]. In the only other study, the
pharmacokinetics of Lfx was investigated in 22 children <8 years of
age (median age 3 years) receiving Lfx 15 mg/kg either for MDR-TB
disease or preventive treatment [240]. Although children in the
Mase study received a lower dose than children in the study by
Thee et al. the Cmax as well as the AUC0-∞8 were similar in the two
studies [147,240]. In the study by Mase et al. Lfx was given as oral
gel of verified potency, while in the Thee study, Lfx tablets, either
whole or crushed, were administered [147,240] and no association
was found between age and Lfx, exposure, although weight pre-
dicted drug exposure [240].
5.4. Moxifloxacin pharmacokinetics in children
We only identified two studies on Mfx pharmacokinetics in
children. One is a single case study in a premature infant with
Mycoplasma hominismeningitis, with limited generalizability [261].
The other study included 23 children (age 7e15 years) with MDR-
TB receiving Mfx at a daily dose of 10 mg/kg, showing that children
were exposed to lower serum levels than adults receiving a com-
parable dose, and that HIV infection is associated with lower Mfx
serum concentrations [239].
In summary, the available information on fluoroquinolone
pharmacokinetics in children show substantially lower serum
concentrations compared to adults, using noncompartmental
analysis. There is a paucity of data especially in children <5 years of
age and HIV-infected children and child friendly drug formulations
are lacking, making the study of drugs like Mfx in younger children
challenging. Pharmacokinetic modelling and meta-analyses of
larger combined datasets might be useful tools to compare paedi-
atric versus adult data, and assess covariate effects.
6. Pharmacodynamics
Pharmacodynamic (PD) indices are used as surrogate markers
for clinical efficacy. An AUC0-24/MIC ratio of >100e125 or Cmax/MIC
of 8e10 is associated with clinical and microbiological success in
Gram-negative bacteria and presumably also in M. tuberculosis
[88,268]. In non-mycobacterial respiratory infections AUC/MIC is
the best PD index for fluoroquinolones, and data in mice support
the applicability to TB [54,158,208,214]. In an EBA study, an AUC/
MIC >100 of Lfx and Mfx showed similar activity against
M. tuberculosis as INH [119]. There are no human studies prospec-
tively establishing the target AUC/MIC ratios for the fluo-
roquinolones against M. tuberculosis [158,214].
A Mfx dose of 800 mg in adults has been identified in in vitro
studies and in mathematical modelling as the dose most likely to
achieve the proposed drug targets [98,214,282]. In adult MDR-TB
patients, an oral Mfx dose of 400 mg resulted in less favourable
Gree AUC/MIC ratios than a Lfx dose of 1,000 mg [173]. Existing
evidence from in vitro and animal studies shows that either higher
doses or the use of newer fluoroquinolones with a lower MIC
should be considered to achieve proposed AUC/MIC targets
[11,44,54,214,280].
PD indices in the treatment of TB need to be prospectively
assessed. For paediatric TB there is no information on fluo-
roquinolone drug targets available. An improved understanding of
the relative importance of Cmax/MIC ratio versus AUC/MIC ratio is
particularly important for children, who may more easily approx-
imate the adult Cmax but have much lower AUCs due to more rapid
drug elimination.
7. Safety
The fluoroquinolones are generally well-tolerated compounds.
Adverse effects were described as mild to moderate in severity and
necessitated discontinuation of treatment in 1e2% in adults
[160,161,171,203]. The most common adverse effects reported in
adults were gastrointestinal disturbances (0.9e4.7%), neurotoxicity
(0.9e4.7%), hypoglycemia, anaemia, conjunctivitis, and rash
[45,127,154]. Further rare adverse effects include phototoxicity,
tendonitis, prolongation of QT interval and ophthalmological and
nephrologic complications [45,221].
The use of fluoroquinolones in children has been limited
because of their potential to induce arthropathy in juvenile animals
(see below) [46,77,236]. However, the majority of adverse effects
reported with fluoroquinolones use in children are mild, require
little or no intervention and are reversible with cessation of the
drug [93].
7.1. Gastrointestinal adverse effects
In a report on >1,700 children receiving Cfx for compassionate
use, adverse effects involving the digestive system were the most
common, occurring in 5% [100]. In a cohort of 186 children
receiving ofloxacin, ethambutol, and high-dose isoniazid as part of
MDR-TB preventive therapy, loss of appetite and nausea were the
most common grade 2 or higher adverse events (12 children
[6.2%]), followed by itchy skin (9 children [4.7%]), disturbance of
sleep or mood (7 children [3.6%]), and skin rash (7 children [3.6%])
[209]. Grade 3 events were only reported in 6 children (3.2%), and
no grade 4 events occurred [209]. No dose-related increase in
gastrointestinal adverse effects was seen for Lfx in adult dose-
ranging studies [42].
7.2. Central nervous system (CNS) reactions
Central nervous system reactions aremostly mild (e.g. dizziness,
headache, tiredness, sleeplessness, restlessness), are dose depen-
dent [23], typically start within a few days after initiation of fluo-
roquinolone treatment and stop with cessation of the
fluoroquinolone [45,225,249]. Nevertheless, in adults, there are
reports on peripheral neuropathy and possibly Guillain-Barr!e-
syndrome associated with fluoroquinolone use [8]. Few case re-
ports on benign raised intracranial pressure associated with fluo-
roquinolone use have been published [133,263]. In a cohort of
children receiving an Ofx-containing MDR-TB preventive treatment
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regimen, 9 (4.6%), 4 (2.1%) and 3 (1.5%) of 193 children experienced
Grade 1, 2 and 3 mood/sleep disturbances, respectively, the latter
probably related to inadvertent overdosing of Ofx [210]. Some cases
of hallucinations following treatment with Ofx have also been re-
ported [34,209]. In several previous reports on management of
children with MDR-TB, neurological adverse effects occasionally
occurred, but were attributed to cycloserine [66,73,207]. Subtle
neurological adverse effects (e.g. sleep disturbances) have to be
specifically ascertained and might be underreported.
7.3. Chondrotoxicity
Fluoroquinolones at high doses (e.g. Ofx 600 mg/kg) cause
irreversible joint cartilage defects in studies in juvenile rats [77],
while in dogs, representing the most sensitive species, cartilage
lesions are inducible at a rather low dose of Ofx 10e50 mg/kg/
d [223]. The underlying mechanism may be chelation of magne-
sium in joints leading to subsequent reactions, including radical
formation [101]. Data from juvenile rats indicate that chondrotox-
icity of Ofx not only increased with increasing single oral doses, but
also when the drug is given for several days [222]. Although
chondrotoxicity is considered a class effect, considerable differ-
ences seem to exist. Absorption, tissue penetration and AUC of
fluoroquinolones have to be taken into account to assess the risks
associated with individual fluoroquinolones [224]. Tendinopathies
are another described toxic effect with a higher risk with
concomitant corticoid therapy [188,222]. Although multiple
observational studies have demonstrated no unequivocal docu-
mentation of fluoroquinolone-induced arthropathy in children or
adolescents, their use in children remains debated and the available
paediatric data limited [19,24,27,100,205]. Schaad reviewed pub-
lished reports which included monitoring for fluoroquinolone-
induced cartilage toxicity and found no unequivocal documenta-
tion of fluoroquinolone-induced arthropathy in children [204].
Clinical observations temporally related to quinolone use are
reversible and are coincidental rather than representing adverse
effects [204]. Multiple further reviews of fluoroquinolone safety in
children concluded that there may be some association between
fluoroquinolones and reversible arthralgia in children, but there is
no evidence for severe or irreversible arthropathy and no evidence
for sustained injury on bone or joint growth [1,7,24,48,100,194,203].
In a comprehensive review on quinolone arthropathy in children
versus animals, Burkhardt et al. identified 10 published case reports
of suspected quinolone arthropathy, of which 7 were associated
with treatment with pefloxacin, 2 with Cfx and 1with nalidixic acid
[27]. With the exception of one case, complete clinical recovery was
observed. In 31 further reports frommulti-patient studies in >7000
children, arthralgia following the use of either Cfx, naldixic acid,
norfloxacin or Ofx did not occur beyond the level of severity ex-
pected as a result of the underlying disease [27]. The authors
concluded that quinolone arthropathy is not convincingly corre-
lated with use of these compounds in children and estimated that
the occurrence of chondrotoxicity, as seen in juvenile animals,
would not be greater than 0.04% [27]. In a prospective trial
comparing safety of fluoroquinolone use in children (n ¼ 276) to
that of other antibiotics in children (n ¼ 249) with different un-
derlying conditions, adverse events (including musculoskeletal
events) occurred more frequently in the fluoroquinolone group
than in the control group but were all transient [31]. No relation-
ship between dose and duration of therapy was seen. Prescribed
fluoroquinolones were Cfx (87%), Ofx (9%) and pefloxacin (4%). No
adverse event was associated with Ofx use [31].
Noel et al. assessed the safety profile of Lfx in 2523 children based
on observations for 1 year after therapy [162]. The incidence of pre-
definedmusculoskeletaldisorders (arthralgia, arthritis, tendinopathy,
gait abnormality) was statistically greater in Lfx-treated children and
occurred in about 1 of 400 children treated with Lfx. Arthralgia in
weight-bearing joints was the major complaint. Lfx was given in a
dose of 10 mg/kg twice daily to a maximum of 500 mg/day for 7e14
days.Reported incidenceofmusculoskeletal adverseeffects increased
over time, even after exposure to Lfx, but disorders were typically
transient and resolved spontaneously without sequelae. The authors
noted that the lack of blinding may have biased these results,
particularlyas thedifferencewasmainly related tosubjectiveparental
reports of arthralgia [162]. After 5 years of followup on 1340 children
receiving Lfx, no long-term effects on the musculoskeletal system
were seen [24]. In a retrospective study of more than 6000 children,
the incidence of tendon or joint disorders associated with the use of
Ofx, Lfx or Cfx was <1% and comparable with the reference group
receiving azithromycin [270]. Data on the risk of arthropathy in
children on long-term fluoroquinolone therapy (as for anti-TB treat-
ment) is limited. Seddonet al. reported joint,muscleorbonepainonly
asgrade1or2 in13of137 (9%) children receivingOfx15e20mg/kg as
part of a multi-drug preventive therapy for MDR-TB (once-daily
dosing for 6 months) [209].
7.4. Cardiovascular reactions
The fluoroquinolones prolong the QT interval by blocking
voltage-gated potassium channels expressed by the human ether-
a-go-go-related gene, HERG [201], potentially leading to the
development of torsades de pointes, which may degenerate into
ventricular fibrillation and, potentially, sudden death. Studies
in vitro and with healthy volunteers show that Mfx has the highest
potency for QT prolongation compared with Lfx and Ofx
[56,122,163,164], although even for Mfx the amplitude of QT-
prolongations is small, and the risk of torsades de pointes is ex-
pected to be minimal at the current recommended doses [25,56].
However, fluoroquinolones should not be used in patients with
predisposing factors for torsades de pointes including electrolyte
disturbances and bradycardia or during coadministration of
proarrhythmic drugs [25,56].
An additional consideration for patients onMDR-TB treatment is
the frequent drug-induced hypothyroidism related to para-ami-
nosalicylic acid or ethionamide. Hypothyroidism and subclinical
hypothyroidism are associated with prolongation of the QT interval
[13,169]. Care should be taken if other drugs with potential to
prolong the QT interval (e.g. delamanid, bedaquiline, clari-
thromycin or clofazamine) are used in combination with fluo-
roquinolones [30,84,179,277].
Our search did not identify any report on QT prolongation,
arrhythmia or sudden death associated with fluoroquinolone use in
children. Garazzino et al. reported no QT prolongation in 9 children
with MDR TB treated with Mfx [78]. In two further studies on
children with MDR-TB treated with Lfx (n ¼ 23) or Mfx (n ¼ 23) no
QT-prolongation >450 ms was seen [239,240].
7.5. Other adverse effects
Mild, usually transient, elevations in hepatic enzymes have been
associated with fluoroquinolone therapy, while the incidence of
acute liver injury is very low (<1 per 100,000 users) [14,55,239].
There are two reports on higher frequencies of hepatitis, if Ofx or
Lfx are given in combinationwith pyrazinamide [2,190]. Acute liver
failure reporting rates using U.S. Food and Drug Administration
(FDA) data per 10 million prescriptions have been given as 2.1 for
Lfx, compared with 6.6 for Mfx [253].
Disordered glucose regulation, either hypo- or hyperglycemia,
can occur with any of the fluoroquinolones, with marked differ-
ences between individual fluoroquinolones [136]. For Lfx and Mfx
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the risk is reported to be low [95,151]. We did not identify any
report on hypoglycaemia or acute liver failure in children receiving
fluoroquinolones.
8. Conclusions
Existing data from in vitro, animal and human studies consis-
tently demonstrate the efficacy of Ofx, Lfx and Mfx against
M. tuberculosis. The later-generation fluoroquinolones Lfx and Mfx
have shown a higher potency than Ofx. Mfx is currently considered
the most potent against M. tuberculosis, but Lfx at higher doses
(1000 mg/d or 20 mg/kg) may be equivalent. If available, Mfx and
Lfx should be the fluoroquinolones of choice in the treatment of
MDR-TB. Despite a lack of RCTs of the fluoroquinolones in the
treatment of MDR-TB in adults or children, their strong bactericidal
and sterilizing activity, favourable pharmacokinetics and toxicity
profile have made them the most important component of existing
MDR-TB treatment regimens. The current evidence on Mfx con-
taining regimen does not yet support their use in the shortening of
TB treatment for DS-TB.
Existing pharmacokinetic data suggests that fluoroquinolones
should be given at higher doses in children compared to adults.
Further studies are needed to evaluate these higher doses and their
safety in long-term anti-TB treatment in children, including in
children below 2 years of age and HIV-infected children. Data on
drugedrug interactions between fluoroquinolones and antiretro-
viral agents is largely absent in children. Existing formulations
make appropriate dosing of the fluoroquinolones in the paediatric
population challenging. It is common practice to split or crush
tablets to administer to children without available information on
subsequent bioavailability and therefore efficacy. Widely available,
child-friendly formulations especially of Mfx and Lfx, for children
with MDR-TB, are urgently needed.
The use of fluoroquinolones has been traditionally restricted in
children due to safety concerns, especially drug-induced arthrop-
athy. The available data does not demonstrate any serious
arthropathy or other severe toxicity in children. Although there is a
paucity of paediatric data for the treatment of MDR-TB, extended
administration of fluoroquinolones in adults with MDR-TB does not
show serious adverse effects and there is no evidence suggesting
less tolerability of fluoroquinolones in children.
Available data supports the use of newer fluoroquinolones as
key components in the treatment of drug resistant TB in children,
while their role in treatment shortening and preventive therapy in
children needs further investigation.
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   Chapter	  5	   	  
The	  pharmacokinetics	  of	  the	  second-­line	  anti-­tuberculosis	  drugs	  




The	   second-­‐line	   anti-­‐tuberculosis	   agents	   ethionamide	   (ETH)	   and	   the	   fluoroquinolones	  
ofloxacin	   (OFX),	   levofloxacin	   (LFX)	   and	   moxifloxacin	   (MFX)	   were	   selected	   for	  
pharmacokinetic	  investigation	  in	  children.	  ETH,	  because	  it	  is	  widely	  used	  in	  multidrug-­‐
resistant	   tuberculosis	   (MDR-­‐TB)	   as	   well	   as	   in	   drug-­‐susceptible	   (DS)-­‐TB;	  
fluoroquinolones,	   because	   they	   form	   the	   backbone	   of	   MDR-­‐TB	   chemoprevention	   and	  
treatment	   of	   MDR-­‐TB	   not	   only	   in	   current	   regimens,	   but	   will	   also	   be	   used	   in	   future	  
regimens	  with	  novel	  compounds-­‐	  both	  for	  DR-­‐TB	  and	  DS-­‐TB	  
	  
5.1.	  The	  pharmacokinetics	  of	  ethionamide	  in	  children	  with	  tuberculosis	  
	  
The	  aim	  of	  this	   first	  study	  investigating	  the	  pharmacokinetics	  of	  ethionamide	  (ETH)	  in	  
children,	  was	  to	  document	  the	  pharmacokinetics	  ETH	  in	  children	  3	  months-­‐<2	  years,	  2-­‐
<6	  years,	  and	  6-­‐12	  years	  of	  age	  receiving	  the	  current	  WHO	  recommended	  dosage	  of	  ETH	  
(15-­‐20	   mg/kg/day)	   (310).	   For	   anti-­‐tuberculosis	   therapy,	   a	   maximum	   serum	  
concentration	  (Cmax)	  of	  2.5µg/ml	  has	  been	  suggested	  (72).	  The	  hypothesis	  was	  that	  the	  
current	   dosing	   recommendations	   for	   ETH	   would	   achieve	   serum	   concentrations	   in	  
children	   with	   TB	   treated	   with	   a	  multiple	   drug	   regimen	   (with	   and	  without	   rifampicin	  
[RMP])	  comparable	  to	  those	  found	  in	  adults	  treated	  with	  a	  standard	  dose	  of	  ETH	  500-­‐
750mg/day.	  	  
Two	   groups	   of	   children	   were	   studied:	   those	   receiving	   ETH	   with	   RMP,	   and	   those	  
receiving	  ETH	  without	  accompanying	  RMP,	  in	  order	  to	  detect	  possible	  influences	  on	  the	  
pharmacokinetics	  of	  ETH	  by	  the	  strong	  enzyme	  inducer	  RMP.	  In	  this	  explorative	  study	  a	  
valid	  estimation	  of	  number	  of	  cases	  needed	  for	  statistical	  significance	  could	  not	  be	  made	  
as	   there	   were	   neither	   data	   on	   ETH	   serum	   concentrations	   nor	   on	   ETH	   standard	  




deviations	  in	  children	  of	  different	  age	  groups.	  Sample	  size	  considerations	  were	  based	  on	  
reasons	   of	   practicability	   and	   according	   to	   the	   frequency	   of	   treatment	   regimen	   use	   in	  
children	  containing	  ETH.	  	  
Children	  younger	  than	  13	  years	  of	  age	  with	  TB	  routinely	  admitted	  to	  Brooklyn	  Hospital	  
for	   Chest	   Diseases	   (BHCD)	   were	   included.	   Pharmacokinetic	   assessment	   of	   ETH	   was	  
completed	   through	   an	   intensive	   sampling	   approach	   approximately	   1	   month	   after	  
starting	  a	  routine	  anti-­‐tuberculosis	  treatment	  regimen	  which	  included	  ETH,	  and	  again	  at	  
4	  months	  of	  anti-­‐tuberculosis	  treatment,	   in	  order	  to	  assess	   intra-­‐individual	  differences	  
and	   changes	   in	   the	   pharmacokinetics	   of	   ETH	   over	   time.	   Blood	   samples	   were	   drawn	  
before	   and	   at	   1,	   2,	   3,	   4	   and	   6	   hours	   after	   oral	   administration	   of	   ETH.	   The	   serum	  
concentrations	  were	   determined	   by	   high	   performance	   liquid	   chromatography	   (HPLC).	  
Cmax,	  time	  until	  Cmax	  (tmax),	  and	  area	  under	  the	  curve	  (AUC)	  of	  ETH	  concentrations	  were	  
primary	  outcome	  measures.	  	  
Thirty-­‐one	   (n=31)	   children	   (median	   age	   2.8	   years)	   were	   included.	   Twelve	   children	  
(39%)	  were	  HIV-­‐infected,	  and	  16	  had	  pulmonary	  TB	  (52%).	  Observed	  mean	  (SD)	  ETH	  
PK	  measures	  after	  1	  month	  of	  therapy	  with/without	  RMP	  in	  children	  <2years,	  2-­‐6years	  
and	  6-­‐12years	  were	  as	   follows:	  Cmax	  3.8	  (1.6)/3.9	  (1.6)µg/ml,	  4.4	  (1.2)/3.6	  (1.4)µg/ml,	  
and	   3.6	   (1.3)/5.4	   (1.2)µg/ml	   respectively;	   AUC0-­‐6	   7.6	   (3.5)/8.4	   (3.7)mg∙h/l,	   10.6	  
(5.6)/8.3	   (3.5)mg∙h/l,	   and	   12.3	   (4.3)/13.9	   (4.9)mg∙h/l,	   respectively.	   Younger	   children	  
were	  exposed	  to	  lower	  ETH	  concentrations	  than	  older	  children	  at	  the	  same	  mg/kg	  body	  
weight	  dose.	  Age	  correlated	  significantly	  with	  AUC	  after	  both	  1	  month	  (r=0.50,	  p=0.001)	  
and	   4	  months	   (r=0.63,	   p=0.001)	   of	   therapy.	   HIV	   co-­‐infection	   led	   to	   lower	   ETH	   serum	  
concentrations	   (statistically	   significant).	   Neither	   co-­‐medication	   with	   RMP	   nor	   the	  
duration	  of	  ETH	  treatment	  influenced	  pharmacokinetic	  measures	  of	  ETH	  in	  children.	  
This	   study	   showed	   that	   with	   an	   ETH	   dose	   as	   currently	   recommended	   by	   WHO,	   the	  
majority	  of	  children	  achieved	  sufficient	  serum	  concentrations.	  Children	  younger	  than	  2	  
years	   of	   age	   and	   HIV-­‐infected	   children	   were	   exposed	   to	   substantially	   lower	   ETH	  
concentrations	   than	  older	   children	  or	  HIV-­‐uninfected	   children.	  This	  may	   imply	  a	  need	  
for	  a	  higher	  dosage	  in	  younger	  and	  HIV-­‐infected	  children,	  which	  should	  be	  evaluated	  in	  
future	  studies.	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Ethionamide (ETH), a second-line antituberculosis drug, is frequently used in treating childhood tubercu-
losis. Data supporting ETH dose recommendations in children are limited. The aim of this study was to
determine the pharmacokinetic parameters for ETH in children on antituberculosis treatment including ETH.
ETH serum levels were prospectively assessed in 31 children in 3 age groups (0 to 2 years, 2 to 6 years, and 6
to 12 years). Within each age group, half received rifampin (RMP). Following an oral dose of ETH (15 to 20
mg/kg of body weight), blood samples were collected at 0, 1, 2, 3, 4, and 6 h following 1 and 4 months of ETH
therapy. The maximum serum concentration (Cmax), time to Cmax (Tmax), and area under the time-concentra-
tion curve from 0 to 6 h (AUC0–6) were calculated. Younger children were exposed to lower ETH concentrations
than older children at the same mg/kg body weight dose. Age correlated significantly with the AUC after both
1 month (r ! 0.50, P ! 0.001) and 4 months (r ! 0.63, P ! 0.001) of therapy. There was no difference in the
AUC or Cmax between children receiving concomitant treatment with RMP and those who did not. Time on
treatment did not influence the pharmacokinetic parameters of ETH following 1 and 4 months of therapy. HIV
infection was associated with lower ETH exposure. In conclusion, ETH at an oral dose of 15 to 20 mg/kg results
in sufficient serum concentrations compared to current adult recommended levels in the majority of children
across all age groups. ETH levels were influenced by young age and HIV status but were not affected by
concomitant RMP treatment and duration of therapy.
The thioamides, ethionamide (ETH) and prothionamide,
are among the most frequently used second-line drugs for the
management of pediatric tuberculosis (TB) and are active
against several species of mycobacteria. They are oral drugs
recommended for treatment of multidrug-resistant tuberculo-
sis (MDR-TB) and also used to treat drug-susceptible tuber-
culous meningitis (TBM) and miliary disease due to good
cerebrospinal fluid penetration (8, 19). Absorption of ETH
from the intestinal tract is almost complete, and food and
antacids appear to have little effect on this process (2). Protein
binding is approximately 30% (9). ETH is distributed with ease
throughout the body (28). In adults, peak plasma concentra-
tions of ETH occur at approximately 2 h postdosing (2, 10, 29).
For clinical purposes, the suggested serum levels for suscepti-
ble strains of Mycobacterium tuberculosis vary in the literature,
as follows: 2.5 !g/ml or between 1 and 5 !g/ml (13, 14, 22).
There is evidence that ETH has a bactericidal effect in higher
doses (15). Higher doses are often poorly tolerated, limiting
the dose in adults to 500 to 1,000 mg per day. A very small
proportion of the drug is excreted unchanged, and the first step
in thioamide metabolism in the liver is transformation to the
active sulfoxide metabolites by monooxygenases (17). These
monooxygenases have many properties in common with the
cytochrome P450 system (CYP) and often have overlapping
substrate specificities (17). Rifampin (RMP), commonly used
with ETH, is a potent inducer of hepatic and intestinal cyto-
chrome P450 enzymes and p-glycoprotein and activates the
nuclear pregnane X receptor and the constitutive androstane
receptor (20).
The optimal dose of ETH for children has not yet been
established. While a total daily pediatric dose of 10 to 20 mg/kg
of body weight has been suggested by the WHO and 15 to 20
mg/kg is the standard in South Africa, the resulting serum
levels in children of different ages are largely unknown. Little
is known regarding the accumulation of ETH during continu-
ous therapy or whether drug interactions relevant to combina-
tion TB therapy in children lead to changes in ETH serum
levels over time.
In drug-susceptible tuberculous meningitis or miliary dis-
ease, ETH is given in a combination regimen which includes
RMP. The effects of coadministered drugs, such as RMP, on
the concentrations of ETH are unknown.
We studied ETH serum levels in children of different age
groups who were routinely on two different treatment regimens
in a hospital setting at 1 and 4 months after initiation of routine
antituberculosis treatment. Besides a single previous study of
two children, this is to our knowledge the first evaluation of
ETH pharmacokinetics in children (29).
MATERIALS AND METHODS
This study was conducted at Brooklyn Hospital for Chest Diseases (BHCD),
Cape Town, South Africa. From September 2009 through May 2010, children
aged 3 months to 13 years admitted to BHCD were eligible for enrollment.
Children were divided in 3 age groups (3 months to 2 years, 2 to 5 years, and 6
* Corresponding author. Mailing address: Department of Paediatric
Pneumology and Immunology, Charité, Universitätsmedizin Berlin,
Berlin, Germany. Phone: 493030354470. Fax: 493089647815. E-mail:
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to 13 years of age), with 10 children in each age stratum, of whom half routinely
received RMP.
All parents or legal guardians gave written informed consent for their child’s
participation prior to enrollment. The study was approved by the Health Re-
search Ethics Committee of the Faculty of Health Sciences of Stellenbosch
University, South Africa, where ETH is licensed for use in children.
Diagnosis of tuberculosis. The diagnosis of TB was based on a chest radio-
graph compatible with a diagnosis of pulmonary TB and/or clinical signs of
extrapulmonary TB (e.g., peripheral lymph nodes, meningitis, abdominal TB)
with supporting special investigations, including mycobacterial culture. Middle-
brook 7H9 broth base (mycobacterial growth indicator tubes [MGIT]; Becton
Dickinson, Sparks, MD) culture medium was used for primary isolation. The
presence of M. tuberculosis was confirmed by PCR amplification. Phenotypic
drug susceptibility testing was done using the Bactec 460TB system (Becton
Dickinson, Sparks, MD), according to international criteria. Strain susceptibility
was judged by comparing growth of organisms in drug- versus nondrug-contain-
ing media. Resistance was defined as 1% or more bacterial growth in the drug-
containing media (24). A history of household TB contact and a positive Man-
toux tuberculin skin test (TST), along with suggestive symptoms, were considered
supportive evidence. When no culture was obtained, children were treated em-
pirically according to the drug susceptibility result of isolates from the likely
source case.
Treatment. Children were included if ETH was part of their standard antitu-
berculosis daily treatment and only if they could tolerate taking ETH as a single
daily dose. South African Medicines Control Council-approved ETH 250-mg
tablets (Sanofi Aventis, South Africa) were used.
All children received supplementary pyridoxine and multivitamin syrup. Tri-
methoprim-sulfamethoxazole was given to all HIV-infected children. Antiretro-
viral treatment consisted of two nucleoside reverse transcriptase inhibitors (lami-
vudine and stavudine) and either lopinavir-ritonavir (boosted with extra ritonavir
if on RMP) in children younger than 3 years of age or efavirenz in children older
than 3 years of age.
Pharmacokinetic investigation. A routine recommended ETH dose of 15 to 20
mg per kg of body weight was calculated for each child, and ETH tablets were
measured accordingly. ETH was administered by study personnel in the morning
after an overnight fast (minimum of 4 h of fasting in younger children). In
children who were "2 years of age and if necessary in other children, ETH
tablets were crushed and suspended in 2 to 5 ml of water. For one child, all drugs
were given via a gastrostomy tube. Children had breakfast only after the 1-hour
blood sample was taken. In case of HIV infection, antiretroviral therapy was
given with breakfast, while other treatment was given after the last blood sample
was taken.
Blood samples were collected at 0, 1, 2, 3, 4, and 6 h following dosing and
following 1 and 4 months of antituberculosis therapy.
Blood samples were collected in EDTA-containing sampling vials, centrifuged,
frozen at #80°C, and stored. To 100 !l of sample, 300 !l of methanol, containing
1.0 !g/ml thiacetazone (Sigma, St. Louis, MO), was added. The supernatant was
transferred into autosampler vials for analysis using a 5-!l injection volume.
Specimens were analyzed using a binary high-performance liquid chromatog-
rapher (HPLC) (Agilent series 1100 HPLC; Agilent Technologies, Waldbronn,
Germany) equipped with an Agilent Zorbax analytical column (150 mm by 2.1
mm inside diameter [i.d.], 3.5-!m particle size). The column temperature was
maintained at 40°C at a flow rate of 300 !l/min. The mobile phase A was water
containing 0.1% formic acid (FA) (Fluka Chemie GmbH, Buchs, Switzerland),
while phase B was methanol (E. Merck, Darmstadt, Germany) containing 0.1%
FA. All solvents were of HPLC grade. The concentration of ETH was deter-
mined using an API 2000 tandem mass spectrometer (MS/MS; Applied Biosys-
tems, MDS Sciex, Foster City, CA) equipped with an atmospheric turbulon
ionization chamber. A single transition range for ETH of m/z 167.13/107.00 was
used, while for the internal standard, a transition of m/z 237.12/119.96 was used.
All samples and spiked standards were analyzed in duplicate. The within-day
variation between the duplicates was less than 2%. The overall analytical preci-
sion over the entire duration of the study was not more than 3% over the entire
calibration range. The day-to-day variation of standards and patient samples was
TABLE 1. Demographic, clinical, and radiological features of children by age group and treatment regimens
Characteristica
No. of children:
"2 yr (n $ 10)
without/with RMP
2 to 6 yr (n $ 11)
without/with RMP
6 to 12 yr (n $ 10)
without/with RMP
Total 5/5 6/5 5/5
Mean age (SD) 1.0 (0.7)/1.0 (0.6) 2.7 (1.2)/3.2 (1.3) 9.3 (2.1)/8.5 (1.7)
Female 3/3 4/1 5/1
Culture of M. tuberculosis or AFB positive 2/4 4/2 4/2
Household TB contact 4/4 2/3 4/1
HIV infected 2/2 2/2 3/1
Mantoux test done 5/4 4/3 2/2
Clinical features
Pulmonary TB 5/2 5/0 4/0
Tuberculous meningitis 0/3 0/5 0/5
Hepatomegaly at inclusion 3/1 2/2 2/1
Nutritional statuses
Mass " 3rd percentile 1/0 0/2 2/1
Mean wt, 1 month (SD) 8.3 (2.6)/8.7 (2.4) 13.1 (2.0)/12.8 (2.6) 26.1 (7.5)/23.7 (2.0)
Mean wt, 4 months (SD) 9.6 (2.6)/9.2 (2.7) 13.5 (2.1)/13.0 (2.7) 25.7 (7.3)/23.1 (2.0)
Mean MUAC, 1 month (SD) 13.6 (2.1)/14.1 (2.0) 16.0 (1.2)/15.6 (0.9) 17.9 (1.9)/17.6 (0.9)
Mean MUAC, 4 months (SD) 14.4 (2.1)/15.7 (2.2) 15.8 (1.1)/15.2 (1.2) 18.0 (2.0)/17.2 (0.6)
Mean BMI, 1 month (SD) 15.8 (3.0)/16.9 (1.7) 15.8 (1.1)/16.6 (2.0) 15.5 (2.1)/15.2 (1.2)
Mean BMI, 4 months (SD) 16.9 (2.7)/16.4 (2.6) 15.7 (0.9)/15.8 (1.6) 15.2 (2.0)/14.4 (0.6)
Radiological featuresb
Hilar adenopathy 3/3 3/1 2/1
Airway compression 2/0 1/1 0/1
Alveolar opacification 4/1 4/2 2/2
Cavitation 1/0 0/1 2/0
Bronchopneumonic opacification 1/0 0/0 1/0
Pleural effusion 1/0 1/0 0/0
a SD $ standard deviation; AFB $ acid-fast bacilli; MUAC $ mid-upper-arm circumference; BMI $ body mass index (kg/m2).
b For one child with tuberculous meningitis, no chest X-ray was available.
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in the range of 1.5 to 2.0%. The retention times of ETH and thiacetazone were
2.73 min and 7.0 min, respectively. The temperature of the nebulizer gas of the
ionization chamber was set to be 400°C. Spiked calibrators in the range of 0.5
!g/ml to 15.0 !g/ml showed a linear relationship. Quality control samples were
added to each sample batch.
Pharmacokinetic parameters. Cmax is the observed maximum serum concen-
tration for each individual, and Tmax is the time at which Cmax is recorded. The
elimination rate constant (kel) was determined from the concentration versus
time curve. The area under the time-concentration curve (AUC) from 0 to 6
hours (AUC0–6) was calculated according to the linear trapezoidal rule. AUC0-%
and clearance were also calculated.
Statistical methods. The data were summarized as means and standard devi-
ations (SD). The Z-score for weight for age was calculated according to WHO
growth charts (27).
For binominal data, differences between groups were determined using Fisher’s
exact test. The Spearman rank correlation coefficient described associations between
continuous variables. A mixed-model repeated-measures analysis of variance
(ANOVA) was performed to evaluate the influence of HIV infection and to assess
the differences for the pharmacokinetic parameters between the two treatment
groups and following 1 and 4 months of therapy.
RESULTS
A total of 31 children were enrolled; 15 children received a
regimen that included ETH and RMP, and 16 received an
ETH-containing regimen without RMP. For one 2-year-old
child, RMP was added only after inclusion in the study and
after completion of the first study day. For one child, the
4-month data point was missing because of failed venipunc-
ture. All HIV-infected children were established on antiretro-
viral therapy (at least 2 to 4 weeks of therapy) at enrollment.
The demographics, diagnostic criteria, and clinical features
of participants are shown in Table 1. A RMP-including treat-
ment regimen is used in the treatment of TBM but usually not
in the treatment of MDR-TB, explaining the different clinical
features in the two study groups.
ETH pharmacokinetic parameters are displayed in Table 2.
The variability of pharmacokinetic parameters at both time
points was high (Table 2). Children were on daily treatment
with ETH for a mean of 36 days (SD, 7.13 days) at the 1-month
sampling point and 120 days (SD, 5.5 days) at the 4-month
sampling point, respectively. The mean ETH doses adminis-
tered at the respective sampling points were 17.8 mg/kg (SD,
2.4 mg/kg) and 17.6 mg/kg (SD, 1.9 mg/kg), respectively.
Low maximum serum levels (Cmax " 2.5 !g/ml) were found
in 4 children (2 were "2 years of age) at the 1-month sampling
and in 7 children (5 were "2 years of age) following 4 months
of therapy. Only one child had a Cmax below 2.5 !g/ml at both
time points. Cmax ranged between 2.5 !g/ml and 5.0 !g/ml in
15 children (48%) at 1 month and in 13 children (42%) fol-
lowing 4 months of therapy.
HIV coinfection was associated with reduced exposure to
ETH at both time points (1 month/4 months, Cmax P $ 0.002/
0.023, AUC0–6 P $ 0.523/0.047; ANOVA); there was no HIV-
associated delay in absorption or elimination (1 month/4
months, Tmax P $ 0.594/0.970, half-life [t1/2] P $ 0.435/0.602).
We found no association between body mass index, mid-
upper-arm circumference, or weight-for-age Z scores and any
ETH pharmacokinetic parameters (data not shown).
Differences between age groups. Mean ETH serum concen-
trations are shown by treatment regimens depicted in Fig. 1a
and b, and the corresponding pharmacokinetic parameters ap-
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Children in both treatment groups (n $ 31) were therefore
combined for analysis of pharmacokinetic parameters in dif-
ferent age groups.
After month 1 [referred to by subscripted “(1)”], younger
children were exposed to lower ETH concentrations than older
children. AUC0–6(1) in children of "2 years of age was lower
than that in children 6 to "12 years (P $ 0.035 and 0.013,
respectively) (Table 2). While the differences in Cmax(1) be-
tween children of "2 years of age and older children were
slight (P $ 0.756 and 0.2922, respectively), absorption [Tmax(1),
P $ 0.372 and 0.004, respectively] and elimination [t1/2(1), P $
0.215 and 0.038, respectively; kel(1), P $ 0.197 and 0.036, re-
spectively] occurred more rapidly in younger children.
At month 4 [referred to by subscripted “(4)”], differences be-
tween the age groups (children of "2 years of age and older
children) became more pronounced [AUC0–6(4), P $ 0.027 and
0.001, respectively]. Cmax(4) in children younger than 2 years of
age was significantly lower than that in older children (P $ 0.034
and 0.002, respectively). Again, absorption [Tmax(4), P $ 0.033
and 0.08, respectively] and elimination [t1/2(4), P $ 0.168 and
0.051, respectively; kel(4), P $ 0.140 and 0.002, respectively] oc-
curred more rapidly in younger children than in older children.
FIG. 1. (a and b) Mean ETH serum concentrations after oral intake of 15 to 20 mg/kg ETH in children of different age groups with or without
concomitant treatment with rifampin (RMP). y, years.
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Age correlated significantly with Tmax(1) (r $ 0.43, P $ 0.02),
AUC0–6(1) (r $ 0.50, P $ 0.001), and clearance(1) (r $ 0.44,
P $ 0.01) at month 1, while the correlations with Cmax(1) (r $
0.18, P $ 0.32), kel(1) (r $ #0.34, P $ 0.06), and t1/2(1) (r $
0.34, P $ 0.06) were not statistically significant. At month 4,
age correlated significantly with Tmax(4) (r $ 0.47, P $ 0.01),
AUC0–6(4) (r $ 0.63, P $ 0.001), Cmax(4) (r $ 0.60, P $ 0.00),
kel(4) (r $ 0.43, P $ 0.02), and t1/2(4) (r $ 0.43, P $ 0.02) but
was not correlated with ETH clearance (2) (r $ #0.10, P $
0.60).
Differences: RMP/no RMP. No differences in ETH pharma-
cokinetic parameters were detected at either sampling point
between children receiving a RMP-including regimen or not (1
month/4 months of therapy), as follows: Cmax, P $ 0.530/0.859;
Tmax, P $ 0.304/0.748; AUC0–6, P $ 0.835/0.627; kel, P $
0.735/0.109; t1/2, P $ 0.891/0.102; and clearance, P $ 0.833/
0.372.
Similar results were obtained in the RMP/no RMP analysis
stratified by age (data not shown).
Differences in ETH levels over time. Differences in ETH
serum levels at 1 and 4 months of therapy are shown in Fig. 2a
to c by age group.
Taking all children together, there was no difference be-
tween the two time points for Cmax (P $ 0.6934), AUC0–6 (P $
0.131), kel (P $ 0.887), and clearance (P $ 0.949). Tmax was
significantly lower at 1 month [mean Tmax(1) versus mean
Tmax(4), 78 min versus 98 min, respectively; P $ 0.048], as was
t1/2 [t1/2(1) versus t1/2(4), 71 min versus 83 min, respectively; P $
0.035].
DISCUSSION
With an ETH dose as currently recommended by WHO, the
majority of children achieved sufficient serum levels. Children
younger than 2 years of age were exposed to lower ETH con-
centrations than older children receiving the same mg/kg dose.
This may imply a need for a higher dosage in this age group.
HIV coinfection led to lower ETH serum levels.
Neither comedication with RMP nor the duration of ETH
treatment influenced ETH pharmacokinetic parameters in
children.
Our study documents high variability in ETH serum levels in
children receiving a standard oral dose of ETH of 15 to 20
mg/kg body weight. In adults, significant intra- and interindi-
vidual variations in ETH serum concentrations have been re-
ported (2, 19, 21), consistent with our findings. Although in the
youngest children, the observed variability might be partly at-
tributable to difficulties in taking medication, we observed sim-
ilar variability in older children, where no such difficulties were
experienced.
ETH peak serum concentrations and the resulting drug ex-
posures were lower in younger children. In up to 50% of
children (5 of 10) younger than 2 years of age, recommended
FIG. 2. (a to c) Mean ETH serum levels before and after intake of
ETH after 1 and 4 months of antituberculosis therapy including ETH.
Both children with and without RMP are combined in graphs (n $ 31).
CI, confidence interval.
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serum levels of ETH were not achieved. Lower levels of first-
line antituberculosis drugs have previously been reported in
children than in adults; these have been attributed to changes
in the relative size of body compartments and body surface
area (BSA) and changes in the ability to absorb, metabolize,
and excrete drugs (1, 4, 7, 25, 26, 29). While the time until
maximum serum concentrations were reached was similar
(Tmax, 1 to 2 h), Cmax was considerably lower in children
younger than 2 years than in older children or adults. After the
first weeks of life, gastrointestinal absorption is less relevant
for the bioavailability of a drug than the volume of distribution
and first-pass metabolism (3). ETH is widely distributed into
body tissues and fluids, resulting in a high volume of distribu-
tion in adults and children (28). After maturation of liver
enzymes, the rate of metabolism is determined mainly by liver
growth, which correlates well with BSA. Most hepatic enzymes
are mature by the age of 1 year (3). Therefore, a comparatively
larger liver size and correspondingly higher hepatic blood flow
in young children may account for the high first-pass effect,
resulting in reduced bioavailability of ETH. The same princi-
ples are the reason for the more rapid elimination of ETH in
children than in adults. In studies of ETH pharmacokinetics in
adults, a kel of 0.4/h and a corresponding elimination half-life
of 1.6 to 1.8 h has been reported (2, 29). In our study, the mean
half-life in children below 2 years of age was approximately 1 h
and increased with age. Because ETH metabolism is predom-
inantly by hepatic sulfoxidation, ETH dosing according to BSA
should therefore be considered to allow for age-related
changes in liver size.
Comedication with RMP did not influence the pharmacoki-
netics of ETH in the present study. RMP is a strong inducer of
several enzymes, including different monooxygenases (17). Re-
duced bioavailability of several drugs (e.g., antiretroviral drugs,
oral contraceptives, and oral anticoagulants) when given in
combination with RMP has been reported (5, 16), and reduced
serum levels of antituberculosis drugs in the context of an
RMP-containing treatment regimen has therefore been a con-
cern. RMP does not influence the bioavailability of isoniazid
(18). The monooxygenases responsible for ETH sulfoxidation
are not part of the P450 system. We did not find any evidence
that these monooxygenases are induced by RMP, which is, to
our knowledge, the first study to have assessed this potential
drug interaction.
Accumulation or self-induction of metabolism during con-
tinuous antituberculosis therapy might alter the pharmacoki-
netic parameters of a drug over time. For ETH, both the
absorption and elimination seemed to be delayed after 4
months of therapy. The reason for this is unclear. Slowing
down of the enzyme activity responsible for ETH metabolism
over time might be a possible reason but has not yet been
described. However, since children were exposed to the same
amount of drug, measured by the AUC at the beginning of and
during continuous therapy, the clinical relevance of this finding
is probably minor.
Although not part of our primary study aims, we found that
HIV-infected children were exposed to lower ETH concentra-
tions than their HIV-uninfected counterparts. Reduced serum
levels of several antituberculosis drugs in HIV-infected adults
and children have been reported and have been attributed to
malabsorption caused by drug-drug interactions, diarrhea,
and/or concurrent gastrointestinal infections (6, 11, 13, 23).
Despite the observed differences, the mean ETH serum con-
centrations in children of all age groups were above the rec-
ommended serum level of 2.5 !g/ml following a standard oral
dose of ETH of 15 to 20 mg/kg. In older children and adults,
ETH causes dose-dependent serious gastrointestinal irritability
and clinically, dosing is therefore driven by tolerance rather
than efficacy. Lower mg/kg doses in older children might there-
fore increase patients’ tolerability and compliance to ETH-
inclusive treatment regimes without reducing the potential
therapeutic efficacy. Despite adequate doses in most children,
some possible concerns regarding lower ETH doses remain, as
follows: a considerable proportion of children in our study
were exposed to low ETH serum concentrations, and after 4
months of therapy, 7 of 31 children (5 aged "2 years) did not
achieve the recommended ETH serum levels. A previous study
of children with TBM compared ETH concentrations in the
cerebrospinal fluid (CSF) after an oral dose of ETH at 15
mg/kg versus 20 mg/kg (8). After the 15-mg/kg dose, the rec-
ommended ETH level was achieved in the CSF in very few
children (27%); therefore, a single daily dose of 20 mg/kg ETH
was recommended for treatment of TBM (8). There is evi-
dence that ETH can produce a bactericidal effect in concen-
trations of 2.5 to 5.0 !g/ml in vitro, with a 99% killing of M.
tuberculosis (15). In vivo, ETH is metabolized mainly to ETH-
sulfoxide, which is less stable than ETH but also has antimy-
cobacterial activity and might add to the therapeutic efficacy of
ETH (12). At this stage, it is unknown whether higher in vivo
ETH serum concentrations (e.g., above 2.5 !g/ml) increase the
bactericidal activity or if lower ETH levels are sufficient in the
presence of this active metabolite. A limitation of our study is
that adverse effects were not studied systematically. Our find-
ings in this relatively small study group also need to be vali-
dated in further studies.
In conclusion, ETH at the recommended oral dose of 15 to
20 mg/kg leads to mean serum levels at or above the recom-
mended concentration in the majority of children of all ages.
ETH levels are not influenced by concomitant treatment with
RMP and do not change substantially during treatment. Nev-
ertheless, the variability in ETH serum levels is high, and
inadequate levels in some children were achieved. Younger
children and HIV-infected children are at higher risk for sub-
therapeutic serum levels, and higher dosages can be consid-
ered if clinically tolerated. The recommended dose of 15 to 20
mg/kg seems appropriate in older children.
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5.2.	  The	  pharmacokinetics	  of	  ofloxacin,	  levofloxacin,	  and	  moxifloxacin	  in	  children	  
with	  tuberculosis	  
	  
In	   these	   observational,	   intensive	   sampling	   pharmacokinetic	   studies,	   the	  
pharmacokinetic	   measures	   of	   the	   3	   most	   frequently	   used	   fluoroquinolones	   in	   anti-­‐
tuberculosis	  therapy,	  OFX,	  LFX	  and	  MFX,	  were	  investigated	  in	  children	  younger	  than	  15	  
years	  of	  age	  with	  MDR-­‐TB	  (359,	  360).	  MFX,	   the	  most	  effective	   fluoroquinolone	  against	  
M.	   tuberculosis,	   is	   currently	  only	   available	   in	  400mg	   tablets,	  which	  are	  only	  breakable	  
into	  half.	  Therefore	  appropriate	  dosing	  is	  only	  possible	  in	  children	  weighing	  more	  than	  
20kg	  (older	   than	  8	  years).	  Following	   the	  revision	  of	   the	  2013	  South	  African	   treatment	  
guidelines,	   which	   had	   previously	   recommended	   OFX	   as	   the	   only	   available	  
fluoroquinolones	   in	   the	  country	  (361),	   children	  older	   than	  8	  years	  would	  receive	  MFX	  
and	   children	   younger	   than	   8	   years	   LFX	   instead	   of	   OFX.	   OFX	   is,	   however,	   still	   used	  
extensively	   in	   other	   settings	   where	   the	   newer,	   more	   costly	   fluoroquinolones,	   are	   not	  
readily	  available.	  Paediatric	  data	  on	  the	  pharmacokinetics	  of	  OFX	  will	  therefore	  remain	  
highly	   relevant.	   I	   hypothesized	   that	   the	   current	   dosing	   recommendations	   for	   the	  
fluroquinolones	   OFX,	   LFX	   and	   MFX,	   would	   achieve	   similar	   serum	   concentrations	  
compared	  to	  adult	  target	  values	  (see	  chapter	  4).	  	  
In	  adults,	  standard	  daily	  doses	  of	  the	  fluoroquinolones	  are	  OFX	  800mg,	  LFX	  750mg	  and	  
MFX	  400mg.	  Following	  these	  doses	  a	  Cmax	  of	  8.5-­‐10	  µg/ml	  for	  OFX,	  7-­‐12µg/ml	  for	  LFX,	  
and	  2.5-­‐6µg/ml	  for	  MFX	  and	  an	  AUC	  of	  70-­‐100μg∙h/ml	  for	  OFX,	  70-­‐110	  μg∙h/ml	  for	  LFX	  
and	  25-­‐60	  μg∙h/ml	  for	  MFX,	  have	  been	  reported	  (362-­‐368).	  Proposed	  pharmacodynamic	  
targets	   for	   fluoroquinolones	  against	  M.	  tuberculosis	  are	  AUC0-­‐24/MIC	  >100	  or	  Cmax/MIC	  
8-­‐10	  (71,	  369-­‐371).	  Efficacy	  studies	  of	  fluoroquinolones	  in	  Middlebrook	  7H11	  revealed	  
the	   following	  MICs:	   1.0µg/ml	   for	  Ofx	   (370,	   372,	   373),	   0.5-­‐1.0µg/ml	   for	   Lfx	   (370,	   372-­‐
374)	   and	   0.25-­‐0.5µg/ml	   for	  Mfx	   (373-­‐375).	   Following	   these	   assumptions,	   presumably	  
efficacious	  AUCs	  for	  anti-­‐TB	  therapy	  are:	  100µg!h/ml	  for	  Ofx,	  50-­‐100µg!h/ml	  for	  Lfx	  and	  
25-­‐50	   µg!h/ml	   for	   Mfx.	   This	   is	   matching	   well	   the	   drug	   exposure	   achieved	   in	   adults	  
following	   standard	   fluoroquinolone	   therapy	   (as	   shown	   above).	   Although	   not	   optimal,	  
the	  major	  tools	  at	  hand	  to	  determine	  desired	  serum	  levels	  of	  an	  anti-­‐TB	  drug	  in	  children	  
are	   comparative	   clinical	   data	   from	   adults	   and	   their	   pharmacokinetic	   “optimal”	   target	  
values.	  




Noncompartemental	  analysis	  (NCA)	  based	  on	  serum	  concentrations	  following	  extensive	  
sampling	   schedule	   of	   6	   samples	   over	   8	   hours	   were	   used	   to	   derive	   standard	  
pharmacokinetic	  measures	   for	  OFX,	  LFX	  and	  MFX.	  Co-­‐variates	  of	   interest	   included	  age,	  
HIV	  co-­‐infection	  and	  nutritional	  status.	  These	  fluoroquinolone	  pharmacokinetic	  studies	  
were	  sub-­‐studies	  (principal	  investigator	  S.	  Thee)	  nested	  in	  a	  larger	  ongoing	  NIH-­‐funded	  
study	   investigating	   the	   pharmacokinetics	   and	   toxicity	   of	   second-­‐line	   anti-­‐tuberculosis	  
drugs	   in	   HIV-­‐infected	   and	   uninfected	   children	   with	   MDR-­‐TB	   (N11/03/059:	   principal	  
investigator	  A.	  Hesseling).	  	  
Eligibility	  criteria	  for	  these	  studies	  included:	  HIV-­‐infected	  and	  -­‐uninfected	  children	  aged	  
0-­‐<15	  years,	   routinely	  started	  on	  second-­‐line	   treatment	   regimen	   for	  drug-­‐resistant	  TB	  
(DR-­‐TB)	  disease	  or	  preventive	  therapy	  and	  which	  included	  a	  fluoroquinolones.	  	  Written	  
informed	   consent	   and	   assent	   for	   all	   aspects	   of	   the	   study	   as	   age-­‐appropriate	   was	  
obtained.	  The	  serum	  concentrations	  of	  OFX,	  LFX	  and	  MFX	  were	  determined	  by	  LC-­‐mass	  
spectrometry	  methodology	   at	   the	   Division	   of	   Pharmacology	   of	   the	   University	   of	   Cape	  
Town	   (University	   of	   Cape	   Town,	   by	   collaborators	   Professors	   Peter	   Smith	   and	   Helen	  
McIlleron).	   The	  medians	   of	   Cmax,	   tmax,	   and	  AUC	  were	   compared	  by	   age,	  HIV	   status	   and	  
study	  group	  using	  the	  Mann-­‐Whitney	  U	  test.	  	  
	  
Ofloxacin	  and	  Levofloxacin	  	  
The	   pharmacokinetics	   of	   OFX	   and	   LFX	  were	   studied	   in	   23	   children	   (median	   age	   3.14	  
years,	   interquartile	   range	   [IQR]	   1.3-­‐4.0	   years).	   Four	   children	   were	   HIV-­‐infected.	  
Following	   an	   oral	   dose	   of	   OFX	   20mg/kg	   and	   LFX	   15mg/kg	   the	   median	   (IQR)	  
pharmacokinetic	   measures	   for	   Ofx/Lfx	   were	   as	   follows:	   Cmax	   9.7	   (7.5-­‐10.9)/6.8	   (4.7-­‐
8.1)µg/ml,	  tmax	  1.6	  (0.73)/1.4	  (0.5)h,	  AUC0-­‐8	  43.8	  (36.7-­‐54.5)/30.5	  (24.4-­‐36.4)μg∙h/ml.	  
This	  study	  documents	  substantially	   lower	  OFX	  and	  LFX	  drug	  exposure	  represented	  by	  
the	   AUC	   in	   children	   compared	   to	   adult	   studies,	   and	   also	   compared	   to	   other	   reported	  
paediatric	   studies.	   This	   may	   be	   related	   to	   differences	   in	   drug	   formulation	   or	  
administration	   method,	   or	   the	   study	   population.	   Although	   elimination	   tended	   to	   be	  
higher	  in	  younger	  children,	  we	  found	  no	  difference	  in	  drug	  exposure	  to	  OFX	  and	  LFX	  by	  
age	  group.	  This	  may	  be	  attributable	  to	  confounding	  by	  HIV,	  as	  HIV	  infection	  is	  associated	  
with	   reduced	   absorption	   of	   some	   anti-­‐tuberculosis	   agents,	   and	   all	   the	   children	   in	   our	  




study	  >6	  years	  of	  age	  were	  HIV-­‐infected.	  Children	  in	  this	  study	  failed	  to	  achieve	  an	  AUC0-­‐
24/MIC	  >100,	  even	  if	  a	   lower	  MIC90	  was	  used.	   	  These	  data	  are	  concerning,	  and	  indicate	  
the	  need	  to	  optimize	  the	  dosing	  of	   fluoroquinolones	   in	  children	  with	  TB.	  Nevertheless,	  
our	  estimated	  pharmacodynamic	  indices	  favour	  LFX	  over	  OFX.	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Pharmacokinetics of Ofloxacin and Levofloxacin for Prevention and
Treatment of Multidrug-Resistant Tuberculosis in Children
S. Thee,a,b A. J. Garcia-Prats,a H. M. McIlleron,c L. Wiesner,c S. Castel,c J. Norman,c H. R. Draper,a P. L. van der Merwe,d
A. C. Hesseling,a H. S. Schaafa
Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africaa;
Department of Paediatric Pneumology and Immunology, Charité Universitätsmedizin Berlin, Berlin, Germanyb; Division of Clinical Pharmacology, Department of
Medicine, University of Cape Town, Cape Town, South Africac; Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africad
Limited data on fluoroquinolone pharmacokinetics and cardiac effects in children exist. Among 22 children receiving drug-resis-
tant tuberculosis prophylaxis or treatment, serum concentrations following oral doses of levofloxacin (15 mg/kg of body weight)
and ofloxacin (20 mg/kg) were lower than those expected from existing pediatric data, possibly due to differences in the formula-
tions (crushed tablets). Drug exposures were lower than those in adults following standard doses and below the proposed phar-
macodynamic targets, likely due to more rapid elimination in children. No QT prolongation was observed.
Multidrug-resistant tuberculosis (MDR-TB) (i.e., resistanceto rifampin and isoniazid) is an emerging epidemic with an
estimated 63,000 pediatric cases per year (1, 2). Fluoroquinolones
are essential in drug-resistant TB (DR-TB) treatment, but phar-
macokinetic and safety data (including data on potential QT in-
terval prolongation) for children are limited (3–6). South African
DR-TB treatment guidelines were revised during 2012 to recom-
mend levofloxacin (Lfx) and moxifloxacin (Mfx) instead of
ofloxacin (Ofx) in children. Due to tablet sizes, children !8 years
receive Mfx and children "8 years receive Lfx for prevention or
treatment of DR-TB. We aimed to characterize the pharmaco-
kinetics and cardiac effects of Ofx and Lfx in children "8 years
of age.
A prospective crossover intensive pharmacokinetic sampling
study was conducted at Brooklyn Chest Hospital and Tygerberg
Children’s Hospital in Cape Town, South Africa from May 2012
through March 2013. Children aged 3 months to 8 years routinely
started on either Ofx or Lfx for the prevention or treatment of
MDR-TB were eligible. Exclusion criteria were a hemoglobin level
of "8 g/dl or a weight of "5 kg. Child contacts ("5 years or HIV
infected) of infectious MDR-TB cases without TB disease received
preventive therapy, including 20 mg/kg of body weight Ofx or 15
mg/kg Lfx daily for 6 months. Children with MDR-TB received
MDR-TB treatment based on World Health Organization recom-
mendations (7). South African Medicines Control Council-ap-
proved tablets of Ofx (Tarivid, 200-mg tablets; Sanofi-Aventis,
Midrand, South Africa) and Lfx (250-mg tablets; Cipla, Cape
Town, South Africa) were used.
Two pharmacokinetic samplings were done, alternately for
Ofx and Lfx, both at steady state. Exact doses of Ofx of 20 mg/kg
and of Lfx of 15 mg/kg were used, and the tablets were broken
accordingly and weighed to the nearest 0.1 mg. After an overnight
fast, tablets were given whole or crushed and suspended in water,
and the dose taken was observed. Blood samples were collected
predose and at 1, 2, 4, 6, and 8 h after dosing in EDTA-containing
tubes and centrifuged, and plasma was separated and frozen
within 30 min at #80°C. Lfx concentrations were determined us-
ing a validated liquid chromatography-tandem mass spectrome-
try (LC-MS/MS) assay developed in the Division of Clinical
Pharmacology, University of Cape Town, South Africa. Plasma
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TABLE 1 Demographic and clinical characteristics of children receiving
ofloxacin and levofloxacin for prevention or treatment of DR-TBa
Characteristic
MDR disease group
(n $ 12) (n [%])
MDR PTb group
(n $ 11) (n [%])
Age at enrollment
0–2 yr 4 (36.4) 5 (45.5)
2–6 yr 3 (27.3) 6 (54.6)
!6 yr 4 (36.4) 0 (0.0)
Male 6 (54.6) 7 (63.6)
Previous TB episode or treatment 4 (36.4) 0 (0.0)
Certainty of TB diagnosis (n $ 12)
Bacteriological confirmation 5 (45.5)
Probable TB 5 (45.5)
Suspected TB 1 (9.1)
TB disease type (n $ 12)
PTBc only 7 (63.6)
EPTBd only 0 (0.0)
PTB and EPTB 4 (36.4)
Reason DR PT started (n $ 11)
DR contact only 8 (72.7)
DR contact and positive TSTe 3 (27.3)
HIV infected at baseline 4 (36.4)f 0 (0.0)
Weight-for-age Z score " #2.0 (n $ 23) 5 (45.5) 1 (9.1)
Height-for-age Z score " #2.0 (n $ 22) 6 (54.6) 2 (18.2)
Weight-for-length Z score " #2.0 (n $ 22) 1 (9.1) 0 (0.0)
a DR-TB, drug-resistant tuberculosis.
b PT, preventive therapy.
c PTB, pulmonary TB.
d EPTB, extrapulmonary TB.
e TST, tuberculin skin test.
f Note that all HIV-infected children were !6 years of age.
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samples were extracted, and chromatographic separation was
achieved on a Gemini-NX 5-%m C18 (50-mm by 2-mm) analyti-
cal column. An AB Sciex API 3000 mass spectrometer was oper-
ated at unit resolution in the multiple reaction monitoring mode.
The calibration curve fitted a linear (weighted by 1/concentration)
regression over the range of 0.0781 to 5.0 %g/ml. Ofx plasma con-
centrations were determined using an LC-MS/MS method vali-
dated over the concentration range of 0.0781 to 20.0 %g/ml (8).
Noncompartmental analysis was used to calculate pharmaco-
kinetic measures. The area under the curve from 0 to 8 h (AUC0-8)
and the AUC from 0 to 24 h (AUC0-24) were calculated according
to the trapezoidal rule. Extrapolated Lfx and Ofx concentrations at
24 h were estimated assuming first-order elimination. The phar-
macodynamic indices AUC0-24/MIC and the maximum concen-
tration of drug in serum (Cmax)/MIC ratios were calculated using
published MIC90 estimates for Ofx of 1.0 and 2.0 %g/ml and for
Lfx of 0.5 and 1.0 %g/ml (9–12). Stata 12.1 (StataCorp, College
Station, TX) was used for analysis. A 12-lead electrocardiogram
(ECG) was done at 3 h postdose on each pharmacokinetic assess-
ment day, and corrected QT intervals (QTc) were calculated (ac-
cording to Fridericia [13]). A QTc of !450 ms was considered
prolonged.
Parental written informed consent was obtained. The study
was approved by the Stellenbosch University Human Research
Ethics Committee.
Twenty-three children (median age, 3.14 years; interquartile
range, 1.3 to 4.0 years) were enrolled and completed both phar-
macokinetic assessments (Table 1). One child was excluded be-
cause of incorrect dosing of Lfx. Seven Ofx and 10 Lfx concentra-
tion measures sampled at time zero were listed as below the limit
of quantitation and were taken as 0; there were no missing con-
centration measurements for Ofx or Lfx. Summary pharmacoki-
netic parameters are described in Table 2, with pharmacokinetic
measures stratified by the clinical characteristics shown in Tables 3
(Ofx) and 4 (Lfx). Table 5 shows the estimated pharmacodynamic
measures which favored Lfx. The mean QTc was 361 ms (standard
deviation [SD], 37 ms) for Ofx and 369 ms (SD, 22 ms) for Lfx. No
child in either group had a QTc of !450 ms.
This study documents lower drug exposure to Ofx and Lfx in
children compared to the expected values based on existing pedi-
TABLE 2 Summary statistics for pharmacokinetic parameters of ofloxacin and levofloxacin in children receiving treatment or prophylaxis for
multidrug-resistant tuberculosis (n $ 22)a
Drug Cmax (%g/ml) Tmax (h) kel (1/h) t1/2
b (h) AUC0–8 (%g · h/ml) AUC(0–&) (%g · h/ml)
Ofloxacin 9.75 (7.51–10.90) 1.59 (0.73) 0.22 (0.20–0.25)c 3.18 (2.83–3.44)d 43.84 (36.73–54.46) 47.51 (40.26–58.50)
Levofloxacin 6.79 (4.69–8.06) 1.45 (0.51) 0.22 (0.20–0.26) 3.16 (2.68–3.51) 30.47 (24.41–36.39) 32.92 (25.44–40.88)
a All parameters are reported using medians (interquartile ranges [IQRs]), except for time to maximum concentration in serum (Tmax), which is reported using means (SDs).
b t1/2, half-life.
c One child was excluded from the analysis because a wrong dose of Lfx (10 mg/kg) was given.
d One child had a late peak in the concentration-time curve. For this reason, no half-life or elimination rate constant is reported for that child.
TABLE 3 Pharmacokinetic measures of ofloxacin by study group, age, HIV status, and nutritional status (n $ 22)
Clinical
characteristic
Pharmacokinetic measure of ofloxacin






(SD) (h) P No.
Median (IQR)
(%g · h/ml) P No. Median (IQR) (h) P
Study group
MDR disease 11 10.20 (7.51–10.90) 11 1.82 (0.87) 11 46.53 (38.88–54.98) 10 3.13 (2.89–3.44)
MDR PTb 11 8.88 (7.05–12.70) 0.77c 11 1.36 (0.51) 0.15c 11 43.34 (29.75–50.89) 0.53c 11 3.18 (2.64–3.61) 0.89c
Age group
0–2 yr 9 10.90 (10.20–12.70) 9 1.22 (0.44) 9 46.53 (43.05–54.46) 9 2.91 (2.61–3.26)
2–6 yr 9 8.78 (5.39–9.82) 9 1.56 (0.53) 9 44.34 (28.99–48.76) 9 3.21 (3.00–3.61)
!6 yrd 4 7.69 (6.21–9.39) 0.02e 4 2.5 (1.0) 0.01e 4 39.01 (33.47–48.06) 0.54c 3 3.44 (2.89–3.57) 0.29e
HIV status
HIV infectedf 4 7.69 (6.21–9.39) 4 2.5 (1.0) 4 39.01 (33.47–48.06) 3 3.44 (2.89–3.57)
HIV uninfected 18 9.86 (8.09–11.57) 0.25c 18 1.39 (0.50) 0.11c 18 44.67 (36.73–54.46) 0.55e 18 3.16 (2.63–3.34) 0.48c
WAZg
!#2.0 18 10.05 (8.78–11.57) 18 1.44 (0.51) 18 45.77 (39.12–54.98) 18 3.20 (2.89–3.44)
"#2.0 4 6.63 (5.15–7.98) 0.04c 4 2.25 (1.26) 0.29c 4 29.37 (28.52–34.45) 0.03c 4 2.64 (2.56–3.57) 0.42c
a t1/2, half-life. For one child, no t1/2 could be reported due to a late peak serum concentration of Ofx.
b PT, preventive therapy.
c P value was calculated using the Mann-Whitney U test.
d One child was excluded from the analysis because a wrong dose of Lfx (10 mg/kg) was given.
e P value was calculated using the Kruskal-Wallis test.
f Note that all of the HIV-infected children were also !6 years old.
g WAZ, weight-for-age Z score using WHO reference standards (29).
Child Pharmacokinetics of Ofx and Lfx for MDR-TB
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atric studies (4–6). This may be related to differences in drug
formulations or administration methods. Tablets are the only oral
formulation available in our setting; these need to be crushed for
administration to young children. Although crushing might influ-
ence absorption, which is almost complete for the fluoroquinolo-
nes (4, 5, 14, 15), a study in adults comparing the pharmacokinet-
ics of tablets and oral solutions of Ofx showed no differences (16).
Although elimination tended to be higher in younger children,
there were no differences for the Ofx and Lfx AUCs by age group.
This may be related to confounding by HIV, as HIV infection is
associated with reduced absorption of some anti-TB agents (17–
19), and all the HIV-infected children in our study were !6 years
of age. A larger study sample would better characterize the phar-
macokinetics of these drugs and provide insights into any differ-
ences in this population compared to those in previous reports.
We also documented lower Ofx and Lfx exposures in children
compared to those in adults using the currently recommended
doses (20–22). Children eliminated Ofx and Lfx more rapidly than
adults, with a half-life of 3 to 4 h and an elimination rate constant
(kel) of 0.22 h
#1 in our study compared to half-lives of 4 to 8 h and
kel of 0.09 to 0.13 h
#1 in adults (14, 20–22); this is likely due to the
well-described age-related changes in drug clearance in children
compared to drug clearance in adults (23). The proposed phar-
macodynamic targets for fluoroquinolones against Mycobacte-
rium tuberculosis are an AUC0-24/MIC of !100 and Cmax/MIC of 8
to 10 (12, 24–26). Children in this study failed to achieve an AUC0-
24/MIC of !100 even if a lower MIC90 was used. Nevertheless, our
estimated pharmacodynamic indices favor Lfx over Ofx. The fail-
ure to approximate adult exposures or to achieve the pharmaco-
dynamic targets has important implications for current and future
dosing recommendations in children for these essential anti-TB
drugs. With the current recommended dosing, successful
MDR-TB treatment outcomes are reported in 80 to 90% of chil-
dren (27, 28). However, to optimize treatment, higher or more
frequent dosing of Ofx and Lfx in young children may be required
to approximate adult exposures and meet the proposed pharma-
codynamic targets.
Although the ECG timing may have been suboptimal in our
study and additional research is needed, the lack of any QT pro-
longation is reassuring.
The limitations of this study are the modest sample size, the
unavailability of individual MICs, and the administration of dif-
TABLE 4 Pharmacokinetic measures of levofloxacin by study group, age, HIV status, and nutritional status (n $ 22)
Clinical
characteristic
Pharmacokinetic measure of levofloxacin






(SD) (h) P No.
Median (IQR)
(%g · h/ml) P No. Median (IQR) (h) P
Study group
MDR disease 11b 7.00 (4.69–8.06) 11b 1.46 (0.52) 11b 32.50 (24.41–38.83) 11b 3.24 (3.01–3.99)
MDR PTc 11 6.32 (4.63–8.17) 0.53d 11 1.46 (0.52) 1.00d 11 29.89 (21.07–32.75) 0.34d 11 2.98 (2.64–3.51) 0.31d
Age group
0–2 yr 9 7.00 (6.32–8.06) 9 1.33 (0.50) 9 29.89 (24.50–36.39) 9 2.79 (2.62–3.14)
2–6 yr 9 6.86 (4.69–7.51) 9 1.56 (0.53) 9 31.69 (23.81–33.11) 9 3.22 (2.98–4.24)
!6 yre 4 4.98 (4.52–7.48) 0.40f 4 1.50 (0.58) 0.66f 4 27.49 (24.73–34.03) 0.91f 4 3.37 (3.12–4.01) 0.18f
HIV status
HIV-infectede 4 4.98 (4.52–7.48) 4 1.5 (0.58) 4 27.49 (24.73–34.03) 4 3.37 (3.12–4.01)
Not HIV-infected 18 6.88 (5.36–8.06) 0.39c 18 1.44 (0.51) 0.85c 18 31.38 (24.41–36.39) 0.67c 18 3.09 (2.64–3.51) 0.23c
WAZg
!#2.0 17 6.86 (4.69–8.06) 17 1.47 (0.52) 17 31.06 (23.81–36.39) 17 3.14 (2.78–3.51)
"#2.0 5 6.71 (5.38–7.12) 0.91c 5 1.40 (0.55) 0.79c 5 29.24 (25.75–32.50) 0.91c 5 3.23 (2.68–3.51) 0.97c
a t1/2, half-life.
b One child was excluded from the analysis because a wrong dose of Lfx (10 mg/kg) was given.
c PT, preventive therapy.
d P value was calculated using the Mann-Whitney U test.
e Note that all of the HIV-infected children were also !6 years old.
f P value was calculated using the Kruskal-Wallis test.
g WAZ, weight-for-age Z score using WHO reference standards (29).
TABLE 5 Estimated pharmacodynamic parameters using published MICs of ofloxacin and levofloxacin for Mycobacterium tuberculosis in children
Pharmacokinetic parameter
Estimate for 20 mg/kg ofloxacin
with MIC (%g/ml) of:
Estimate for 15 mg/kg levofloxacin
with MIC (%g/ml) of:
Pa2.0 1.0 1.0 0.5
AUC0–24/MIC (n $ 21) (mean [SD]) 31.5 (10.3) 63.0 (20.5) 43.8 (13.3) 87.6 (26.7) "0.01
Cmax/MIC (n $ 22) (mean [SD]) 4.5 (1.5) 9.6 (3.1) 6.5 (2.0) 13.1 (4.0) "0.01
a Paired t test comparing pharmacodynamic parameters of Ofx and Lfx with an MIC of 2.0 %g/ml for Ofx versus an MIC of 1.0 %g/ml for Lfx and an MIC of 1.0 mg/ml for Ofx
versus an MIC of 0.5 %g/ml for Lfx.
Thee et al.
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ferent oral formulations of Ofx and Lfx. Additional studies on the
safety and pharmacokinetics of Ofx and Lfx in children using
higher doses to determine any impacts on treatment responses
and outcomes should be considered.
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The	  pharmacokinetics	  of	  MFX	  were	  studied	  in	  23	  children	  (median	  age	  11.1	  years;	  IQR	  
9.212.0);	   6/23	   (26.1%)	  were	   HIV-­‐infected.	   Following	   an	   oral	   Mfx	   dose	   of	   10mg/kg	   a	  
median	  (IQR)	  Cmax	  of	  3.1	  (2.8-­‐3.8)µg/ml	  and	  a	  median	  AUC0-­‐8	  of	  17.2	  (14.5-­‐22.0)μg∙h/ml	  
were	   found.	   Three	   children,	   all	   HIV-­‐infected,	   were	   underweight-­‐for-­‐age	   (UWA).	   HIV	  
infection	  and	  UWA	  were	  both	  associated	  with	  lower	  MFX	  AUC0-­‐8,	  while	  Cmax	  and	  tmax	  did	  
not	  differ	  by	  nutritional	  status.	  There	  was	  a	  non-­‐significant	  trend	  towards	  a	  lower	  Cmax	  
in	  HIV-­‐infected	  children	  (p=0.08).	  AUC0-­‐8	  was	  reduced	  by	  6.85μg∙h/ml	  (95%	  CI	  -­‐11.15-­‐
2.56)	   in	   HIV-­‐infected	   children.	   Crushing	   of	   tablets	   was	   associated	   with	   more	   rapid	  
absorption	  of	  MFX,	  while	  Cmax	  or	  AUC	  did	  not	  differ	  by	  administration	  method.	  
This	  first	  study	  investigating	  the	  pharmacokinetic	  and	  safety	  of	  MFX	  in	  children	  with	  TB	  
demonstrated	  that	  exposure	  to	  MFX	  was	  substantially	   lower	  than	  that	  achieved	  with	  a	  
standard	  dose	  of	  400mg	  in	  adults,	  despite	  the	  relatively	  high	  mg/kg	  dose	  compared	  to	  
adult	  dosing.	  In	  our	  study,	  MFX	  MIC	  of	  isolates	  from	  the	  children	  could	  not	  practically	  be	  
determined	  and	  MFX	  MIC90	  of	  0.5µg/ml	  was	  taken	  from	  published	  data	  from	  the	  same	  
study	  setting	   (376).	  Children	   failed	   to	  achieve	   the	  proposed	  pharmacodynamic	   targets	  
for	   MFX	   with	   a	   median	   AUC0-­‐24/MIC	   (IQR)	   of	   46.6	   (38.5-­‐84.6)	   (n=12)	   and	   a	   median	  
Cmax/MIC	  (IQR)	  of	  6.2	  (5.7-­‐7.6)	  (n=23).	  	  
With	   increasing	   numbers	   of	   paediatric	  MDR-­‐TB	   especially	   in	   the	   context	   of	   HIV,	   anti-­‐
tuberculosis	   drug	   doses	   need	   be	   optimized	   to	   further	   improve	   outcome,	   shorten	   the	  
duration	  of	  treatment	  and	  prevent	  the	  emergence	  of	  resistance.	  Since	  fluoroquinolones	  
are	  the	  backbone	  of	  existing	  MDR-­‐TB	  therapy	  and	  will	  remain	  fundamentally	  important	  
in	   novel	   regimens	   that	   may	   be	   shorter	   and	   injectable-­‐sparing,	   their	   optimal	   use	   in	  
children	  with	  MDR-­‐TB,	   and	   also	  DS-­‐TB,	   is	   critically	   important.	   Failure	   to	   approximate	  
adult	  exposures	  or	  to	  achieve	  pharmacodynamic	  targets	  has	  important	  implications	  for	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Pharmacokinetics and Safety of Moxifloxacin in
Children With Multidrug-Resistant Tuberculosis
Stephanie Thee,1,2 Anthony J. Garcia-Prats,1 Heather R. Draper,1 Helen M. McIlleron,3 Lubbe Wiesner,3 Sandra Castel,3
H. Simon Schaaf,1,a and Anneke C. Hesseling1,a
1Desmond Tutu Tuberculosis Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, South
Africa; 2Department of Paediatric Pneumology and Immunology, Universitätsmedizin Berlin, Charité, Germany; and 3Division of Clinical Pharmacology,
Department of Medicine, University of Cape Town, South Africa
Background. Moxifloxacin is currently recommended at a dose of 7.5–10 mg/kg for children with multidrug-
resistant (MDR) tuberculosis, but pharmacokinetic and long-term safety data of moxifloxacin in children with tu-
berculosis are lacking. An area under the curve (AUC) of 40–60 µg × h/mL following an oral moxifloxacin dose of
400 mg has been reported in adults.
Methods. In a prospective pharmacokinetic and safety study, children 7–15 years of age routinely receiving mox-
ifloxacin 10 mg/kg daily as part of multidrug treatment for MDR tuberculosis in Cape Town, South Africa, for at least
2 weeks, underwent intensive pharmacokinetic sampling (predose and 1, 2, 4, 8, and either 6 or 11 hours) and were
followed for safety. Assays were performed using liquid chromatography–tandem mass spectrometry, and pharma-
cokinetic measures calculated using noncompartmental analysis.
Results. Twenty-three children were included (median age, 11.1 years; interquartile range [IQR], 9.2–12.0 years);
6 of 23 (26.1%) were human immunodeficiency virus (HIV)-infected. The median maximum serum concentration
(Cmax), area under the curve from 0–8 hours (AUC0–8), time until Cmax (Tmax), and half-life for moxifloxacin were
3.08 (IQR, 2.85–3.82) µg/mL, 17.24 (IQR, 14.47–21.99) µg × h/mL, 2.0 (IQR, 1.0–8.0) h, and 4.14 (IQR, 3.45–6.11),
respectively. Three children, all HIV-infected, were underweight for age. AUC0–8 was reduced by 6.85 µg × h/mL
(95% confidence interval, −11.15 to −2.56) in HIV-infected children. Tmax was shorter with crushed vs whole tablets
(P = .047). Except in 1 child with hepatotoxicity, all adverse effects were mild and nonpersistent. Mean corrected QT
interval was 403 (standard deviation, 30) ms, and no prolongation >450 ms occurred.
Conclusions. Children 7–15 years of age receiving moxifloxacin 10 mg/kg/day as part of MDR tuberculosis treat-
ment have low serum concentrations compared with adults receiving 400 mg moxifloxacin daily. Higher moxifloxacin
dosages may be required in children. Moxifloxacin was well tolerated in children treated for MDR tuberculosis.
Keywords. moxifloxacin pharmacokinetics; moxifloxacin toxicity; children; MDR tuberculosis.
The estimated global incidence of multidrug-resistant
(MDR) tuberculosis (ie, resistance to at least isoniazid
and rifampin) exceeded 450 000 cases in 2012 [1]. The
true burden of tuberculosis in children is unknown, but
approximately 1 million children are estimated to have
developed tuberculosis in 2010, of whom 32 000 had
MDR tuberculosis [2]. New diagnostic tools, such as
the Xpert MTB/RIF assay, will likely increase the num-
ber of MDR tuberculosis cases diagnosed in adults and
therefore increase the number of children identified re-
quiring MDR tuberculosis treatment [3]. MDR tuber-
culosis treatment should typically comprise 4–5 drugs
to which the isolate of the child or the source case is sus-
ceptible, including an injectable drug for 6 months and
a total duration of therapy of 18–24 months [4]. Fluoro-
quinolones have shown good in vitro and in vivo activ-
ity against Mycobacterium tuberculosis [5] and are an
essential part of current MDR tuberculosis treatment
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regimens in adults and children [4, 6]. Moxifloxacin (MFX) has
an early bactericidal activity close to that of isoniazid and is
currently considered the most potent fluoroquinolone against
M. tuberculosis [7, 8]. There is good evidence for its clinical
efficacy at a standard dose (400 mg) in antituberculosis treatment
in adults [9, 10].
The pharmacokinetics of MFX have been well characterized
in adults with tuberculosis [10–15]. Bioavailability after oral in-
take of MFX is >90%, with little effect of food on absorption
[16]. About half of the drug is metabolized in the liver, whereas
45% is excreted unchanged in urine and feces [17]. Following
the standard oral dose, MFX pharmacokinetic measures in
adults are as follows: maximum serum concentration (Cmax)
4–6 µg/mL, elimination half-life (T1/2) up to 12 hours, and
area under the concentration–time curve (AUC) of 40–60
µg × h/mL [8, 12–14, 18]. Coadministration of rifampin lowers
MFX serum concentrations by up to 30% [11].
Although there are no prospective randomized trials of fluoro-
quinolones for the treatment of tuberculosis in children, high-qual-
ity observational data underscore their importance in successful
MDR tuberculosis treatment in children [19, 20]. Pharmacokinetic
data in children are limited to a single case study in a 1-month-old
1000-g former 28-week premature infant treated for Mycoplasma
hominis meningitis [21]. Despite its routine use in children with
MDR tuberculosis, there are limited data on MFX safety.
The South African treatment guidelines for MDR tuberculo-
sis were revised during 2012 to recommend the use of levoflox-
acin and MFX both at a dose of 7.5–10 mg/kg instead of the less
potent ofloxacin in children, consistent with World Health Or-
ganization (WHO) guidelines [4]. For MFX, appropriate dosing
is not feasible in children weighing <20 kg (typically <8 years of
age) due to the lack of a pediatric formulation. Only the 400-mg
tablet formulated for adults is available. Hence, children weigh-
ing≥20 kg routinely receive MFX and children weighing <20 kg
receive levofloxacin (which is available in a 250-mg tablet), for
the treatment of drug-resistant tuberculosis in most settings.
We characterize the pharmacokinetics and safety of MFX rou-
tinely given in combination with individualized optimized back-
ground regimen for the treatment of MDR tuberculosis in children
>7 years of age and describe the effect of key clinical covariates.
METHODS
Study Design and Setting
This was a prospective intensive pharmacokinetic sampling
study among children with MDR tuberculosis in Cape Town,
South Africa.
Study Population
FromMay 2012 through March 2014, human immunodeficien-
cy virus (HIV)-infected and -uninfected children aged 7–15
years routinely started on MDR tuberculosis therapy including
MFX were eligible. Children underwent pharmacokinetic sam-
pling if on MDR tuberculosis treatment for 2–8 weeks. HIV-
infected children also had to be on combination antiretroviral
therapy (cART) for ≥2 weeks. Exclusion criteria were laborato-
ry-documented anemia (hemoglobin <8 g/dL) or lack of in-
formed consent/assent. Pharmacokinetic sampling in children
with severe acute illness was deferred until patients were clini-
cally stable.
Diagnosis of Tuberculosis
The diagnosis was made according to consensus clinical re-
search case definitions for pediatric tuberculosis [22]. Bacterio-
logic confirmation was attempted using sputum and other
specimens and Middlebrook 7H9 broth-base (Mycobacterial
Growth Indicator Tubes; Becton Dickinson, Sparks, Maryland)
culture medium; a commercial molecular line probe assay was
used to detect resistance to isoniazid and rifampin (GenoType
MTBDRplus assay; Hain Lifescience, Nehren, Germany). In the
absence of bacteriologic confirmation, children were treated
empirically according to the drug susceptibility test results of
the likely source cases’ isolates.
Children received individualized treatment regimens, based
on WHO recommendations and in accordance with their
drug susceptibility test results or that of their source case,
where known [4]. Approved tablets of MFX (moxifloxacin hy-
drochloride 400-mg tablets; Dr Reddy’s Laboratories Ltd, Hy-
derabad, India) were used. All HIV-infected children received
trimethoprim-sulfamethoxazole and cART consisting of 2 nu-
cleoside reverse transcriptase inhibitors (lamivudine, stavudine,
or abacavir) and either efavirenz (4 of 6 children) or lopinavir/
ritonavir (2 of 6 children).
Pharmacokinetic Investigation
Children receiving MFX 7.5–10 mg/kg once daily (according to
WHO and South African MDR tuberculosis treatment guide-
lines) underwent pharmacokinetic sampling 2–8 weeks follow-
ing initiation of tuberculosis treatment, when MFX would be
expected to be at steady state. On the day of sampling, exact
10 mg/kg doses were calculated for each child. Tablets were
cut and weighed accordingly (to the nearest 0.1 mg), and
given either whole or crushed and suspended in water, accord-
ing to patient tolerance. All tuberculosis drugs were adminis-
tered with a small amount of water in the morning after a
minimum of 4 hours of fasting; a standard breakfast was offered
1 hour later. HIV-infected children were given cART with
breakfast. Blood samples were collected predose (time 0), and
at 1, 2, 4, 8, and either 6 or 11 hours after dosing, in ethylene-
diaminetetraacetic acid–containing vacutainer tubes, centri-
fuged, and plasma was separated and frozen within 30 minutes
at −80°C.
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MFX concentrations were determined using a validated liq-
uid chromatography–tandem mass spectrometry (LC-MS/MS)
assay, at the Division of Clinical Pharmacology, University of
Cape Town. The assay was validated according to US Food
and Drug Administration and European Medicines Agency
guidelines. Plasma samples were extracted and chromatograph-
ic separation achieved on a Gemini-NX 5 µm C18, 50 mm × 2.1
mm analytical column. An AB Sciex API 3000 mass spectrom-
eter was operated at unit resolution in the multiple reaction
monitoring mode, monitoring the transition of the protonated
molecular ions at mass-to-charge ratio (m/z) 402.2 to the prod-
uct ions at m/z 384.2 for MFX, and monitoring the transition of
the protonated molecular ions at m/z 406.3 to the product ions
at m/z 388.2 for the stable isotope-labeled internal standard,
MFX-d4. The calibration curve fitted a linear (weighted by
1/concentration) regression over the range 0.0628–16.1 µg/mL.
MFX pharmacokinetic measures were calculated using non-
compartmental analysis (NCA). Stata 12.1 SE software (StataCorp
2011, College Station, Texas) was used for NCA and other analy-
ses. Cmax and time until Cmax (Tmax) were taken directly from the
concentration-time data. The area under the curve from 0–8
hours (AUC0–8) was calculated using the linear trapezoidal rule.
The T1/2 was denoted as ln(2)/Kel, where Kel (elimination rate
constant) is the negative slope of the log-linear regression of ≥3
final data points. Kel and T1/2 were not evaluated in patients with
<3 concentration data points during the elimination phase. The
area under the curve from 0–24 hours (AUC0–24) was calculated
using exponential extrapolation from the patient’s final concen-
tration data point at either 8 or 11 hours.
Statistical Analysis
Demographic and clinical characteristics were summarized
using descriptive statistics. MFX pharmacokinetic measures
were reported as medians and interquartile ranges (IQRs).
The AUC0–8, Cmax, and Tmax were compared by HIV status,
nutritional status (weight-for-age z score [WAZ] ≤ −2 vs
WAZ > − 2) using British growth charts, and administration
method (crushed vs whole tablets) using the Wilcoxon rank-
sum test. A multivariable linear regression model was generated
to determine which covariates were associated with AUC0–8.
The clinically relevant variables HIV, nutritional status, and
age were included in the model. Estimated pharmacodynamic
indices (AUC0–24/MIC [minimum inhibitory concentration]
and Cmax/MIC) were calculated using an approximate MFX an-
timicrobial concentration that inhibits growth of 90 % of the
strains (MIC90) of 0.5 µg/mL based on published studies [5, 23].
Assessment of Toxicity
All children had clinical safety assessments monthly for the first
6 months of treatment, then every 2 months until treatment was
completed. Laboratory assessment was done every 2 months
and included blood cell count (for children on cART and line-
zolid), liver function tests, creatinine, and thyroid function (for
children on ethionamide or para-aminosalicylic acid). Toxicity
and drug adverse effects were determined using combined data
sources including chart and routine clinical review, laboratory
investigation, and parental and children’s report. Standard Di-
vision of AIDS (National Institute of Allergy and Infectious
Diseases) criteria were used to grade severity of adverse events.
Adverse events were considered MFX-related if they were pos-
sibly, probably, or definitely drug-related, and likely due to
MFX or if they were not otherwise able to be attributed to an-
other specific drug. Adverse events reported at consecutive fol-
low-up visits without intervening asymptomatic periods were
considered a single adverse event. Person time was calculated
from the baseline study assessment until treatment completion
or at the last available study visit if the child withdrew from the
study or was still on treatment at the time of analysis.
A 12-lead electrocardiogram (ECG) was completed on the
pharmacokinetic sampling day at 3 hours after drug dosing.
ECGs were evaluated using a standard approach by a single pe-
diatric cardiologist, with the corrected QT (QTc) interval calcu-
lated using the method described by Fridericia [24]; a QTc
>450 ms was classified as prolonged.
Written informed consent was obtained from parents/legal
guardians and written informed assent from children. The
study was approved by the Health Research Ethics Committees,
Stellenbosch University (reference number N11/03/059A) and
Table 1. Demographic and Clinical Characteristics of Children
(n = 23)
Characteristic No. (%)
Male sex 9 (39.1)
Race
Black 13 (56.5)
Mixed ethnicity 10 (43.5)
Previous tuberculosis episode or treatment 11 (47.8)
Known current tuberculosis source case 12 (52.2)
Certainty of tuberculosis diagnosisa
Bacteriologically confirmed 20 (87.0)
Probable tuberculosis 3 (13.0)
Tuberculosis disease type
PTB only 14 (60.9)
EPTB only 3 (13.0)
PTB and EPTB 6 (26.1)
HIV-infected 6 (26.1)
Weight-for-age z score <− 2.0b 3 (13.0)
Abbreviations: EPTB, extrapulmonary tuberculosis; HIV, human immunodefi-
ciency virus; PTB, pulmonary tuberculosis.
a According to Graham et al [22].
b Calculated using 1990 British growth charts.
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the University of Cape Town, South Africa (reference number
200/2012).
RESULTS
Twenty-three children, with a median age of 11.1 years (IQR,
9.2–12.0 years) and median weight of 28.9 kg (range, 21.4–66
kg), were included; 6 of 23 (26.1%) were HIV-infected. Three
children, all HIV-infected, were underweight for age (UWA).
Clinical and demographic features are summarized in Table 1.
Pulmonary tuberculosis was predominant (20 children [87%]).
Antituberculosis medication used included ethambutol, pyrazi-
namide, amikacin, kanamycin, MFX, ethionamide, terizidone,
para-aminosalicylic acid, high-dose isoniazid, linezolid, clofazi-
mine, amoxicillin-clavulanate, and rifampin. The median num-
ber of antituberculosis drugs given was 7 (IQR, 6–7).
Table 2 shows summary MFX pharmacokinetic measures.
The interindividual variability of MFX serum concentrations
was high, especially during the absorption phase (Figure 1).
MFX concentrations at 0 hour were below the limit of quanti-
fication in 3 participants and were taken as zero when generat-
ing the NCA parameters. When Kel was available, AUC0–24 was
extrapolated. Kel could only be evaluated in 12 of 23 children.
These 12 children did not differ from the 11 children without
Kel calculation regarding AUC0–8 or Cmax. Tmax occurred faster
in children with Kel calculation (data not shown).
Table 3 shows pharmacokinetic measures stratified by HIV
status, nutritional status, and administration method. Serum
concentration-time curves following an oral MFX dose of 10
mg/kg stratified by HIV status are presented in Figure 2. HIV
infection and UWA were associated with lower MFX AUC0–8,
whereas Cmax and Tmax did not differ by nutritional status.
There was a nonsignificant trend toward a lower Cmax in
HIV-infected children (P = .08). Crushing of tablets was associ-
ated with more rapid absorption of MFX, whereas Cmax or AUC
did not differ by administration method. Neither sex nor race
had an influence on MFX pharmacokinetic measures (data
not shown). In a simple linear regression model, AUC0–8 was
reduced by 6.85 µg × h/mL (95% confidence interval [CI],
−11.15 to −2.56 µg × h/mL) in HIV-infected children, and for
each unit decrease in WAZ, AUC was reduced by 2.39 µg × h/
mL. In a multivariable regression model, AUC0–8 was reduced
by 5.62 µg × h/mL (95% CI, −10.94 to −.30 µg × h/mL) among
patients with HIV infection compared with uninfected patients,
adjusting for age and nutritional status.
Children were followed for a median of 236 days (IQR, 142–
541 days). Table 4 shows all adverse events noted as well as
adverse effects potentially related to MFX. The main adverse
effects potentially related to MFX were gastrointestinal (nausea
and vomiting; n = 12), headache (n = 5), elevated alanine ami-
notransferase (ALT) (n = 4), and arthralgia (n = 4).
In 13 of 23 children, ECG data were available. Mean QTc
interval was 403 ms (standard deviation, 30 ms). None had a
QTc interval >450 ms.
DISCUSSION
This is the first study to our knowledge investigating the phar-
macokinetics and safety of MFX in children with tuberculosis.
Exposure to MFX was lower than that achieved with a standard
dose of 400 mg in adults receiving MFX for MDR tuberculosis
(Supplementary Table 1) despite the slightly higher dose given
to children (median dose of 6.7–8 mg/kg in adults vs 10 mg/kg
in children) in our study.
A considerably lower AUC in children compared with adults
has also been described for levofloxacin, ofloxacin, and many
Figure 1. Individual serum concentrations in children 7–15 years of age
following an oral moxifloxacin (MFX) dose of 10 mg/kg/day.
Table 2. Summary Statistics for Pharmacokinetic Measures in
Children Following an Oral Moxifloxacin Dose of 10 mg/kg
Pharmacokinetic Measure No. Moxifloxacin
Cmax, µg/mL 23 3.08 (2.85–3.82)
Tmax, h 23 2.0 (1.0–8.0)
CL/F, L/h 12 10.53 (7.23–14.14)
Vd, L 12 70.61 (57.53–77.70)
C0, µg/mL 12 4.27 (3.38–4.86)
T1/2, h 12 4.14 (3.45–6.11)
AUC0–8, µg× h/mL 23 17.24 (14.47–21.99)
AUC0–24, µg× h/mL 12 23.31 (19.24–42.30)
All pharmacokinetic measures are reported as median and interquartile range,
except for Tmax, which is reported as median and range.
Abbreviations: AUC0–8, area under the curve from 0–8 hours; AUC0–24, area
under the curve from 0–24 hours; C0, concentration at time 0; CL, clearance;
Cmax, maximum serum concentration; F, fraction absorbed; T1/2, half-life;
Tmax, time until Cmax; Vd, volume of distribution.










Stellenbosch University  https://schola.sun.ac.za
other first- and some second-line antituberculosis agents, and
has been attributed to a more rapid elimination of drugs in chil-
dren [25–28]. In 12 children, in whom it was possible to calcu-
late, the T1/2 of 4 hours was roughly half of that in adults (7–10
hours). However, our data may be biased toward demonstrating
more rapid elimination, as the T1/2 could not be calculated in
children with a later Tmax and potentially slower elimination.
Although drug elimination is expected to be more rapid in
children because of allometric scaling [29], the degree of differ-
ence from adult values is surprising given that these relatively
older children should be metabolically mature and have phar-
macokinetics more closely approximating that of adults.
In general, adult activity of phase II enzymes is achieved
within the first years of life, although some enzyme isoforms
may exceed adult values during childhood [30]. Additionally,
the extrapolated AUC0–24 may be underestimated as the
Table 3. Pharmacokinetic Measures by HIV Status, Nutritional Status, and Administration Method of Moxifloxacin in Children (n = 23)
Characteristic
Cmax, µg/mL Tmax, h AUC0–8, µg× h/mL
No. Median (IQR) P Value No. Median (Range) P Value No. Median (IQR) P Value
HIV-status
HIV-infected 6 2.83 (2.36–2.94) 6 2.0 (1.0–4.0) 6 13.19 (11.89–15.90)
HIV-uninfected 17 3.21 (2.95–3.82) .080 17 4.0 (1.0–8.0) .334 17 19.98 (16.71–25.21) .003
WAZ
≥− 2.0 20 3.08 (2.87–3.71) 20 2.0 (1.0–8.0) 20 18.76 (16.43–23.60)
<− 2.0 (UWA) 3 2.78 (1.99–4.06) .411 3 2.0 (1.0–4.0) .594 3 14.47 (9.95–15.90) .045
Administration
Whole 20 2.96 (2.82–3.71) 20 3.0 (1.0–8.0) 20 17.36 (14.93–23.60)
Crushed 3 3.21 (3.08–4.06) .294 3 1.0 (1.0–2.0) .047 3 17.24 (14.47–19.53) .715
Abbreviations: AUC0–8, area under the curve from 0–8 hours; Cmax, maximum serum concentration; HIV, human immunodeficiency virus; IQR, interquartile range;
Tmax, time until Cmax; UWA, underweight for age; WAZ, weight-for-age z score.
Figure 2. Effect of human immunodeficiency virus (HIV) on moxifloxacin (MFX) serum concentrations in children aged 7–15 years following an oral dose of
10 mg/kg/day.
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extrapolation does not account for a 2-compartment model,
which has been described for MFX [13].
In our study, HIV-infected and UWA children had lower
MFX concentrations. The multivariate model suggests that
this association of UWA with lower exposures may be due to
confounding by HIV status. HIV infection has been associated
with reduced absorption of antituberculosis agents in adults
and children [27, 31] due to drug–drug interactions or gastroin-
testinal disturbances. In our study, Cmax in HIV-infected chil-
dren seemed to be lower than in HIV-uninfected children,
potential evidence for reduced absorption. Our search did not
identify any study investigating drug–drug interactions of anti-
retrovirals and MFX. MFX is not metabolized by the cyto-
chrome P450 system, but other interactions, such as has been
described with rifampin [11], are possible.
Because of the lack of child-friendly formulations for many
second-line tuberculosis drugs, it is common practice to crush
tablets and administer these with water. The effect of such prac-
tices on the bioavailability has not been evaluated for any of the
fluoroquinolones. Our data indicate that absorption occurs
more rapidly if MFX tablets are crushed (median Tmax, 1.0
hour vs 3.0 hours) with no influence on the AUC; however,
the number of participants is small and additional evaluation
is warranted. When crushed, MFX tablets are bitter and rarely
tolerated by children. Child-friendly formulations of fluoro-
quinolones are urgently needed.
Fluoroquinolones have concentration-dependent bactericidal
activity, with the AUC/MIC ratio most closely associated with
in vivo efficacy against M. tuberculosis in mice [7]. Proposed
targets for the fluoroquinolones against M. tuberculosis are
AUC0–24/MIC ratio of >100 or Cmax/MIC of 8–10 [7, 8]; how-
ever, their clinical relevance remains unclear, particularly for
children who typically have paucibacillary tuberculosis. In our
study, MFX MIC of isolates from the children could not be de-
termined, and the MFX MIC90 of 0.5 µg/mL was taken from
published data from the same study setting [23]. Children failed
to achieve the proposed pharmacodynamic targets, with a me-
dian AUC0–24/MIC of 46.6 (IQR, 38.5–84.6) (n = 12) and a me-
dian Cmax/MIC of 6.2 (IQR, 5.7–7.6) (n = 23).
In vitro, M. tuberculosis resistance development depends on
the fluoroquinolone concentration, and insufficient exposures
may fail to prevent development of resistance [32]. However,
Table 4. Adverse Events in Children Receiving Treatment for Multidrug-Resistant Tuberculosis Including Moxifloxacin
Adverse Event
All Adverse Events Any Grade (1, 2, 3, 4)






































Arthralgia 5 6 1 0 0 7 0.341 4 4 1 0 0 5 0.243
Arthritis 0 0 0 0 0 0 . . . 0 0 0 0 0 0 . . .
Pain other than
traumatic injury
7 9 1 0 0 10 0.487 1 1 0 0 0 1 0.049
Headache 8 10 1 1 0 12 0.584 5 4 1 0 0 5 0.243
Neurosensory
alteration
1 1 0 0 0 1 0.049 0 0 0 0 0 0 . . .
Insomnia 0 0 0 0 0 0 . . . 0 0 0 0 0 0 . . .
Fatigue/malaise 3 2 1 0 0 3 0.146 1 1 0 0 0 1 0.049
Nausea 15 22 1 0 0 23 1.119 9 9 0 0 0 9 0.438
Vomiting 11 13 1 0 0 14 0.681 3 3 0 0 0 3 0.146
Anorexia 2 2 0 0 0 2 0.097 0 0 0 0 0 0 . . .
Cutaneous
reaction
2 2 0 0 0 2 0.097 1 1 0 0 0 1 0.049
Pruritus 6 8 0 0 0 8 0.389 2 4 0 0 0 4 0.195
Acute systemic
allergic reaction
0 0 0 0 0 0 . . . 0 0 0 0 0 0 . . .
Elevated ALT 6 4 2 1 1 8 0.389 4 2 2 1 0 5 0.243
Bilirubin 1 0 1 0 0 1 0.049 1 0 1 0 0 1 0.049
Grading of adverse events according to Division of AIDS criteria. 23 patients followed for a median time of 236 days (interquartile range, 142–541 days); total person
years = 20.55.
Abbreviations: ALT, alanine aminotransferase; PY, person-years.










Stellenbosch University  https://schola.sun.ac.za
the limited clinical data suggest that children treated with cur-
rently recommended doses of MFX have better outcomes than
adults with MDR tuberculosis [20, 33, 34].
Nevertheless, with increasing numbers of pediatric MDR tu-
berculosis, especially in the context of HIV, antituberculosis
treatment needs be optimized to further improve outcome,
shorten the duration of treatment, and to prevent emergence
of resistance. Because fluoroquinolones are the backbone of ex-
isting MDR tuberculosis therapy and will remain fundamentally
important in novel regimens that may be shorter and injectable-
sparing, their optimal use in children with MDR tuberculosis is
critically important.
Overall, MFX with prolonged dosing was well tolerated. Gas-
trointestinal intolerance, headache, and mildly elevated ALT
were the most frequent adverse effects. Our conservative ap-
proach may reflect an overestimation of MFX adverse effects
in these children receiving multidrug regimens; adverse effects
that may have been associated with other drugs of the antituber-
culosis treatment, but could not be convincingly attributed to
them, were considered possibly MFX related. Except for 1
child with grade 3 ALT elevation, all adverse effects were mild
and did not require cessation of therapy.
Use of fluoroquinolones in children has been limited because
of their potential to induce arthropathy in juvenile animals [35];
however, no unequivocal documentation of similar fluoroquin-
olone-induced arthropathy in children has been observed [36,
37]. Five children in our study reported mild arthralgia; none
had clinical evidence of arthritis. All resolved spontaneously
without adjusting or stopping MFX. Although arthralgia/arthri-
tis requiring cessation of fluoroquinolones has been reported in
children with MDR tuberculosis receiving MFX therapy [20,
34], our report adds to a growing body of evidence showing
the long-term use of currently recommended doses of fluoro-
quinolones to be safe [19, 38, 39]. This might partly be due to
the low drug exposure in children; safety for higher, adult-
equivalent doses should be evaluated.
Fluoroquinolones are known to prolong the QT interval,
with MFX having the largest effect [40]. It is reassuring that
we did not observe any QTc prolongation; however, we evalu-
ated only a small number of participants and lacked a prefluor-
oquinolone baseline QTc assessment for comparison. Further
evaluation in children is warranted given that in the future,
MFX may be combined with novel tuberculosis drugs also
known to cause QT prolongation, such as bedaquiline and
delamanid.
Our study is limited by the modest number of children and
the resulting difficulty in separating the effects of important co-
variates such as HIV status, nutritional status, or drug admin-
istration method as well as the influence of concomitant
antituberculosis and antiretroviral medication. We were also
limited by the lack of later sampling time points, which
precluded our ability to characterize drug elimination in some
participants. Future studies with larger study cohorts using pop-
ulation pharmacokinetic modeling techniques could overcome
these limitations.
In conclusion, we demonstrate low MFX serum concentra-
tions in children 7–15 years of age with MDR tuberculosis fol-
lowing an oral dose of MFX 10 mg/kg bodyweight. MFX was
well tolerated with long-term administration. To approximate
serum concentrations found in adults on standard doses, higher
dosing of MFXmay be required in children. Evaluation of safety
and pharmacokinetics with higher doses as well as with child-
friendly formulations should be considered.
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The	   importance	   of	   ethionamide	   (ETH)	   and	   the	   fluoroquinolones	   in	   the	   treatment	   of	  
drug-­‐resistant	  (DR)	  and	  drug-­‐susceptible	  (DS)	  tuberculosis	  (TB)	  has	  been	  highlighted	  in	  
chapter	  3.	  Because	  these	  are	  widely	  used	  in	  current	  anti-­‐tuberculosis	  regimens	  and	  are	  
also	   included	   as	   components	   of	   future	   regimens,	   I	   have	   selected	   ETH	   and	   the	   3	  most	  
frequently	  used	  fluoroquinolones	  (ofloxacin	  [OFX],	   levofloxacin	  [LFX]	  and	  moxifloxacin	  
[MFX])	  for	  investigation	  of	  safety	  in	  children.	  
	  
6.1.	  Effects	  of	  ethionamide	  on	  thyroid	  function	  in	  children	  with	  tuberculosis	  
	  
For	   ETH,	   hypothyroidism	   is	   a	   known	   reversible	   adverse	   effect	   that	   has	   not	   been	  
systematically	   studied	   in	   children	   with	   TB.	   Children	   are	   a	   vulnerable	   group	   where	  
development,	   especially	   brain	   development,	   might	   be	   negatively	   influenced	   by	  
hypothyroidism.	  I	  hypothesized	  that	  ETH	  at	  the	  routine	  current	  dose	  recommendations	  
is	  safe	  to	  use	  with	  respect	  of	  thyroid	  function	  in	  children	  with	  TB.	  
In	  order	  to	  answer	  this	   important	  question,	   I	  performed	  a	  retrospective	   folder	  review.	  
All	   children	  with	  MDR-­‐TB	  or	  TB	  meningitis	   treated	  with	  a	   regimen	   that	   included	  ETH	  
(15-­‐20mg/kg/day)	   in	   Tygerberg	   Children’s	   Hospital	   or	   BHCD	   between	   January	   2008	  
and	   February	   2010	   were	   included.	   Routine	   investigations	   of	   thyroid	   function	   (serum	  
thyroid-­‐stimulating	   hormone	   (TSH)	   and	   free	   thyroxine	   (fT4)	   levels)	   and	   clinical	  
assessment	  were	  completed	  as	  per	  fixed	  clinical	  schedule	  and	  recommended	  standard	  of	  
care.	   In	   binominal	  measurements,	   comparison	  was	  made	   using	   the	   Chi-­‐Square	   test	   or	  
Mann-­‐Whitney	  test	  in	  ordinal	  measurements,	  respectively.	  	  
	  




A	  total	  of	  137	  children	  (median	  age	  2.9	  years)	  were	  enrolled;	  104	  children	  (76%)	  were	  
treated	  for	  pulmonary	  TB,	  44	  (32%)	  were	  HIV-­‐infected.	  Abnormal	  thyroid	  function	  tests	  
were	  found	  frequently,	  in	  58%	  of	  children,	  with	  at	  least	  41%	  of	  those	  with	  abnormalities	  
likely	   due	   to	   ETH	   (340).	   HIV	   infection	   (OR	   3.27,	   CI	   1.23-­‐8.67,	   p=0.015)	   and	   co-­‐
medication	   with	   PAS	   (OR	   9.17,	   CI	   2.29-­‐36.73,	   p=0.001)	   increased	   the	   odds	   of	   having	  
hypothyroidism.	   This	   study	   revealed	   a	   high	   frequency	   of	   hypothyroidism	   in	   children	  
treated	  with	  ETH	  and	  indicated	  the	  need	  for	  regular	  thyroid	  function	  test	  monitoring	  in	  
children	   on	   long-­‐term	   ETH	   treatment,	   especially	   in	   the	   case	   of	   HIV	   co-­‐infection	   and	  
concomitant	  use	  of	  PAS.	  The	  study	  is	  limited	  by	  its	  retrospective	  nature	  and	  limited	  data	  
on	  potential	   alternative	  diagnoses.	  The	   impact	   of	   abnormal	   thyroid	   function	   tests	   and	  
the	   need	   and	   influence	   of	   thyroxine	   supplementation	   on	   treatment	   outcome	   requires	  
assessment	  in	  children	  with	  TB.	  Future	  prospective	  studies,	  investigating	  the	  cause	  and	  
the	  evolution	  of	  hypothyroidism	  in	  children	  with	  TB	  are	  needed.	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Ethionamide (ETH) treatment may cause hypothyroid-
ism. Clinical data, serum thyroid stimulating hormone 
(TSH) and free thyroxine (fT4) levels were retrospectively 
assessed in 137 children receiving anti-tuberculosis 
treatment including ETH. Abnormal thyroid function 
tests (TFTs) were recorded in 79 (58%) children: ele-
vated serum TSH and suppressed fT4 (n = 30), isolated 
elevated serum TSH (n = 20), isolated low serum fT4 (n 
= 28) and isolated low TSH (n = 1). The risk for bio-
chemical hypothyroidism was higher for children on 
regimens including para-aminosalicylic acid and in hu-
man immunodefi ciency virus infected children. TFT ab-
normalities are frequent in children on ETH and are 
mainly due to primary hypothyroidism or euthyroid sick 
syndrome. 
K E Y  W O R D S :  ethionamide; children; tuberculosis; thy-
roid function
ETHIONAMIDE (ETH) is a second-line drug com-
monly used in the treatment of tuberculous meningi-
tis (TBM) and drug-resistant tuberculosis (TB). Hy-
pothyroidism has been reported as an adverse effect 
of ETH in adults.1 ETH, which is structurally similar 
to the thyrostatic drug methimazole, seems to inhibit 
thyroid hormone synthesis by the inhibition of or-
ganifi cation.2 From in vitro studies, it appears that 
ETH also inhibits the uptake of iodine into thyroid 
cells.1 Para-aminosalicylic acid (PAS) may also cause 
hypothyroidism by inhibiting thyroid peroxidase.3,4 
Another common thyroid function abnormality ex-
pected in chronic diseases, including TB, is that asso-
ciated with the euthyroid sick syndrome (ESS).5,6 
Nevertheless, there are several reports on primary hy-
pothyroidism associated with ETH.1,7 Based on these 
concerns, routine thyroid function monitoring for 
children on ETH treatment was initiated at our clini-
cal paediatric TB services. 
METHODS
A retrospective folder review was completed to inves-
tigate the occurrence of abnormal thyroid function 
tests (TFTs) in children treated with anti-tuberculosis 
regimens including ETH and PAS in Tygerberg Chil-
dren’s Hospital (TCH) and the Brooklyn Hospital for 
Chest Diseases (BHCD) in Cape Town, South Africa 
(January 2008–February 2010). Ethical approval was 
obtained from the Institutional Review Board of Stel-
lenbosch University. 
ETH was given at a daily dosage of 15–20 mg per 
kg body weight and PAS at a dosage of 150 mg/kg. 
Human immunodefi ciency virus (HIV) infected chil-
dren were routinely treated with highly active anti-
retro viral therapy (HAART). 
Thyroid stimulating hormone (TSH) and free thy-
roxine (fT4) levels were measured using two different 
assays: ARCHITECT i2000 System® (Abbott Labo-
ratories, Abbott Park, IL, USA) and ADIVA® Cen-
taur™ analyzer (Bayer Diagnostics, Tarrytown, NY, 
USA). TSH and fT4 values were considered abnormal 
if they were >5% beyond the reference ranges pro-
vided by the respective laboratories.
Comparisons between groups were made using the 
χ2 test (in binominal measurements) or the Mann-
Whitney test (in ordinal measurements), using SPSS 
version 17.0 (Statistical Package for Social Sciences, 
Chicago, IL, USA).
RESULTS
A total of 137 children (median age 2.9 years, range 
4 months–15.8 years) were enrolled: 104 (76%) were 
diagnosed with pulmonary and 33 (24%) with extra-
pulmonary TB (11 tuberculous meningitis [TBM], 
S U M M A R Y
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7 lymph-node TB, 15 others). Nineteen children (14%) 
were treated for monoresistant TB (either isoniazid 
or rifampicin [RMP]), 106 (68%) for multidrug- or 
polydrug-resistant TB. A positive culture for TB was 
obtained in 53 children (39%). 
TFT measurements were repeated every 55–90 days, 
and between 1 and 8 times in a single child. The me-
dian (interquartile) duration of ETH treatment at 
the fi rst four TFT measurements was respectively 
70 (27–124), 148 (85–212), 217 (143–319) and 302 
(213–392) days.
In 79 (58%) children, TSH and/or fT4 values were 
>5% above/below the reference range at some time 
point during treatment (Figure). Four patterns of thy-
roid function abnormalities were identifi ed (Table): 
high serum TSH and low serum fT4, high serum TSH 
(with normal fT4), low serum TSH (with normal fT4) 
and an isolated low serum fT4. Of the 16 children 
(12%) receiving both ETH and PAS, 13 (81%) had 
abnormal TFTs (Table). 
Eighteen children (13%) were given thyroxine treat-
ment by the attending clinician. Forty-four (32%) 
were HIV-infected; of these, 33 (75%) had at least 
one abnormal TFT compared to 45/93 (48%) non-
HIV-infected children (odds ratio [OR] 3.63, 95% 
confi dence interval [CI] 1.61–8.19, P = 0.001; Ta-
ble). Children with high TSH and low fT4 (biochemi-
cal primary hypothyroidism, n = 30) showed no dif-
ferences in age (P = 0.676), sex (P = 0.886), diagnosis 
of TBM (P = 0.208), type of TB (pulmonary vs. extra-
pulmonary TB, P = 0.493) or concomitant treatment 
with RMP (P = 0.812) compared to children with 
normal TFT (n = 58). Children with biochemical pri-
mary hypothyroidism were more likely to be on regi-
mens including PAS (OR 9.17, CI 2.29–36.73, P = 
0.001) and be HIV-infected (OR 3.27, CI 1.23–8.67, 
P = 0.015) than children with normal TFT. 
Figure Overview of thyroid hormone measures obtained in chil-
dren on ethionamide treatment (n = 137). TFT = thyroid function 
test; TSH = thyroid stimulating hormone; fT4 = free thyroxine.
Table Characteristics of children with normal and abnormal thyroid function test results, classifi ed in four groups based on TSH 
















Number* 30 (22) 20 (15) 28 (20) 1 (<1) 58 (42)
Age, years, median [range] 2.2 [0.3–13.7] 4.5 [0.3–14.2] 3.6 [0.5–13.3] 1.8 2.6 [0.4–15.8]
Sex
 Female 16 (53) 13 (65) 14 (50) 1 (100) 30 (52)
 Male 14 (46.7)  7 (35) 14 (50) 0 28 (48)
Nutritional status for age
 Normal 19 (63) 12 (60) 19 (67) 1 (100) 39 (67)
 Underweight 11 (37)  8 (40)  9 (32) 0 19 (33)
Goitre  1 (3)  0  0 0  4 (7)
On PAS 10 (33)  0  3 (11) 0  3 (5)
On RMP  9 (30)  9 (45)  8 (29) 0 16 (28)
On INH 29 (97) 20 (100) 18 (100) 1 (100) 54 (93)
HIV-infected 13 (43)  7 (35) 13 (46.4) 0 11 (19)
TBM  3 (10)  3 (15)  3 (11) 0  2 (3)
* Percentage given of all children participating in study; otherwise percentages are given for specifi c groups.
TSH = thyroid stimulating hormone; fT4 = free thyroxine; PAS = para-aminosalicylic acid; RMP = rifampicin; INH = isoniazid; HIV = human immunodefi ciency 
virus; TBM = tuberculous meningitis.
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DISCUSSION
TFTs were frequently abnormal in hospitalised chil-
dren treated for TB with an ETH-containing regi-
men. The most common abnormality was a high se-
rum TSH and a low serum fT4, indicating primary 
hypothyroidism. The second most common TFT ab-
normality identifi ed in our study was a suppressed se-
rum fT4 with a normal serum TSH. The differential 
diagnosis includes ESS, central hypothyroidism and a 
potential drug effect.6 Typically, during progression 
of ESS, a drop in both total and free serum T3 and 
T4, without an elevation of serum TSH, may occur. 
Total T4 is affected fi rst, followed by a drop in fT4.6 
A drug-related adverse effect is likely if primary 
hypothyroidism developed during treatment. In 41% 
of the children in our study with impaired TFT, the 
initial TFT was within normal limits, suggesting TB 
treatment as a likely cause of hypothyroidism. 
There are several reports of hypothyroidism in 
adults treated with ETH.1 Most of these cases pre-
sented with clinical hypothyroidism which was then 
confi rmed biochemically (mainly raised serum TSH). 
Limited data have been published on adverse effects 
of ETH in the treatment of children: in a single re-
port on children treated for multidrug-resistant TB, 
hypothyroidism, based on elevated serum TSH, oc-
curred in 3/38 children (8%).7 In our study, only one 
child with biochemical hypothyroidism also had a 
goitre. To make a clinical diagnosis of hypothyroid-
ism in children with TB is challenging, as many symp-
toms of hypothyroidism, such as fatigue or loss of 
appetite, are common symptoms of TB and also pos-
sibly of anti-tuberculosis treatment.
In our study, children on a regimen that contained 
both PAS and ETH were twice as likely to develop 
primary hypothyroidism as if they were on ETH only, 
suggesting a signifi cant clinical additive effect of PAS. 
We found evidence of HIV-associated abnormal 
TFTs in children on ETH. ESS has frequently been re-
ported among HIV-infected children with advanced 
disease,8,9 and stavudine has been identifi ed as a risk 
factor for hypothyroidism in HIV-infected patients.8 
In our study, primary hypothyroidism was more likely 
in the presence of HIV co-infection. In 20 children, 
isolated elevated serum TSH levels were found. This 
could be due to true subclinical hypothyroidism, it 
could be drug-related or it could be due to the recovery 
phase of ESS.10 In the latter, an elevated TSH is, how-
ever, short-lived and not very high (usually <10 mU/
l). This was the case in 18 children, indicating that 
the recovery phase of ESS is the most likely cause. 
This study is limited by its retrospective nature, 
the use of two laboratories, the lack of fT3 levels in 
the workup, and limited data on potential alternative 
diagnoses. Furthermore, age-related reference ranges 
are not available for all methods and populations.11,12
In conclusion, this study shows that TFT abnor-
malities in children on anti-tuberculosis treatment 
that includes ETH are common. This risk is higher in 
HIV-infected children or when PAS is included in the 
treatment regimen. Prospective studies are needed to 
determine the clinical signifi cance of these fi ndings 
and the potential role of thyroxine therapy in chil-
dren on anti-tuberculosis treatment.
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Un traitement à l’éthionamide (ETH) peut provoquer de 
l’hypothyroïdie. On a évalué de manière rétrospective 
les données cliniques, les niveaux sériques d’hormone 
stimulante de la thyroïde (TSH) ainsi que de thyroxine 
libre (fT4) chez 137 enfants bénéfi ciant d’un traitement 
antituberculeux comportant l’ETH. On a noté des ano-
malies de la fonction thyroïdienne (TFT) chez 79 en-
fants (58%) : une élévation du TSH sérique et une sup-
pression du fT4 (n = 30), une élévation isolée du TSH 
(n = 20), un taux sérique isolé faible du fT4 (n = 28) et 
un taux isolé faible du TSH (n = 1). Le risque d’hypo-
thyroïdie biochimique est plus élevé chez les enfants qui 
ont un régime incluant de l’acide para-aminosalicylique 
ainsi que chez les enfants infectés par le virus de l’im-
munodéfi cience humaine. Les anomalies de la TFT sont 
fréquentes chez les enfants sous ETH et sont dues prin-
cipalement à une hypothyroïdie primaire ou à un syn-
drome de maladie euthyroïdienne.
El tratamiento con etionamida (ETH) puede dar lugar a 
hipotiroidismo. Se estudiaron en forma retrospectiva los 
datos clínicos, la determinación sérica de tirotropina y 
de tiroxina libre (fT4) en 137 niños que recibían trata-
miento antituberculoso con ETH, entre otros medica-
mentos. Se observaron cifras anormales en las pruebas 
de función tiroidea (TFT) en 79 niños (58%): alta con-
centración sérica de tirotropina y supresión de fT4 (n = 
30), niveles bajos de fT4 aislados (n = 28) y bajas con-
centraciones aisladas de tirotropina (n = 1). El riesgo de 
presentar hipotiroidismo bioquímico fue mayor en los 
niños con pautas terapéuticas que comportaban ácido 
p-aminosalicílico y en los niños infectados por el virus 
de la inmunodefi ciencia humana. Los trastornos de las 
TFT son frecuentes en los niños que reciben ETH y se 
deben principalmente un hipotiroidismo primario o al 
síndrome del eutiroideo enfermo. 
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6.2.	  Safety,	  including	  cardiotoxicity,	  in	  children	  with	  tuberculosis	  on	  
fluoroquinolone	  therapy	  
	  
Fluoroquinolones	  are	  known	  to	  prolong	  the	  QT-­‐interval	  with	  moxifloxacin	  (MFX)	  having	  
the	  greatest	  potential,	  but	  this	  has	  never	  been	  investigated	  in	  children.	   Information	  on	  
this	   adverse	   effect	   is	   highly	   relevant,	   because	   the	   fluoroquinolones	   might	   not	   only	  
become	  first-­‐line	  agents,	  but	  will	  also	  remain	  part	  of	  optimized	  background	  therapy	  in	  
regimens	   including	   new	   drugs,	   such	   as	   bedaquiline	   and	   the	   nitro-­‐imidazoles	   (e.g.	  
delamanid).	  These	  new	  drugs	  have	  shown	  to	  cause	  QT	  prolongation,	  potentially	  leading	  
to	  an	  additive	  cardiotoxic	  effect	  in	  combination	  with	  fluoroquinolones.	  
Children	  enrolled	  in	  the	  pharmacokinetic	  studies	  on	  ofloxacin	  (OFX),	  levofloxacin	  (LFX)	  
and	   MFX	   (chapter	   5)	   were	   systematically	   monitored	   for	   adverse	   effects	   including	  
cardiotoxic	   effects	   (360,	   377).	   The	   analysis	   of	   the	   broader	   range	   of	   potential	   adverse	  
events	   other	   than	   cardiotoxic	   effects	   of	   OFX	   and	   LFX	   is	   currently	   being	   prospectively	  
evaluated	  in	  larger	  prospective	  cohort	  studies	  and	  is	  beyond	  the	  scope	  of	  this	  PhD	  thesis	  
(see	  appendix).	  
For	  MFX,	   clinical	   safety	  assessments	  using	   combined	  data	   sources	   including	   chart	   and	  
routine	   clinical	   review,	   laboratory	   investigation,	   parental	   and	   children’s	   report	   during	  
MFX	   therapy	   were	   performed.	   Standard	   Division	   of	   Acquired	   Immunodeficiency	  
Syndrome	  (NIH	  US;	  DAIDS)	   criteria	  were	  used	   to	  grade	  severity	  of	  adverse	  events.	  To	  
assess	   cardiotoxicity	   of	   all	   three	   fluoroquinolones,	   a	   12-­‐lead	   electrocardiogram	   (ECG)	  
was	  performed.	  Due	  to	  logistical	  reasons,	  ECGs	  were	  only	  obtained	  in	  children	  receiving	  
fluoroquinolone	  as	  part	  of	  MDR-­‐TB	  preventive	  therapy.	  An	  ECG	  was	  performed	  on	  each	  
of	   the	  pharmacokinetic	  assessment	  days	  at	  3	  hours	  after	  drug	  dosing,	   to	  coincide	  with	  
the	  likely	  fluoroquinolone	  tmax.	  ECGs	  were	  evaluated	  using	  a	  standardized	  approach	  by	  a	  
single	  paediatric	  cardiologist,	  with	  the	  corrected	  QT-­‐interval	  (QTc)	  calculated	  using	  the	  
method	  described	  by	  Fridericia	  (378)	  with	  a	  QTc	  >450ms	  or	  a	  change	  from	  baseline	  of	  
>60	  ms	  classified	  as	  prolonged	  (360).	  	  
In	   children	   receiving	  OFX	   and	   LFX	   the	  mean	  QTc	  was	   361ms	   (SD	   37ms)	   for	  OFX	   and	  
369ms	  (SD	  22ms)	  for	  LFX.	  No	  children	  in	  either	  group	  had	  a	  QTc	  >450	  ms.	  In	  6	  children,	  
all	   in	   the	   preventive	   therapy	   group,	   baseline	   ECGs	   before	   initiation	   of	   any	  
fluoroquinolone	   therapy	   were	   obtained.	   In	   one	   child	   in	   the	   LFX	   group,	   a	   QTc	  




prolongation	   of	  more	   than	   60ms	   from	   baseline	   (QTc	   342ms)	   occurred	  with	   a	   QTc	   of	  
403ms	  being	  still	  within	  the	  normal	  range.	  In	  5	  children	  receiving	  either	  OFX	  or	  LFX	  ECG	  
abnormalities	  other	  than	  QTc	  prolongation	  were	  documented	  that	  could	  not	  be	  related	  
to	  fluoroquinolone	  therapy	  (377).	  
Children	   on	  MFX	  were	   followed	   for	   a	  median	   of	   236	   days	   (IQR	   142-­‐541	   days).	   Main	  
adverse	  effects	  potentially	  related	  to	  MFX	  were	  gastrointestinal	   (nausea	  and	  vomiting;	  
n=12),	   headache	   (n=5),	   elevated	   alanine-­‐aminotransferase	   (ALT;	   n=4)	   and	   arthralgia	  
(n=4).	   In	   13/23	   children	   on	   MFX	   ECG	   data	   was	   available.	   Mean	   QTc	   was	   403ms	   (SD	  
30ms).	  None	  had	  a	  QTc	  –interval	  >450ms.	  	  
Although	   fluoroquinolones	  are	  known	  to	  prolong	  the	  QT-­‐interval	  with	  MFX	  having	   the	  
largest	  effect	  (chapter	  4)(379),	  we	  did	  not	  observe	  any	  concerning	  QTc	  prolongation	  in	  
children;	   although	   the	   largest	   cohort	   to	   date,	   we	   evaluated	   a	   modest	   number	   of	  
participants	  and	   in	   the	  majority	  of	  children	   lacked	  a	  pre-­‐fluoroquinolone	  baseline	  QTc	  
assessment	   for	   comparison	   (359,	   360).	   	   Further	   evaluation	   in	   children	   is	   warranted	  
given	  that	  in	  future	  fluoroquinolones	  (esp.	  MFX)	  may	  be	  combined	  with	  novel	  TB	  drugs	  
which	   are	   also	   known	   to	   cause	   QT	   prolongation,	   such	   as	   bedaquiline	   and	   delamanid	  
(380,	  381),	  which	  are	  both	  under	  evaluation	  in	  children.	  More	  information	  is	  provided	  in	  
the	  articles	  included.	  	  




Chapter	  7:	  Conclusions	  and	  future	  directions	  	  
	  
The	   global	   burden	   of	   tuberculosis	   (TB)	   in	   children	   remains	   high	   and	   TB	   has	   high	  
morbidity	   and	   mortality	   especially	   amongst	   young	   children.	   Despite	   this	   burden	   of	  
disease,	   TB	   in	   children	   has	   been	   a	   neglected	   disease	   and	   has	   only	   in	   the	   last	   decade	  
started	  receiving	  the	  necessary	  attention.	  The	  emerging	  epidemic	  of	  multidrug-­‐resistant	  
TB	   (MDR-­‐TB)	   is	   also	   a	   threat	   for	   children	   –	   maybe	   even	   more	   than	   for	   adults,	   as	  
information	  on	  the	  use	  of	  second-­‐line	  drugs	  in	  children	  is	  very	  limited	  (5,	  382),	  and	  data	  
on	  the	  use	  of	  new	  drugs	  is	  absent.	  
Pharmacokinetics,	  drug	  doses	  and	  safety	  of	  anti-­‐tuberculosis	  drugs	  are	  generally	  poorly	  
studied	  in	  children,	  even	  of	  those	  developed	  more	  than	  6	  decades	  ago.	  Evidence-­‐based	  
dosing	  and	  data	  on	  safety	  of	  drugs	  in	  children	  are	  critical	  for	  optimizing	  treatment	  and	  
developing	  acceptable	  formulations.	  
The	   first	   literature	   review	   in	   this	   thesis	   confirmed	   that	   information	   on	   the	   optimal	  
dosing	  of	  isoniazid	  (INH),	  the	  first-­‐line	  anti-­‐tuberculosis	  drug	  most	  extensively	  used	  for	  
preventive	  therapy	  and	  TB	  treatment,	  in	  the	  youngest	  and	  most	  vulnerable	  age	  group	  of	  
children	  (children	  <2	  years	  of	  age)	  is	  still	  limited.	  My	  study	  on	  the	  pharmacokinetics	  of	  
INH	   provided	   supportive	   evidence	   for	   the	   new	   World	   Health	   Organization	   (WHO)	  
dosing	  recommendation	  of	  INH	  given	  at	  10mg/kg	  (range	  7-­‐15	  mg/kg)	  in	  South	  African	  
children	  <2	  years	  of	  age	  (excluding	  neonates)	  (118).	  Further	  pharmacokinetic	  and	  safety	  
studies	   are	   needed	   to	   determine	   whether	   young	   children	   in	   other	   populations	   with	  
different	   distributions	   of	   NAT2-­‐acetylator	   status	   and	   possible	   different	   risk	   for	   INH-­‐
induced	  toxicity	  require	  different	  dosages	  of	  INH.	  	  
Several	  paediatric	  pharmacokinetic	  studies	  have	  shown	  that	  higher	  doses	  of	  rifampicin	  
(RMP)	  than	  the	  previously	  recommended	  WHO	  doses	  of	  10mg/kg	  (range	  8-­‐12	  mg/kg)	  
are	  needed	  to	  achieve	  serum	  concentrations	  comparable	  to	  those	  in	  adults	  after	  a	  dose	  
of	  600mg/day	   (55,	  98,	  120,	  172,	  182-­‐187).	   I	  have	  provided	  evidence	   that	  a	  dose	  of	  at	  
least	  15	  mg/kg	  daily	  is	  needed	  in	  children	  <2	  years	  of	  age	  to	  achieve	  adult	  target	  Cmax	  of	  
8-­‐24μg/ml	   (118,	   160).	   It	   has	   been	   shown	   that	   activity	   against	   Mycobacterium	  
tuberculosis	   as	   well	   as	   the	   development	   of	   RMP	   drug	   resistance	   is	   concentration-­‐
dependent	   and	   therefore	   high	   doses	   of	   RMP	   up	   to	   35mg/kg	   have	   currently	   been	  




evaluated	   in	   adults	   in	   order	   to	   optimize	   RMP	   dose	   and	   to	   potentially	   shorten	   TB	  
treatment	   regimens	   (383).	   Doses	   of	   RMP	   30-­‐35mg/kg	   showed	   favourable	   extended	  
early	   bactericidal	   activity	   compared	   to	   lower	   RMP	   doses	   with	   no	   increase	   in	  
hepatotoxicity	   (383).	   There	   is	   robust	   evidence	   that	   severe	  RMP	  hepatotoxicity	   is	   rare	  
and	  is	  not	  dose-­‐dependent	  in	  children	  (122).	  Therefore,	  if	  a	  higher	  RMP	  dose	  is	  shown	  to	  
be	  beneficial	  in	  further	  adult	  studies,	  doses	  achieving	  similar	  RMP	  concentrations	  to	  the	  
higher	   adult	   dose	   eventually	   chosen	   also	   need	   to	   be	   evaluated	   in	   children.	   This	   is	  
especially	   relevant	   in	   young	   children	  who	   have	   an	   increased	   risk	   for	   central	   nervous	  
system	  (CNS)	  TB,	  as	  penetration	  of	  RMP	  across	  the	  blood-­‐brain	  barrier	   is	  only	  modest	  
(170).	  
Pyrazinamide	  (PZA)	  drug	  concentrations,	  different	  to	  INH	  and	  RMP,	  reach	  similar	  Cmax	  at	  
the	   same	   mg/kg	   body	   weight	   dose	   in	   adults	   and	   children	   (223-­‐225).	   However,	  
information	  on	   the	  pharmacokinetics	   in	   young	   children	   (<2	  years)	   is	   limited.	  There	   is	  
uncertainty	  regarding	  the	  optimal	  pharmacokinetic	  or	  pharmacodynamic	  target	  for	  PZA	  
in	   adults	   and	   children.	   Should	   it	   be	   confirmed	   that	   a	   PZA	   Cmax	   of	   <35µg/ml	   is	   indeed	  
associated	  with	  a	  poorer	  treatment	  outcome	  as	  shown	  by	  Chideya	  et	  al.	  (22),	  PZA	  doses	  
of	  at	  least	  30-­‐35mg/kg	  would	  be	  required	  in	  children	  including	  children	  <2	  years	  of	  age	  
(174,	  219).	  Again,	  this	  needs	  to	  be	  studied	  in	  a	  larger	  number	  of	  children	  with	  different	  
genetic	  backgrounds.	  
The	  data	  presented	  in	  this	  thesis	  provides	  supportive	  evidence	  for	  the	  implementation	  
of	   the	   revised	   WHO	   guidelines	   for	   first-­‐line	   anti-­‐tuberculosis	   treatment	   in	   young	  
children.	   Following	   the	   new	   WHO	   dosing	   recommendations	   for	   INH,	   RMP	   and	   PZA,	  
fixed-­‐dose	   combinations	   are	   currently	   in	   development.	   These	   will	   be	   most	   likely	  
manufactured	  in	  a	  dispersible	  tablet	  containing	  INH	  50mg,	  RMP	  75mg	  and	  PZA	  150mg	  
(384).	   If	   ongoing	   studies	  demonstrate	   superiority	   of	   higher	   rifampicin	   concentrations,	  
the	   rifampicin	   compound	  might	   be	   increased	   to	   e.g.	   100mg.	   The	   relatively	   small	   drug	  
amounts	   in	   each	   tablet	   and	   the	   dispersible	   formulation	  will	   simplify	   dosing	   in	   young	  
children	   and	  will	   avoid	   crushing	   and	   splitting	   of	   tablets	  with	   unknown	   effect	   on	  drug	  
bioavailability.	   Nevertheless,	   in	   simulations	   based	   on	   a	   population	   pharmacokinetic	  
model,	   these	   fixed-­‐dose	   combinations	   led	   to	   INH	   and	   PZA	   exposures	   lower	   than	   in	  
adults,	  especially	  in	  young	  children	  (174).	  Studies	  of	  such	  new	  fixed-­‐dose	  combinations	  
administered	  according	  to	  weight-­‐banded	  dosing	  will	  also	  need	  to	  be	  done	  in	  different	  




settings.	  The	  pharmacokinetics	  of	  first-­‐line	  agents	  in	  infants	  below	  12	  months	  of	  age	  are	  
currently	  under	  investigation	  (385).	  	  
Further	   research	   is	   ongoing	   to	   develop	   appropriate	   child-­‐friendly	   formulations	   of	   the	  
current	   standard	   first-­‐line	   TB	   treatment	   (386),	   and	   also	   to	   examine	   the	   effect	   of	   the	  
revised	  WHO	  dose	  recommendations	  and	  the	  influence	  on	  concomitant	  treatment	  with	  
antiretroviral	   therapy	   in	   children	   (DATiC	   NCT01637558;	   Treat	   Infant	   TB;	   and	   PK-­‐
PTBHIV01,	  SHINE	  trial,	  ISRCTN63579542).	  	  
Drug-­‐resistant	  TB,	  especially	  MDR-­‐TB,	  is	  increasing	  globally,	  also	  in	  children,	  as	  children	  
are	   typically	   infected	   by	   adult	   drug-­‐resistant	   source	   cases	   and	   do	   not	   acquire	  
mycobacterial	  drug	  resistance.	  Therefore	  pharmacokinetic	  studies	  to	  confirm	  the	  dosing	  
and	  safety	  of	  the	  second-­‐line	  agents	  in	  children	  have	  become	  a	  matter	  of	  urgency.	  
Of	  the	  second-­‐line	  anti-­‐tuberculosis	  drugs,	  I	  prioritized	  the	  study	  of	  ethionamide	  (ETH)	  
(which	   is	   similar	   to	   prothionamide	   (PTH))	   and	   the	   3	   most	   frequently	   used	  
fluoroquinolones	   (and	   currently	   the	   best	   second-­‐line	   TB	   drugs)	   ofloxacin	   (OFX),	  
levofloxacin	  (LFX)	  and	  moxifloxacin	  (MFX).	  
By	  reviewing	  the	  literature,	  I	  highlighted	  gaps	  in	  the	  current	  knowledge	  on	  dosing	  and	  
safety	  of	  EHT/PTH	  in	  children.	  	  With	  the	  first	  study	  on	  ETH	  pharmacokinetics	  I	  provided	  
supporting	   evidence	   for	   the	   current	   dosing	   recommendation	   of	   ETH	   15-­‐20mg/kg	   in	  
children	  with	  TB.	   	   In	   this	   study	   I	   found	   that	  young	  children	  and	  HIV-­‐infected	  children	  
were	  at	  risk	  for	  lower	  ETH	  serum	  concentrations,	  but	  that	  the	  mean	  drug	  exposure	  was	  
still	  within	  range	  of	  the	  adult	  Cmax	  reference	  target	  (2.5µg/ml)	  (310).	  	  
Along	  with	  pharmacokinetic	  data	  on	  ETH,	  I	  showed	  for	  the	  first	  time,	  that	  there	  is	  a	  high	  
frequency	  of	  thyroid	  function	  abnormalities	  in	  children	  treated	  with	  ETH,	  indicating	  the	  
need	   for	   careful	   thyroid	   function	   test	   monitoring	   in	   children	   on	   long-­‐term	   ETH	  
treatment,	   especially	   in	   case	   of	   HIV	   co-­‐infection	   and	   concomitant	   use	   of	   para-­‐
aminosalisylic	   acid	   (PAS).	   The	   study	   was	   limited	   by	   its	   retrospective	   nature	   and	   the	  
inability	  to	  evaluate	  the	  clinical	  impact	  of	  the	  findings	  on	  TB	  treatment	  outcome.	  
Future	   studies	   on	   the	   optimal	   pharmacodynamic	   target(s)	   for	   ETH/PTH	   in	   anti-­‐
tuberculosis	   treatment	   and	   pharmacokinetic	   and	   safety	   studies	   in	   a	   larger	   number	   of	  
children	  are	  warranted.	  The	  focus	  should	  be	  on	  the	  most	  vulnerable	  groups:	  young	  and	  




HIV-­‐infected	   children.	   Careful	   attention	   needs	   to	   be	   given	   to	   other	   relevant	   clinical	  
covariates.	  	  
MFX	   and	  LFX	   at	   higher	   doses	   (1,000mg)	  have	  been	   identified	   as	   the	   two	  most	   potent	  
fluoroquinolones	   against	   M.	   tuberculosis	   in	   adults.	   Because	   these	   newer	  
fluoroquinolones	   are	   not	   readily	   available	   in	   resource-­‐limited,	   TB	   high-­‐burden	  
countries,	  the	  less	  active	  but	  inexpensive	  OFX	  is	  still	  widely	  used.	  	  
My	   literature	  review	  on	   the	  use	  of	   fluoroquinolones	   in	  childhood	  TB	  revealed	   that	   the	  
strong	   bactericidal	   and	   sterilizing	   activity,	   favourable	   pharmacokinetics,	   and	   toxicity	  
profile	  have	  made	  the	  fluoroquinolones	  the	  most	  important	  component	  of	  existing	  MDR-­‐
TB	  treatment	  regimens	  not	  only	   in	  adults	  but	  also	   in	  children	  (387).	  Although	  current	  
evidence	  on	  MFX-­‐containing	  regimens	  does	  not	  yet	  support	  their	  use	  in	  the	  shortening	  
of	  TB	  treatment	  for	  drug-­‐susceptible	  TB	  (DS-­‐TB),	  future	  regimens	  including	  higher	  MFX	  
doses	   and/or	   combining	   MFX	   with	   novel	   anti-­‐tuberculosis	   agents	   may	   still	   show	  
promise	  in	  shortening	  regimens	  (388).	  Data	  on	  the	  possible	  role	  of	  fluoroquinolones	  in	  
treatment	  shortening	  for	  paediatric	  DS-­‐TB,	  including	  TB	  meningitis,	  is	  needed.	  
There	   is	   limited	  data	  on	   fluoroquinolone	  pharmacokinetics	  and	  safety	   in	  children	  with	  
TB.	  My	  pharmacokinetic	   studies	  on	  OFX,	  LFX	  and	  MFX	   in	   children	  have	  demonstrated	  
that	   children	   eliminate	   fluoroquinolones	   faster	   than	   adults,	   leading	   to	   substantially	  
lower	   drug	   exposure	  with	   failure	   to	   achieve	   the	   proposed	   primary	   pharmacodynamic	  
target	  for	  fluoroquinolones	  of	  AUC/MIC	  >100	  at	  the	  currently	  recommended	  doses	  (359,	  
360).	   Failure	   to	   approximate	   adult	   exposures	   or	   to	   achieve	   pharmacodynamic	   targets	  
has	  important	  implications	  for	  current	  and	  future	  dosing	  recommendations	  in	  children	  
for	   these	   essential	   anti-­‐tuberculosis	   drugs.	  While	  Cmax	   is	   considered	  more	   relevant	   for	  
the	   development	   of	   resistance	   (389),	   AUC/MIC	   is	   associated	   with	   treatment	   success	  
(71).	  Limitations	  of	  my	  pharmacokinetic	   studies	  were	   the	  modest	  sample	  size	  and	   the	  
lack	  of	  well	  defined	  pharmacodynamic	  targets	  for	  treatment	  of	  childhood	  TB.	  No	  serious	  
adverse	   effects,	   especially	   no	   cardiotoxic	   effect	  with	   prolongation	   of	   the	   QTc-­‐interval,	  
occurred	  in	  the	  children	  included	  in	  these	  studies.	  Although	  numbers	  were	  modest	  and	  a	  
baseline	  ecg	  not	  always	  available,	  this	  is	  reassuring	  and	  adds	  to	  the	  body	  of	  evidence	  of	  
safe	  use	  of	  fluoroquinolones	  in	  childhood	  TB.	  	  
Studies	   of	   LFX	   for	   MDR-­‐TB	   preventive	   therapy	   (TB-­‐CHAMP,	   V-­‐Quin)	   and	   for	   the	  
treatment	  of	  TB	  meningitis	  (TBM-­‐KIDS	  study)	  are	  currently	  being	  planned	  in	  both	  adults	  




and	  children.	  For	  the	  foreseeable	  future,	  LFX	  and	  MFX	  are	  likely	  to	  be	  used	  in	  children	  
and	   information	   on	   their	   effective	   use	   in	   childhood	   TB	   is	   critical.	   Their	   role	   in	   future	  
treatment	  shortening	  trials	  of	  MDR-­‐and	  DS-­‐TB	  will	  also	  remain	  important.	  	  
For	  the	  second-­‐line	  drugs,	  no	  child	  friendly	  formulations	  or	  lower	  dose	  strength	  tablets	  
are	  available,	  making	  dosing	  in	  children	  challenging.	  In	  daily	  practice,	  TB	  medicines	  are	  
routinely	   crushed	   and	   mixed	   with	   different	   fluids	   and	   foods	   to	   facilitate	   their	  
administration	   to	   young	   children.	   This	   causes	   a	   high	   risk	   of	   inaccurate	   dosing	   –	   both	  
over-­‐and	  under-­‐dosing.	   	  Additionally,	  information	  on	  the	  influence	  of	  these	  procedures	  
on	   stability	   and	   bioavailability	   of	   the	   anti-­‐tuberculosis	   agents	   is	   lacking.	   The	   Sentinel	  
Project	  on	  Pediatric	  Drug-­‐Resistant	  Tuberculosis	  is	  conducting	  a	  laboratory-­‐based	  study	  
to	   evaluate	   the	   stability	   and	   availability	   of	   ETH,	   LFX,	   cycloserine,	   and	   linezolid	   when	  
mixed	  with	  different	  foods;	  results	  are	  still	  pending.	  	  
For	   ethionamide,	   a	   dose	   of	   15-­‐20mg/kg	   seems	   to	   be	   appropriate	   in	   children.	   To	  
adequately	  dose	  younger	  children	  a	  tablet	  strength	  lower	  than	  the	  standard	  250mg	  ETH	  
tablet	  is	  needed.	  In	  India,	  125mg	  ETH	  tablets	  are	  already	  available	  and	  a	  prototype	  of	  a	  
scored	  dispersible	  ETH	  tablet	  is	  in	  development	  (356).	  
For	   the	   fluoroquinolones,	   data	   necessary	   to	   develop	   appropriately	   dosed	   paediatric	  
formulations	   is	   still	   lacking.	  Nevertheless,	   given	   the	  available	  data,	   the	  use	  of	  LFX	  and	  
MFX	   is	   recommended	   over	   OFX.	   For	   LFX,	   a	   dose	   of	   15-­‐20mg/kg/d	   and	   for	   MFX	   of	  
10mg/kg/d	  seems	  appropriate	  (49,	  390).	  In	  the	  case	  of	  MFX,	  standard	  400mg	  tablets	  are	  
not	   scored	  and	  very	  bitter	  when	  crushed.	  MFX	  use	   is	   therefore	  generally	   restricted	   to	  
older	   children,	   therefore	   excluding	   the	   most	   vulnerable	   group	   of	   children.	   A	   tablet	  
strength	   of	   100-­‐150mg	   for	   LFX	   and	   of	   100mg	   for	   MFX	   is	   proposed.	   Issues	   of	  
acceptability	  and	  palatability	  also	  warrants	  further	  drug	  investigation. 
Development	   of	   child-­‐friendly	   formulations	   of	   first-­‐	   and	   second-­‐line	   agents	   is	   critical;	  
Fixed	  drug	   combinations	   (FDC)	   in	   order	   to	   reduce	   tablet	   burden	   are	   available	   for	   the	  
first-­‐line	  agents,	  but	  have	  not	  been	  developed	  for	  MDR	  anti-­‐tuberculosis	  treatment.	  MDR	  
treatment	   regimens	  differ	   in	  different	   countries/regions	  due	   to	   susceptibility	  patterns	  
and	  availability	  of	  second-­‐line	  agents.	  As	  a	  child-­‐friendly	  formulation,	  dispersible	  tablets	  
are	  preferred	  over	  liquids,	  because	  liquids	  are	  bulky,	  not	  easy	  to	  store,	  frequently	  come	  
in	  breakable	  bottles	  and	  often	  need	  refrigeration	  after	  opening.	  New	  formulations	  need	  




to	  be	  informed	  by	  rigorous	  pharmacokinetic	  and	  safety	  studies	  in	  children	  with	  different	  
genetic	   backgrounds.	  Once	   developed,	   their	   availability	   to	   those	  most	   in	   need,	   that	   is,	  
children	  in	  high-­‐burden,	  low	  resource	  settings,	  needs	  to	  be	  ensured.	  
Taken	  together,	  paediatric	  pharmacokinetic	  studies	  have	  revealed	  that	  higher	  doses	  of	  
first-­‐	  and	  secondline	  anti-­‐tuberculosis	  agents	  compared	  to	  adults	  are	  needed	  to	  achieve	  
comparable	   blood	   concentrations.	   These	   higher	   doses	   (that	   might	   even	   be	   increased	  
depending	   on	   efficacy	   results	   of	   ongoing	   adult	   studies)	   need	   to	   be	   thoroughly	  
investigated,	   including	   their	   safety	   in	   children	  with	   TB.	   Therefore,	   intensive	   sampling	  
pharmacokinetic	  studies	  as	  well	  as	  sparse	  sampling	  studies	  in	  a	  larger	  group	  of	  children	  
with	   different	   genetic	   backgrounds,	   different	   ages,	   different	   nutritional	   status,	   HIV-­‐
infected	   and	   HIV-­‐uninfected	  with	   and	  without	   receiving	   ARTs	   need	   to	   be	   undertaken	  
and	  mathematical	  modeling	  (population	  pharmacokinetic	  models)	  be	  applied	  in	  order	  to	  
optimally	   characterize	   the	   pharmacokinetics	   in	   childhood	   TB.	   For	   safety	   analysis,	  
children	  need	   to	  be	  monitored	  on	  a	  regular	  basis-­‐	  clinically	  as	  well	  as	  with	   laboratory	  
investigations.	   Valuable	   endpoints	   for	   efficacy	   of	   anti-­‐tuberculosis	   treatment	   in	  
childhood	  TB	  are	  difficult	  to	  define.	  The	  disease	  diversity	  in	  childhood	  TB	  is	  high	  and	  the	  
natural	  history	  of	  these	  manifestations	  vary	  considerably,	  making	  it	  difficult	  to	  judge	  the	  
success	   of	   treatment.	   Because	   sputum	   cultures	   are	   frequently	   negative,	   evaluation	   of	  
treatment	   outcome	   often	   rely	   on	   radiological	   and	   clinical	   improvement.	   For	   study	  
purposes	  children	  need	  to	  be	  followed	  up	  until	  the	  end	  of	  treatment	  and	  optimally	  until	  
one	  year	  thereafter.	  
Once	   the	   pharmacokinetics	   of	   the	   anti-­‐tuberculosis	   agents	   (and	   their	   child-­‐friendly	  
formulations)	  have	  been	  better	  defined	  in	  children,	  the	  actual	  MIC	  distribution	  of	  clinical	  
M.	   tuberculosis	   strains	   should	   be	   established,	   because	   of	   the	   variability	   of	   MICs	   from	  
region	  to	  region.	  This	  would	  guide	  the	  most	  appropriate	  drug	  doses	  needed	  to	  achieve	  
proposed	  pharmacodynamic	  targets	  and	  doses	  could	  be	  individualised	  accordingly.	  The	  
pharmacokinetic	  studies	  in	  children	  revealed	  a	  high	  inter-­‐individual	  variability	   in	  drug	  
concentrations.	   This	   is	   especially	   of	   concern	   in	   second-­‐line	   agents	   where	   the	   margin	  
between	  efficacy	  and	  toxicity	  is	  narrow.	  Nevertheless,	  also	  for	  INH	  individualized	  dosing	  
has	  been	  shown	   to	  be	  beneficial	   for	   treatment	  success	  and	   toxicity	   (391).	  Because	   the	  
traditional	   venipuncture-­‐based	   method	   is	   currently	   not	   feasible	   for	   routine	   care	  
purposes,	   new	   therapeutic	   TB	   drug	   monitoring	   like	   dried	   blood	   spot	   assays	   are	  
currently	  being	  evaluated	   (Pediatric	  Tuberculosis:	  enabling	  early	  detection	  of	   children	  




at-­‐risk	  for	  treatment	  failure	  (Dried-­‐blood	  spot	  sub-­‐study),	  PI	  Anneke	  Hesseling).	  Assays	  
further	  research	  (48).	  The	  feasibility	  of	  such	  monitoring	  in	  routine	  care	  settings	  should	  
still	  be	  evaluated.	  
	  
	  
Impact	  on	  policy	  and	  practice	  
	  
My	  research	  generated	  supportive	  evidence	   for	  the	  current	   for	  determination	  of	  drugs	  
or	  their	  metabolites	  in	  saliva	  or	  urine	  could	  also	  be	  a	  focus	  for	  	  
WHO	  dose	  recommendations	  of	  INH,	  RMP	  and	  PZA	  in	  children	  younger	  than	  two	  years	  
of	   age	   and	   for	   ETH	   in	   children	   younger	   than	   12	   years	   of	   age.	   This	   data	   can	   enter	  
population	   pharmacokinetic	   models,	   aiming	   to	   identify	   and	   quantify	   sources	   of	  
variability	   and	   facilitating	   sparse-­‐sampling	   strategies,	   which	   are	   highly	   relevant	   in	  
children.	  
Influenced	  by	  my	  pharmacokinetic	   study,	  LFX	   is	   currently	  being	  evaluated	  at	   a	  higher	  
dose	   of	   LFX	   20mg/kg	   in	   children	   in	   the	   same	   study	   setting,	   and	  may	   be	   evaluated	   at	  
higher	   doses	   in	   future,	   including	   in	   an	   international	   TB	  meningitis	   trial.	   International	  
LFX	   dose	   recommendations	   have	   now	   been	   increased	   from	   7.5-­‐10	   mg/kg	   to	   15-­‐
20mg/kg	  based	  on	  these	  results.	  For	  MFX,	  the	  dose	  is	  still	  7.5-­‐10mg/kg,	  but	  aiming	  for	  
the	  high	  end	  of	  the	  range	  is	  recommended	  –	  further	  evaluation	  is	  needed	  at	  higher	  doses	  
and	  will	  be	  studied	  in	  recently	  funded	  trials.	  
The	  study	   I	  have	  conducted	  has	   increased	  awareness	  about	  hypothyroidism	  occurring	  
during	  ETH	  therapy,	  and	  routine	  testing	  of	  thyroid	  function	  is	  now	  being	  recommended	  
in	  international	  MDR-­‐TB	  treatment	  guidelines	  for	  children	  (392).	  
In	   conclusion,	   my	   research	   has	   identified	   and	   addressed	   critical	   gaps	   in	   the	   current	  
knowledge	   in	   the	   management	   of	   children	   with	   both	   drug-­‐susceptible	   and	   drug-­‐
resistant	  TB.	   I	  have	  provided	  essential	  evidence	  on	  both	  the	  dosing	  and	  safety	  of	   first-­‐	  
and	   second-­‐line	   anti-­‐tuberculosis	   agents,	   informing	   international	   treatment	   guidelines	  
for	   childhood	   TB.	   More	   data	   is	   needed	   in	   a	   larger	   number	   of	   children	   with	   different	  
genetic	   backgrounds,	   with	   and	   without	   HIV	   co-­‐infection	   and	   with	   higher	   drug	   doses.	  	  
Novel	   more	   child-­‐friendly	   treatment	   regimens	   and	   child-­‐friendly	   formulations	   are	  
urgently	  needed	  to	  further	  optimize	  anti-­‐tuberculosis	  treatment	  in	  children.	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suggest	  that	  with	  the	  new	  WHO	  dosing	  guidelines	  and	  using	  available	  paediatric	  fixed-­‐
dose	   combinations,	   children	   will	   receive	   adequate	   RMP	   exposures	   compared	   with	  
adults,	  but	  with	  a	  larger	  degree	  of	  variability.	  PZA	  and	  INH	  exposures	  in	  many	  children	  
will	  be	  lower	  than	  in	  adults.	  
	  
	  
7.	  Garcia-­‐Prats	  T,	  Draper	  HR,	  Thee	  S,	  Dooley	  KE,	  McIlleron	  HM,	  Seddon	  JA,	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Castel	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   Schaaf	   HS,	   Hesseling	   AC:	   The	   pharmacokinetics	   and	   safety	   of	   ofloxacin	   in	  
children	  with	  drug-­‐resistant	  tuberculosis.	  Accepted	  at	  AAC,	  AAC01404-­‐15.	  	  
	  
The	   pharmacokinetics	   and	   safety	   of	   ofloxacin	   (OFX)	   in	   children	   <15	   years	   routinely	  
receiving	  ofloxacin	  for	  MDR-­‐TB	  treatment	  or	  preventive	  therapy	  at	  a	  dose	  of	  20mg/kg	  
were	  assessed.	  Children	  with	  MDR-­‐TB	  disease	  underwent	  long-­‐term	  safety	  monitoring.	  
Eighty-­‐five	   children	   (median	   age	   3.4years)	   were	   included.	   OFX	   was	   safe	   and	   well	  
tolerated	   in	   children	   with	   MDR-­‐TB,	   but	   exposures	   were	   well	   below	   reported	   adult	  
values.	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Ethambutol in paediatric tuberculosis: aspects of ethambutol 
serum concentration, efficacy and toxicity in children
S. Thee,* A. Detjen,*† D. Quarcoo,† U. Wahn,† K. Magdorf*†
* Department of Paediatric Pneumology and Immunology Allergy, Helios Klinikum Emil von Behring, Chest 
Hospital Heckeshorn, Berlin, † Department of Paediatric Pneumology and Immunology, Charité, Universitätsmedizin
S U M M A R Y
Berlin, Berlin, Germany
SETTING: Ethambutol (EMB) is used as a fourth drug in
paediatric anti-tuberculosis treatment. In current recom-
mendations the dosage of EMB is calculated per kg body
weight.
OBJECTIVE: To present two studies investigating an ap-
propriate EMB dosage in children, and observational
data on its toxicity and efficacy.
DESIGN: EMB serum levels in children of different age
groups were determined after single oral administration
of EMB alone as well as after EMB combined with ri-
fampicin, and optimal dosages were established. The ef-
ficacy and toxicity of these EMB dosages were examined
retrospectively.
RESULTS: EMB serum levels were lower than those ex-
pected in adults receiving a similar oral dose, due to dif-
ferent pharmacokinetics and pharmacodynamics in child-
hood. Thereafter, children were treated with EMB doses
calculated by body surface (867mg/m2). Ocular toxicity
occurred in 0.7% of cases and relapses in 0.8%.
CONCLUSION: Current recommended EMB dosages in
childhood tuberculosis lead to subtherapeutic serum
levels. It appears to be more valid to calculate the EMB
dosage on the basis of body surface rather than body
weight, leading to higher dosages especially in younger
children. With these dosages, therapeutic serum levels
are reached in all age groups, leading to a high efficacy
of anti-tuberculosis treatment without increased ocular
toxicity.
KEY WORDS: anti-tuberculosis agents; drug therapy
pharmacokinetics; ethambutol; children
ETHAMBUTOL (EMB) was first recommended for
use in the treatment of tuberculosis (TB) in 1966. In
dosages used for therapy, EMB has bacteriostatic ac-
tivity against Mycobacterium tuberculosis.1–3 The
main advantages of EMB are its low toxicity, low costs
and administration by the oral route. In children, EMB
is included in an anti-tuberculosis regimen when there
is an increased likelihood of the disease being caused
by organisms resistant to isoniazid (INH) or when the
child has ‘adult-type tuberculosis’.4–6 Especially in
countries with a high TB burden, there are very few al-
ternatives to the use of EMB if a fourth drug is needed
in the treatment of childhood TB.5,6
Very few reports have been published on the phar-
macokinetics, pharmacodynamics, efficacy and the
resulting adequate dosage of EMB in children. Cur-
rent recommendations for the dosage of EMB in chil-
dren vary from 15 to 25 mg/kg body weight.2,5–11 A
sufficiently high tissue level is essential for the efficacy
of all chemotherapeutics. The minimum inhibition
concentration (MIC) of EMB for M. tuberculosis in
vitro is 0.5–2.0 !g/ml, depending upon the media
used.2,5–7,12,13 In vivo, the target range of EMB serum
concentration is 2.6 !g/ml for daily doses.6,12,14
EMB distributes well and rapidly through the body,
but the pharmacokintetics and pharmacodynamics dif-
fer between children and adults.6,15 In children, the ex-
travascular space is much larger in relation to the body
weight than in adults, changing with age and result-
ing in a different age-dependent drug distribution.16–18
Two studies to determine the ideal dosage of EMB
in the treatment of TB in children were performed
at the Department of Pediatric Pneumology of the
Chest Hospital Heckeshorn, Berlin, Germany, in
1971 and 1973.19,20 These nationally published find-
ings were never made accessible to the international
medical community, and they are thus presented here.
In the first study, EMB was given to children in single
doses of 15 mg/kg followed by 25 mg/kg; in the sec-
ond study, doses of 35 mg/kg EMB were given alone
and later in combination with 10 mg/kg rifampicin
(RMP). The EMB dosage was higher than the cur-
rently recommended dosage (between 15 and 25 mg/
kg EMB).5,6,8,9,11,19,20
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EMB is a relatively well tolerated compound, with
side effects observed in 3–6% of adults.10,21 Its most
important adverse effect is ocular toxicity.1,2,10,22 Be-
cause of the difficulty of identifying this rare but seri-
ous side effect in young children, national and inter-
national guidelines currently recommend that EMB
should only be given with caution to children aged
#5 years.5,6,11
The results reported here add to the data about
EMB in the treatment of childhood TB. We also
present follow-up data regarding ocular toxicity and
the efficacy of EMB in children treated at our depart-
ment until 1981.
PATIENTS AND METHODS
During the time of the studies all children diagnosed
with TB for the first time at our department were in-
cluded. They had not received any previous anti-
tuberculosis medication before inclusion in the studies.
Both studies were approved by the ethics committee
of the Free University Berlin; parents gave informed
written consent for participation.
Twenty children were enrolled in the first study,
and 28 children in the second.19,20 Any history of vi-
sual disturbance was a criterion for exclusion. Chil-
dren were divided into three age groups: 2 to #6 years,
6 to #10 years and 10–14 years.
In the 1971 study, all children received a single
dose of 15 mg/kg EMB. After an adequate wash-out
time of 1 week, they received a single dose of 25 mg/kg
EMB. In the 1973 study, 35 mg/kg EMB was given,
and after the wash-out time the same children re-
ceived 35 mg/kg EMB plus 10 mg/kg RMP.20
Blood was taken by venipuncture before the medi-
cation and 1, 2, 4, 7 and 24 h thereafter. The samples
were centrifuged within 30 min. Serum and blood
were separated and frozen at $18%C. EMB was deter-
mined in the serum by a modified microbiological ver-
tical diffusion test with the rapid growing mycobacte-
rial ATCC 607 strain, as previously described.23 After
the study measurements, standard combined anti-
tuberculosis treatment was initiated.
RESULTS
Mean EMB serum levels after oral application of
15 mg/kg body weight EMB are shown in Figure 1,
and serum levels after intake of 25 mg/kg are shown
in Figure 2. After 15 mg/kg EMB, none of the chil-
dren reached the serum target range of 2 !g/ml. After
25 mg/kg EMB, detectable serum levels were achieved
over an extended period (up to 7 h). While in children
aged 6–10 years the serum levels stayed below 2 !g/ml,
the youngest children reached serum EMB levels of
2 !g/ml after 4 h and the eldest group (10–14 years)
already exceeded this level after 2 h.
Finally, the EMB dose of 25 mg/kg was calculated
per body surface as well as per body weight (Table 1).
Figure 1 Mean serum levels of EMB (!g/ml) in children at dif-
ferent age groups after the intake of 15 mg/kg body weight EMB
in a single dose before breakfast. Source: Hussels and Otto.19
EMB & ethambutol.
Figure 2 Mean serum levels of EMB (!g/ml) in children at dif-
ferent age groups after the intake of 25 mg/kg body weight EMB
in a single dose before breakfast. Source: Hussels and Otto.19
EMB & ethambutol.
Differences in the actual doses are explained by the
smallest drug capsules available, containing 100 mg
EMB and 50 mg RMP. The dosage calculated by body
surface varies more than the dosage calculated by
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body weight in the different age groups; younger chil-
dren receive smaller doses per m2 than adults or older
children.
Figure 3 and Table 2 show pharmacokinetic data
from the second study after a dose of EMB 35 mg/
kg.20 With this dose, children in age groups 6 to #10
and 10–14 years exhibited higher mean levels of EMB
than after 25 mg/kg.20 In children in the age group 2 to
#6 years, the mean values did not reach 2.0 !g EMB/
ml at any time. The time until maximum serum con-
centrations were reached as well as the serum concen-
trations themselves differed widely between individ-
ual children.
EMB serum levels were then measured after com-
bined administration of 35 mg/kg EMB and 10 mg/kg
RMP (Table 3 and Figure 4).20 In children aged be-
tween 2 and #6 years, average EMB serum levels ex-
ceeded 2 !g/ml 3 h and 4 h after administration of the
combined drugs; mean serum levels of EMB in all age
groups were higher than after the single application of
EMB. This difference in average serum levels reached
statistical significance in the 2–6 year age group 4 h
after EMB and RMP were given in combination (P #
0.02), and was still close to statistical significance
after 5 h (P # 0.05), but was not generally significant
due to the wide variations in standard deviation.
EMB toxicity
During the time of the described studies, no child was
identified with any change in visual acuity or colour vi-
sion.19,20 To detect decreased colour vision, Panel D15-
Desaturé or Ishihara tables were used in older children,24
while those aged 2–6 years underwent only fundus-
copy and testing of colour vision (Panel D15-Desaturé).
Following these studies, until 1981, 567 children
treated with EMB in our department were examined
for ocular toxicity.15 As the standard regimen children
received a triple course of anti-tuberculosis drugs
Table 1 Comparison of dosage calculation by mg/kg body 
weight and mg/m2 body surface in the different age groups 






Calculated by mg/kg body weight
Min 24.0 24.0 22.2 —
Max 25.9 25.3 25.7 —
Mean 24.7 24.6 24.6 25.
Calculated by mg/m2 body surface
Min 555.6 625.0 688.1 —
Max 614.0 707.5 846.9 —
Mean 587.5 652.6 755.7 867.1
Source: Hussels and Otto.19
EMB & ethambutol.
Figure 3 Mean values of EMB serum concentrations (!g/ml)
after administration of 35 mg/kg EMB. Source: Hussels, Kroenig
and Magdorf.20 EMB & ethambutol.
Table 2 Mean values of EMB serum levels (!g/ml) after administration of 35 mg/kg EMB. Mean values and maximum (Cmax) 
serum levels observed in every child during the experiment were calculated. The time intervals until maximum serum levels were 
reached were also averaged and designated Tmax.
Age,
years n
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Source: Hussels, Kroenig and Magdorf.20
EMB & ethambutol.
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consisting of INH, RMP and EMB for 6 months, fol-
lowed by INH and RMP for a further 6 months, and
then INH monotherapy for 1 year. During this pe-
riod, the EMB dosage was calculated in our depart-
ment by body surface based on the standard dosage in
adults of 867 mg EMB/m2 body surface.19 Daily dos-
age in toddlers was equivalent to about 35 mg/kg
bodyweight, and decreased stepwise to a dosage of
about 25 mg/kg in adolescents.
Ocular toxicity was monitored every 4 weeks dur-
ing treatment, including funduscopy and perimetry. To
detect decreased colour vision, Panel D15-Desaturé or
Ishihara tables were used in older children.24 Children
aged 3–6 years only received funduscopy and testing
of colour vision (Panel D15-Desaturé). Of 567 chil-
dren examined, decreased colour vision was only iden-
tified in four children (0.7%): anti-tuberculosis treat-
ment of a 10-year-old with a daily dosage of 22 mg/kg
EMB had to be stopped after 3 months; two other chil-
dren (aged 4 and 8 years) had received a daily dosage
of 35 mg/kg EMB for 3 and 2 months, respectively.
Data are no longer available for the fourth child. Al-
though at that time all children were treated with higher
doses than currently recommended, the percentage of
cases of optic toxicity stayed below 1% (0.7%).
DISCUSSION
The data presented suggest that in children aged #10
years an oral dosage of 15–25 mg/kg EMB can lead to
serum levels below the MIC for M. tuberculosis of 2 !g
EMB/ml.12,21 Similar findings have been reported by
other authors.6,14,25,26 As shown above, the EMB serum
levels reached after oral administration increase with
age. Children aged between 10 and 14 years displayed
a sufficiently high serum EMB level after oral admin-
istration of 25 mg/kg. With an oral dose of 35 mg/kg,
children aged 6–10 years also had serum EMB levels
above 2 !g/ml. In children aged 2–6 years, sufficient se-
rum levels were measured after the 25 mg/kg dose, but
not after 35 mg/kg. As adsorption varies widely be-
tween individuals, these contrary findings might be due
to the small number examined in this age group (four
children). In comparison, maximum serum concentra-
tions of EMB in adults after an oral dose of 15, 25 and
50 mg/kg are 2–4, 4–6 and 8 !g/ml, respectively.1,14,16,27
In combined EMB/RMP treatment (35 mg/kg
EMB " 10 mg/kg RMP), adequate serum levels were
also reached in children aged 2–6 years (8 children
examined). In the group aged 10–14 years, EMB
serum levels after combined treatment were unusually
high.20 Consequently, it is not necessary to increase
the dosage of EMB in the age group 10–14 years to
35 mg/ml when EMB is given in combination with
RMP. While there are other data on pharmacokinetics
of EMB in children used as monotherapy, none com-
pare the serum levels of EMB in combined treatment.
Our data suggest an interaction between EMB and
RMP leading to higher EMB serum concentrations in
all age groups, although these differences do not reach
statistical significance.
The association of EMB serum levels and age might
be explained by the larger extravasal space relative to
body weight in younger children.16,17 The body com-
partments grow disproportionately, resulting in a dif-
ference in volume of distribution between children
and adults.16 As intra- and extracellular EMB concen-
trations are the same, serum concentrations give a
good estimate of therapeutic efficacy and are very use-
ful in optimising drug therapy.21,26
Not only does distribution differ between children
and adults, but so does the absorption and elimina-
tion of EMB.13,14 After oral application in adults, max-
Table 3 Maximum values of ethambutol serum levels (Cmax) 
after combined administration of 35 mg/kg EMB and 10 mg/kg 
RMP and time until these serum levels are reached (Tmax)
Age, years









Cmax, !g/ml (SD) 3.0 ('0.4) 2.8 ('0.5) 6.6 ('1.4)
Source: Hussels, Kroenig and Magdorf.20
EMB & ethambutol; RMP & rifampicin; SD & standard deviation.
Figure 4 Mean values of EMB serum concentrations after com-
bined administration of 35 mg/kg EMB and 10 mg/kg RMP. As
serum levels could not be measured in every child every hour,
the number of examined patients differ. The reasons for the drop
out are no longer available. Source: Hussels, Kroenig and Mag-
dorf.20 EMB & ethambutol.
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imum serum concentrations of EMB are reached after
approximately 2 h.13 In children aged #6 years, peak
serum levels are found approximately 4 h after inges-
tion of 25 mg/kg or 35 mg/kg EMB. This is in line with
the findings of Zhu et al., who reported an adsorption
delay in children receiving daily doses of EMB and
also described an decrease of elimination (lengthen-
ing of half-life t½) with age.14 These results suggest
not only lower serum concentrations but also a short-
ened period of maximum serum concentrations in
young children as compared to adults. The efficacy of
EMB is time-dependent, and thus the duration of ef-
fective serum levels also has to be considered when es-
tablishing optimal EMB dosage in children.3,26 Taking
into account body distribution and pharmacokinetic
parameters of EMB in children, it would appear to be
better to calculate the dosage in relation to body sur-
face rather than body weight. However, these calcula-
tions might not always be convenient in daily prac-
tice, especially under the conditions often found in
developing countries. On the basis of our calculations
using body surface, we therefore consider an EMB
dosage of 35 mg/kg for children aged #10 and of 25
mg/kg EMB for children aged (10 years as adequate.
Finding the optimum dosage means a balance be-
tween efficacy and toxic effects. Efficacy of EMB in
adult pulmonary TB is evaluated by negativity of spu-
tum culture.12,28,29 In children, the efficacy of anti-
tuberculosis regimens is measured by clinical im-
provement, the number of relapses or the reduction of
bacteria in sputum cultures, although TB in children
is mostly paucibacillary and cultures are often initially
negative.29 Of 567 children treated with standard
combination therapy for TB in the local department
until 1981, 364 children were followed up for at least
2 years after the end of treatment. Only three relapses
of TB (0.8%) were observed during this period.15
Regarding side effects, the use of EMB with higher
dosages always raises the concern of ocular toxicity
leading to optic neuritis, causing decreased visual acu-
ity, blurred vision and the loss of red/green colour vi-
sion. Ocular toxicity is related to dosage and duration
of treatment and is fortunately usually reversible after
cessation of therapy.8,22,30
In adults, ocular toxicity has been associated with
EMB daily doses )25 mg/kg and hence higher serum
concentrations; it occurs in 3–6% of patients.14,31 Lei-
bold showed a dose-dependent toxicity of EMB in
adults. Of 59 patients with EMB dosages )35 mg/kg/
day, 11 developed ocular toxicity, but only two did so
when receiving EMB dosages below 30 mg/kg/d.30
Several studies that included ophthalmological
follow-up have been performed in children using daily
EMB dosages between 13 and 25 mg/kg.32–34 Apart
from one case (an 11-year-old child) with slight
oedema of the optic disk after 7 months of treatment,
no changes in visual evoked potentials or any sign of
optic neuritis were reported in these studies.32–34 As
shown in our studies, maximum serum concentrations
after ingestion of EMB are generally lower in children
than in adults. In a recently published review, Donald
et al. assumed that the rare EMB toxicity is due to the
considerably lower serum concentrations reached in
children.5,6 Although children in our department were
treated with EMB dosages of up to 35 mg/kg/day in
combined treatment, the frequency of visual side ef-
fects stayed below 1% (0.7%; 4/567 children).15 This
indicates that children who are exposed to the serum
concentrations similar to those among adults are not
exposed to a higher risk of ocular toxicity. However,
some cases of optic neuritis have been reported with
low doses in adults, showing that there is no so-called
‘safe’ dosage of EMB, but rather some kind of drug-
incompatibility independent of dose-related toxic-
ity.12,13,35 Although EMB toxicity occurs quite rarely,
it has to be kept in mind that in developing countries,
where EMB finds its main application, regular moni-
toring of vision cannot be guaranteed.
Limitations of our studies are the small number of
patients in whom serum concentrations were mea-
sured. The investigations were conducted more than
30 years ago, and some details of the methods and re-
cruitment of the patients are no longer available.
CONCLUSION
Our results add to the sparse pharmacokinetic data for
the use of EMB in children. An adequate dosage is es-
sential for the efficacy of anti-tuberculosis treatment,
especially in the era of multidrug-resistant tuberculo-
sis. Due to differences in pharmacokinetics and phar-
macodynamics, EMB serum levels in children are
lower than those in adults receiving similar oral mg/kg
doses. Therefore, recent recommendations for oral
dosage of EMB in childhood might be too low. For
the efficient treatment of childhood TB, our data in-
dicate that the dosage should be calculated according
to body surface area based on the standard dosage in
adults of 867 mg EMB/m2, leading to an equivalent
dosage of 25 mg/kg EMB in children aged (10 years
and 35 mg/kg in children aged #10 years. It has been
demonstrated that these comparatively high dosages
are efficient without increasing the rate of ocular tox-
icity. More studies with larger numbers of patients are
needed on the pharmacokinetics and side effects of
EMB in different paediatric age groups.
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R É S U M É
CONTEXTE : L’éthambutol (EMB) est utilisé comme qua-
trième médicament dans le traitement antituberculeux en
pédiatrie. Dans les recommandations actuelles, le dosage
d’EMB est calculé par kilogramme de poids corporel.
OBJECTIF : Ce travail présente deux études investigant
un dosage approprié d’EMB chez les enfants ainsi que des
données observationnelles sur sa toxicité et son efficacité.
SCHÉMA : Les niveaux sériques d’EMB chez les enfants
de différents groupes d’âge ont été déterminés après ad-
ministration unique de l’EMB ainsi qu’après EMB en
combinaison avec rifampicine ; on a élaboré les dosages
optimalisés. L’efficacité et la toxicité des dosages d’étham-
butol ont été examinées rétrospectivement.
RÉSULTATS : Les niveaux sériques d’EMB sont plus bas
que ceux attendus chez les adultes recevant une dose orale
similaire, par suite de différences pharmacocinétiques et
pharmacodynamiques chez l’enfant. Ensuite, les enfants
ont été traités par des doses d’EMB calculées en fonction de
la surface corporelle (867 mg/m2). On a observé une toxi-
cité oculaire dans 0,7% des cas et des rechutes dans 0,8%.
CONCLUSION : Les dosages d’EMB actuellement recom-
mandés pour la tuberculose de l’enfant entraînent des
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niveaux sériques sous-thérapeutiques. Il semble plus vala-
ble de calculer la dose d’EMB sur la base de la surface
corporelle plutôt que sur le poids corporel, ce qui entraîne
des dosages plus élevés, particulièrement chez les enfants
plus jeunes. Grâce à ces dosages, les taux sériques théra-
peutiques sont atteints dans tous les groupes d’âge, ce qui
entraîne une efficacité élevée du traitement antitubercu-
leux sans accroissement de la toxicité oculaire.
R E S U M E N
MARCO DE REFERENCIA : En pediatría, el etambutol
(EMB) se emplea como cuarto medicamento en el trata-
miento de la tuberculosis. En las recomendaciones vi-
gentes, la posología del EMB se calcula por kilo de peso
corporal.
OBJETIVO : En este artículo se presentan dos estudios que
investigan la dosis adecuada de EMB en niños y los datos
observados sobre su toxicidad y eficacia.
MÉTODO : Se determinó la concentración sérica de EMB
en niños de diferentes grupos de edad, después de una
administración única y exclusiva de EMB y después de
suministrar EMB combinado con rifampicina y se defi-
nieron luego las posologías óptimas. La eficacia y la toxi-
cidad de estas pautas posológicas se analizaron en forma
retrospectiva.
RESULTADOS : Las concentraciones séricas de EMB fue-
ron inferiores a aquellas previstas en adultos que reciben
dosis equivalentes, debido a una farmacocinética y a una
farmacodinámica diferentes en los niños. A partir de este
momento, el tratamiento de los niños comportó dosis
calculadas según la superficie corporal (867 mg por m2).
Se observó toxicidad ocular en 0,7% y recaídas en 0,8%
de los casos.
CONCLUSIÓN : Las pautas posológicas de EMB vigentes
en pediatría conducen a concentraciones séricas insufi-
cientes. Pareciera más válido calcular la posología del
EMB según la superficie corporal y no según el peso, con
el fin de alcanzar dosis más altas, en particular en los
niños pequeños. Con estas pautas terapéuticas se alcan-
zan concentraciones séricas óptimas en todos los grupos
de edad y se obtiene una alta eficacia del tratamiento
antituberculoso sin aumentar la toxicidad ocular.
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Pyrazinamide (PZA) is one of the fi rst-line drugs in anti-
tuberculosis treatment. In the present study, PZA serum 
levels in 34 children aged 1 to 14 years were measured ei-
ther after oral application of PZA alone or after combina-
tion therapy with isoniazid and rifampicin. Serum levels 
did not differ statistically with age, in PZA monotherapy 
or in combination therapy. With a dosage of 30 mg /kg 
PZA, effi cient serum levels were reached. Because PZA is 
distributed uniformly in the body, serum levels are related 
to body weight, and a dose of 30 mg /kg bodyweight is 
appropriate in children.
K E Y  W O R D S :  childhood tuberculosis; pyrazinamide; 
serum levels; pharmacokinetics
PYRAZINAMIDE (PZA) is an essential component 
in the initial phase of chemotherapy regimes for tuber-
culosis (TB). Although Mycobacterium bovis is intrin-
sically resistant to PZA, the drug has highly specifi c 
intra- and extracellular activity against M. tuberculosis 
and is valued particularly for its sterilising effect and 
bactericidal activity.1 
In adults, PZA is well absorbed and well distrib-
uted when taken orally; it is hydrolysed by liver en-
zymes and excreted primarily by glomerular fi ltration. 
Although in general liver metabolisation and glomer-
ular fi ltration are assumed to be well developed by the 
age of 2 years, differences in pharmacokinetics in chil-
dren compared to adults, for example due to adsorp-
tion and distribution, are yet to be evaluated, and no 
data are available to date concerning children at dif-
ferent ages.
A study investigating PZA serum levels in children, 
performed in 1983 at the Department of Paediatric 
Pneumology and Allergology, Heckeshorn, Berlin, 
Germany, was published only nationally.2 PZA serum 
levels were measured after oral medication with PZA 
alone or in combination with rifampicin (RMP) and 
isoniazid (INH) to examine whether the resultant PZA 
serum levels differ in children of different age groups.
MATERIALS AND METHODS
Thirty-four children aged between 1 and 14 years re-
ceiving treatment for pulmonary tuberculosis (without 
extra-pulmonary manifestations) at the Department of 
Pediatric Pneumology and Allergology, Heckeshorn, 
Berlin, Germany, were enrolled in the study. The study 
was approved by the ethics committee of the Free Uni-
versity Berlin. Parents gave informed written consent 
for participation.
Twenty-one children received only PZA orally at 
30 mg /kg body weight and another 13 children also re-
ceived INH (5–10 mg /kg) and RMP (10–15 mg /kg). In-
dividual doses were administered with 100 mg PZA tab-
lets and given on an empty stomach before breakfast. 
Venipuncture was performed at 2, 3, 4, 8 and 24 h after 
medication. Samples were centrifuged within 30 min; 
PZA serum levels were determined by mass fragmen-
tography with a detection limit of 1.5 μg /ml.3 A mini-
mal inhibition concentration (MIC) of 16–32 μg /ml 
PZA was considered effective against M. tuberculosis.4
For further analysis, children were separated into 
three age groups: <6 years (monotherapy n = 8, com-
bination therapy n = 4), 6–10 years (n = 6, n = 6) 
and 10–14 years (n = 7, n = 3).
RESULTS
Mean serum levels after oral application of a single dose 
of 30 mg /kg body weight PZA alone (Figure 1) were 
not statistically different between the age groups at any 
time. Group analysis was performed using Student’s 
t-test. Peak serum levels (Cmax) were reached after 3 h 
in all age groups, with mean maximum serum levels 
of 38.1 μg /ml in children aged <6 years, 37.7 μg /ml 
in children aged 6–10 years and 39.1 μg /ml in those 
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aged 10–14 years. After combination treatment with 
RMP and INH (Figure 2), peak serum levels were 
reached after 3 h in children aged ⩾6 years and after 
2 h in children aged <6 years. Peak serum levels in the 
youngest age group (37.9 μg /ml) were higher than in 
children aged 6–10 years (31.3 μg /ml) and 10–14 years 
(33.3 μg /ml), although the differences were not statis-
tically signifi cant. 
PZA serum levels of all age groups after oral ap-
plication of 30 mg /kg PZA alone were higher than 
levels after combination treatment. However, these 
differences did not reach statistical signifi cance. 
Severe side effects were not observed. Some chil-
dren showed a slight elevation of serum uric acid. 
The number of children with side effects is no longer 
available.
The volume of distribution for PZA in combina-
tion therapy was 20.5 l/kg (standard deviation [SD] 
9.9), normalised per kg body weight 0.8 l/kg (SD 0.2) 
and in monotherapy 18.3 l/kg (SD 8.2), normalised 
0.9 l/kg (SD 0.3). There was no statistical difference be-
tween the age groups.
Regardless of whether PZA was administered alone 
or in combination, serum levels stayed above the MIC 
for M. tuberculosis (16–32 μg /ml) for more than 6 h 
in all age groups.
DISCUSSION
The data presented show that effi cient serum levels are 
reached in children of all age groups with a PZA dos-
age of 30 mg /kg body weight, with no statistically sig-
nifi cant difference between PZA administered alone 
and PZA given in combination with RMP and INH. In 
adults, PZA is absorbed almost entirely from the gastro-
intestinal tract and penetrates well into body tissues, 
reaching comparable levels in serum, cerebrospinal 
fl uid and body tissue.5,6 Assuming a one-compartment 
model, PZA serum levels are related to body weight 
rather than body surface, and the disproportionate 
growth of body compartments in children does not 
have an important impact on serum levels of PZA.5 
Our results confi rm that the same dose of PZA per kg 
body weight can be administered in children until the 
age of 14 years.
Compared to adults, in whom peak serum levels 
are found after 1–2 h, PZA is absorbed more slowly 
in children.7,8 Consistent with our fi ndings, delayed 
absorption of ⩾3 h was previously reported in chil-
dren.7 However, a recently published study found the 
PZA absorption time to be comparable in children 
and adults.9 Between the youngest and the oldest 
children in our study, there was no difference in time 
until maximum serum concentrations were reached 
in PZA monotherapy.
Figure 1 PZA serum levels in children after an oral dose of 
30 mg/kg in monotherapy. PZA = pyrazinamide; SD = standard 
deviation.
Figure 2 PZA serum levels in children after an oral dose of 
30 mg/kg in combination treatment (RMP 10–15 mg/kg + INH 
5–10 mg/kg). PZA = pyrazinamide; RMP = rifampicin; INH = 
isoniazid; SD = standard deviation.
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Maximum concentrations of PZA serum levels dif-
fer widely between individuals. In our study, mean 
maximum serum concentrations were not statistically 
different between the age groups, but were slightly 
lower than the PZA serum levels reported in adults 
receiving a similar dose per kg body weight.5,7 Mean 
maximum PZA serum levels in children were above 
32 μg /ml in all age groups, and therefore well above 
the MIC for M. tuberculosis.4
Boulahbal et al. reported that PZA peak serum 
levels in adults were up to 40% lower when adminis-
tered in combination than in monotherapy, and at-
tributed this to modifi cations in intestinal absorption 
of PZA or in liver enzyme induction.10 In our study in 
children, PZA serum levels were also slightly lower 
when PZA was given in combination therapy, but these 
differences did not reach statistical signifi cance. Re-
garding the effi cacy of PZA at the site of infection, 
PZA is only active in vitro against M. tuberculosis in 
acidic environments. The surface of a pulmonary cav-
ity, for example, is basic, while in caseous tissue and 
in macrophages the environment is acidic.2 There is 
nevertheless some evidence that PZA does kill myco-
bacteria in the walls of pulmonary cavities despite the 
alkaline environment in vivo, raising uncertainty 
about the MIC of PZA.11
CONCLUSION
PZA serum levels after an oral dosage of 30 mg/kg 
do not differ between children of all age groups up to 
the age of 14 years suffering from TB, regardless of 
whether PZA is given alone or in combination with 
INH and RMP. The question as to whether effi cient 
serum levels can be achieved with lower oral dosages 
of PZA of 25 mg/kg (range 20–30), as currently recom-
mended by the World Health Organization for adults 
and children, was not discussed in this study.12 There 
seems to be evidence that even dosages as low as 15 mg/ 
kg might be effi cient in children, but large studies in 
children are scarce.9
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R É S U M É
R E S U M E N
Le pyrazinamide (PZA) fait partie du traitement de pre-
mière ligne de la tuberculose. Dans cette étude, les niveaux 
sériques de PZA ont été mesurés chez 34 enfants âgés de 
1 à 14 ans, soit après administration du seul PZA par voie 
orale, soit après un traitement combiné comportant 
également l’isoniazide et la rifampicine. Il n’y a pas eu de 
différences signifi catives des niveaux sériques ni en fonc-
tion de l’âge, ni en fonction du traitement par PZA en 
monothérapie ou en combinaison. Avec une dose de PZA 
de 30 mg /kg, on atteint des niveaux sériques effi cients. 
Comme le PZA se distribue de manière uniforme dans 
l’organisme, les niveaux sériques sont en relation avec le 
poids corporel et une dose de 30 mg /kg de poids corpo-
rel est appropriée chez les enfants.
La pirazinamida (PZA) es un medicamento de primera 
línea en el tratamiento de la tuberculosis. En el presente 
estudio se midió la concentración sérica de PZA en 
34 niños entre 1 y 14 años, después de su ingestión oral 
aislada o en asociación con isoniazida y rifampicina. No 
se observó variación estadísticamente signifi cativa de la 
concentración sérica de PZA con la edad en la monotera-
pia ni en el tratamiento mixto. Con una dosis de 30 mg /
kg, se alcanzaron concentraciones séricas efi cientes. Puesto 
que la PZA se distribuye en forma uniforme en el cuerpo, 
existe una correlación entre la concentración sérica y el 
peso corporal y una dosis de 30 mg /kg es apropiada en 
los niños.
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B A C K G R O U N D :  Rifampicin (RMP) is an essential drug 
in paediatric anti-tuberculosis treatment. The current 
World Health Organization (WHO) guidelines recom-
mend an oral dosage of 10 (8–12) mg per kg body 
weight.
O B J E C T I V E :  To present a study investigating RMP se-
rum levels in children after oral medication of RMP 
alone and after combination treatment with ethambutol 
(EMB).
D E S I G N :  RMP serum levels in children of different age 
groups were determined after a single oral administra-
tion of 10 mg/kg RMP alone as well as after combina-
tion with 35 mg/kg EMB.
R E S U LT S :  RMP serum levels were lower than those ex-
pected in adults receiving a similar oral dose. RMP se-
rum levels in combination treatment were even lower 
than in monotherapy.
C O N C L U S I O N :  Currently recommended RMP dosages 
in childhood tuberculosis lead to serum levels lower than 
those recommended for adults, probably due to different 
pharmacokinetics and pharmacodynamics in children. 
In children, it appears to be more valid to calculate RMP 
dosage on the basis of body surface area rather than body 
weight, leading to higher dosages especially in younger 
children.
K E Y  W O R D S :  childhood tuberculosis; rifampicin; se-
rum levels; pharmacokinetics
WITH AN ESTIMATED 1 million cases worldwide 
each year, paediatric tuberculosis (TB) is a serious 
health problem.1 Rifampicin (RMP) is an important 
pillar in modern short-course treatment regimens, and 
RMP resistance is a disaster for both patients and con-
trol programmes.2 RMP has moderate early bacteri-
cidal activity (EBA) against Mycobacterium tuberculo-
sis, but in combination with isoniazid (INH), its 
sterilising ability is unique.3 RMP is well absorbed 
from the gastrointestinal tract and distributes exten-
sively throughout the body despite a protein binding 
of 80%.4,5 It is metabolised in the liver mainly by acet-
ylation to 25-O-desacetyl-rifampicin, which is also ac-
tive against M. tuberculosis and excreted through the 
bile and, to a lesser extent, through urine.4–7 In adults, 
serum levels of the order of 10 μg/ml occur 2 h after 
a single oral dose of 600 mg RMP, and are associated 
with effi cacy in clinical studies.4,5,8,9 As the principles 
of anti-tuberculosis treatment in children do not differ 
from those for adults, children should be exposed to 
the same serum levels.10 The RMP dosage for children 
currently recommended by the World Health Organi-
zation (WHO) and the American Thoracic Society 
(ATS) is respectively 10 (8–12) and 10–20 mg per kg 
bodyweight.11–13
Children experience signifi cant changes during 
growth, not only in height and weight, but also in the 
relative size of the body compartments as well as in 
their ability to absorb, metabolise and excrete drugs, 
leading to pharmacokinetics that differ from those in 
adults. There is a lack of pharmacokinetic data on 
anti-tuberculosis drugs in children and fundamental 
uncertainties about age-appropriate RMP dosage.14
A study in children investigating RMP serum levels 
performed in 1973 at the Department of Paediatric 
Pneumology and Allergology, Chest Hospital Hecke-
shorn, Berlin, Germany, was published only nation-
ally at the time.15 These fi ndings were never made ac-
cessible to the international medical community, and 
they are thus presented here.
RMP serum levels were measured in children of 
different age groups after oral medication with RMP 
alone and in combination with ethambutol (EMB). 
EMB pharmacokinetics were also studied, and the 
data on EMB were published previously.16
MATERIALS AND METHODS
Previously untreated children diagnosed with pulmo-
nary TB at the Department of Paediatric Pneumology 
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and Allergology, Chest Hospital Heckeshorn, Berlin, 
Germany, were included in the study in 1973. Twenty-
seven children aged between 2 and 14 years were en-
rolled in the study, which was approved by the ethics 
committee of the Free University Berlin. Parents gave 
informed written consent for participation. Serum 
levels were studied after the fi rst dose of RMP was 
given. After completion of all study measurements, 
standard multidrug anti-tuberculosis treatment was 
initiated.
In the fi rst part of the study, children received a 
single dose of RMP orally at 10 mg/kg body weight. 
In the second part, 10 mg/kg RMP in combination 
with 35 mg/kg EMB was given as a single dose after 
an adequate wash-out time of 1 week. Tablets were 
administered on an empty stomach after overnight 
fasting. Venipuncture was performed at 1, 2, 3, 4, 5, 7 
and 24 h after medication. Samples were centrifuged 
within 30 min and the serum stored at –18°C.
RMP serum levels were measured by a microbio-
logical method based on the agar diffusion disc tech-
nique in a modifi cation previously described.17 This 
was the standard technique 30 years ago, at the time 
the study was performed. A staphylococcus strain 
highly sensitive to RMP was used as the indicator 
strain. As staphylococcus strains are less sensitive to 
the main metabolite of RMP, desacetyl-rifampicin, 
than M. tuberculosis, assays with Staphylococcus au-
reus slightly underestimate the total activity against 
M. tuberculosis.18 As the S. aureus strain was EMB-
resistant, combination treatment had no infl uence on 
measurements of RMP, and RMP levels could also be 
determined when both drugs were given in combina-
tion. For further analysis, children were separated 
into three age groups: 2–<6 years (n = 7), 6–<10 
years (n = 11) and 10–14 years (n = 9).
The mean RMP serum levels of all children were 
calculated for each time point. The means of the max-
imum serum levels (Cmax) as well as the time until 
these levels were reached (Tmax) were determined. 
Group analysis was performed using Student’s t-test. 
The area under the serum concentration-vs.-time 
curve from time 0 to 7 h (AUC0–7h) was determined 
by the linear trapezoideal rule.
RESULTS
The mean RMP serum levels after oral application of 
10 mg/kg are shown in Figure 1 and the mean serum 
levels after combined administration of RMP (10 mg/
kg) plus EMB (35 mg/kg) are shown in Figure 2. Ta-
bles 1 and 2 show the Cmax and standard deviations 
(SDs), Tmax, mean half-life and the AUC0–7h of RMP 
after single and combined treatment, respectively. 
The mean serum levels of the different age groups 
showed a high variability, with mean maximum se-
rum levels of 6.5–7.1 μg/ml in monotherapy and 4.5–
5.4 μg/ml in combination therapy. Mean maximum 
serum concentrations in children aged <6 years after 
single and after combined drug administration tended 
to be lower than those found in the older children, al-
though these differences fail to reach statistical signif-
icance. Compared to monotherapy, the mean maxi-
mum serum levels in combined therapy were lower in 
all age groups. These differences in maximum serum 
levels were up to 2.0 μg/ml, but again fail to reach 
statistical signifi cance, probably due to the small sam-
ple size and a high variability in individual serum 
concentrations (data not shown). The mean Tmax was 
Figure 2 Mean serum levels of RMP among children in different 
age groups after combined administration of RMP 10 mg/kg + 
EMB 35 mg/kg body weight. RMP = rifampicin; EMB = 
ethambutol.
Figure 1 Mean serum levels of RMP among children in differ-
ent age groups after the intake of RMP 10 mg/kg body weight 
in a single dose. RMP = rifampicin.
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3.5– 4.3 h in all children, with only minor differences 
between the age groups and independently of whether 
monotherapy or combination therapy was received. 
Again, variability was high. 
The elimination half-life was 1.9–2.6 h in mono-
therapy and 2.1–2.5 h in combination therapy. Chil-
dren aged >10 years seemed to eliminate RMP faster 
than those aged <6 years. The AUC0–7h in all age 
groups on monotherapy was greater than that for 
combination therapy. In monotherapy, the AUC0–7h 
rose with age, while in combination therapy the age 
group 6–10 years had a lower AUC0–7h than the young-
est children, whereas children aged >10 years had the 
highest AUC0–7h.
DISCUSSION
In this study, RMP serum levels after oral intake of 
RMP alone and in combination with EMB in children 
of different age groups are described.
In children aged between 2 and 14 years, after a 
dosage of 10 mg/kg RMP is given, RMP serum levels 
are lower than those observed in adults after a stan-
dard dose of 600 mg. RMP serum levels in children 
are even lower if RMP is given in combination with 
EMB. RMP serum levels in adults after a standard oral 
dose of 600 mg RMP are in the range of 8–24 μg/ml 
2 h postdose.19,20 Serum levels in children in single or 
in combination therapy found in our study are even 
below the lower limit.
As low drug concentrations reduce therapeutic ef-
fi cacy, higher doses of RMP than those currently rec-
ommended by the WHO (8–12 mg/kg) might there-
fore be necessary.11
Lower RMP serum levels after oral administration 
in children have been reported previously.4,5,21,22 Se-
rum levels in children treated with 10 mg/kg body-
weight were found to correspond to one third to one 
tenth of that in adults receiving 600 mg, and thus were 
similar to those in adults treated with a dose of 250 mg 
RMP.4 On the other hand, serum levels of 9–11 μg/ml 
were found in another study in children where 10 mg/
kg RMP was used as prophylaxis against Haemophi-
lus infl uenzae type b disease.23 This might be partly 
explained by the use of RMP suspension in this study, 
which could lead to improved RMP absorption. As a 
special in-house preparation for the RMP suspension 
was used, its pharmaceutical formulation might also 
differ from commercially available products, with pos-
sible impact on its pharmacokinetics and pharmaco-
dynamics.
To our knowledge, no other studies have compared 
RMP serum levels in children after monotherapy with 
combination therapy with EMB. Similar to our fi nd-
ings in children, a decreased RMP area under the curve 
(AUC) has been reported in adults when the drug is 
given in combination with EMB.22 Findings of serum 
levels of RMP given in combination therapy with INH 
are confl icting: both higher and lower RMP levels, as 
well as no change, have been described.22–26 However, 
in combination therapy with INH and pyrazinamide 
(PZA), serum concentrations of RMP do not seem to 
differ from those with monotherapy.24,26,27
In the study, only a two-drug combination of 
RMP+EMB was examined to exclude the infl uence 
from other drugs, although in anti-tuberculosis treat-
ment RMP is rarely given in combination with EMB 
alone. As the differences in RMP serum levels in mono- 
and combination therapy with EMB are not statisti-
cally signifi cant, no conclusion can be drawn about 
Table 1 Mean RMP serum levels and SDs among children in 
different age groups after intake of RMP 10 mg/kg in a single 
dose
2–<6 years










1 0.8* <0.4* 1.2*
2 1.5* 1.5* 1.9*
3 5.2 (1.9) 4.1 (1.3) 5.2 (0.2)
4 4.7 (0.9) 5.7 (1.1) 5.1 (0.6)
5 3.9 (0.6) 5.1 (0.9) 4.3 (0.7)
7 2.1 (0.3) 3.0 (0.4) 2.1 (0.2)
24 <0.4 <0.4 <0.4
Cmax 6.5 (1.2) 7.1 (1.2) 6.6 (0.8)
Tmax, h [min–max] 3.8 [3.0–5.0] 4.0 [4.0–5.0] 3.5 [1.5–5.0]
t1/2, h 2.1 2.6 1.9
AUC0–7h, µgh/ml 20.15 21.75 22.75
*As variability was high, SDs were not calculated. 
RMP = rifampicin; SD = standard deviation; Cmax = maximum serum level; 
Tmax = time to maximum serum level; t1/2 = elimination half-life; AUC0–7h = 
area under the serum concentration vs. time curve from time 0 to time 7 h.
Table 2 Mean RMP serum levels and SDs after ingestion of 
10 mg/kg RMP in combination with 35 mg/kg EMB in children 
in different age groups
2–<6 years
(n = 7) 
µg/ml (SD)
6–<10 years







1 <0.4* 0.5* <0.4*
2 0.5* 0.9* 0.6*
3 2.8 (1.0) 2.3 (0.7) 3.1 (0.6)
4 4.0 (1.1) 2.9 (0.6) 4.4 (0.8)
5 3.8 (0.9) 3.5 (0.7) 4.7 (0.7)
7 1.9 (0.3) 2.8 (0.8) 2.8 (0.4)
24 <0.4 <0.4 <0.4
Cmax 4.5 (1.1) 5.3 (0.7) 5.4 (0.6)
Tmax, h [min–max] 4.0 [3.5–5.0] 3.7 [2.0–5.0] 4.3 [3.0–5.0]
t1/2, h 2.5 2.2 2.1
AUC0–7h, µgh/ml 14.90 13.60 17.95
* As variability was high, SDs were not calculated. 
RMP = rifampicin; SD = standard deviation; EMB = ethambutol; Cmax = max-
imum serum level; Tmax = time to maximum serum level; t1/2 = elimination 
half-life; AUC0–7h = area under the serum concentration vs. time curve from 
time 0 to time 7 h.
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the clinical relevance of the lower RMP serum levels 
in combination therapy found in our study.
After oral intake of RMP, absorption from the in-
testinal tract is almost complete in adults, and peak 
serum levels are found after 2 h.4,19,28 In children, ab-
sorption seems to be delayed, and peak serum levels 
were found after 4 h in our study, in line with previ-
ously reported fi ndings.4
Unlike RMP absorption, there seems to be no major 
difference in elimination half-life (t½) between adults 
and children. In adults, the t½ is dose-dependent, and 
ranges from 2.3 h to 5.1 h, which is in line with our 
results and previously described fi ndings of an aver-
age t½ of 2.9 h in children after a 10 mg/kg dose of 
RMP.7,23
To explain these lower serum levels in children, 
different pharmacokinetic aspects have to be consid-
ered. Food has been shown to signifi cantly reduce the 
absorption of RMP.29 However, the children in our 
study received medication after overnight fasting.
Many more factors, such as gastric pH, gastric 
emptying, intestinal transit time, functional absorp-
tive area, metabolic capacity and carrier mechanisms 
or drug transporters in the gastrointestinal tract, in-
fl uence gastro-intestinal absorption of a drug.19,30 
However, as gastric pH, gastric emptying and intesti-
nal transit time reach adult values within the fi rst 
year of life, they would have a marginal infl uence on 
serum levels in older children compared to adults.31 A 
decrease in the functional absorptive area of the in-
testine in TB patients has also been considered to ex-
plain reduced serum levels.19 A prehepatic metabolism 
of RMP was described previously, probably localised 
in the gut wall in adults.32 However, very little is known 
about the metabolic capacity or maturation of drug 
transporters in the gut wall in children and their in-
fl uence on the quantity and time of absorption.30
Not only has delayed absorption been described in 
children but also a bioavailability of only 50% after 
oral administration of RMP.33 RMP is well distrib-
uted throughout the body. As about 25% of the drug 
is ionised at a physiological pH, while the molecule as 
a whole is lipid-soluble, RMP concentrations in the 
various tissues of the human body differ.6,7
Observed differences in peak serum levels have 
mainly been attributed to age-related differences in 
extracellular body water compartments, which de-
crease from 45–60% in newborns to approximately 
20% in adulthood.4,7,22,31
Although RMP is a strong inducer of the cyto-
chrome P450 system, RMP itself is mainly metabolised 
in the liver by B-esterases.34,35 Most liver enzymes 
mature after the fi rst year of life.31 As the half-life for 
serum levels and the appearance of RMP in the urine 
are similar in children and adults, maturation of these 
two systems probably has only a minor infl uence on 
RMP serum levels.4–6
The low maximum serum concentrations found in 
this study raise further questions regarding the clini-
cal effi cacy of RMP at a dosage of 10 mg/kg in child-
hood TB. In an in vitro study, it was shown that the 
effi cacy of RMP is dependent on concentration rather 
than time.36 This was also shown to be valid in vivo 
by a concentration-dependent drop in colony-forming 
units of M. tuberculosis in the sputum of patients with 
pulmonary TB as well as in clinical trials with different 
doses of RMP.3,37,38 The EBA of a 1200 mg RMP dose 
was almost double that found at a dose of 600 mg 
RMP in adults.39 Clinical outcome, as manifested by 
a lower rate of sputum conversion and a higher rate 
of treatment failures, was less good in patients with 
TB treated with dosages of 450 mg RMP per day than 
in patients treated with 600 mg per day.38 RMP se-
rum levels of 6–7 μg/ml, as found among children in 
our study, correspond to expected serum levels in 
adults after a dose of only 300– 450 mg.4
Comparison of study results might be diffi cult be-
cause of the different analytical methods used. In the 
present study, a microbiological agar diffusion tech-
nique was used for the determination of RMP con-
centration, which was found to yield results that are 
essentially identical to those of high-performance liq-
uid chromatography used today.22 The staphylococcal 
strains used in the microbiological assay in this study 
are less sensitive to the main active metabolite of RMP, 
desacetyl-rifampicin, than M. tuberculosis. In adults, 
the metabolite concentrations are about 10% of those 
of the parent drug, and the total activity against M. tu-
berculosis might therefore be slightly under estimated 
in our study.18 The amount of desacetyl- rifampicin of 
the parent drug in children is not known.
In children as well as in adults, there is consider-
able intra- and inter-individual variation in RMP se-
rum levels, limiting the signifi cance of data obtained 
from small study groups.4,5,15 Taken together, a uni-
form dosage of 10 mg/kg RMP does not appear to be 
appropriate in children of all age groups, and espe-
cially not in children aged <6 years. In adults, RMP 
serum levels in continuous treatment are lower than 
at the beginning of treatment due to self-induction of 
RMP metabolisation.4 As serum levels in this study in 
children were measured at the beginning of treatment, 
it implies that they would be even lower in continu-
ous treatment. It is possible that even a single dose of 
RMP induces its own metabolisation; this could ex-
plain in part the lower RMP concentrations in com-
bination therapy, where RMP is given for the second 
time.
As many physiological functions, including the wa-
ter compartments at various ages, are proportional to 
body surface area (BSA), dosing according to body 
surface might be more appropriate.40 An RMP dos-
age of 300 mg/m2 BSA given to children at the age of 
3 months to 2.9 years leads to mean RMP serum levels 
of 9.1 μg/ml, which is close to the desired serum level 
of 10 μg/ml.29 We therefore assumed that effi cient 
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serum levels should be achieved with an RMP dos-
age in children corresponding to the adult value of 
350 mg/m2 BSA (standard BSA in adults of 1.73 m2 
and a standard RMP dose of 600 mg), although these 
suggestions need to be validated by further studies. 
These calculations lead to a dosage of 15 mg/kg RMP 
in toddlers and young children, decreasing to 10 mg/kg 
RMP in adolescents.41 ATS dosage recommendations 
of up to 20 mg/kg are even higher.13
Higher dosages always raise concerns about side 
effects. The most common side effects of RMP include 
gastrointestinal intolerance, elevation of liver enzymes 
and, in intermittent regimens, which are rarely ap-
plied to children, a fl u-like syndrome.35,42 RMP also 
turns urine, stool, sweat and plasma red. In adults, 
side effects are observed more frequently in doses 
above 900 mg.27
Reports of side effects of RMP in children are 
scarce. After an intravenous dosage of RMP of 20 mg/
kg given to children, adverse effects (mainly cutane-
ous reactions) were observed frequently (fi ve of nine 
patients).42 In standard oral anti-tuberculosis regi-
mens in children, RMP seems to be well tolerated.37 
After the single dose of RMP and EMB, none of the 
children in our study showed any side effect. In 567 
children treated in our department between 1970 and 
1980 for TB with a three- or four-drug regimen con-
sisting of RMP, INH, EMB and PZA, the effi cacy and 
toxicity of anti-tuberculosis treatment was evaluated 
retrospectively.41 Only minor hepatotoxic side effects 
corresponding to RMP were found in 1.8% of the 
children.41
CONCLUSION
According to our study, the currently recommended 
RMP doses in childhood TB result in lower serum 
levels than in adults, running the risk of lower clinical 
effi cacy.11–13,20 Doses based on body surface (350 mg/
m2) might be more adequate for children. Larger stud-
ies are needed to validate these data and to base RMP 
doses in children on well-founded evidence. 
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C O N T E X T E  :   La rifampicine (RMP) est un médicament 
essentiel dans le traitement antituberculeux chez les en-
fants. Selon les recommandations actuelles de l’Organi-
sation mondiale de la Santé, le dosage oral est de 10 (8–
12) mg par kg de poids corporel.
O B J E C T I F  :   Investiguer les niveaux sériques de RMP 
chez les enfants après administration orale de RMP seule 
ou après traitement en combinaison avec l’éthambutol 
(EMB).
S C H É M A  :   Les niveaux sériques de RMP chez les enfants 
de différents groupes d’âge ont été déterminés après une 
administration unique de 10 mg/kg de RMP seule ainsi 
qu’après sa combinaison avec 35 mg/kg d’EMB. 
R É S U LTAT S  :   Les niveaux sériques de RMP sont plus 
faibles que ceux attendus chez les adultes recevant une 
dose orale similaire. Les niveaux sériques de RMP dans 
les traitements en combinaison sont même plus faibles 
qu’en cas de monothérapie.
C O N C L U S I O N  :   Les dosages de RMP actuellement re-
commandés pour la tuberculose de l’enfant entraînent 
des taux sériques plus faibles que ceux recommandés chez 
les adultes, probablement en raison de différences phar-
macocinétiques et pharmacodynamiques chez l’enfant. 
Chez les enfants, il semble plus valable de calculer la 
dose de la RMP sur base de la surface corporelle plutôt 
que sur base du poids corporel, ce qui entraînerait des 
doses plus élevées, particulièrement chez les jeunes 
enfants. 
M A R C O  D E  R E F E R E N C I A  :   La rifampicina (RMP) es un 
medicamento esencial en el tratamiento de la tuberculo-
sis (TB) en los niños. Según las recomendaciones vigentes 
de la Organización Mundial de la Salud, la dosis oral es 
de 10 mg (8–12 mg) por kilogramo de peso corporal. 
O B J E T I V O  :   Analizar las concentraciones séricas alcan-
zadas con la administración oral de RMP sola o asociada 
con etambutol (EMB) en una población infantil. 
M É T O D O S  :   Se determinaron las concentraciones séricas 
de RMP en niños de diferentes grupos de edad, después 
de la administración de una dosis única de10 mg/kg de 
RMP y de una asociación con 35 mg/kg de EMB. 
R É S U LTA D O S  :   Las concentraciones séricas de RMP 
fueron inferiores a las previstas en adultos que reciben 
una dosis oral equivalente. Con la administración com-
binada, las concentraciones de RMP fueron aún más 
bajas que con la monoterapia.
C O N C L U S I Ó N  :   Las dosis recomendadas actualmente 
para los niños en el tratamiento de la TB originan con-
centraciones séricas inferiores a las recomendadas en los 
adultos, probablemente en razón de las diferencias de la 
farmacocinética y la farmacodinamia. Pareciera que en 
los niños, el cálculo de la dosis de RMP en función de la 
superfi cie corporal fuese más adecuado que con respecto 
al peso ; esto implica pautas posológicas más altas, sobre 
todo en los niños más pequeños.
R É S U M É
R E S U M E N
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Introduction 
 Isoniazid (INH) is one of the most important drugs 
for the treatment of tuberculosis (TB) caused by drug-
susceptible Mycobacterium tuberculosis. It is valued 
for its high early bactericidal activity in the initial 
phase of treatment, as well as for its important role in 
preventing drug resistance during the intensive phase 
of treatment [1]. It is also recommended for preven-
tive chemotherapy of TB infection in children [2]. 
 INH is completely absorbed after oral admi-
nistration, with peak serum levels after 1–2 h and 
distributed widely intra- and extracellularly in a com-
partment corresponding to the total body water [3]. 
INH is not appreciably bound to plasma protein. It 
is mainly acetylated in the liver and the small intes-
tine to acetyl-isoniazid. The capacity for acetylation 
is genetically determined and a trimodality in elimi-
nation of INH has been demonstrated [4]. Therefore 
in humans there are slow, intermediate and fast 
acetylators. Only little INH is excreted unmetabo-
lized in the urine. 
 Although INH has been used for half a century 
in the treatment of childhood TB, there is still 
disagreement on the dose recommendations for 
children, partly due to the limited data on INH 
pharmacokinetics in children. Very recently the World 
Health Organization (WHO) increased the recom-
mended daily oral dose of INH in children to 10–15 
mg/kg bodyweight (BW), being the same dose rec-
ommended by the Centers for Disease Control and 
Prevention (CDC) [5,6]. Current British Thoracic 
Society (BTS) guidelines recommend only 5 mg/kg 
BW for both adults and children [7]. Several studies 
have suggested higher doses of INH [8–11]. In a 
recently published study, McIlleron et al. state that 
younger children require INH doses of 8–12 mg/kg 
BW to achieve INH concentrations similar to those 
in adults after a 5 mg/kg BW dose [10]. 
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 Abstract 
 Isoniazid (INH) is one of the most important drugs for the treatment of tuberculosis (TB). In the current international 
recommendations there is still disagreement on the optimal dosage of INH in childhood TB. This paper presents data from 
2 studies, one performed in 1960 and the other in 1961, investigating INH serum levels in children of different age groups, 
not yet presented internationally. Doses were calculated according to bodyweight (BW) as well as according to body surface 
area (BSA). In the fi rst study, INH serum levels at different time points in children of different age groups were determined 
after oral INH administration at 5 mg/kg BW. In the second study, INH serum levels were measured once, 4 h after sub-
cutaneous application of 5 mg/kg BW and once, 4 h after subcutaneous application of INH 200 mg/m 2  BSA 1 week later. 
These data was compared to adult data on INH collected prior to these studies. After application of 
5 mg/kg BW oral dose, INH serum levels were much lower in children than in adults at all time points, especially in children 
younger than 8 y. In contrast, after dosing according to 200 mg/m 2 BSA, similar serum levels were achieved in children 
and adults. Dose recommendations of INH 5 mg/kg BW in childhood TB lead to lower serum concentrations than those 
recommended for adults. In children, it appears to be more appropriate to calculate the INH dose on the basis of body 



















































Stellenbosch University  https://schola.sun.ac.za
 Isoniazid pharmacokinetic studies of the 1960s 295
 In the light of the ongoing discussion, we present 
data from 2 pharmacokinetic studies performed in 
the early 1960s at our institute – the Chest Hospital 
Heckeshorn, Berlin [12,13]. These fi ndings have 
not previously been accessible to the international 
medical community. 
 Methods 
 Both studies included previously untreated children 
diagnosed with pulmonary TB at the Department 
of Paediatric Pneumology and Allergology, Chest 
Hospital Heckeshorn, Berlin, Germany. The studies 
were approved by the Ethics Committee of the Free 
University Berlin. Parents gave written informed 
consent for participation. Serum levels were studied 
after the fi rst and second dose of INH. 
 After completion of all study measurements, 
standard multidrug treatment was initiated. At the 
time of the study the standard combination therapy 
was INH, para-aminosalicylic acid (PAS) and strep-
tomycin. 
 Blood samples were centrifuged within 30 min 
and the serum stored at –18°C. INH levels were 
measured by a biological method based on the agar 
diffusion technique in a modifi cation previously 
described [14]. The highly sensitive Mycobacterium 
tuberculosis H37Ra was used as indicator strain 
[14]. At the time of the study this was the standard 
technique. In contrast to the chemical and radio-
chemical methods used today, the biological method 
measured all biologically active INH. 
 In the fi rst study, 20 children aged between 1 and 
13 y were enrolled [12]. Children received a single 
dose of INH orally at 5 mg/kg BW. Tablets were 
administered on an empty stomach after an over-
night fast. Venipuncture was performed before med-
ication and 1, 2, 4 and 6 h after medication. For 
analysis, children were separated into 3 age groups: 
1 to !4 y ( n " 7), 4 to !8 y ( n " 7) and 8–13 y ( n " 6). 
In a previous study, data for 24 adults also receiving 
INH 5 mg/kg were collected at the same institute 
[12]. The area under the serum concentration-
versus-time curve from time 0 to 6 h (AUC 0 – 6 ) was 
determined by the linear trapezoidal rule. 
 In the second study, another 25 children aged 
between 1 and 13 y were enrolled [13]. In the same 
children, INH was given subcutaneously at a dose 
according to bodyweight as well as according to 
body surface area (BSA). Subcutaneous application 
was a common form of drug administration in 
children at the time of the study. In the fi rst part, 
children received a dose of 5 mg/kg BW and in the 
second part, after an adequate wash-out time of 
1 week, the dose was 200 mg/m 2 BSA. This is based 
on the standard dosage in adults of 200 mg/m 2 , 
which corresponds to a dosage of 5 mg/kg BW in an 
adult of 70 kg [13]. The children did not receive 
other anti-tuberculosis treatment during this week. 
None of the children were acutely ill and all were 
clinically stable. Again, data from adults ( n " 22) 
collected in previous studies at our institute were 
added. 
 In both parts of the second study (INH dose of 
5 mg/kg BW and 200 mg/m 2 BSA), INH serum lev-
els were measured only once, 4 h after medication. 
The time point of 4 h was chosen because in previous 
data on INH pharmacokinetics in adults collected 
at the Chest Hospital Heckeshorn, Berlin, it was 
shown that inter-individual differences are less after 
4 h than at other time points [12]. Also, at the time 
of the studies the discrimination between slow and 
fast acetylators of INH was based on the INH serum 
level 4 h after medication. Genetic determination of 
acetylator status was not yet available. 
 Results 
 Mean serum levels of INH in children of different age 
groups as well as adults after oral intake of 5 mg/kg 
BW at different time points are shown in Figure 1; 
the corresponding AUC 0 – 6  are shown in Table I. The 
curve progression in adults and children showed sim-
ilar results, but INH serum levels were much lower 
in children than in adults at all time points, especially 
in children younger than 8 y. Accordingly, the AUC 
for 0–6 h was much smaller in younger children. As 
only the mean values of the INH serum levels were 
still available for this presentation, an analysis for sta-
tistical signifi cance could not be made. 
 Table II shows the mean INH serum levels 
4 h after subcutaneous medication. In comparison to 
adults, INH serum levels in children after dosing 
5 mg/kg BW were only about half of the values found 
in adults after the same per kg dose. In contrast, after 
Figure 1. Mean serum levels of isoniazid (INH; µg/ml) after oral 
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 Table I. Area under the curve (AUC, µg/h/ml) after oral medication 
of isoniazid 5 mg/kg bodyweight. 
Age
1–4 y 
( n " 7)
4–8 y 
( n " 7)
8–13 y 
( n " 6)
Adults 
( n " 24)
AUC 0 – 6 9.75 7.4 13.2 16.2
Table II. Mean isoniazid levels 4 hafter subcutaneous isoniazid 
medication according to bodyweight (5 mg/kg) and body surface 
area (200 mg/m2).
Mean INH levels 4 h after 
subcutaneous medication with:
Age n 5 mg/kg BW 200 mg/m2 BSA
1–13 y (all children) 25 0.99 1.82
1–4 y  2 -a -a
4–8 y 13 1.10 1.93
8–13 y 10 1.14 1.99
adults 22 2.05 2.05
INH, isoniazid; BW, bodyweight; BSA, body surface area.
aData not calculated.
dosing 200 mg/m 2 BSA, similar serum levels were 
achieved in children as in adults. 
 Figure 2 shows a dosing curve based on our 
calculations of 200 mg INH/m 2 BSA for children 
weighing up to 50 kg .
 Discussion 
 The presented data from 2 previous studies 
performed in 1960 and 1961 show that serum 
levels of INH in children after oral or subcutaneous 
dosing according to BW are lower than in adults 
receiving the same per kg dose. Similar serum 
levels in children and adults can be achieved if 
the paediatric dose is calculated according to BSA 
(200 mg/m 2  BSA). 
 As can be seen in Figure 1, INH serum levels in 
children after an oral dose of 5 mg/kg BW INH are 
lower than in adults at all time points measured. 
The mean maximum serum concentration is reached 
in all groups after 1 h and conforms to previous 
reports [3,15]. 
 If INH is given subcutaneously at the same mg/
kg dose, INH serum levels also differ between chil-
dren and adults. There are no further data comparing 
INH pharmacokinetic parameters after oral and sub-
cutaneous dosing. However, in the study of Olson 
et al., after intramuscular administration of INH in 
children, nearly equivalent plasma concentrations to 
the oral dose were reached [15]. Nevertheless, some 
uncertainty remains regarding whether or not sub-
cutaneous and oral application of INH lead to the 
same serum levels, as large studies comparing these 
2 application forms have never been performed. Due 
to INH acetylation in the gut wall, INH serum levels 
after oral intake might be lower than after parenteral 
medication [3]. In the 2 study groups presented, the 
4 h INH serum levels were similar whether INH was 
given orally or subcutaneously. 
 Lower INH serum levels in children compared 
to adults have been described previously [8,10,11]. 
They have been explained by the larger liver mass 
relative to whole bodyweight in children, leading to 
a higher hepatic metabolic capacity than in adults 
[8,11]. In infants the metabolism of INH is further 
infl uenced by the ongoing maturation of hepatic and 
renal functions. Furthermore, the body compart-
ments grow at different rates, resulting in different 
volumes of distribution between children and adults. 
Younger children have a larger volume of distribu-
tion of INH in comparison to older children and 
adults [3,8,10]. INH distributes in a compartment 
comparable to total body water. During growth, 
the proportion of total body water to bodyweight 
changes from 70% at birth to 50% in adulthood 
[16,17]. As total body water closely correlates to 
BSA, INH dosing according to BSA has been sug-
gested [10,18,19]. 
 The presented data show that after subcutaneous 
application, INH serum levels comparable to adults 
can be achieved in young children if the INH dose 
is calculated according to BSA rather than BW. How-
ever, these calculations might not always be conve-
nient in daily practice, especially under conditions 
often found in developing countries. On the basis of 
our calculations using BSA, we created a graph on 
which the INH dose for each BW can simply be read 
off (Figure 2) [19]. This corresponds approximately 
to a dose of 8–10 mg/kg BW in children aged 0–5 y, 
7–8 mg/kg BW for age 6–9 y, 6–7 mg/kg BW for age 
10–14 y and 5–6 mg/kg BW for age 15–18 y. These 
calculations are based on data after subcutaneous 
Figure 2. Isoniazid (INH) dose according to 200 mg INH/m2 body 
surface area for children up to 50 kg bodyweight. (As no difference 
in serum levels could be found after oral and subcutaneous 
application of INH 5 mg/kg, we adapted these calculations based 
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application of INH. In our studies in children, the 
INH serum levels after oral and subcutaneous appli-
cation were similar. We therefore assume that these 
calculations are valid for oral intake of INH as well. 
It has also previously been shown for ethambutol that 
dosing according to BSA is more appropriate in 
childhood tuberculosis [20]. Recently it has been 
proposed that weight to the power of ¾ should be 
used for calculating paediatric drug doses [21]. It 
remains to be shown whether these calculations lead 
to INH serum levels equivalent to those achieved in 
adults. 
 Studies indicate a dose-related response to INH 
with a maximum early bactericidal activity at a dose 
of 300 mg (4–6 mg/kg BW) in adults [22]. According 
to extensive pharmacokinetic studies in adults, the 
proposed INH peak concentration after oral intake 
is 3–5 µg/ml [23–25]. In the presented study, this is 
barely achieved in children younger than 8 y after 
oral intake of INH 5 mg/kg BW. 
 A microbiological method was used for the 
determination of INH serum levels. This method 
might overestimate INH concentrations because 
both INH and metabolites with anti-TB activity 
were measured [3,14,26]. In the presented investi-
gations INH metabolites were not measured sepa-
rately. Hence, INH serum levels in children younger 
than 8 y after an oral dose of 5 mg/kg BW might 
actually be lower than indicated by these presented 
studies. 
 INH is mainly eliminated through acetylation by 
the N-acetyltransferase 2 (NAT2) enzyme system, 
which shows a trimodal distribution [3,4,11]. 
Individuals may be homozygotic fast, heterozygotic 
fast or homozygotic slow acetylators of INH, also 
leading to differences in INH exposure in children 
[4,11]. In homozygotic fast acetylators, lower INH 
serum levels are achieved than in slow acetylators. 
The time of exposure to therapeutic serum levels is 
shorter in fast acetylators due to the faster elimina-
tion of INH [11]. At the time of the presented stud-
ies, determination of NAT2 genotype was not 
available and a phenotypical differentiation of the 
acetylator status was not performed in this study 
group. 
 Whether the acetylator status should be taken 
into consideration for dosing of INH in adults as well 
as in children is still part of the ongoing discussion 
[10,27]. 
 Limitations of the presented studies are the small 
number of patients in which serum concentrations 
were measured. Especially in young infants who have 
potentially important differences in physiology to 
older children (e.g. maturation of metabolic enzymes), 
the number of patients was limited. The investiga-
tions were conducted nearly 50 y ago and some of 
the patient data necessary for statistical analysis are 
no longer available. Nevertheless, this data contrib-
utes to our knowledge of INH pharmacokinetics in 
childhood TB and to the ongoing discussion on 
dose regimens. Due to the small number of pharma-
cokinetic studies on INH in childhood, an agree-
ment on INH dose has still not been reached. More 
data are urgently needed for children across ranges 
of age, weight and body composition in order to 
establish the superiority of surface area-based dosing 
for the oral route. 
 Conclusions 
 In children younger than 8 y an INH dose of 5 mg/kg 
BW, as recommended by some international author-
ities, given either orally or subcutaneously, leads to 
lower serum levels than in adults receiving the same 
per kg dose [6,7,12,13]. The effi cacy of maximum 
serum levels of 3–5 µg/ml in adults has been shown 
in extensive studies [22–24]. With an INH dose of 
200 mg/m 2 BSA (in this study given subcutaneously), 
serum levels comparable to those in adults are also 
achieved in younger children. 
Declaration of interest: The authors report no 
confl icts of interest. The authors alone are respon-
sible for the content and writing of the paper.
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Summary Objective: The aminoglycosides and polypeptides are vital drugs for the manage-
ment of multidrug-resistant (MDR) tuberculosis (TB). Both classes of drug cause hearing loss.
We aimed to determine the extent of hearing loss in children treated for MDR-TB.
Methods: In this retrospective study, children (<15 years) admitted to Brooklyn Chest Hospital,
Cape Town, South Africa, from January 2009 until December 2010, were included if treated for
MDR-TB with injectable drugs. Hearing was assessed and classified using audiometry and otoa-
coustic emissions.
Results: Ninety-four children were included (median age: 43 months). Of 93 tested, 28 (30%)
were HIV-infected. Twenty-three (24%) children had hearing loss. Culture-confirmed, as op-
posed to presumed, diagnosis of TB was a risk factor for hearing loss (OR: 4.12; 95% CI:
1.13e15.0; p Z 0.02). Seven of 11 (64%) children classified as having hearing loss using audi-
ometry had progression of hearing loss after finishing the injectable drug.
Conclusions: Hearing loss is common in children treated for MDR-TB. Alternative drugs are re-
quired for the treatment of paediatric MDR-TB.
ª 2012 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Abbreviations: MDR, multidrug-resistant; DR, drug-resistant; TB, tuberculosis; WHO, World Health Organization; PTA, pure tone audiome-
try; OAE, otoacoustic emission; DPOAE, distortion product otoacoustic emission; BCH, Brooklyn Chest Hospital; IM, intramuscular; ASHA,
American Speech and Hearing Association; OR, odds ratio; CI, confidence intervals; IQR, inter-quartile range.
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Introduction
Multidrug-resistant (MDR) tuberculosis (TB) is an evolving
global challenge with the World Health Organization (WHO)
estimating there to be over 650,000 prevalent cases of
MDR-TB in 2010.1 MDR-TB is caused by Mycobacterium tu-
berculosis resistant to at least isoniazid and rifampicin.2
As paediatric TB constitutes 15e20% of all TB cases in
high burden settings,3,4 a large number of children are
likely to be affected by MDR-TB. Due to the paucibacillary
nature of the pathology, few cases of paediatric MDR-TB
have traditionally been accurately diagnosed or appropri-
ately treated, but with the imminent roll-out of molecular
diagnostic tests,5,6 these numbers are likely to rise. In addi-
tion to the difficulties in diagnosis, treatment is frequently
required for greater than twelve months and is associated
with significant adverse effects.7e9
The aminoglycosides (amikacin and kanamycin), to-
gether with capreomycin (a polypeptide), are classified as
group two drugs by WHO. These injectable second-line
agents are vital for the management of MDR-TB.2 Although
strains resistant to rifampicin but susceptible to isoniazid
can be treated with slightly less intense regimens, these ri-
fampicin mono-resistant (RMR) cases are usually treated as
MDR-TB in most National TB Programmes. This is due to the
limitations of modern molecular diagnostic tests which ei-
ther do not test for isoniazid resistance10 or miss a signifi-
cant proportion of cases which have phenotypic
resistance.11 In most circumstances rifampicin resistance
is seen as a surrogate for multidrug resistance.
Both the aminoglycosides and polypeptides are known to
have adverse effects that include renal and eighth cranial
nerve impairment.12e14 The effects on the kidneys are
thought to be temporary but those on the vestibulo-
cochlear system are permanent.15,16 Hearing loss related
to injectable TB drug use usually starts in the high frequen-
cies and if treatment continues, there is progression to the
lower frequencies required for communication; however, in
some cases severe hearing loss can develop acutely. Hear-
ing is vital not only for effective communication but also
for neurological development. Children with hearing defi-
cits have delayed developmental and communication mile-
stones compared to children with normal hearing.17e19
Hearing testing for children is performed for two
reasons. The first is to identify and quantify hearing loss
to enable the provision of support, education, training and
hearing aids. The second is to identify hearing loss early,
when it is mild and only at high frequencies, so that
treatment, where possible, can be changed to prevent
further damage. The testing of hearing is challenging in
children. Pure tone audiometry (PTA) is the method of
choice for testing adults and allows the testing of different
frequencies and amplitudes in both ears independently.20
PTA is only possible in children on therapy who are able
to understand commands and co-operate with testing,
which effectively precludes its use in children younger
than five years. As young children are at high risk of devel-
oping TB following infection and as young children bear the
brunt of the epidemic in many settings,21 this means that
many children are excluded from this form of testing. Audi-
tory brainstem response (ABR) testing is the optimal testing
methodology for young children22 but is only available in
South Africa in specialist centres. Otoacoustic emission
(OAE) testing can assess cochlear patency in younger chil-
dren and is widely available. OAEs are not fully validated
for quantifying hearing loss and do not provide as compre-
hensive an assessment as PTA or ABR. Although the technol-
ogy is improving for OAEs, with newer tests able to provide
diagnostic evaluations, due to the difference in testing
methodology it is not possible to directly compare OAE
and PTA. In some studies correlation has been shown to
be good between the two types of testing in children,23
but in others, significant discrepancies are seen.24 OAE in
South Africa is currently used as a screening test.
The frequency and severity of hearing loss is unknown in
children treated for MDR-TB with injectable medications.
Some data are available for children given these injectable
drugs as short antibiotic courses for the treatment of other
bacterial infections.13,25 Some data regarding ototoxicity
are available for adults treated for MDR-TB,26 but few stud-
ies have examined the adverse effects of injectable drugs
in children treated for MDR-TB. The aim of this study was
to determine the frequency and extent of hearing loss in
children treated with an aminoglycoside or polypeptide as
part of an MDR-TB regimen.
Methods
Setting and standard of care
The Western Cape Province of South Africa had a TB
notification rate of 976 per 100,000 in 2009.27 Amongst chil-
dren routinely diagnosed with culture-confirmed TB at a ter-
tiary hospital in the Province, 8.9% were identified as
MDR.28 Children with MDR- and RMR-TB present to various
regional health centres but once diagnosed and stabilized
all children requiring injectable TB medications are trans-
ferred to Brooklyn Chest Hospital (BCH). BCH is a specialist
TB hospital with a sixty bed paediatric capacity.
MDR-TB (or RMR-TB) is diagnosed as confirmed or pre-
sumed disease. A confirmed diagnosis is made when M. tu-
berculosis is isolated using liquid culture with
demonstrated resistance.28 A presumed diagnosis is made
if the child had symptoms, signs and/or radiology highly
suggestive of TB in the presence of either a drug-resistant
source case or when the child was failing first-line TB ther-
apy. Routine hearing testing for children treated with in-
jectable TB medications was introduced in 2008. Children
are assessed prior to starting injectable drugs and then
monthly. If there are challenges to testing or if abnormali-
ties are found, testing is carried out every two weeks.
Where hearing loss is determined, treatment with the in-
jectable medication is (if possible without compromising
treatment efficacy) stopped or switched to an alternative
medication. Children with severe hearing loss are referred
for hearing aids and educational support. Children are
treated for MDR- and RMR-TB with amikacin (20 mg/kg
once daily via intramuscular [IM] injection) for between
four and six months. Children treated for isolates resistant
to amikacin are treated with capreomycin (20 mg/kg once
daily IM) or streptomycin (20 mg/kg once daily IM) depen-
dent on drug susceptibility test results. Amikacin is used
in preference to kanamycin due to the availability of
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smaller ampoule size available (less wastage), its lower
minimal inhibitory concentration compared to kanamycin
and capreomycin, and the anecdotal impression that injec-
tions are less painful.
Study population
This retrospective study included all children routinely
admitted to BCH from January 2009 until December 2010,
aged 0e15 years, if they had been a) diagnosed with
confirmed or presumed MDR- or RMR-TB, were b) treated
with an injectable TB drug for at least a month, and c) had
received at least one audiological assessment.
Audiological assessments
Children were assessed using a combination of otoscopy,
tympanometry, PTA (including conditioned play audiome-
try) and/or distortion product otoacoustic emissions
(DPOAEs). Otoscopy was used to ensure that there were
no anatomical abnormalities and that the external ear
canal was clear of occluding wax, foreign bodies or
obstruction. A Welch Allyn 262 tympanometer (MFI Medical
Equipment Inc. San Diego, USA) was used to assess middle
ear function using a 226 Hz probe tone. The probe was
placed into the child’s ear canal ensuring a tight seal with
no leakage. Static compliance between 0.2 and 1.8 cm3,
middle ear pressure between þ100 and "150 dekapascals,
and ear canal volume of 0.2e2.0 cm3 were used. If a type
B tympanogram (indicating possible middle ear infection)
was noted, the audiologist would notify the attending phy-
sician. A five day course of oral antibiotics was usually pre-
scribed before reassessment. If the problem persisted, the
child was referred to the ear, nose and throat team.
PTAwas performed in a sound-proof boothwith calibrated
equipment. The AC40 dual channel audiometer (Interacous-
tics, Assens, Denmark) and the MA51 audiometer (MAICO
DiagnosticsGmbH,Berlin,Germany)wereused.Pure toneair
conduction hearing thresholds were obtained for children
between six and fifteen years of age, for each ear by testing
the octave bands from 250 Hz to 8 kHz. Audiologists followed
the modified Hughson-Westlake procedure29 (i.e. 10 dB
down, 5 dB up, repeated twice to reliably determine hearing
threshold). Stimuli were presented in the following order:
1 kHz, 2 kHz, 4 kHz, 8 kHz, repeated at 1 kHz, then 500 Hz
and 250 Hz. If there was a difference of 20 dB between con-
secutive frequencies the audiologist would test half octave
frequencies, i.e. 750 Hz, 1.5 kHz, 3 kHz and 6 kHz. For partic-
ipants younger than six years, either conditioned play audi-
ometry or DPOAE were performed. For descriptive purposes
we considered thresholds of <25 dB as normal, 26e40 dB as
mild, 41e55dBasmoderate, 56e70dBasmoderately severe,
71e90 dB as severe and >90 dB as profound hearing
impairment.30,31
DPOAEs were obtained using an OtoRead! machine
(Interacoustics, Assens, Denmark). A rubber-tipped probe
was placed in the external ear canal to create a tight seal.
Two simultaneous pure tone signals were then presented to
each ear at two different primary frequencies (f1 and f2,
where f2 > f1) with f1:f2 ratio of 1.22 and an intensity of
65 dB Sound Pressure Level (SPL) and 55 dB SPL
respectively. Frequencies 2 kHz, 4 kHz, 6 kHz, 8 kHz,
10 kHz and 12 kHz were tested. In order for a child to
pass the DPOAE, the emission amplitude needed to be
6 dB or greater above the noise floor. If a child was unable
to be tested for any reason, or if the test was abnormal,
they were re-tested two weeks later. If the child passed
the DPOAE, then they were assessed monthly. DPOAE re-
sults were classified as pass, fail or unable to test.
Data collection
BCH admission records were reviewed to identify all
patients treated for MDR- and RMR-TB over the study
period. Records were compared with data from the audi-
ology department to determine which of the patients had
received audiological testing. Clinical records were re-
viewed to determine the dosage and duration of injectable
treatment, demographic and clinical details, as well as
audiological and laboratory data.
Data classification and analysis
We drew a distinction between hearing deficit and hearing
loss. Hearing deficit describes the absolute impairment in
hearing experienced by a child at treatment completion
whereas hearing loss is a measured deterioration in hearing
function between two assessments. Children could there-
fore have hearing deficit at the end of treatment but if
previous assessments were not carried out, hearing loss
could not be determined. Conversely, it was possible for
children to have hearing deficit at the beginning and at the
end of treatment, but to experience no hearing loss
between assessments.
Hearing deficit assessed by PTA was classified as, at the
last hearing assessment, a threshold of greater than or
equal to 25 dB at any tested frequency, in the presence of
normal tympanograms. When testing using OAEs, a classifi-
cation of hearing deficit was made if the child failed the
assessment in the presence of normal tympanograms. When
assessed using PTA, hearing loss was classified according to
the American Speech and Hearing Association (ASHA)
guidelines: a) an increase in pure tone thresholds of greater
than or equal to 20 dB at any one test frequency, b) an
increase of greater than or equal to 10 dB at any two
adjacent test frequencies, or c) a loss of three consecutive
frequencies.20,32,33 A diagnosis of hearing loss using OAE
was made if the child failed the assessment in the presence
of normal tympanograms having passed a previous assess-
ment. The classification of hearing deficit and hearing loss
used is shown in Table 1.
Risk factors for hearing loss were determined by com-
paring the frequency or mean/median value for children
with hearing loss (determined by both PTA and OAE) vs.
children without. Chi square (or Fisher’s Exact) tests,
student t-tests or Mann Whitney tests were used; odds ra-
tios (OR) and 95% confidence intervals (CIs) calculated.
Ethical considerations
Ethical approval for this retrospective study was obtained
from the Ethics Committees of Stellenbosch University
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(which oversees paediatric research at BCH) and the
London School of Hygiene and Tropical Medicine.
Results
Patient characteristics
Ninety-four children were included in the study from 113
who were started on injectable treatment for MDR-TB
(Fig. 1). Median age was 43 months (inter-quartile range
[IQR]: 20e110). Forty-five (48%) were boys and 30 (32%)
had evidence of extrapulmonary TB. Children were gener-
ally malnourished with weight-for-age z-scores a mean of
1.48 standard deviations below the reference mean and
median body mass index of 15.5 kg/m2 (IQR: 14.5e17.3).
Fifty-two (55%) had a culture-confirmed diagnosis and the
majority (62 children; 66%) were treated for MDR-TB. The
other children either had disease with more extensive resis-
tance or were started on treatment for MDR-TB but were
later confirmed to have less resistant organisms. Twenty-
eight children (out of 93 tested; 30%) were HIV-infected
of which 20 (71%) were already on antiretroviral therapy
at the start of TB treatment. Most children (n Z 82; 87%)
were treated with amikacin (Table 2).
Audiological testing
Thirty-six children were assessed using PTA and 58 assessed
using OAEs. Hearing deficit is demonstrated in Fig. 1, and
hearing loss in Fig. 2. When combining results of both PTA
and OAE testing, 23 (24%) children had hearing loss and 27
(29%) had normal hearing. Forty-four (47%) children could
not be classified using this approach. In 7 of the 11 children
who had hearing loss determined by PTA (Table 3), hearing
loss progressed even after the injectable medication was
discontinued. In no child who had been shown to have hear-
ing loss did his/her hearing improve on subsequent testing.
Assessment of risk factors for hearing loss
A culture-confirmed diagnosis of TB (OR: 4.12; 95% CI:
1.13e15.0; p Z 0.02) was significantly associated with
Table 1 Classification of hearing deficit and hearing loss using otoacoustic emissions and pure tone audiometry.
Otoacoustic emissions Pure tone audiometry
Hearing deficit No hearing deficit # A normal OAE in the last
month of therapy or after
completing injectable medication
# All frequencies better than 25 dB
in the last month of or after
completing injectable medication
with no subsequent abnormal tests
Hearing deficit # An abnormal OAE in the
presence of normal tympanograms
# Any frequency greater than 25 dB at
any point before, during, or after
therapy in the presence of normal
tympanograms
Unable to classify # Abnormal tympanograms
# Unable to test child due to
noise or child unable to co-operate
#Normal OAE but performed
before the last month of therapy
# Abnormal tympanograms
# Unable to test child due to noise or
child unable to co-operate
Hearing loss No hearing loss # A normal OAE in the last month
of therapy or after completing
injectable medication
# A normal PTA (all frequencies better
than 25 dB) in the last month of or after
completing injectable medication with
no subsequent abnormal tests or
# No significant deterioration (as determined
by ASHA criteria)1 between an audiogram
performed before or within the first month
of therapy and one performed after within
the last month of therapy with no subsequent
deterioration
Hearing loss # A normal OAE documented before
or during therapy followed by an
abnormal OAE in the presence of
normal tympanograms
# A significant deterioration (as determined
by the ASHA criteria)1 between an audiogram
performed before or during therapy and one
performed later during therapy or after
completing therapy in the presence of
normal tympanograms
Unable to classify # Normal final OAE but performed
before the last month of therapy
# Abnormal tympanograms
# Abnormal OAE throughout therapy
# Unable to test child due to noise or
child unable to co-operate
# An abnormal audiogram without an earlier
audiogram for comparison
# A normal final audiogram (all frequencies
better than 25 dB) before the last month
of therapy
# Abnormal tympanograms
# Unable to test child due to noise or child
unable to co-operate
OAE: otoacoustic emission; PTA: pure tone audiometry; ASHA: American Speech and Hearing Association.
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hearing loss (Table 4). There was a trend towards the me-
dian duration of injectable antibiotic use being longer in
children with hearing loss: (164 days; IQR: 119e184 vs.
123; IQR: 70e183; p Z 0.07).
Discussion
We have demonstrated that both hearing deficit and
hearing loss are common in children treated for MDR-TB.
The association between hearing loss and culture-
confirmed TB disease may reflect the extent or severity of
disease and might suggest that treating clinicians are more
likely to continue injectable drug use in children with
extensive pathology. However, it is also possible that some
aspect of having severe disease, such as changes in in-
flammation, altered immune response or differing drug
absorption and elimination may contribute to hearing loss.
Since we aimed to describe children with definitive hearing
loss or normal hearing, we developed a classification
system which precluded the accurate classification of
a relatively large number of children. However, despite
our conservative estimates, over half of the children had
hearing deficit at the end of therapy and a quarter of
children experienced hearing loss.
In addition to documenting the risk and degree of
hearing loss in children treated for MDR-TB, our study
highlights some of the challenges in the assessment of
hearing in children, including the classification of hearing
deficit and hearing loss. Hearing testing is partially sub-
jective, requires relatively sophisticated equipment,
trained staff and co-operative patients. Elements of the
frequency (pitch), amplitude (volume), laterality (unilat-
eral or bilateral) and aetiology (sensorineural, conductive
or both) need to be considered; all of these factors need to
be monitored longitudinally and change classified. We
adhered to the established ASHA criteria to classify
whether hearing loss occurred between two PTA assess-
ments. However, we developed a classification system to
determine whether children in this study should be classi-
fied as having hearing loss or not. This lack of established
existing criteria limits meaningful comparisons between
different studies.
Several studies have documented the treatment of MDR-
TB, mainly in adults; only a handful have systematically
assessed hearing loss and analysed risk factors for ototox-
icity. De Jager et al. found no association between clinical
or treatment factors and the incidence of hearing loss.34
Peloquin et al. assessed whether the size and frequency
of dosage affected hearing loss and found no association,
but demonstrated that older age and cumulative dose
were associated with an increased risk.35 Sturdy et al.
found that impaired renal function, older age and the use
of amikacin were associated with hearing loss in adults
treated for MDR-TB.36 A number of studies describe cohorts
including small numbers of children but few have included
those less than ten years of age. Only two previous paediat-
ric studies examine the adverse effects of children on
treatment for MDR-TB. The first describes 38 children
treated in Peru; 30 underwent hearing assessments.8 The
testing methodology and classification was not specified;
audiology testing was undertaken in children receiving an
injectable for more than six months. Two children were
found to have mild, high-frequency, conductive hearing
loss. The second was carried out in Lesotho where six out
of 19 (32%) children developed hearing loss.37 Studies of
short courses of aminoglycoside use in neonates38 and chil-
dren with cystic fibrosis39 demonstrate limited toxicity but
assessment of hearing loss in children receiving longer
courses of aminoglycosides following liver transplantation
Figure 1 Hearing deficit in children treated for multidrug-resistant tuberculosis with second-line injectable drugs. Percentages
calculated from the number of children meeting eligibility criteria (n Z 94).
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found hearing loss in 15 of 66 children evaluated, using
a 35 dB loss at one frequency to define hearing loss.40
Hearing has particular relevance in children since they
need hearing to develop skills and acquire language. The
primary means of education is through oral teaching.
Hearing loss during childhood can therefore have profound
implications for development.17e19,41e44 If ototoxicity is
identified early, rapid intervention can be
implemented.45,46
Our study has a number of strengths and limitations. We
report the largest study to date documenting hearing loss in
children treated for MDR-TB and assess risk factors for
hearing loss using a robust classification system. We report
on hearing loss resulting from care provided under routine,
programmatic conditions. The retrospective nature of the
study limited systematic data collection; therefore some
audiological assessments were missing, irregular or incom-
plete. Clinical parameters were determined from routine
data and were incomplete in some instances. One partic-
ular example was the lack of information regarding pre-
vious TB treatment which may have influenced hearing loss.
Our findings may not be representative of all children
treated for MDR-TB since we report on children admitted
to hospital. Also, as so few children were treated with drugs
other than amikacin, it was not possible to assess the
relative toxicity of different drugs. Finally, we were unable
to classify and analyse a considerable number of children
due to the rigorous classifications used and we did not have
Table 2 Demographic and treatment data in children treated for multidrug-resistant tuberculosis (n Z 94).
Characteristic Number (% unless
indicated otherwise)
Median age in months (IQR) 43 (20e110)
Male gender 45 (47.9)
Type of TB Pulmonary 64 (68.1)
Extrapulmonary 17 (18.1)
Both extrapulmonary and pulmonary 13 (13.8)
Site of extrapulmonary TB (n Z 30) Miliary 1 (3.3)
Pleural effusion 2 (6.7)
TB meningitis 8 (26.7)
Abdominal TB 4 (13.3)
Lymph node TB 6 (20.0)
Musculoskeletal TB 9 (30.0)
Median weight in kg (IQR) 13.5 (10.1e21.2)
Median height/length in cm (IQR) (n Z 90) 93 (78e121)
Median MUAC in cm (IQR; n Z 83) 15.3 (14e17)
Mean weight for age z-score (SD) "1.48 (1.55)
Median BMI (IQR) 15.5 (14.5e17.3)
Certainty of TB diagnosis Culture-confirmed 52 (55.3)
Presumed 42 (44.7)






HIV-infected (n Z 93) 28 (30.1)
On ART prior to TB diagnosis (n Z 28) 20 (71.4)
Type of injectable drug given Amikacin 82 (87.2)
Capreomycin 9 (9.6)
Streptomycin 1 (1.1)
Two or more injectables 2 (2.1)
Mean dose of injectable drug (mg; SD) 320 (189)
Mean dose of injectable drug (mg/kg; SD) 19.4 (2.04)
Mean duration of injectable drug uses (days; SD) 136.2 (51.6)
IQR: inter-quartile range; TB: tuberculosis; MUAC: mid upper arm circumference; BMI: body mass index; DST: drug susceptibility testing;
HIV: human immunodeficiency virus; ART: antiretroviral therapy; DS: drug-susceptible; HMR: isoniazid-monoresistant; RMR: rifampicin-
monoresistant; MDR: multidrug-resistant; XDR: extensively drug-resistant; Pre-XDR-TB: MDR-TB with additional resistance to either a flu-
oroquinolone or an injectable medication but not both.
Confirmed diagnosis: M. tuberculosis isolated from child with resistance demonstrated.
Presumed diagnosis: child treated for MDR-TB due to a clinical diagnosis of TB and either contact with an MDR-TB source case or follow-
ing failure of first-line therapy.
a These three children were started on treatment for MDR-TB due to contact with an MDR-TB source case but were subsequently found
to have DS- or HMR-TB.
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pharmacokinetic data for children on the injectable drugs
to correlate with toxicity.
Despite these factors, we document that hearing loss
occurs in at least a quarter of children treated with
a second-line injectables for MDR-TB. Clinicians should
give careful consideration to the use of injectable medica-
tions. Children should be screened prior to beginning
injectable medications with either PTA or OAE (dependent
Figure 2 Hearing loss in children treated for drug-resistant tuberculosis with second-line injectable drugs (n Z 94).
Table 3 Characteristics of children treated for multidrug-resistant tuberculosis with hearing loss determined using pure tone
audiometry (n Z 11).
Age Gender HIV
status
DST Diagnosis Treatment Hearing loss




Unilateral severe high frequency hearing loss at
the first assessment carried out one month after
the start of treatment. One month later bilateral
severe high frequency hearing loss so injectable
stopped. No further hearing loss.
10 yr Girl Pos MDR Confirmed PTB 5 ½ months
amikacin
Normal hearing at baseline and at monthly
intervals whilst on therapy. Moderately severe
high frequency hearing loss detected two months
after competing injectable treatment.
5 yr Girl Neg MDR Confirmed PTB 6 months
amikacin
Normal hearing at baseline and throughout
therapy. At the end of therapy found to have
unilateral moderate high frequency hearing loss.
10 yr Boy Neg MDR Confirmed LN TB 6 months
amikacin
Normal hearing at baseline and throughout
therapy. At the end of therapy found to have
moderately severe unilateral high frequency
hearing loss. A further month later found to have
bilateral moderately severe high frequency loss.
10 yr Girl Neg MDR Confirmed PTB 6 months
amikacin
Normal hearing at baseline and throughout
therapy. Two months after completing therapy
found to have unilateral high frequency moderate
loss.
12 yr Boy Pos MDR Confirmed PTB 8 months
amikacin
Normal hearing at baseline. After four months
found to have unilateral moderate high frequency
loss, progressing to severe unilateral high
frequency loss by the end of therapy and to
bilateral high frequency loss, severe in one ear
and moderate in the other by 4 months after
finishing.
13 yr Boy Pos MDR Confirmed PTB 6 months
amikacin
Normal hearing at baseline and monthly
throughout treatment. At end of therapy found to
have bilateral moderately severe high frequency
loss.
(continued on next page)
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on age) and should be screened at least every month. If it is
possible without compromising MDR-TB treatment, inject-
able drugs stopped or switched if there are any audiological
concerns. Monitoring for hearing should continue after the
drug has been stopped and therapeutic drug monitoring
should be considered. Certain inherited mitochondrial
mutations have been shown to predispose patients to
hearing loss47e50 and there is evidence that aspirin and L-
carnitine may offer some protection.51,52 These require fur-
ther investigation, as does the relationship between dose
schedule, resulting drug serum concentration and toxicity.
Pharmacokinetic data on the use of injectable drugs in
children treated for MDR-TB are limited and there are no
pharmacodynamic data. New, safer and effective drugs
for the treatment of MDR-TB are urgently needed in
children.
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Table 4 Univariate assessment of risk factors of hearing loss in children treated for multidrug-resistant tuberculosis.
Hearing loss (n Z 23) No hearing loss (n Z 27) Or (95% CI) P-value
Age in months (IQR) 52 (28e132) 53 (25e120) 0.90
Male gender 9 11 0.94 (0.30e2.95) 0.91
EP involvement 9 6 2.25 (0.63e8.00) 0.20
WFA z-score "1.07 ("2.29e0.32) "0.82 ("2.34e0.33) 0.78
BMI in kg/m2 (IQR) 15.9 (13.9e17.6) 16.1 (14.9e17.3) 0.48
MUAC in cm (IQR) 15.0 (14.0e17.0) 16.4 (14.5e18.1) 0.28
Culture-confirmed diagnosis of
TB
17 11 4.12 (1.13e15.0) 0.02
HIV-infected 9 6 2.14 (0.60e7.63) 0.23
Amikacin use 21 24 0.76 (0.11e5.11) 0.78
mg/kg dose injectable (IQR) 19.6 (18.3e20.4) 19.4 (17.4e20.1) 0.30
Duration of injectable in days
(IQR)
164 (119e184) 123 (70e183) 0.07
Pre-XDR or XDR-TB 4 5 0.93 (0.21e4.01) 0.92
EP: extrapulmonary; WFA: weight-for-age; BMI: body mass index; MUAC: mid upper arm circumference; HIV: human immunodeficiency
virus; XDR: extensively drug-resistant; OR: odds ratio; CI: confidence interval.
Table 3 (continued )
Age Gender HIV
status
DST Diagnosis Treatment Hearing loss
8 yr Girl Pos MDR Confirmed PTB 2 ½ months
amikacin
Normal hearing at first assessment one month
after starting therapy. After two months found to
have bilateral moderately severe high frequency
loss. After stopping the injectable, hearing loss
progressed to severe bilateral hearing loss
affecting all frequencies. Hearing aid required.
3 yr Boy Neg MDR Confirmed LN TB 4 months
amikacin
Normal hearing at baseline. Found to have
moderate unilateral high frequency loss after four
months so injectable stopped. No further tests
carried out.
12 yr Girl Neg MDR Presumed PTB 5 months
amikacin
Normal hearing at baseline and at the end of
therapy. One month after completing injectable
medications found to have moderate unilateral
high frequency loss, progressing to bilateral high
frequency loss (mild in one ear and moderately
severe in the other) after a further month.
10 yr Girl Pos MDR Confirmed PTB 4 months
amikacin
Found at first assessment (2 months after starting
therapy) to have bilateral moderate high
frequency loss. By 2 months after completing
therapy high frequency loss progressed in one ear
to severe.
HIV: human immunodeficiency virus; TB: tuberculosis; RMR: rifampicin-monoresistant; MDR: multidrug-resistant; PTB: pulmonary TB;
LN: lymph node.
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Objectives: To describe the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children
and evaluate the adequacy of steady-state exposures.
Patients and methods: We used previously published data for 76 South African children with tuberculosis to
describe the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid. Monte Carlo simulations
were used to predict steady-state exposures in children following doses in fixed-dose combination tablets in
accordance with the revised guidelines. Reference exposures were derived from an ethnically similar adult popu-
lation with tuberculosis taking currently recommended doses.
Results: The final models included allometric scaling of clearance and volume of distribution using body weight.
Maturation was included for clearance of isoniazid and clearance and absorption transit time of rifampicin. For a
2-year-old child weighing 12.5 kg, the estimated typical oral clearances of rifampicin and pyrazinamidewere 8.15
and 1.08 L/h, respectively. Isoniazid typical oral clearance (adjusted for bioavailability) was predicted to be 4.44,
11.6 and 14.6 L/h for slow, intermediate and fast acetylators, respectively. Higher oral clearance values in inter-
mediate and fast acetylators also resulted from 23% lower bioavailability compared with slow acetylators.
Conclusions: Simulations based on our models suggest that with the new WHO dosing guidelines and utilizing
available paediatric fixed-dose combinations, children will receive adequate rifampicin exposures when com-
pared with adults, but with a larger degree of variability. However, pyrazinamide and isoniazid exposures in
many children will be lower than in adults. Further studies are needed to confirm these findings in children admi-
nistered the revised dosages and to optimize pragmatic approaches to dosing.
Keywords: pharmacometrics, anti-Mycobacterium, paediatrics, NONMEM, modelling and simulation
Introduction
Tuberculosis is themost frequent infectious cause of death world-
wide with high impact in developing countries.1 In high-burden
settings, children comprise 15%–20% of tuberculosis cases.2
Young children (,5 years of age) and children with HIV infection
are prone to rapid progression to tuberculosis disease following
infection and frequently experience severe forms of tuberculosis,
including disseminated disease and meningitis.2 Isoniazid and
rifampicin are important for their bactericidal activity against
metabolically active Mycobacterium tuberculosis. The sterilizing
activities of pyrazinamide and rifampicin prevent the relapse of
disease after treatment.3,4 Isoniazid plays an important role in
preventing the development of resistance to companion drugs
such as rifampicin.5 Dosages of rifampicin higher than those
currently employed have been suggested to improve efficacy.6
# The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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Until recently, the daily dosages of first-line antituberculosis
drugs recommended in children were derived from the adult
dosage based on the assumption that the same dose per kg is
appropriate across all ages of patients. Even though rifampicin,
isoniazid and pyrazinamide have been available for many years,
the limited pharmacokinetic information in children suggests
that young children receiving adult-derived dosages have drug
exposures lower than adults.7–9 In children, factors such as mat-
uration of metabolizing enzymes and transporters, body compos-
ition, organ function, nutritional status and the pathophysiology
of severe forms of tuberculosis may contribute to changes in
pharmacokinetics, drug response and toxicity.10 Previous studies
have reported reduced tuberculosis drug concentrations in adults
with HIV infection,11 but the effect of HIV infection on the
pharmacokinetics of tuberculosis drugs has not been adequately
evaluated in children. The WHO has recently recommended
increased dosages of first-line antituberculosis drugs for chil-
dren,12 which are to be implemented using dispersible fixed-dose
combination (FDC) tablets for paediatric use, manufactured
according to newly recommended specifications, with each tablet
containing 50 mg of isoniazid, 75 mg of rifampicin and 150 mg of
pyrazinamide.13
In this paper, we describe the population pharmacokinetics of
rifampicin, pyrazinamide and isoniazid in non-linearmixed-effects
models, using previously published data from children with tuber-
culosis aged 2 months to 11.3 years who were given a wide range
of dosages.7,8,14,15 In addition, we used our finalmodels to predict
the steady-state area under the concentration–time curve (AUC)
and maximum plasma concentration (Cmax) in a paediatric popu-
lation and compared them with the corresponding pharmacoki-
netic measures in ethnically similar adults with tuberculosis.
Patients and methods
Patient population
Combined data of 76 children obtained from previously published studies
describing the plasma concentrations of rifampicin, pyrazinamide and
isoniazid in two cohorts of South African children with tuberculosis were
used for analysis.7,8,14,15On the basis of analysis of genetic polymorphisms
of the arylamine N-acetyltransferase 2 (NAT2) gene, the children were
categorized as slow-, intermediate- or fast-acetylator genotypes for
acetylation of isoniazid. The methods used in the classification of NAT2
genotypes have been previously described for Cohort 19 and Cohort 2.15
The demographic and clinical characteristics of all the children are sum-
marized in Table 1.
Patient treatment and pharmacokinetic sampling
Daily doses of rifampicin and isoniazid were given for 6 months with
pyrazinamide added for the first 2 months. Dispersible FDC tablets
formulated for children were used7,8,14,15 and details about the dosing
are included in Table 1. In Cohort 1, the median daily doses of rifampicin,
pyrazinamide and isoniazid approximated 10, 23 and 5 mg/kg,
respectively. In Cohort 2, on the first pharmacokinetic occasion, the
median daily doses were similar to Cohort 1: 10 mg/kg for rifampicin,
25 mg/kg for pyrazinamide and 5 mg/kg for isoniazid. For the second
pharmacokinetic occasion, the doses were adjusted, so the median
values increased: 15 mg/kg for rifampicin, 36 mg/kg for pyrazinamide
and 10 mg/kg for isoniazid. For Cohort 1, blood sampling for pharmaco-
kinetic analysis was conducted at 1 and 4 months after starting treat-
ment. At each sampling occasion, venous blood was drawn at 0.75,
1.5, 3, 4 and 6 h post-dose. Cohort 2 underwent pharmacokinetic sam-
pling ≥2 weeks after initiation of antituberculosis therapy and sampling
was repeated 1 week later, with samples drawn pre-dose and at 0.5, 1.5,
3 and 5 h after the dose. Cohort 1 plasma concentrations of rifampicin,
pyrazinamide and isoniazid were determined by liquid chromatog-
raphy– tandem mass spectrometry (LC/MS/MS) as detailed previ-
ously.7,14,16 The lower limit of quantification (LLOQ) for both rifampicin
and isoniazid was 0.1 mg/L and for pyrazinamide was 0.2 mg/L.
In Cohort 2, isoniazid and pyrazinamide plasma concentrations were
determined by HPLC and UV detection,15 whereas rifampicin was deter-
mined by LC/MS/MS.15 The lower limit of detection (LLOD) in Cohort 2,
under which no concentration was reported, was 0.25, 0.5 and
0.15 mg/L for rifampicin, pyrazinamide and isoniazid, respectively.
Moreover, the assay could not guarantee 5% precision between the
LLOD (0.75, 1.5 and 1 mg/L for rifampicin, pyrazinamide and isoniazid,
respectively) and LLOQ values.
Table 1. Patient demographic and clinical characteristics
Covariate Cohort 1a Cohort 2a Combined
Number of patients 56 20 76
Sex (males/females) 29/27 11/9 40/36
Genotype (S/I/F/Ms) 20/24/8/4 8/4/8/0 28/28/16/4
HIV positive (males/females) 22 (12/10) 5 (2/3) 27 (14/13)
Age (years) 3.22 (0.598, 10.9) 1.10 (0.321, 1.99) 2.17 (0.417, 10.7)
Weight (kg) 12.5 (4.87, 26.9) 7.80 (4.12, 12.8) 10.5 (4.90, 21.8)
RIF dose 1st PK (mg/kg) 9.54 (6.70, 13.3) 10.1 (9.0, 10.5) 9.71 (7.07, 13.2)
RIF dose 2nd PK (mg/kg) 9.57 (5.46, 16.0) 15.4 (10.4, 15.8) 10.3 (6.37, 15.9)
PZA dose 1st PK (mg/kg) 22.7 (15.9, 26.7) 25.2 (22.5, 26.5) 24.6 (17.6, 26.5)
PZA dose 2nd PK (mg/kg) 22.2 (12.2, 26.3) 36.2 (33.4, 39.5) 33.7 (15.6, 39.1)
INH dose 1st PK (mg/kg) 4.92 (3.35, 12.8) 5.04 (4.50, 5.36) 5.03 (3.56, 12.1)
INH dose 2nd PK (mg/kg) 4.95 (2.36, 16.0) 10.2 (8.74, 10.8) 9.77 (2.73, 13.3)
S/I/F, slow/intermediate/fast arylamine N-acetyltransferase acetylators; Ms, missing covariate data; RIF, rifampicin; PZA, pyrazinamide; INH, isoniazid;
1st PK and 2nd PK, first and second pharmacokinetic sampling occasion, respectively.
aContinuous variables reported asmedian (2.5th percentile, 97.5th percentile), while the size of each group is reported for categorical covariates.7,8,14,15
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Pharmacokinetic data analysis
The concentration–time data for each drug were analysed separately
using a non-linear mixed-effects approach. The estimation of typical
population pharmacokinetic parameters, along with their random inter-
individual variability (IIV) and inter-occasional variability (IOV), was per-
formed in NONMEM7 (Icon Development Solutions, Ellicott City, MD,
USA)17 using a first-order conditional estimation method with 1–h inter-
action (FOCE INTER).18 For all three drugs (rifampicin, pyrazinamide and
isoniazid), model development was carried out first by developing the
structural and stochastic model, including allometric scaling, and then
investigating covariate effects. Graphical diagnostics were created using
Xpose 4.19 In all models, allometric scaling was applied on the oral clear-
ance (CL) and apparent volume of distribution in plasma (Vc) according to
Anderson and Holford.20 As reference, the median body weight of 12.5 kg
from Cohort 1 (Table 1) was used.
CLi = CLstd · (WTi/12.5)0.75 (1)
Vi = Vstd · (WTi/12.5)1 (2)
CLi is the scaled typical value of CL for individual i, CLstd is the typical CL for
an individual of 12.5 kg and WTi is the body weight of individual i in kg.
A similar notation applies to Vi. In the case of a two-compartment
model, allometric scaling was also applied on the inter-compartmental
clearance (Q) (as in Equation 1) and on the apparent peripheral volume
of distribution (Vp) (as in Equation 2). After allometric scaling was included,
the need for including maturation models following the approach previ-
ously described by Anderson and Holford21 was evaluated. Thematuration
factor (MF) was calculated using Equation 3:
MF = 1/[1+ (PMA/TM50)−Hill] (3)
where PMA is age derived by adding 36 weeks to the post-natal age,22
assuming no premature birth. TM50 is the age at whichmaturation reaches
50% of the final value and Hill is the coefficient that regulates the rate of
onset of the maturation. Models with and without the Hill factor fixed to 1
were tested.
The structural models tested included one- and two-compartment
models with first-order elimination. Different absorption models were
explored, such as first-order absorption or a sequence of zero- and first-
order absorption incorporating either lag times or transit compartment
absorption.23,24 The effect of a dose dependency on the pharmacokinetic
parameters was also tested. For relative bioavailability (F), first-order
absorption rate constant (ka), mean transit time (MTT) and CL of rifampicin
(a substrate of polymorphic OATP1B1 transporter)25 and isoniazid
(a substrate of polymorphic metabolizing enzyme NAT2) the possibility
of subpopulations having different parameter estimates was tested
using mixture models. A log-normal model for IIV and IOV was used
and shrinkage in the post hoc estimates was derived. Additive and/or pro-
portional models for the residual unexplained variability were evaluated.
In Cohort 1, the drug concentrations reported as below the LLOQ were
0.6%, 0% and 3.4% for rifampicin, pyrazinamide and isoniazid, respect-
ively. In Cohort 2, the values below the LLOD were 19%, 5.5% and
17.1% for rifampicin, pyrazinamide and isoniazid, respectively.
Additionally, 4.5%, 3% and 24.1% of the concentrations of rifampicin, pyr-
azinamide and isoniazid, respectively, were in the ‘low precision’ range of
the assay, but above the LLOD. The larger proportion of low concentrations
in Cohort 2 is partly due to the collection of a pre-dose sample. All the data
below the LLOQ in Cohort 1 were handled by fixing the error structure to
additive with size LLOQ/2, to include these samples in the fit while
accounting for the lower precision. In Cohort 2, values below the LLOD
were replaced with LLOD/2, discarding consecutive undetectable concen-
trations in a series. Moreover, for all LLOD values and the samples in the
‘low precision’ range of the assay, the error structure was fixed to additive
andwith size half of the threshold of low precision of the assay, once again
to account for the larger uncertainty in these measurements.
The effect of age, sex and HIV infection was tested on F, CL, Vc, Vp, ka
and MTT. Armmuscle area (AMA) was tested as a predictor of CL, Vc and Vp
while albumin and other nutritional status measures (weight-for-age,
weight-for-height and height-for-age z scores) were tested on F, CL, Vc
and Vp.
The AMA values were derived from percentiles from the US Health and
Nutrition Examination Survey I from 1971 to 197426 and the z scores were
derived from National Center for Health Statistics/CDC/WHO international
reference standards.27 Missing continuous covariate data were replaced
with the individual information from the other dosing and sampling occa-
sion, if available. Otherwise, median values from the cohort were used.
Missing categorical covariates were replaced with the most common cat-
egory, except for acetylator genotype. For themissing genotype data (four
individuals), amixturemodel was used. The likelihood of belonging to each
acetylator status was fixed to the frequency observed in the subjects for
whom the information was available.
Potential covariate relationships were identified by clinical and statis-
tical significance. The covariate relationships were tested in the model
by stepwise addition (forward step) using a difference in the NONMEM
objective function value (DOFV) of≥3.84 (P≤0.05) as the cut-off for inclu-
sion, followed by stepwise deletion (backward step) using DOFV of ≥6.83
(P≤0.01) as a requisite for covariate retention.
The effect of continuous covariates was parameterized as shown in
Equation 4:
PAR = up · [1+ ucov · (COV− COVmed)] (4)
where up is the parameter (PAR) estimate in a typical patient (a child with
median covariate value of COVmed), while ucov is the fractional change in
PAR with each unit change in the covariate (COV) from COVmed.
For categorical covariates, such as acetylator genotype, a separate
typical value for the parameter under test was estimated in each group.
Model evaluation
Model selection was based on the graphical assessment of conditional
weighted residuals versus time, basic goodness-of-fit plots, changes in
the OFV, precision of parameter estimates as provided by the covariance
step (if successfully completed) and visual predictive checks (VPCs).28
Simulations
Using Monte Carlo simulations, the final models were used to simulate the
steady-state AUC and Cmax for children using pragmatic weight bands
(adhering as closely as possible to the revised guidelines in dose per unit
weight)12 using one to four undivided tablets of an FDC with the newly
recommended specifications (i.e. 75/50/150 mg of rifampicin/isoniazid/
pyrazinamide in each FDC tablet).13 The AUC and Cmax were predicted
for children weighing 5.0–7.9, 8.0–11.9, 12.0–15.9 and 16.0–24.0 kg
receiving respective daily doses of one, two, three and four FDC tablets.
Individual weight and age values used in the simulations were additionally
obtained from historical data of 246 South African children with tubercu-
losis; 72%were infected with HIV (2%with HIV status unknown) and 54%
were males. Pooling these with the present data from the two cohorts
(Table 1), we obtained a dataset of baseline values for 322 children. The
pharmacokinetic models were applied (1000 repetitions) to this in silico
population, using the WHO-recommended dosing guidelines, and the
AUC and Cmax values were collected for each weight band. To obtain refer-
ence values for comparison, previously published pharmacokinetic mod-
els24,29,30 from an ethnically similar population of adult patients were
used to simulate AUC and Cmax ranges using the current
Population pharmacokinetics of antituberculosis drugs in children
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WHO-recommended dosing guidelines for adults.31 The respective daily
doses used for simulations in adults weighing 30.0–37.9, 38.0–54.9,
55.0–69.9 and ≥70 kg were: 300, 450, 600 and 750 mg for rifampicin;
800, 1200, 1600 and 2000 mg for pyrazinamide; and 150, 225, 300 and
375 mg for isoniazid.
Results
Rifampicin
A total of 629 concentration–time data points were available for
67 children.8,15 The final pharmacokinetic model for rifampicin
was a one-compartment model with transit compartments
absorption23 and first-order elimination. The parameter estimates
of the final model are shown in Table 2. The absorption transit
model was simplified by fixing ka to the same value as the first-
order transit rate constant (ktr), since the two were not
significantly different. HIV status, age and albumin levels had no
influence on the pharmacokinetics of rifampicin. Age maturation
was supported for CL and MTTand resulted in a 23 point improve-
ment in OFV, explaining 16% IIV in CL and 17% IOV in MTT (no IIV
in MTT was present in the model). TM50 was estimated to be
58.2 weeks, which is 22.2 weeks (0.43 years) after birth for both
CL and MTT. The proportional change of each parameter with
post-natal age is shown in Figure 1. The final model included
IIV, expressed as percentage coefficient of variation (%CV), in CL
(33%) and Vc (43%), while IOV was significant for CL (25%), F
(48%) and MTT (40%). The residual error model had both additive
(0.122 mg/L for Cohort 1 and 0.63 mg/L for Cohort 2) and propor-
tional (23% for both cohorts) terms. The final pharmacokinetic
model described the data well, as shown in the VPC (Figure 2).
When scaled to a 70 kg individual, the typical values for CL and
Vc were 29.7 L/h and 90.7 L, respectively.
Pyrazinamide
A total of 518 concentration–time data points were available for
55 children.14,15 The final pharmacokinetic model for pyrazina-
midewas a one-compartment distributionmodel with absorption
transit compartments, first-order absorption and elimination. The
final parameter estimates are shown in Table 3. No significant cov-
ariate relationships were supported by the data. IIV, expressed as
%CV, was supported for CL (27%), while IOVwas significant for CL
(26%), ka (86%), F (25%) and MTT (112%). The residual error
model was proportional (10% for Cohort 1 and 6% for Cohort 2).
The VPC for the final model is displayed in Figure 2, showing that
the final model described the data well. The typical values of CL
and Vc were 3.9 L/h and 54 L, respectively, when scaled to a
70 kg individual.
Isoniazid
A total of 715 concentration–time data points were available for
all 76 children.7,15 A two-compartment distribution model with
absorption transit compartments and first-order elimination
best described the pharmacokinetics of isoniazid. The final param-
eter estimates are shown in Table 4. TheNAT2 genotypewas a sig-
nificant covariate for CL and F. The OFV improved by 55.7 points
when including the acetylator status, which explained 45% of
the IIV in CL. Estimation of F for intermediate and fast acetylators
(relative to slow acetylators) and accounting for age maturation
of CL further improved the OFV by 11 and 16 points, respectively.
The age maturation explained 6% IIV in CL. With respect to inter-
mediate acetylators (CL¼8.94 L/h), slow acetylators had 50%
lower CL (4.44 L/h), while fast acetylators had 26% higher CL
(11.3 L/h). Also, F in intermediate and fast acetylators was esti-
mated to be 77.2%, which is 23% lower than in slow acetylators.
Thus, combining the genotype effect on CL and bioavailability, the
value of CL/F is 4.44, 11.6 and 14.6 L/h for slow, intermediate and
fast acetylators, respectively. The final model included IIV,
expressed as %CV, in CL (25%) and IOV in ka (61%), MTT (94%)
and F (40%). The maturation of CL is represented in Figure 1 and
the VPC for the final model is shown in Figure 2. When scaled to a
70 kg individual, the typical values of CL (not CL/F, so before
adjusting for the effect of NAT2 genotype on F) were 16.2, 32.5
and 41.1 L/h for slow, intermediate and fast acetylators, respect-
ively, and Vc and Vp were 61.6 and 28.2 L.
Simulations
Using the final models and WHO’s newly recommended higher
dosages utilizing revised FDC recommendations, the predicted
steady-state AUCs for all weight bands are shown in Figures 3–
5 for rifampicin, pyrazinamide and isoniazid, respectively.
Median rifampicin exposures were similar to those in adults,
although wider variability was present in the simulated paediatric








CLstd (L/h) 8.15 (9.00) 32.6 (27.7) 25.1 (20.0)
Vc.std (L) 16.2 (10.2) 43.4 (19.8)
MTT (h) 1.04 (6.10) 40.6 (8.60)
NN 8.04 (11.9)
F (%) 1 (fixed) 48.1 (12.7)








Proportional error (%) 23.4 (4.50)
CLstd and Vc.std, oral clearance and apparent volume of distribution,
respectively (the values reported refer to a 12.5 kg child and for CL at
full maturation); MTT, absorption mean transit time (value at full
maturation); NN, number of transit compartments; F, relative
bioavailability; TM50, post-menstrual age at which 50% of clearance and
mean transit time maturation is achieved; Hill, steepness of the
maturation function.
aRSE, relative standard error reported on the approximate standard devi-
ation scale.
bIIV, inter-individual variability expressed as percentage coefficient of vari-
ation (%CV).
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AUCs, as shown in Figure 3. Exposures after pyrazinamide and iso-
niazid were adequate, but younger children, particularly those in
the lowest weight band, had lower exposures than those in the
reference adult population and intermediate and fast acetylators
had reduced isoniazid exposures compared with the majority of
adults. Our results also predicted that from 3 months to 2 years
of age, the AUCdecreased by 56%and 50% for rifampicin and iso-
niazid, respectively, but by only 18% for pyrazinamide [refer to
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Figure 1. Maturation of oral clearance (CL) andmean transit time (MTT) of rifampicin and CL of isoniazid in a typical patient with post-natal age. The plot
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Figure 2. VPCs for the final models of rifampicin, pyrazinamide and isoniazid. The lower, middle and upper lines are the 5th percentile, median and 95th
percentile of the observed data, respectively. The shaded areas are the 95%CIs for the 5th percentile, median and 95th percentile of the simulated data.
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Discussion
We described the population pharmacokinetics of rifampicin, pyr-
azinamide and isoniazid in South African children treated for
tuberculosis. In addition, drug exposures resulting from the
dosages recently recommended by the WHO were investigated.
Our simulations predicted that, even with the increased dosages,
smaller children would achieve relatively low exposures to pyrazi-
namide and isoniazid. Moreover, intermediate and fast acetyla-
tors (together comprising 61% of our population) may be
underdosed with respect to isoniazid if exposures in an ethnically
similar population of adults are considered therapeutic (Figure 5).
It should be noted that the doses of pyrazinamide and isoniazid
used for these predictions tended to be somewhat lower than the
recommended dose per kg, especially in the youngest children.
Our choice of weight bands was based on ongoing discussions
about the optimal dose of the FDC by weight band, pragmatic
considerations, such as the stability and equal distribution of
active ingredients in each portion after breaking the FDC tablets,
and concern that pharmacokinetic maturation could still be
incomplete in young children.9,32,33Our proposed doseswere opti-
mized assuming that dividing the FDC tablets should be avoided if
possible.
The typical paediatric parameter estimates for rifampicin CL/F
and Vc/F are in line with adult values reported in an ethnically
similar population.24 After adjusting for the difference in body
size (the median weight of the adult population used for compari-
son was 50 kg), CL/F was 23.1 L/h in children versus 19.2 L/h in
adults and Vc/F was 64.8 versus 53.2 L, respectively. This suggests
that pharmacokinetic differences between children and adults
could mainly be explained by differences in body size (which
was accounted for by allometric scaling in our models) and
enzyme maturation. Our data did not support non-linearity in
the pharmacokinetics of rifampicin, even though the doses
given ranged from $5 to almost 18 mg/kg daily. Our results
therefore suggest that at the doses used in the children studied,
rifampicin may not display the dose-dependent non-linear
pharmacokinetics in children that has been described in adults.34
However, further studies, including sufficient numbers of children
being given the increased dosages, would be needed to confirm
this. Low rifampicin concentrations are associated with the devel-
opment of acquired rifamycin monoresistance (ARR)35 and a Cmax
of 8 mg/L has been suggested for rifampicin,36 although even
higher concentrations are likely necessary for maximal bacteri-
cidal activity.6 However, such concentrations are rarely achieved
in children prescribed 8–12 mg/kg/day doses of rifampicin.8 If
the pharmacokinetics in an ethnically similar adult population24









CLstd (L/h) 1.08 (5.60) 27.1 (16.3) 25.5 (11.3)
Vc.std (L) 9.64 (2.60)
ka (h
21) 4.48 (6.10) 86.4 (14.6)
MTT (h) 0.10 (17.7) 112 (22.5)
NN 3.94 (8.00)







CLstd and Vc.std, oral clearance and apparent volume of distribution,
respectively (the values reported refer to a 12.5 kg child); ka, first-order
absorption rate constant; MTT, absorption mean transit time (value at
full maturation); NN, number of transit compartments; F, relative
bioavailability.
aRSE, relative standard error reported on the approximate standard devi-
ation scale.
bIIV, inter-individual variability expressed as percentage coefficient of vari-
ation (%CV).
cIOV, inter-occasional variability expressed as percentage coefficient of
variation (%CV).









d 4.44 (11.6) 25.1 (12.3)
CLstd.ia (L/h)
d 8.94 (13.1) 25.1 (12.3)
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21) 2.47 (12.8) 61.6 (12.4)






Fsa 1 (fixed) 39.7 (5.80)
Fim/fa 0.772 (30.3) 39.7 (5.80)








CLstd.sa, CLstd.ia and CLstd.fa, oral clearance for slow, intermediate and fast
acetylators, respectively (they refer to a child weighing 12.5 kg and at full
maturation); Vc.std, apparent volume of distribution in the central
compartment for 12.5 kg child; ka, first-order absorption rate constant;
MTT, absorption mean transit time; NN, number of hypothetical transit
compartments; Qstd, inter-compartmental clearance for 12.5 kg child;
Vp.std, volume of distribution in the peripheral compartment for 12.5 kg
child; Fsa, relative bioavailability of slow acetylators; Fim/fa, relative
bioavailability of intermediate and fast acetylators relative to slow
acetylators; TM50, post-menstrual age at 50% of adult clearance; Hill,
steepness of the maturation function.
aRSE, relative standard error reported on the approximate standard
deviation scale.
bIIV, inter-individual variability expressed as percentage coefficient of
variation (%CV).
cIOV, inter-occasional variability expressed as percentage coefficient of
variation (%CV).
dIn order to obtain the values of CL/F, Vc/F, Q/F and Vp/F, the values in the
table should be divided by the respective value of bioavailability, which
changes according to acetylator status.
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given the currently recommended doses is used for comparison,
the majority of our children fall within the 5th–95th percentile
range of exposures in the adult patients (Figure 3). The simulated
adult exposures were similar to those found in a large pharmaco-
kinetic study conducted in adults with pulmonary tuberculosis in
Botswana.37 Our simulations for children using the newly recom-
mended WHO paediatric guidelines predicted more variable
rifampicin exposures than those for the reference adult popula-
tion (Figure 3). Moreover, both the predicted mean Cmax using
the revised paediatric guidelines (6.6 mg/L) and the current
doses recommended by WHO in the adult reference population
(4.8 mg/L) were lower than the proposed minimum Cmax of
8 mg/L,36 implying that even higher doses of rifampicin should
be considered for both children and adults.
Using the final pyrazinamide model and parameter estimates
for CL/F and Vc/F scaled to the median weight of the adult popu-
lation used for comparison (51.5 kg),30 the children had similar
CL/F ($3.1 versus 3.42 L/h) and higher Vc/F (39.7 versus 29.2 L)
compared with the adults. The higher Vc/F in children could partly
be due to malnutrition and severe forms of tuberculosis disease.
When we targeted previously reported exposures in an ethnically
similar adult population who received doses recommended by
WHO, our simulation results predicted that children weighing
5.0–7.9 kg may be underdosed (Figure 4). As noted above,
Dose (mg) 75 150 225 300
Dose (mg/kg) 10.7-18.8 13.6-18.8 15.0-18.8 12.5-18.8
>5th, <95th (%) 79.9 79.7 80.5 81.0
<5th (%) 7.7 4.2 3.8 3.8
>95th (%) 12.4 16.1 15.8 15.1
Weight (kg) 5.0-7.9 8.0-11.9 12.0-15.9 16.0-24.0














Figure 3. Box plot of simulated steady-state AUC of rifampicin across different age and weight bands, obtained adhering as closely as possible to the
revised guidelines in dose per unit weight according toWHO 2010 dosing guidelines. Each box shows the 25th–75th percentile of simulated AUCand the
symbol ‘x’ shows data falling outside 1.5 times the IQR (25th–75th). The lower, middle and upper broken lines are the derived 5th percentile
(9.0 mg.h/L), median (30.7 mg.h/L) and 95th percentile (52.4 mg.h/L) of the adult AUC, respectively. The grey shaded area is the 25th–75th
(21.9–39.5 mg.h/L) percentile of the adult AUC.
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children in the lowest weight band tended to receive doses some-
what lower than the 30–40 mg/kg target proposed in the revised
guidelines. Our simulations suggest that a 50 mg/kg dose for
children in the lowest weight band of 5.0–7.9 kg would achieve
the same median AUC as that in the adults. The pyrazinamide
exposures we simulated for our reference adult population were
similar to those in the large cohort in Botswana.37 In addition,
the majority of adults had simulated Cmax within the suggested
range of 20–50 mg/L.36 Importantly, patients in the Botswana
cohort with pyrazinamide Cmax ,35 mg/L had an increased risk
of poor treatment outcome.
Isoniazid pharmacokinetics is highly dependent on the poly-
morphic NAT2, which is a major determinant of isoniazid plasma
concentrations.38 Targeting average exposures simulated for
ethnically similar adults following doses currently recommended
by WHO, the new doses recommended by the WHO for children
are adequate for slow acetylators, but insufficient for inter-
mediate and fast acetylators (Figure 5). We have noted wide
IIV in the systemic concentrations and AUC mostly because
children were not dosed according to the NAT2 acetylator geno-
type. Hence, further studies are needed to adequately define
the implications of IIV for safety and efficacy in children.
Interestingly, children who were younger than 1 year old had
higher AUC irrespective of their weight band. In addition, isoniazid
CL showed maturation with age and this supports the notion that
finer weight bands in conjunction with age should be considered
to avoid overdosing very young children. The reduced bioavailabil-
ity for intermediate and fast acetylators is most likely a result of
Dose (mg) 150 300 450 600
Dose (mg/kg) 21.4-37.50 27.3-37.7 30.0-37.5 25.0-37.5
>5th, <95th (%) 43.4 69.8 73.2 73.4
<5th (%) 55.4 23.4 15.5 13.6
>95th (%) 1.2 6.7 11.3 13.0
Weight (kg) 5.0-7.9 8.0-11.9 12.0-15.9 16.0-24.0














Figure 4. Box plot of simulated steady-state AUCof pyrazinamide across different age andweight bands, obtained adhering as closely as possible to the
revised guidelines in dose per unit weight according toWHO 2010 dosing guidelines. Each box shows the 25th–75th percentile of simulated AUCand the
symbol ‘x’ shows data falling outside 1.5 times the IQR (25th–75th). The lower, middle and upper broken lines are the derived 5th percentile
(244.0 mg.h/L), median (427.0 mg.h/L) and 95th percentile (675.0 mg.h/L) of the adult AUC, respectively. The grey shaded area is the 25th–75th
(346–547 mg.h/L) percentile of the adult AUC.
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increased pre-systemic metabolism, which also correlates with
systemic clearance. The lower exposure in intermediate and fast
acetylators may predispose to the development of ARR. In the
CDC Study 22,39 an association was found between low isoniazid
plasma concentrations and the occurrence of relapse in patients
on a regimen of once-weekly rifapentine and isoniazid, suggesting
that isoniazidmight have been ineffective in preventing the devel-
opment of rifamycin resistance.
In all our models, we decided to scale clearance and volume
with allometric scaling and this choice over using weight as a lin-
ear covariate was also supported by the data following general
criteria such as the NONMEM OFV. The use of allometrics to
account for differences in pharmacokinetics due to body size is
supported by both empirical observation and biological theory,
as discussed in depth by Anderson and Holford.20,21
Although our children received similar formulations across the
two cohorts, formulation is known to be an important determin-
ant of bioavailability.40,41Other factors encounteredwhen prepar-
ing suspensions and administering the drug are likely to play a role
in young children who cannot swallow tablets. There is a need for
studies to evaluate such sources of variability in paediatric drug
exposure and to develop solutions to reduce it. Genetic diversity
Dose (mg) 50 100 150 200
Dose (mg/kg) 7.1-12.5 9.1-12.5 10.1-12.5 8.3-12.5
Genotype
S I F S I F S I F S I F
>5th, <95th (%) 89.1 50.7 32.9 85.9 67.2 49.4 85.2 69.2 52.3 86.0 70.9 52.1
<5th (%) 3.3 49.2 67.1 0.63 32.7 50.6 0.4 29.3 47.3 0.4 29.0 47.9
>95th (%) 7.5 0.1 0.0 13.5 0.1 0.0 14.4 1.5 0.5 13.6 0.1 0.0
Weight (kg) 5.0-7.9 8.0-11.9 12.0-15.9 16.0-24.0















Figure 5. Box plot of simulated steady-state AUC of isoniazid in slow (S), intermediate (I) and fast (F) acetylators across different age and weight bands,
obtained adhering as closely as possible to the revised guidelines in dose per unit weight according toWHO 2010 dosing guidelines. Each box shows the
25th–75th percentile of simulated AUCand the symbol ‘x’ shows data falling outside 1.5 times the IQR (25th–75th). The lower,middle and upper broken
lines are the derived 5th percentile (9.8 mg.h/L), median (23.4 mg.h/L) and 95th percentile (55.6 mg.h/L) of the adult AUC, respectively. The grey
shaded area is the 25th–75th (15.6–35.5 mg.h/L) percentile of the adult AUC.
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is also an important consideration when extrapolating the results
of pharmacokinetic studies. There is considerable geographical
variation in the distribution of NAT2 polymorphisms.42,43
Moreover, recent studies have identified polymorphisms of
SLCO1B1 (which encodes the OATP1B1 transporter) occurring in
relatively high frequencies in African populations, associated
with substantially reduced rifampicin exposure.25,44 Hence, phar-
macogenetic studies in childrenmay allow further optimization of
dosing strategies.
Limitations of our model include the fact that the AMA values
and z scores used to test anthropometric associations with the
pharmacokinetic parameters were not derived specifically from
an African population and thus they may not have correctly
described the children in our study population. Finally, a limitation
of our simulation approach is that it does not account for any non-
linearity in the pharmacokinetics that may occur at the higher
doses; hence, our predictions should be confirmed in pharmaco-
kinetic studies in children dosed according to the revised
guidelines.
In conclusion, our models describe the population pharmaco-
kinetics of rifampicin, pyrazinamide and isoniazid in children with
tuberculosis. Simulations based on our models predict that the
newly recommended weight band-based doses in WHO guide-
lines for children result in rifampicin exposures in our paediatric
population that are similar to those in adults. However, when
dosed in pragmatic weight bands, there is wide variability in
drug exposure and pyrazinamide and isoniazid exposures in
many children will be lower than those in an ethnically similar
adult population. Hence, adjustment of the recommended
doses may be warranted should the findings be confirmed in
other populations.
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Pharmacokinetics and Safety of Ofloxacin in Children with Drug-
Resistant Tuberculosis
Anthony J. Garcia-Prats,a Heather R. Draper,a Stephanie Thee,a,b Kelly E. Dooley,c Helen M. McIlleron,d James A. Seddon,e
Lubbe Wiesner,d Sandra Castel,d H. Simon Schaaf,a Anneke C. Hesselinga
Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africaa;
Department of Paediatric Pneumology and Immunology, Charité Universitätsmedizin Berlin, Berlin, Germanyb; Department of Medicine, Johns Hopkins University,
Baltimore, Maryland, USAc; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africad; Department of Paediatrics,
Imperial College London, London, United Kingdome
Ofloxacin is widely used for the treatment of multidrug-resistant tuberculosis (MDR-TB). Data on its pharmacokinetics and
safety in children are limited. It is not known whether the current internationally recommended pediatric dosage of 15 to 20
mg/kg of body weight achieves exposures reached in adults with tuberculosis after a standard 800-mg dose (adult median area
under the concentration-time curve from 0 to 24 h [AUC0 –24], 103 !g · h/ml). We assessed the pharmacokinetics and safety of
ofloxacin in children <15 years old routinely receiving ofloxacin for MDR-TB treatment or preventive therapy. Plasma samples
were collected predose and at 1, 2, 4, 8, and either 6 or 11 h after a 20-mg/kg dose. Pharmacokinetic parameters were calculated
using noncompartmental analysis. Children with MDR-TB disease underwent long-term safety monitoring. Of 85 children (me-
dian age, 3.4 years), 11 (13%) were HIV infected, and of 79 children with evaluable data, 14 (18%) were underweight. The ofloxa-
cin mean (range) maximum concentration (Cmax), AUC0 – 8, and half-life were 8.97 !g/ml (2.47 to 14.4), 44.2 !g · h/ml (12.1 to
75.8), and 3.49 h (1.89 to 6.95), respectively. The mean AUC0 –24, estimated in 72 participants, was 66.7 !g · h/ml (range, 18.8 to
120.7). In multivariable analysis, AUC0 –24 was increased by 1.46 !g · h/ml for each 1-kg increase in body weight (95% confidence
interval [CI], 0.44 to 2.47; P " 0.006); no other assessed variable contributed to the model. No grade 3 or 4 events at least possibly
attributed to ofloxacin were observed. Ofloxacin was safe and well tolerated in children with MDR-TB, but exposures were well
below reported adult values, suggesting that dosage modification may be required to optimize MDR-TB treatment regimens in
children.
Globally, in 2013 there were an estimated 480,000 new cases ofmultidrug-resistant tuberculosis (MDR-TB), defined as My-
cobacterium tuberculosis resistant to isoniazid (INH) and rifampin
(RIF) (1). Precise incidence data in children are unavailable, but
modeling estimates suggest that there were 33,000 new pediatric
MDR-TB cases in 2010 (2). In addition, assuming an average of
two child contacts for each adult MDR-TB source case (3), there
may be as many as 900,000 children newly exposed to MDR-TB
globally each year. Fluoroquinolones are a key component of ex-
isting regimens for treatment (4) and prevention (5) of MDR-TB
in adults and children.
Ofloxacin, a fluoroquinolone, has potent activity against M.
tuberculosis (6, 7) and has been routinely used in MDR-TB
treatment. The current World Health Organization (WHO)
recommended adult dose of ofloxacin for MDR-TB is 800 mg
daily. Ofloxacin is not metabolized; rather, it is excreted un-
changed in the urine (8). It is well absorbed after oral admin-
istration, and food intake does not affect its pharmacokinetics
appreciably (9–12).
There are limited data on ofloxacin pharmacokinetics in chil-
dren, particularly in children !5 years of age, to guide appropriate
dose selection (11, 13). The WHO recommends a pediatric ofloxa-
cin dose for MDR-TB of 15 to 20 mg/kg of body weight daily (14);
however, it is unknown if this dose achieves exposures in children
approximating those in adults after the recommended 800-mg
dose. Concerns regarding arthropathy (15, 16) had initially lim-
ited the use of fluoroquinolones in children. Although safe in
short courses (16–18), there are limited data on fluoroquinolone
safety in children with long-term use (5, 19).
The more potent fluoroquinolones levofloxacin and moxi-
floxacin (20, 21) are beginning to replace ofloxacin for MDR-TB
treatment. However, because of its low cost and widespread avail-
ability, ofloxacin is still used for MDR-TB in many settings, and
optimizing its use in children remains important.
The objective of this study was to evaluate the pharmacokinet-
ics and safety of ofloxacin among a large cohort of HIV-infected
and uninfected children of representative ages who were routinely
receiving ofloxacin for the prevention or treatment of MDR-TB.
MATERIALS AND METHODS
Study design. This was a prospective observational pharmacokinetic
study.
Study setting. The study took place in the Western Cape, South Africa,
where in 2010 the TB notification rate was 954.1 cases per 100,000 popu-
lation, and from 2009 to 2011 MDR-TB represented 7.1% of culture-
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confirmed cases in children !13 years old (22, 23). The diagnosis of
MDR-TB was based on (i) culture of M. tuberculosis from sputum or other
relevant specimens with drug susceptibility testing (DST) demonstrating
resistance to INH and RIF, (ii) clinical and radiologic evidence of TB and
contact with an MDR-TB source case, or (iii) failure of first-line TB treat-
ment. Treatment for MDR-TB in children was provided independent of
the study, according to local and international guidance, based on the
DST of the child’s isolate or the isolate of their most likely source case.
Treatment included at least four drugs likely to be active given for at least
12 to 18 months (14, 24).
In the study setting, child contacts of adult MDR-TB cases are referred
to a specialty clinic for preventive therapy. Children !5 years of age and
those HIV infected without evidence of TB were prescribed 6 months of a
three-drug preventive therapy regimen: ofloxacin, ethambutol, and high-
dose INH (5).
Study population. Children were recruited from a large provincial
referral hospital (Tygerberg Children’s Hospital) and two provincial TB
hospitals (Brooklyn Hospital for Chest Diseases and Brewelskloof Hospi-
tal). Children !15 years of age routinely started on ofloxacin for preven-
tion or treatment of MDR-TB were eligible. Exclusion criteria were a
weight of !5 kg or hemoglobin of !8.0 g/dl. Children treated for
MDR-TB disease were followed longitudinally to assess safety and tolera-
bility during treatment. The safety of this preventive therapy regimen has
been previously documented; these children were followed independent
of the study (5). Data from 23 children from a substudy of this cohort were
previously published and are included in the present analysis (13).
Data collection. Children were categorized as receiving ofloxacin ei-
ther for MDR-TB treatment or prevention. TB was categorized as con-
firmed, probable, or possible according to international consensus defi-
nitions (25) and as pulmonary, extrapulmonary, or both. HIV status was
ascertained in all participants. Weight-for-age Z-score (WAZ) was calcu-
lated using the 1990 British growth reference (26).
All participants underwent intensive pharmacokinetic sampling 2 to 8
weeks after starting ofloxacin. Ofloxacin (200-mg tablets; Sanofi Aventis,
Midrand, South Africa) at a dose of 15 to 20 mg/kg once daily was rou-
tinely prescribed. On pharmacokinetic sampling days, an exact 20 mg/kg
dose of ofloxacin was weighed and administered by the study team after a
minimum 4-h fast with a small amount of water. Medications were given
either as whole tablets or were crushed and given by mouth or nasogastric
tube, depending on what the child would tolerate. Crushed tablets were
ground with a mortar and pestle, mixed with a small amount of water in a
plastic cup along with any other crushed TB medications, and adminis-
tered immediately. Any residue in the cup was rinsed 1 to 2 times with
additional water and administered to the child. All other anti-TB medica-
tions in the regimen were given together with the ofloxacin. One hour
after the TB medications, antiretrovirals were administered (if applicable)
and a standard breakfast was offered. Samples for pharmacokinetic anal-
ysis were drawn predose and then at 1, 2, 4, 8, and either 6 or 11 h post-
dose. Whole-blood samples were collected in EDTA-containing tubes and
immediately centrifuged, and plasma was separated and frozen at "80°C.
Ofloxacin concentrations were determined by high-performance liquid
chromatography coupled with triple quadrupole mass spectrometry (LC-
MS/MS) using a previously described method validated over a range of
0.0781 to 20.0 #g/ml (27).
Children receiving ofloxacin for MDR-TB treatment had clinical
monitoring monthly for the first 6 months and then every 2 months there-
after and laboratory monitoring (potassium, creatinine, alanine amino-
transferase [ALT], total bilirubin, thyroid functions) every 2 months. Ad-
verse events were graded according to standardized Division of AIDS
(National Institute of Allergy and Infectious Diseases) criteria (28) and
were considered attributable to ofloxacin if they were (i) at least possibly
drug related and (ii) thought by the investigator to be likely related to
ofloxacin or if they were not otherwise attributed to another drug. The
person-time of observation began at the initial study visit and ended at
either the final study visit or the date of treatment completion; observa-
tion periods in which the child received an alternative fluoroquinolone for
part of the time (treatment guidelines changed during the study period)
were excluded from safety analyses.
Statistical analysis. Demographic and clinical characteristics were
summarized using descriptive statistics. Pharmacokinetic measures were
estimated using noncompartmental analysis (NCA). Observed maximum
plasma drug concentration (Cmax) and time to Cmax (Tmax) were recorded
directly from the concentration-time data. The area under the concentra-
tion time curve from 0 to 8 h (AUC0 – 8) was calculated using the linear
trapezoidal rule. Oral clearance (CL/F), half-life (t1/2), and AUC0 –24 were
estimated in patients with at least 3 concentration data points in the elim-
ination phase, with the latter based on exponential extrapolation from the
final three time-concentration data points. Fifteen predose drug concen-
trations below the limit of quantification (0.078 #g/ml) were set to zero in
analyses.
The Cmax, AUC0 – 8, AUC0 –24, and t1/2 were compared by age group (0
to !2 years, 2 to !5 years, and !5 years), HIV status, nutritional status
(WAZ, !"2 versus !"2), and administration method (crushed versus
whole tablets). Using simple linear regression, the AUC0 –24 and Cmax were
analyzed separately for associations with age, weight, height, HIV status,
nutritional status, gender, ethnicity, disease status (receiving preventive
therapy versus treatment for MDR-TB), and administration method. Co-
variates with a P of !0.05 in univariable analysis, and factors known to
affect drug disposition (age and weight) were included in multivariable
models. We also assessed whether body surface area (BSA) (29) or lean
body mass (LBM) (30) were better predictors than weight and height.
All analyses were performed using Stata 12.1 SE software (StataCorp,
College Station, TX).
Ethical considerations. Written informed consent was obtained from
the parents or legal guardian, and informed assent was collected from all
children !7 years of age. Ethical approval was provided by the Health
Research Ethics Committees of the Faculty of Medicine and Health Sci-
ences of Stellenbosch University and the Faculty of Health Sciences of the
University of Cape Town.
RESULTS
Baseline characteristics. Eighty-five children were included (Ta-
ble 1). All age groups were well represented. The median age was
3.4 years (interquartile range [IQR], 1.9 to 5.2 years). Eleven
(13%) participants were HIV infected. Fourteen of the 79 patients
with evaluable data (18%) were underweight for age (WAZ, !"2)
and 11 of these children were HIV infected (79%). Overall, 72 of
85 (85%) received crushed tablets on the day of pharmacokinetic
sampling (97% of those !5 years old and 41% of those !5 years
old).
Pharmacokinetics and determinants of drug exposures.
With a dose of 20 mg/kg, the mean AUC0 – 8 (n $ 85) was 44.2 #g ·
h/ml and AUC0 –24 (n $ 72) was 66.7 #g · h/ml; other summary
measures with reported adult values for comparison are shown in
Table 2. Pharmacokinetic values by age group, HIV status, WAZ
category, and type of administration are presented in Table 3.
Half-life was shorter in the youngest children, and there was a
trend toward a higher Cmax in children receiving crushed tablets.
In simple linear regression, no variables assessed were significantly
associated with Cmax, and only weight was significantly associated
with AUC0 –24. In multivariable analysis, Cmax was reduced by 0.44
#g/ml for each 1-year increase in age (95% confidence interval
[CI], "0.74 to "0.13; P $ 0.005) and was increased by 0.13 #g/ml
for each 1-kg increase in body weight (95% CI, 0.10 to 0.24; P $
0.029). In multivariable analysis, AUC0 –24 was increased by 1.46
#g · h/ml for each 1-kg increase in body weight (95% CI, 0.44 to
2.47; P $ 0.006). Controlling for age and weight, no other assessed
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variables contributed to these models. Neither LBM nor BSA im-
proved the model fit over weight.
Safety. Forty-six children contributed a total of 23.8 years of
observation time on ofloxacin to the safety assessment, with a
median time per child of 4.9 months (IQR, 1.2 to 10.2 months)
(Table 4). Adverse events were mostly mild in severity; vomiting
and pruritus were the most frequent. Most adverse events were
not attributed to ofloxacin but represented known toxicities re-
lated to companion MDR-TB drugs. The only grade 3 or 4 events
were two episodes of asymptomatic ALT elevation due to con-
firmed acute hepatitis A, which resolved without complication
after brief interruptions of some TB medications while awaiting
the hepatitis A results.
DISCUSSION
Ofloxacin given at the WHO-recommended dose of 20 mg/kg to
children was safe and well-tolerated, but exposures in this sub-
stantial pediatric cohort were considerably lower than those
achieved in adults taking the standard MDR-TB treatment dose of
800 mg daily.
Although ofloxacin has been widely used for treatment and
prevention of MDR-TB in children, the appropriate dosage has
not been established. Indeed, only one other study evaluating the
pharmacokinetics of ofloxacin in children has been conducted to
our knowledge. In a study in Vietnam, 17 children (aged 5 to 17
years) with typhoid fever received a single oral dose of 7.5 mg/kg of
ofloxacin (11). A Cmax of 5.73 #g/ml and an AUC0 –12 of 26.5
#g/ml were achieved (11). The Cmax (8.97 #g/ml) and AUC0 – 8
(44.1 #g · h/ml) in our study are lower than would be expected
with a 2.5% higher dose given that ofloxacin exposures should be
dose proportional in the dosing range tested (8, 10). It is unclear if
this is because of differences in the study population or drug for-
mulation used, but our findings underline the importance of not
relying on a single study conducted in one geographic location to
inform global dosing recommendations in children.
The differing AUC0 – 8 and AUC0 –24 trends by age in univari-
able analysis may be due to the fact that the proportion of the total
daily AUC that is captured in the first 8 h after dosing is greater in
younger children (data not shown) due to more rapid absorption
and clearance compared to older children. Children with slower
absorption and elimination, and most likely a higher AUC, would
be more likely to be excluded from our estimates of AUC0 –24.
Indeed, AUC0 –24 was not estimated in a higher proportion of
older children (Table 3), suggesting we may have underestimated
the AUC0 –24 in children !5 years old. The differences in t1/2 by age
in univariable analysis and association of AUC0 –24 with weight
are consistent with the principle of allometric scaling, in which
smaller body size is associated with more rapid clearance.
Our large sample allowed us to evaluate covariate effects on the
pharmacokinetics of ofloxacin. In multivariable analysis, age and
weight were associated with AUC0 – 8 and Cmax, and weight was
associated with AUC0 –24. HIV and undernutrition are frequent
concomitant conditions among children with MDR-TB and have
been associated with failure to culture convert at 2 months and
death (31). HIV infection may affect concentrations of some TB
medications (32); however, we did not observe any significant
effect of HIV infection on ofloxacin pharmacokinetics. This is
consistent with the available adult literature (9, 10). Undernutri-
tion also did not have a clinically significant impact on ofloxacin
pharmacokinetics. These data suggest that worse outcomes
among children with HIV coinfection or undernutrition are not
likely due to reduced concentrations of ofloxacin, the key bacteri-
cidal drug in the regimen.
The lack of child-friendly formulations of second-line TB
medications is a major challenge for MDR-TB treatment in chil-
dren, and the impact of formulation manipulation, such as the
crushing or breaking of adult tablets, has not been evaluated fully.
TABLE 2 Summary statistics for ofloxacin pharmacokinetic measures in








Values for adults with
TB given an 800-mg
ofloxacin dosec
Cmax (#g/ml) 85 8.97 (2.47–14.4) 10.5 (8.0–14.3)
Tmax (h) 85 2.0 (1.0–4.0) 1.03 (0.5–6)
t1/2 (h) 72 3.49 (1.89–6.95) 7.34 (3.53–28.3)
CL/F (liter/h/kg) 72 0.31 (0.11–1.06) 0.12 (0.02–0.32)
V (liter/kg) 72 1.45 (0.86–6.49) 1.28 (0.78–2.83)
AUC0–8 (#g · h/ml) 85 44.2 (12.1–75.8)
AUC0–24 (#g · h/ml) 72 66.7 (18.8–120.7) 103 (48–755)
a All values are presented as means (ranges), except for Tmax, CL/F, and V, which are
presented as medians (ranges); adult values are all reported as medians (ranges).
b Cmax, maximum serum concentration; Tmax, time to maximum serum concentration;
t1/2, half-life; CL, clearance; F, fraction absorbed; V, volume of distribution; AUC0–8,
area under the concentration time curve from 0–8 h; AUC0–24, area under the
concentration time curve from 0 –24 h.
c n $ 11 (10).
TABLE 1 Baseline demographic and clinical characteristics of children





disease (n $ 55)
No. (%) receiving
MDR-TB preventive
therapy (n $ 30)
Age at enrollment
0 to !2 yr 16 (29.1) 8 (26.7)
2 to !5 yr 17 (30.9) 22 (73.3)
5 to !15 yr 22 (40.0) 0 (0.00)
Male sex 32 (58.2) 15 (50.0)
Certainty of TB diagnosis
Bacteriological confirmation 20 (36.4)
Probable TB 32 (58.2)
Suspected TB 3 (5.5)
TB disease type (n $ 55)
PTB only 40 (72.7)
EPTB only 5 (9.1)
PTB and EPTB 10 (18.2)
HIV infected 11 (20.0) 0 (0.0)
Weight-for-age Z-score !"2.0
(n $ 79)b
11 (22.5) 3 (10.0)
Height-for-age Z-score !"2.0
(n $ 81)c
19 (35.9) 4 (14.3)
Weight-for-length Z-score
!"2.0 (n $ 60)c
2 (6.3) 1 (3.6)
a PTB, pulmonary tuberculosis; EPTB, extrapulmonary tuberculosis.
b Weight-for-age Z-scores only available for patients aged !10 years.
c The sample size is !85 due to missing data.
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Many children in our study were unable to swallow whole ofloxa-
cin tablets and took them crushed. In univariable analysis, there
was a trend toward a higher Cmax with crushed tablets; however,
crushing did not contribute to the multivariable model, which
included age and weight. The associations of Cmax with age and
weight described here are somewhat unexpected and should be
interpreted cautiously, as crushing was highly associated with
younger age and less so with weight, and it may have been difficult
to separate these effects in the model. There was no association
between crushing and AUC0 – 8 or AUC0 –24. Although this does
not replace a formal assessment of relative bioavailability of
crushed versus whole tablets, it suggests that crushing tablets does
not negatively impact drug exposures and crushing may, in fact,
increase the rate or magnitude of absorption.
When efficacy of a TB drug has been established in adults,
efficacy studies may not be required in children, but studies char-
acterizing a drug’s pharmacokinetics and safety in children are
essential. This allows the selection of dosages that achieve concen-
trations associated with treatment success in adults (9, 10). In a
study of ofloxacin pharmacokinetics after an 800-mg dose (me-
dian dose, 14.5 mg/kg) in adults with MDR-TB at two sites in
South Africa, estimated pharmacokinetic parameters were a t1/2 of
7.8 h and a Cmax of 8.8 to 10.4 mg/liter (9). In a U.S. study, 11
adults with TB (median age, 42 years [range, 22 to 57 years]; me-
dian weight, 64 kg [range, 50 to 86 kg]; 3 HIV infected) underwent
intensive pharmacokinetic sampling on ofloxacin at steady state
with a median dose of 800 mg (range, 600 to 1,200 mg). Assays
were performed using high-performance liquid chromatography,
and data were analyzed using population pharmacokinetic mod-
eling (Table 2). Using simulations based on their population
model generated from these data and from an additional group in
this study having sparse pharmacokinetic sampling, estimated
pharmacokinetic parameters after an 800-mg once-daily dose
were an AUC of 100.7 #g · h/ml and a Cmax of 9.35 #g/ml (10). The
Cmax in our children was only slightly below these reported adult
values, although the children received a higher milligram per ki-
logram dose (20 mg/kg) compared to the adults (9). However, the
estimated AUC0 –24 in our children of 66.7 #g · h/ml was far below
the adult value (103 #g · h/ml) (10). This is likely related to the
more rapid clearance of ofloxacin in children; calculated t1/2 in
children in our study was 3.5 h compared to 7 to 8 h in the adult
studies. That currently recommended dosages of ofloxacin result
in AUCs in children well below those of adult targets has impor-
tant implications for MDR-TB treatment and prevention, partic-
ularly given the fluoroquinolones’ high bactericidal activity (33)
and their key role in current treatment regimens (34). The AUC is
believed to be the most important pharmacodynamic measure for
the fluoroquinolones against M. tuberculosis (35). As our data
were derived in an optimal setting with an exact 20-mg/kg dose,
drug exposures with unsupervised dosages closer to the lower end
of the recommended range (15 to 20 mg/kg) may be even lower.
Although additional studies corroborating the findings in our
study would be useful, it may not be prudent to wait on such
studies before reevaluating pediatric dosing. Population pharma-
cokinetic modeling can be used to predict dosages most likely to
achieve adult targets; this information is urgently needed, and
such an analysis is planned from this cohort. Higher dosages
should be introduced carefully, though, to assess their safety and
tolerability, particularly given that the Cmax may exceed the Cmax
in adults receiving 800 mg daily.
Ofloxacin was generally safe and well tolerated. The overall
person-time of observation for adverse events was more lim-
ited than expected, as many children were switched from
ofloxacin to levofloxacin or moxifloxacin during their treat-
ment, following a national treatment guideline change mid-
study. Adverse effects were of low grade, and there were no
ofloxacin-related grade 3 or 4 events. There was no evidence of
arthralgia or arthropathy in our cohort. Subtle arthralgia may
not have been reported, but it is unlikely clinically significant
arthralgia or arthritis would have been missed. There were two
reports of insomnia attributable to ofloxacin, a well-described
adverse effect of this medication (5, 36). Anecdotally, we have
seen self-limited, mild insomnia and nightmares attributable
to ofloxacin not infrequently; our data may underestimate the
TABLE 3 Pharmacokinetic measures for ofloxacin (20 mg/kg) in children receiving treatment or prevention for multidrug-resistant tuberculosis, by
age, HIV status, nutritional status, and administration methoda
Parameter
No. of
children Cmax (#g/ml) P value
AUC0–8




(#g · h/ml) P value t1/2 (h) P value
Age group
0 to !2 yr 24 10.43 (1.96) 45.9 (8.8) 23 63.9 (15.3) 3.01 (0.53)
2 to !5 yr 39 8.52 (2.37) 43.8 (12.0) 35 66.5 (20.9) 3.52 (0.75)
!5 yr 22 8.18 (2.01) !0.001 43.1 (8.9) 0.632 14 71.7 (17.8) 0.473 4.18 (1.22) !0.001
HIV status
HIV infected 11 8.42 (1.51) 42.5 (9.0) 9 63.4 (16.4) 3.35 (0.59)
Not HIV infected 74 9.05 (2.44) 0.404 44.4 (10.6) 0.560 63 67.1 (19.0) 0.579 3.51 (0.93) 0.614
WAZ
!"2.0 18 8.94 (2.35) 42.7 (11.4) 15 61.0 (20.1) 3.06 (0.49)
!"2.0 67 8.98 (2.35) 0.953 44.6 (10.1) 0.498 57 68.2 (18.1) 0.190 3.60 (0.94) 0.004
Administration
Whole 11 7.87 (1.67) 42.2 (10.6) 8 72.4 (23.4) 4.32 (1.45)
Crushed 72 9.16 (2.40) 0.089 44.6 (10.4) 0.481 62 66.1 (18.1) 0.375 3.39 (0.76) 0.114
a HIV status, nutritional status, and administration method comparisons were generated using t tests; age group comparisons were generated using one-way analyses of variance
(ANOVAs); all values are presented as means (standard deviations). A total of 85 children participated in the study.
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incidence, as many children were admitted to hospital wards
early in their treatment and sleep disturbance may be less no-
ticeable by ward staff than by parents. Our safety assessment is
limited by the lack of a control group and by the difficulty in
attributing adverse effects to individual drugs in a multidrug
regimen that typically includes ethambutol, pyrazinamide,
amikacin, ethionamide, terizidone, and high-dose INH. Our
approach was, however, conservative and more likely to have
overestimated ofloxacin-related adverse effects. These data add
to a growing body of evidence that the fluoroquinolones are
safe in children, including in long-term use (37). The lack of
adverse effects may be related to the relatively low exposures,
and safety should continue to be monitored closely if dosages
are increased.
Treatment outcomes in this cohort were generally good and
will be reported elsewhere; however, one child had docu-
mented acquisition of ofloxacin resistance during treatment.
This HIV-infected child had a complicated course with large
recurrent tuberculous brain abscesses requiring the use of mul-
tiple immunosuppressant medications and was treated with
multiple fluoroquinolones prior to resistance development,
making it difficult to ascribe the resistance acquisition solely to
ofloxacin concentrations. Additionally, this child’s ofloxacin Cmax
and AUC were each above the median. Despite generally good
outcomes, optimized dosing of the fluoroquinolones in children
remains an important priority and may potentially improve out-
comes further and facilitate the use of shorter, injectable sparing
MDR-TB treatment regimens.
In conclusion, in this large cohort of children receiving ofloxa-
cin, exposures were lower than those in adults. Although ofloxacin
is being phased out of MDR-TB treatment regimens in favor of
more potent fluoroquinolones, it is still used in many places and it
is likely underdosed in children. That ofloxacin was safe and well
tolerated is reassuring, particularly if higher dosages that will be
needed to reach adult reference exposure targets are to be evalu-
ated. A better understanding of the pharmacokinetics and safety
profiles of all second-line anti-TB drugs is essential to ensure the
provision of appropriate drugs at appropriate dosages to children
with MDR-TB to optimize treatment outcomes.
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